02179000000000457000450099100020000070000020000270600020000470100020000609100090
00081300027000171510017000440350010000614800027000710300018000989300004001161170
00600120085000300126935001000129031000300139032000200142036000600144042000200150
20000020015206500090015412200030016304800140016604800140018004800240019404900240
02180490030002420490031002720490032003030490029003350430055003640430055004190430
05500474540038800529540040200917540039601319541000601715#1#0#i#1#20110411#Acta O
rtopédica Brasileira#Acta ortop. bras#1413-7852#Atha Comunicação & Editora#Acta 
ortop. bras.#AOB#other#nd#1413-7852#19#1#20111#1#0#20110000#12#^les^hSumario#^lp
t^hSumário#^len^hTable of Contents#^lpt^cAOB110^tEditorial#^lpt^cAOB140^tArtigo 
Original#^len^cAOB140^tOriginal Article#^lpt^cAOB160^tArtigo de Revisão#^len^cAO
B160^tReview Article#^les^tActa ortop. bras.^vvol.19^nno.1^cSão Paulo^a2011#^lpt
^tActa ortop. bras.^vvol.19^nno.1^cSão Paulo^a2011#^len^tActa ortop. bras.^vvol.
19^nno.1^cSão Paulo^a2011#^t<a rel="license" href="http://creativecommons.org/li
censes/by-nc/3.0/"><img alt="Creative Commons License" style="border-width:0" sr
c="http://i.creativecommons.org/l/by-nc/3.0/80x15.png" /></a> Todo el contenido 
de esta revista, excepto dónde está identificado, est&#225; bajo una <a rel="lic
ense" href="http://creativecommons.org/licenses/by-nc/3.0/">Licencia Creative Co
mmons</a>^les#^t<a rel="license" href="http://creativecommons.org/licenses/by-nc
/3.0/"><img alt="Creative Commons License" style="border-width:0" src="http://i.
creativecommons.org/l/by-nc/3.0/80x15.png" /></a> Todo o conteúdo deste periódic
o, exceto onde est&#225 identificado, est&#225; licenciado sob uma <a rel="licen
se" href="http://creativecommons.org/licenses/by-nc/3.0/">Licen&#231;a Creative 
Commons</a>^lpt#^t<a rel="license" href="http://creativecommons.org/licenses/by-
nc/3.0/"><img alt="Creative Commons License" style="border-width:0" src="http://
i.creativecommons.org/l/by-nc/3.0/80x15.png" /></a> All the contents of this jou
rnal, except where otherwise noted, is licensed under a <a rel="license" href="h
ttp://creativecommons.org/licenses/by-nc/3.0/">Creative Commons Attribution Lice
nse</a>^len#BY-NC##
00258000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090005000557080002000600910009000620920007000710020007000787030
00300085#v19n1#V:\SciELO\serial\aob\v19n1\markup\01.htm#S#o#1#1#text#1#20110411#
112516#01.htm#13##
00579000000000361000450000400060000070200410000670500020004770600020004970000020
00517010002000537090005000557080002000600710003000620400003000650010006000680420
00200074120000400076038000300080121000300083049000700086158000300093030001800096
03100030011403200020011706500090011901400070012803500100013512300020014501200140
0147012001400161010003500175002000700210#v19n1#V:\SciELO\serial\aob\v19n1\markup
\01.htm#S#h#2#1#text#1#ed#pt#br1.1#1#4.0#ND#01#AOB110#nd#Acta ortop. bras.#19#1#
20110000#^f0^l0#1413-7852#2#Editorial^lpt#Editorial^len#^rND^nTarcisio E. P.^sBa
rros Filho#01.htm##
00594000000000361000450000400060000070200410000670500020004770600020004970000020
00517010002000537090005000557080002000600710003000620400003000650010006000680420
00200074120000400076038000300080121000300083049000700086158000300093030001800096
03100030011403200020011706500090011901400070012803500100013512300020014501200220
0147012002100169010003500190002000700225#v19n1#V:\SciELO\serial\aob\v19n1\markup
\01.htm#S#f#3#1#text#1#ed#pt#br1.1#1#4.0#ND#01#AOB110#nd#Acta ortop. bras.#19#1#
20110000#^f0^l0#1413-7852#2#<b>Editorial </b>^lpt#<b>Editorial</b>^len#^rND^nTar
cisio E. P.^sBarros Filho#01.htm##
00682000000000373000450000400060000070200410000670500020004770600020004970000020
00517010002000537090005000557080002000600640007000620710003000690400003000720010
00600075042000200081120000400083121000300087049000700090158000300097030001700100
03100030011703200020012006500090012201400070013103500100013812300020014801200140
0150012001400164010003400178002000700212008008900219#v19n1#V:\SciELO\serial\aob\
v19n1\markup\01.htm#S#l#4#1#text#1#^a2011#ed#pt#br1.1#1#4.0#01#AOB110#nd#Acta or
top. bras#19#1#20110000#^f0^l0#1413-7852#2#Editorial^lpt#Editorial^len#^rND^nTar
cisio E. P^sBarros Filho#01.htm#Internet^ihttp://www.scielo.br/scielo.php?script
=sci_arttext&pid=S1413-78522011000100001##
00336000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000500055708000200060704012100062002000700183#v19n1#V:\SciELO
\serial\aob\v19n1\markup\01.htm#S#p#5#1#text#9#<p><a name="top"></a><font face="
Verdana, Arial, Helvetica, sans-serif" size="4"><b>Editorial    </b></font></p> 
    ^cY#01.htm##
00237000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000500055708000200060704002200062002000700084#v19n1#V:\SciELO
\serial\aob\v19n1\markup\01.htm#S#p#6#2#text#9#<p>&nbsp;</p>     ^cY#01.htm##
00237000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000500055708000200060704002200062002000700084#v19n1#V:\SciELO
\serial\aob\v19n1\markup\01.htm#S#p#7#3#text#9#<p>&nbsp;</p>     ^cY#01.htm##
00323000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000500055708000200060704010800062002000700170#v19n1#V:\SciELO
\serial\aob\v19n1\markup\01.htm#S#p#8#4#text#9#<p><font face="Verdana, Arial, He
lvetica, sans-serif" size="2"><b>Prezados Senhores,</b></font></p>     ^cY#01.ht
m##
00998000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000500055708000200060704078300062002000700845#v19n1#V:\SciELO
\serial\aob\v19n1\markup\01.htm#S#p#9#5#text#9#<p><font face="Verdana, Arial, He
lvetica, sans-serif" size="2">H&aacute; mais    de 18 anos, quando foi iniciado 
o projeto da nossa revista Acta Ortop&eacute;dica    Brasileira, era inimagin&aa
cute;vel, mesmo no mais otimista dos cen&aacute;rios,    que ela alcan&ccedil;as
se o patamar em que se encontra hoje. Seu reconhecimento    por v&aacute;rios do
s mais importantes indexadores cient&iacute;ficos do mundo    reflete a alta qua
lidade da produ&ccedil;&atilde;o cient&iacute;fica da Ortopedia    Brasileira, f
ruto do trabalho de todos os membros do Conselho Editorial, assim    como dos pe
squisadores que colaboraram ao longo destes 18 anos e confiaram a    divulga&cce
dil;&atilde;o de sua produ&ccedil;&atilde;o &agrave; Acta Ortop&eacute;dica    B
rasileira.</font></p>     ^cY#01.htm##
00642000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000500056708000200061704042600063002000700489#v19n1#V:\SciELO
\serial\aob\v19n1\markup\01.htm#S#p#10#6#text#9#<p><font face="Verdana, Arial, H
elvetica, sans-serif" size="2">Fa&ccedil;o quest&atilde;o    de deixar registrad
os agradecimentos especiais &agrave;s v&aacute;rias diretorias    da Regional de
 S&atilde;o Paulo da SBOT, que confiaram em nossa gest&atilde;o,    e ao Laborat
&oacute;rio Ach&eacute;, nosso parceiro no desenvolvimento deste    projeto, que
 tanto tem contribu&iacute;do com nossa especialidade.</font></p>     ^cY#01.htm
##
00706000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000500056708000200061704049000063002000700553#v19n1#V:\SciELO
\serial\aob\v19n1\markup\01.htm#S#p#11#7#text#9#<p><font face="Verdana, Arial, H
elvetica, sans-serif" size="2">Por meio desta    mensagem, despe&ccedil;o-me das
 atividades de editor-chefe de nossa revista,    com dupla satisfa&ccedil;&atild
e;o: de dever cumprido e de passar as fun&ccedil;&otilde;es    para o colega e a
migo Olavo Pires de Camargo, o qual tenho a certeza de que    desenvolver&aacute
; esta atividade com toda a compet&ecirc;ncia, conduzindo    a Acta Ortop&eacute
;dica a patamares cada vez mais altos.</font></p>     ^cY#01.htm##
00419000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000500056708000200061704020300063002000700266#v19n1#V:\SciELO
\serial\aob\v19n1\markup\01.htm#S#p#12#8#text#9#<p><font face="Verdana, Arial, H
elvetica, sans-serif" size="2">Obrigado a todos    os envolvidos neste projeto p
ela colabora&ccedil;&atilde;o ao longo destes 18    anos ininterruptos.</font></
p>     ^cY#01.htm##
00343000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000500056708000200061704012700063002000700190#v19n1#V:\SciELO
\serial\aob\v19n1\markup\01.htm#S#p#13#9#text#9#<p align="right"><font face="Ver
dana, Arial, Helvetica, sans-serif" size="2">Tarcisio    E. P. Barros Filho</fon
t></p>     ^cY#01.htm##
00258000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090005000557080002000600910009000620920007000710020007000787030
00300085#v19n1#V:\SciELO\serial\aob\v19n1\markup\02.htm#S#o#1#1#text#1#20110411#
112517#02.htm#14##
00574000000000361000450000400060000070200410000670500020004770600020004970000020
00517010002000537090005000557080002000600710003000620400003000650010006000680420
00200074120000400076038000300080121000300083049000700086158000300093030001800096
03100030011403200020011706500090011901400070012803500100013512300020014501200140
0147012001400161010003000175002000700205#v19n1#V:\SciELO\serial\aob\v19n1\markup
\02.htm#S#h#2#1#text#1#ed#pt#br1.1#1#4.0#ND#02#AOB110#nd#Acta ortop. bras.#19#1#
20110000#^f0^l0#1413-7852#2#Editorial^lpt#Editorial^len#^rND^nOlavo Pires de^sCa
margo#02.htm##
00589000000000361000450000400060000070200410000670500020004770600020004970000020
00517010002000537090005000557080002000600710003000620400003000650010006000680420
00200074120000400076038000300080121000300083049000700086158000300093030001800096
03100030011403200020011706500090011901400070012803500100013512300020014501200220
0147012002100169010003000190002000700220#v19n1#V:\SciELO\serial\aob\v19n1\markup
\02.htm#S#f#3#1#text#1#ed#pt#br1.1#1#4.0#ND#02#AOB110#nd#Acta ortop. bras.#19#1#
20110000#^f0^l0#1413-7852#2#<b>Editorial </b>^lpt#<b>Editorial</b>^len#^rND^nOla
vo Pires de^sCamargo#02.htm##
00678000000000373000450000400060000070200410000670500020004770600020004970000020
00517010002000537090005000557080002000600640007000620710003000690400003000720010
00600075042000200081120000400083121000300087049000700090158000300097030001700100
03100030011703200020012006500090012201400070013103500100013812300020014801200140
0150012001400164010003000178002000700208008008900215#v19n1#V:\SciELO\serial\aob\
v19n1\markup\02.htm#S#l#4#1#text#1#^a2011#ed#pt#br1.1#1#4.0#02#AOB110#nd#Acta or
top. bras#19#1#20110000#^f0^l0#1413-7852#2#Editorial^lpt#Editorial^len#^rND^nOla
vo Pires de^sCamargo#02.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci
_arttext&pid=S1413-78522011000100002##
00337000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000500055708000300060704012100063002000700184#v19n1#V:\SciELO
\serial\aob\v19n1\markup\02.htm#S#p#5#1#text#10#<p><a name="top"></a><font face=
"Verdana, Arial, Helvetica, sans-serif" size="4"><b>Editorial    </b></font></p>
     ^cY#02.htm##
00238000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000500055708000300060704002200063002000700085#v19n1#V:\SciELO
\serial\aob\v19n1\markup\02.htm#S#p#6#2#text#10#<p>&nbsp;</p>     ^cY#02.htm##
00238000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000500055708000300060704002200063002000700085#v19n1#V:\SciELO
\serial\aob\v19n1\markup\02.htm#S#p#7#3#text#10#<p>&nbsp;</p>     ^cY#02.htm##
00321000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000500055708000300060704010500063002000700168#v19n1#V:\SciELO
\serial\aob\v19n1\markup\02.htm#S#p#8#4#text#10#<p><font face="Verdana, Arial, H
elvetica, sans-serif" size="2"><b>Caros leitores,</b></font></p>     ^cY#02.htm#
#
00568000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000500055708000300060704035200063002000700415#v19n1#V:\SciELO
\serial\aob\v19n1\markup\02.htm#S#p#9#5#text#10#<p><font face="Verdana, Arial, H
elvetica, sans-serif" size="2">Teremos a honra    de prosseguir com o projeto pi
oneiro desenvolvido h&aacute; 18 anos com efici&ecirc;ncia    pelo Prof. Tarcisi
o E. Pessoa de Barros Filho, ap&oacute;s termos conseguido,    em 2009, que a Ac
ta Ortop&eacute;dica Brasileira se tornasse uma revista ISI.</font></p>     ^cY#
02.htm##
00479000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000500056708000300061704026200064002000700326#v19n1#V:\SciELO
\serial\aob\v19n1\markup\02.htm#S#p#10#6#text#10#<p><font face="Verdana, Arial, 
Helvetica, sans-serif" size="2">Para alcan&ccedil;armos    este objetivo, ser&aa
cute; necess&aacute;ria a participa&ccedil;&atilde;o homog&ecirc;nea    de toda 
comunidade acad&ecirc;mica da ortopedia brasileira.</font></p>     ^cY#02.htm##
00478000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000500056708000300061704026100064002000700325#v19n1#V:\SciELO
\serial\aob\v19n1\markup\02.htm#S#p#11#7#text#10#<p><font face="Verdana, Arial, 
Helvetica, sans-serif" size="2">Precisamos de um    conselho editorial com maior
 presen&ccedil;a internacional e de trabalhos cient&iacute;ficos    consent&acir
c;neos com a realidade atual da ortopedia mundial.</font></p>     ^cY#02.htm##
00557000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000500056708000300061704034000064002000700404#v19n1#V:\SciELO
\serial\aob\v19n1\markup\02.htm#S#p#12#8#text#10#<p><font face="Verdana, Arial, 
Helvetica, sans-serif" size="2">Ser&atilde;o priorizados    projetos de pesquisa
 originais, com &ecirc;nfase para os estudos com maior n&iacute;vel    de evid&e
circ;ncia, visando, assim, atingir um fator de impacto que viabilize    a nossa 
indexa&ccedil;&atilde;o tamb&eacute;m no Medilne.</font></p>     ^cY#02.htm##
00377000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000500056708000300061704016000064002000700224#v19n1#V:\SciELO
\serial\aob\v19n1\markup\02.htm#S#p#13#9#text#10#<p><font face="Verdana, Arial, 
Helvetica, sans-serif" size="2">Contamos para isso    com o apoio e a atua&ccedi
l;&atilde;o efetiva de todos.</font></p>     ^cY#02.htm##
00340000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000500057708000300062704012200065002000700187#v19n1#V:\SciELO
\serial\aob\v19n1\markup\02.htm#S#p#14#10#text#10#<p align="right"><font face="V
erdana, Arial, Helvetica, sans-serif" size="2">Olavo    Pires de Camargo</font><
/p>     ^cY#02.htm##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v19n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#o#1#1#article#1#201104
11#111835#03.htm#235##
04353000000000637000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000500083038000400088121000300092049000700095158000300102
03000180010503100030012303200020012606500090012801400090013703500100014601200950
01560120102002510100045003530100039003980100046004370100039004830100034005220100
03900556010004900595070009200644083135200736085000802088085003502096085003602131
08500250216708313720219208500080356408500350357208500310360708500250363811700060
3663072000303669112000903672111000903681114000903690113000903699002000703708#v19
n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#
ILUS#GRA#03#AOB140#nd#Acta ortop. bras.#19#1#20110000#^f10^l16#1413-7852#Avaliaç
ão funcional e histológica da oxigenoterapia hiperbárica em ratos com lesão medu
lar^lpt#Functional and histologic evaluation of hyperbaric oxygen therapy in rat
s with spinal cord injury^len#^rND^1A01^nPaulo Eduardo de Carvalho^sGalvão#^rND^
1A01^nAlexandre Fogaça^sCristante#^rND^1A01^nHenrique Mennucci de Haidar^sJorge#
^rND^1A01^nMarcelo Loquette^sDamasceno#^rND^1A01^nRaphael Martus^sMarcon#^rND^1A
01^nReginaldo Perillo^sOliveira#^rND^1A01^nTarcísio Eloy Pessoa de^sBarros Filho
#FMUSP^iA01^1Department of Orthopedics and Traumatology^2Laboratory of Medical I
nvestigation#^lpt^aOBJETIVOS: Avaliar a eficácia da aplicação da oxigenoterapia 
hiperbárica em ratos Wistar, com lesão medular contusa produzida por equipamento
 computadorizado para impacto por queda de peso, NYU Impactor. MÉTODOS: Avaliara
m-se 17 ratos machos com peso variando de 265 a 426 g; realizaram-se impactos co
m peso de 10 g de uma altura pré-determinada de 12,5 mm ao nível da décima vérte
bra torácica, após realização de laminectomia prévia. Os ratos foram divididos a
leatoriamente em grupo controle e grupo oxigênio hiperbárico. Este último, subme
tido à tratamento com oxigenoterapia em câmara hiperbárica, durante uma hora diá
ria por um período de 30 dias. A avaliação da recuperação locomotora foi realiza
da no 2º, 9º, 16º, 23º e 30º dia pós-operatório, avaliados através de escala fun
cional e o sítio de lesão submetido à exame anatomopatológico. RESULTADOS: Demon
strou-se melhora da recuperação locomotora nos ratos tratados com oxigênio hiper
bárico nas fases iniciais de avaliação mas no final da avaliação não havia difer
ença estatisticamente significante entre ambos grupos. O exame anatomopatológico
 comprovou as alterações estruturais da medula espinal nos dois grupos. CONCLUSÃ
O: A lesão medular leve provocada nos ratos evoluiu de maneira diferente no grup
o da oxigenoterapia hiperbárica comparativamente ao grupo controle, na fase inic
ial.#^dnd^i1#^tm^lpt^kOxigenação hiperbárica^i1#^tm^lpt^kTraumatismos da medular
^i1#^tm^lpt^kRatos Wistar^i1#^len^aOBJECTIVE: To evaluate the effectiveness of t
he application of hyperbaric oxygen therapy in Wistar rats with spinal cord cont
usion produced using computerized equipment to create impact by a falling weight
, NYU Impactor. METHODS: We evaluated 17 male rats with weights ranging from 265
 to 426 g; impacts were performed with a weight of 10 g from a pre-determined he
ight of 12.5 mm, at the tenth thoracic vertebra, after completion of prior lamin
ectomy. The rats were randomly divided into a control group and a group treated 
with hyperbaric oxygen. The latter, was treated with oxygen therapy in a hyperba
ric chamber for one hour daily for a period of 30 days. The assessment of locomo
tor recovery was conducted on the 2nd, 9th, 16th, 23rd and 30th postoperative da
ys, measured by the functional scale and the site of injury submitted to anatomo
pathological examination. RESULTS: Improved locomotor recovery was demonstrated 
in the rats treated with hyperbaric oxygen in the initial stages of the evaluati
on, but at the end of the evaluation there was no statistically significant diff
erence between the two groups. The anatomopathological examination showed struct
ural changes of the spinal cord in both groups. CONCLUSION: Spinal cord injury i
n rats evolved differently in the hyperbaric oxygen therapy group compared with 
the control group, in the initial phase.#^dnd^i2#^tm^len^kHyperbaric oxygenation
^i2#^tm^len^kSpinal cord injury^i2#^tm^len^kRats, Wistar^i2#other#17#20090917#17
/09/09#20091123#23/11/09#03.htm##
04430000000000637000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000500083038000400088121000300092049000700095158000300102
03000180010503100030012303200020012606500090012801400090013703500100014601201020
01560120109002580100045003670100039004120100046004510100039004970100034005360100
03900570010004900609070009200658083138700750085000802137085003502145085003602180
08500250221608314000224108500080364108500350364908500310368408500250371511700060
3740072000303746112000903749111000903758114000903767113000903776002000703785#v19
n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#
ILUS#GRA#03#AOB140#nd#Acta ortop. bras.#19#1#20110000#^f10^l16#1413-7852#<b>Aval
iação funcional e histológica da oxigenoterapia hiperbárica em ratos com lesão m
edular</b>^lpt#<b>Functional and histologic evaluation of hyperbaric oxygen ther
apy in rats with spinal cord injury</b>^len#^rND^1A01^nPaulo Eduardo de Carvalho
^sGalvão#^rND^1A01^nAlexandre Fogaça^sCristante#^rND^1A01^nHenrique Mennucci de 
Haidar^sJorge#^rND^1A01^nMarcelo Loquette^sDamasceno#^rND^1A01^nRaphael Martus^s
Marcon#^rND^1A01^nReginaldo Perillo^sOliveira#^rND^1A01^nTarcísio Eloy Pessoa de
^sBarros Filho#FMUSP^iA01^1Department of Orthopedics and Traumatology^2Laborator
y of Medical Investigation#^lpt^a<b>OBJETIVOS:</b> Avaliar a eficácia da aplicaç
ão da oxigenoterapia hiperbárica em ratos Wistar, com lesão medular contusa prod
uzida por equipamento computadorizado para impacto por queda de peso, <i>NYU Imp
actor.</i> <b>MÉTODOS:</b> Avaliaram-se 17 ratos machos com peso variando de 265
 a 426 g; realizaram-se impactos com peso de 10 g de uma altura pré-determinada 
de 12,5 mm ao nível da décima vértebra torácica, após realização de laminectomia
 prévia. Os ratos foram divididos aleatoriamente em grupo controle e grupo oxigê
nio hiperbárico. Este último, submetido à tratamento com oxigenoterapia em câmar
a hiperbárica, durante uma hora diária por um período de 30 dias. A avaliação da
 recuperação locomotora foi realizada no 2º, 9º, 16º, 23º e 30º dia pós-operatór
io, avaliados através de escala funcional e o sítio de lesão submetido à exame a
natomopatológico. <b>RESULTADOS:</b> Demonstrou-se melhora da recuperação locomo
tora nos ratos tratados com oxigênio hiperbárico nas fases iniciais de avaliação
 mas no final da avaliação não havia diferença estatisticamente significante ent
re ambos grupos. O exame anatomopatológico comprovou as alterações estruturais d
a medula espinal nos dois grupos. <b>CONCLUSÃO:</b> A lesão medular leve provoca
da nos ratos evoluiu de maneira diferente no grupo da oxigenoterapia hiperbárica
 comparativamente ao grupo controle, na fase inicial.#^dnd^i1#^tm^lpt^kOxigenaçã
o hiperbárica^i1#^tm^lpt^kTraumatismos da medular^i1#^tm^lpt^kRatos Wistar^i1#^l
en^a<b>OBJECTIVE:</b> To evaluate the effectiveness of the application of hyperb
aric oxygen therapy in Wistar rats with spinal cord contusion produced using com
puterized equipment to create impact by a falling weight, NYU Impactor. <b>METHO
DS:</b> We evaluated 17 male rats with weights ranging from 265 to 426 g; impact
s were performed with a weight of 10 g from a pre-determined height of 12.5 mm, 
at the tenth thoracic vertebra, after completion of prior laminectomy. The rats 
were randomly divided into a control group and a group treated with hyperbaric o
xygen. The latter, was treated with oxygen therapy in a hyperbaric chamber for o
ne hour daily for a period of 30 days. The assessment of locomotor recovery was 
conducted on the 2nd, 9th, 16th, 23rd and 30th postoperative days, measured by t
he functional scale and the site of injury submitted to anatomopathological exam
ination. <b>RESULTS:</b> Improved locomotor recovery was demonstrated in the rat
s treated with hyperbaric oxygen in the initial stages of the evaluation, but at
 the end of the evaluation there was no statistically significant difference bet
ween the two groups. The anatomopathological examination showed structural chang
es of the spinal cord in both groups. <b>CONCLUSION:</b> Spinal cord injury in r
ats evolved differently in the hyperbaric oxygen therapy group compared with the
 control group, in the initial phase.#^dnd^i2#^tm^len^kHyperbaric oxygenation^i2
#^tm^len^kSpinal cord injury^i2#^tm^len^kRats, Wistar^i2#other#17#20090917#17/09
/09#20091123#23/11/09#03.htm##
04474000000000661000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000500090038000400095121000300099049000700102
15800030010903000170011203100030012903200020013206500090013401400090014303500100
01520120095001620120102002570100045003590100039004040100046004430100039004890100
03400528010003900562010004900601070009400650083135200744085000802096085003502104
08500360213908500250217508313720220008500080357208500350358008500310361508500250
36461170006036710720003036771120009036801110009036891140009036981130009037070020
00703716008008903723#v19n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#l#4#1#arti
cle#1#^a2011#oa#pt#br1.1#1#4.0#ilus#gra#03#AOB140#nd#Acta ortop. bras#19#1#20110
000#^f10^l16#1413-7852#Avaliação funcional e histológica da oxigenoterapia hiper
bárica em ratos com lesão medular^lpt#Functional and histologic evaluation of hy
perbaric oxygen therapy in rats with spinal cord injury^len#^rND^1A01^nPaulo Edu
ardo de Carvalho^sGalvão#^rND^1A01^nAlexandre Fogaça^sCristante#^rND^1A01^nHenri
que Mennucci de Haidar^sJorge#^rND^1A01^nMarcelo Loquette^sDamasceno#^rND^1A01^n
Raphael Martus^sMarcon#^rND^1A01^nReginaldo Perillo^sOliveira#^rND^1A01^nTarcísi
o Eloy Pessoa de^sBarros Filho#^iA01^1FMUSP^2Department of Orthopedics and Traum
atology^3Laboratory of Medical Investigation#^lpt^aOBJETIVOS: Avaliar a eficácia
 da aplicação da oxigenoterapia hiperbárica em ratos Wistar, com lesão medular c
ontusa produzida por equipamento computadorizado para impacto por queda de peso,
 NYU Impactor. MÉTODOS: Avaliaram-se 17 ratos machos com peso variando de 265 a 
426 g; realizaram-se impactos com peso de 10 g de uma altura pré-determinada de 
12,5 mm ao nível da décima vértebra torácica, após realização de laminectomia pr
évia. Os ratos foram divididos aleatoriamente em grupo controle e grupo oxigênio
 hiperbárico. Este último, submetido à tratamento com oxigenoterapia em câmara h
iperbárica, durante uma hora diária por um período de 30 dias. A avaliação da re
cuperação locomotora foi realizada no 2º, 9º, 16º, 23º e 30º dia pós-operatório,
 avaliados através de escala funcional e o sítio de lesão submetido à exame anat
omopatológico. RESULTADOS: Demonstrou-se melhora da recuperação locomotora nos r
atos tratados com oxigênio hiperbárico nas fases iniciais de avaliação mas no fi
nal da avaliação não havia diferença estatisticamente significante entre ambos g
rupos. O exame anatomopatológico comprovou as alterações estruturais da medula e
spinal nos dois grupos. CONCLUSÃO: A lesão medular leve provocada nos ratos evol
uiu de maneira diferente no grupo da oxigenoterapia hiperbárica comparativamente
 ao grupo controle, na fase inicial.#^dnd^i1#^tm^lpt^kOxigenação hiperbárica^i1#
^tm^lpt^kTraumatismos da medular^i1#^tm^lpt^kRatos Wistar^i1#^len^aOBJECTIVE: To
 evaluate the effectiveness of the application of hyperbaric oxygen therapy in W
istar rats with spinal cord contusion produced using computerized equipment to c
reate impact by a falling weight, NYU Impactor. METHODS: We evaluated 17 male ra
ts with weights ranging from 265 to 426 g; impacts were performed with a weight 
of 10 g from a pre-determined height of 12.5 mm, at the tenth thoracic vertebra,
 after completion of prior laminectomy. The rats were randomly divided into a co
ntrol group and a group treated with hyperbaric oxygen. The latter, was treated 
with oxygen therapy in a hyperbaric chamber for one hour daily for a period of 3
0 days. The assessment of locomotor recovery was conducted on the 2nd, 9th, 16th
, 23rd and 30th postoperative days, measured by the functional scale and the sit
e of injury submitted to anatomopathological examination. RESULTS: Improved loco
motor recovery was demonstrated in the rats treated with hyperbaric oxygen in th
e initial stages of the evaluation, but at the end of the evaluation there was n
o statistically significant difference between the two groups. The anatomopathol
ogical examination showed structural changes of the spinal cord in both groups. 
CONCLUSION: Spinal cord injury in rats evolved differently in the hyperbaric oxy
gen therapy group compared with the control group, in the initial phase.#^dnd^i2
#^tm^len^kHyperbaric oxygenation^i2#^tm^len^kSpinal cord injury^i2#^tm^len^kRats
, Wistar^i2#other#17#20090917#17/09/09#20091123#23/11/09#03.htm#Internet^ihttp:/
/www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-78522011000100003##
00343000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704012300067002000700190#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#5#1#article#214#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTIGO    ORIGINAL</b> </fon
t></p>     ^cY#03.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#6#2#article#214#<p>&nbsp;</p>     ^cY#03.htm
##
00459000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704023900067002000700306#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#7#3#article#214#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Avalia&ccedil;&atilde;o 
   funcional e histol&oacute;gica da oxigenoterapia hiperb&aacute;rica em ratos 
   com les&atilde;o medular</b></font></p>     ^cY#03.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#8#4#article#214#<p>&nbsp;</p>     ^cY#03.htm
##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#9#5#article#214#<p>&nbsp;</p>     ^cY#03.htm
##
00553000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704033200068002000700400#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#10#6#article#214#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Paulo Eduardo    de Carvalho Galv&atilde;
o; Alexandre Foga&ccedil;a Cristante; Henrique Mennucci    de Haidar Jorge; Marc
elo Loquette Damasceno; Raphael Martus Marcon; Reginaldo    Perillo Oliveira; Ta
rc&iacute;sio Eloy Pessoa de Barros Filho</b></font></p>     ^cY#03.htm##
00442000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704022100068002000700289#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#11#7#article#214#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2">Laboratory of Medical    Investigation of th
e Musculoskeletal System - LIM41 of the Department of Orthopedics    and Traumat
ology of FMUSP</font></p>     ^cY#03.htm##
00369000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704014800068002000700216#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#12#8#article#214#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><a href="#back">Endere&ccedil;o    para Corr
espond&ecirc;ncia</a></font></p>     ^cY#03.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#13#9#article#214#<p>&nbsp;</p>     ^cY#03.ht
m##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#14#10#article#214#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#03.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#15#11#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#03.htm##
00554000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704033200069002000700401#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#16#12#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>OBJETIVOS:</b>    Avaliar a efic&aacute;
cia da aplica&ccedil;&atilde;o da oxigenoterapia hiperb&aacute;rica    em ratos 
Wistar, com les&atilde;o medular contusa produzida por equipamento    computador
izado para impacto por queda de peso, <i>NYU Impactor.</i>    ^cY#03.htm##
01114000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704089200069002000700961#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#17#13#article#214#<br>   <b>M&Eacute;TODOS:<
/b> Avaliaram-se 17 ratos machos com peso variando de 265    a 426 g; realizaram
-se impactos com peso de 10 g de uma altura pr&eacute;-determinada    de 12,5 mm
 ao n&iacute;vel da d&eacute;cima v&eacute;rtebra tor&aacute;cica,    ap&oacute;
s realiza&ccedil;&atilde;o de laminectomia pr&eacute;via. Os ratos    foram divi
didos aleatoriamente em grupo controle e grupo oxig&ecirc;nio hiperb&aacute;rico
.    Este &uacute;ltimo, submetido &agrave; tratamento com oxigenoterapia em c&a
circ;mara    hiperb&aacute;rica, durante uma hora di&aacute;ria por um per&iacut
e;odo de    30 dias. A avalia&ccedil;&atilde;o da recupera&ccedil;&atilde;o loco
motora foi    realizada no 2º, 9º, 16º, 23º e 30º dia p&oacute;s-operat&oacute;r
io, avaliados    atrav&eacute;s de escala funcional e o s&iacute;tio de les&atil
de;o submetido    &agrave; exame anatomopatol&oacute;gico.    ^cY#03.htm##
00677000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704045500069002000700524#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#18#14#article#214#<br>   <b>RESULTADOS:</b> 
Demonstrou-se melhora da recupera&ccedil;&atilde;o locomotora    nos ratos trata
dos com oxig&ecirc;nio hiperb&aacute;rico nas fases iniciais    de avalia&ccedil
;&atilde;o mas no final da avalia&ccedil;&atilde;o n&atilde;o    havia diferen&c
cedil;a estatisticamente significante entre ambos grupos. O exame    anatomopato
l&oacute;gico comprovou as altera&ccedil;&otilde;es estruturais da    medula esp
inal nos dois grupos.    ^cY#03.htm##
00455000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704023300069002000700302#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#19#15#article#214#<br>   <b>CONCLUS&Atilde;O
:</b> A les&atilde;o medular leve provocada nos ratos evoluiu    de maneira dife
rente no grupo da oxigenoterapia hiperb&aacute;rica comparativamente    ao grupo
 controle, na fase inicial.</font></p>     ^cY#03.htm##
00436000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704021400069002000700283#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#20#16#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Descritores:</b>    Oxigena&ccedil;&atil
de;o hiperb&aacute;rica. Traumatismos da medular. Ratos    Wistar.</font></p> <h
r size="1" noshade>     ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#21#17#article#214#<p>&nbsp;</p>     ^cY#03.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#22#18#article#214#<p>&nbsp;</p>     ^cY#03.h
tm##
00336000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011400069002000700183#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#23#19#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b></font></p> 
    ^cY#03.htm##
00917000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704069500069002000700764#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#24#20#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A les&atilde;o    medular &eacute; incapaci
tante, irrevers&iacute;vel e de alto custo econ&ocirc;mico    e social. Caracter
iza-se pela interrup&ccedil;&atilde;o, parcial ou completa,    das principais fu
n&ccedil;&otilde;es da medula espinal, ou seja, das fun&ccedil;&otilde;es    mot
oras, sensitivas, reflexas e por provocar dist&uacute;rbios neurovegetativos    
dos segmentos corporais localizados abaixo do n&iacute;vel da les&atilde;o.    T
em como causa mais frequente o traumatismo, mas tamb&eacute;m &eacute; produzida
    por tumores,<sup>1</sup> infec&ccedil;&atilde;o ou les&atilde;o vascular.<su
p>2</sup></font></p>     ^cY#03.htm##
00802000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704058000069002000700649#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#25#21#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A les&atilde;o    da medula espinal ocorre 
em geral em pacientes jovens, &eacute; mais frequente    em homens e, dessas les
&otilde;es, 70% s&atilde;o traum&aacute;ticas. As causas    mais comuns s&atilde
;o os acidentes com ve&iacute;culos, as quedas, os ferimentos    por arma de fog
o, os ferimentos por arma branca, os esportes e as atividades    recreacionais.<
sup>3</sup> O mergulho em &aacute;guas rasas tem especial significado    pela al
ta preval&ecirc;ncia em nosso pa&iacute;s.<sup>4</sup></font></p>     ^cY#03.htm
##
00793000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704057100069002000700640#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#26#22#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">No Brasil, a preval&ecirc;ncia    do trauma
tismo raquimedular encontra-se em torno de 40 casos novos/ano/milh&atilde;o    d
e habitantes, cerca de 6 a 8 mil casos novos/ano.<sup>5</sup> Em compara&ccedil;
&atilde;o,    no Estado de S&atilde;o Paulo, dados da Secretaria de Estado da Sa
&uacute;de    do Estado de S&atilde;o Paulo, mostram aproximadamente 1.750 casos
 novos/ano    e uma popula&ccedil;&atilde;o atual de aproximadamente 250.000 pac
ientes com    les&atilde;o medular no Brasil.</font></p>     ^cY#03.htm##
00793000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704057100069002000700640#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#27#23#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Nas &uacute;ltimas    duas d&eacute;cadas, 
v&aacute;rias pesquisas s&atilde;o realizadas na tentativa    de obter-se um tra
tamento mais efetivo para a les&atilde;o medular espinal.<sup>6-8</sup>    Todas
 essas pesquisas envolvem basicamente quatro formas de abordagem do paciente    
com les&atilde;o medular aguda: a cir&uacute;rgica, a farmacol&oacute;gica,    a
 biol&oacute;gica e a por meios f&iacute;sicos, sendo a oxigenoterapia hiperb&aa
cute;rica    e a hipotermia suas modalidades.</font></p>     ^cY#03.htm##
00652000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704043000069002000700499#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#28#24#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A oxigenoterapia    hiperb&aacute;rica &eac
ute; uma modalidade terap&ecirc;utica fundamentada na    obten&ccedil;&atilde;o 
de press&otilde;es parciais elevadas de oxig&ecirc;nio    tecidual,<sup>9</sup> 
ao respirar-se o oxig&ecirc;nio puro no interior de uma    c&acirc;mara hiperb&a
acute;rica, a uma press&atilde;o superior &agrave; da atmosfera.</font></p>     
^cY#03.htm##
00967000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704074500069002000700814#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#29#25#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A les&atilde;o    medular apresenta mecanis
mos prim&aacute;rios ou secund&aacute;rios de dano    &agrave; medula espinal, a
 les&atilde;o mec&acirc;nica prim&aacute;ria e a les&atilde;o    secund&aacute;r
ia resultante de um ou mais processos bioqu&iacute;micos e celulares    desencad
eados pela les&atilde;o prim&aacute;ria.<sup>10</sup> O conceito de    les&atild
e;o secund&aacute;ria foi primeiro postulado por Allen,<sup>11</sup>    que prop
&ocirc;s a exist&ecirc;ncia de agentes nocivos presentes no material    necr&oac
ute;tico e hemorr&aacute;gico que causam danos adicionais &agrave; medula    esp
inal e esses agentes s&atilde;o fatores bioqu&iacute;micos.</font></p>     ^cY#0
3.htm##
00976000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704075400069002000700823#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#30#26#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O objetivo desse    estudo &eacute; verific
ar a efic&aacute;cia da terapia por oxig&ecirc;nio hiperb&aacute;rico,    como t
ratamento isolado atrav&eacute;s de estudo experimental, controlado e    randomi
zado, em ratos com uma contus&atilde;o medular leve produzida por um    equipame
nto computadorizado para impacto por queda de peso (<i>NYU Impactor</i>).    Pro
cura-se avaliar o efeito da terapia com oxig&ecirc;nio hiperb&aacute;rico    sob
re a contus&atilde;o medular, a avalia&ccedil;&atilde;o funcional do d&eacute;fi
cit    neurol&oacute;gico atrav&eacute;s da escala BBB,<sup>12</sup> e as altera
&ccedil;&otilde;es    encontradas no exame anatomopatol&oacute;gico.</font></p> 
    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#31#27#article#214#<p>&nbsp;</p>     ^cY#03.h
tm##
00336000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011400069002000700183#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#32#28#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>MATERIAL E M&Eacute;TODO</b></font></p> 
    ^cY#03.htm##
00801000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704057900069002000700648#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#33#29#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Avaliaram-se 17    ratos <i>Wistar</i> mach
os, com peso variando de 265 a 426g, oriundos do Centro    de Bioterismo da Facu
ldade de Medicina da Universidade de S&atilde;o Paulo.    No momento da recep&cc
edil;&atilde;o, todos os ratos foram avaliados quanto    &agrave;s condi&ccedil;
&otilde;es gerais e &agrave; motricidade e identificados    (marca&ccedil;&atild
e;o de listras pretas e vermelhas na cauda). Acondicionaram-se    at&eacute; cin
co ratos de uma mesma ninhada por gaiola (40 x 60cm).</font></p>     ^cY#03.htm#
#
00995000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704077300069002000700842#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#34#30#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Optamos pelo uso    de ratos da ra&ccedil;a
 Wistar em fun&ccedil;&atilde;o de sua disponibilidade    em nosso meio e das me
nores dificuldades t&eacute;cnicas no manuseio desses    animais. A esp&eacute;c
ie preferencial para experimentos com les&atilde;o medular    deveria ser a dos 
primatas, mas sua utiliza&ccedil;&atilde;o &eacute; limitada    em fun&ccedil;&a
tilde;o do custo elevado, pouca disponibilidade, dificuldades    de manuseio e c
onsidera&ccedil;&otilde;es &eacute;ticas.<sup>13</sup> O rato    pode ser uma bo
a alternativa nestes experimentos posto que sua medula possui    organiza&ccedil
;&atilde;o citoarquitet&ocirc;nica e vasculariza&ccedil;&atilde;o    similar ao 
humano.</font></p>     ^cY#03.htm##
00395000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704017300069002000700242#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#35#31#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Adotaram-se    os seguintes crit&eacute;
rios de inclus&atilde;o e exclus&atilde;o:</b> </font></p>     ^cY#03.htm##
00359000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704013700069002000700206#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#36#32#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Crit&eacute;rios    de inclus&atilde;o:<
/b> </font></p> <ul>       ^cY#03.htm##
00349000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012700069002000700196#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#37#33#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Ratos da ra&ccedil;a      <i>Wistar;</i></
font></li>       ^cY#03.htm##
00372000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704015000069002000700219#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#38#34#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Machos adultos      jovens (20 a 25 semana
s de vida inclusive);</font></li>       ^cY#03.htm##
00353000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704013100069002000700200#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#39#35#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Peso entre 250      e 450 gramas, inclusiv
e;</font></li>       ^cY#03.htm##
00396000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704017400069002000700243#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#40#36#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Condi&ccedil;&atilde;o      geral (pelagem
 e estado cl&iacute;nico) e motricidade normal;</font></li>     ^cY#03.htm##
00236000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704001400069002000700083#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#41#37#article#214#</ul>     ^cY#03.htm##
00359000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704013700069002000700206#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#42#38#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Crit&eacute;rios    de exclus&atilde;o:<
/b> </font></p> <ul>       ^cY#03.htm##
00352000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704013000069002000700199#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#43#39#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">&Oacute;bito      ap&oacute;s les&atilde;o
;</font></li>       ^cY#03.htm##
00352000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704013000069002000700199#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#44#40#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Perda de tecido      na &aacute;rea lesada
;</font></li>       ^cY#03.htm##
00384000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704016200069002000700231#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#45#41#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Anomalias da      medula na &aacute;rea le
sada observada macroscopicamente;</font></li>       ^cY#03.htm##
00368000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704014600069002000700215#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#46#42#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Autofagia ou      mutila&ccedil;&atilde;o 
entre os animais;</font></li>       ^cY#03.htm##
00371000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704014900069002000700218#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#47#43#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Infec&ccedil;&atilde;o      profunda ap&oa
cute;s les&atilde;o;</font></li>       ^cY#03.htm##
00401000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704017900069002000700248#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#48#44#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Infec&ccedil;&atilde;o      refrat&aacute;
ria a antibioticoterapia ap&oacute;s les&atilde;o;</font></li>       ^cY#03.htm#
#
00452000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704023000069002000700299#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#49#45#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Infec&ccedil;&atilde;o      urin&aacute;ri
a ap&oacute;s 10 dias de tratamento com antibi&oacute;tico (presen&ccedil;a     
 de sangue na urina);</font></li>       ^cY#03.htm##
00365000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704014300069002000700212#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#50#46#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Aus&ecirc;ncia      de controle de mic&cce
dil;&atilde;o;</font></li>       ^cY#03.htm##
00504000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704028200069002000700351#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#51#47#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Movimenta&ccedil;&atilde;o      normal na 
primeira avalia&ccedil;&atilde;o ap&oacute;s les&atilde;o (21 pontos      na esc
ala BBB (BASSO, BEATTIE e BRESNAHAN) de avalia&ccedil;&atilde;o funcional).</fon
t></li>     ^cY#03.htm##
00236000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704001400069002000700083#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#52#48#article#214#</ul>     ^cY#03.htm##
00362000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704014000069002000700209#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#53#49#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Forma&ccedil;&atilde;o    dos grupos exp
erimentais</b></font></p>     ^cY#03.htm##
00392000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704017000069002000700239#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#54#50#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Os ratos foram    separados aleatoriamente 
(por sorteio) e formaram dois grupos:</font></p> <ul>       ^cY#03.htm##
00598000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704037600069002000700445#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#55#51#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Grupo Controle      - ratos submetidos &ag
rave; les&atilde;o medular leve atrav&eacute;s de um      equipamento computador
izado para impacto medular por queda de peso - <i>NYU      Impactor</i> ("New Yo
rk University Spinal Cord Contusion Sistem - Impactor"),      sem tratamento pos
terior;</font></li>       ^cY#03.htm##
00553000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704033100069002000700400#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#56#52#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Grupo Oxig&ecirc;nio      Hiberb&aacute;ri
co - ratos submetidos ao mesmo protocolo de les&atilde;o leve      com o <i>NYU 
Impactor</i> e, ap&oacute;s, submetidos ao protocolo de oxigenoterapia      hipe
rb&aacute;rica durante 30 dias (1 hora/dia).</font></li>     ^cY#03.htm##
00236000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704001400069002000700083#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#57#53#article#214#</ul>     ^cY#03.htm##
00813000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704059100069002000700660#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#58#54#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Dos 20 ratos inclu&iacute;dos    inicialmen
te, ocorreram tr&ecirc;s exclus&otilde;es. Um rato do grupo Controle    foi excl
u&iacute;do por apresentar locomo&ccedil;&atilde;o normal (21 pontos    na escal
a BBB na primeira avalia&ccedil;&atilde;o) ap&oacute;s a les&atilde;o    (crit&e
acute;rio de exclus&atilde;o). Dois ratos do grupo Oxig&ecirc;nio Hiperb&aacute;
rico    foram a &oacute;bito, um imediatamente ap&oacute;s a les&atilde;o e o se
gundo    entre o segundo e o nono dia ap&oacute;s a les&atilde;o.</font></p>    
 ^cY#03.htm##
00417000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704019500069002000700264#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#59#55#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Previamente &agrave;    les&atilde;o, anest
esiaram-se os ratos com 55 a 75mg/kg de Pentobarbitalintraperitoneal.</font></p>
     ^cY#03.htm##
01166000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704094400069002000701013#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#60#56#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A exposi&ccedil;&atilde;o    da medula para
 contus&atilde;o controlada foi realizada com o aux&iacute;lio    de um microsc&
oacute;pio cir&uacute;rgico. Ap&oacute;s tricotomia, realizou-se    uma incis&at
ilde;o na linha m&eacute;dia dorsal para expor os arcos posteriores    da coluna
 vertebral, de TVIII a TXII. Descolaram-se os m&uacute;sculos inseridos    nos p
rocessos espinhosos e nas l&acirc;minas de TIX &agrave; TXI. Expuseram-se    os 
processos articulares destas v&eacute;rtebras. A hemostasia, quando necess&aacut
e;ria,    foi realizada com um coagulador bipolar. Removeram-se, com um micro sa
cabocados,    o processo espinhoso e a l&acirc;mina da v&eacute;rtebra TX e a me
tade distal    do processo espinhoso da TIX at&eacute; expor a medula e permitir
 o posicionamento    da ponta da haste (pun&ccedil;&atilde;o) do <i>NYU Impactor
</i>.<sup>14</sup></font></p>     ^cY#03.htm##
00478000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704025600069002000700325#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#61#57#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Adotou-se o modelo    experimental de les&a
tilde;o medular do MASCIS ("Multicenter Animal Spinal Cord    Injury Study") pad
ronizado para ratos <i>Wistar</i>.<sup>15,16</sup></font></p>     ^cY#03.htm##
00952000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704073000069002000700799#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#62#58#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Decidiu-se pela    produ&ccedil;&atilde;o d
e les&otilde;es leves atrav&eacute;s do equipamento    computadorizado para impa
cto por queda de peso <i>NYU Impactor</i>. O teste    de impacto consistiu na qu
eda de uma haste de impacto de 10g de peso de uma    altura pr&eacute;-determina
da de 12,5mm entre a ponta da haste (pun&ccedil;&atilde;o)    e a superf&iacute;
cie da medula espinal em queda livre, atrav&eacute;s de um    tubo guia, monitor
ado por computador (velocidade da haste, deforma&ccedil;&atilde;o    absoluta e 
relativa da medula, instante de contato efetivo e tempo de contato)    de maneir
a a reduzir os fatores de imprecis&atilde;o.</font></p>     ^cY#03.htm##
00460000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704023800069002000700307#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#63#59#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O equipamento computadorizado    para impac
to medular por queda de peso monitorada <i>NYU Impactor</i> (<a href="#f1">Figur
a    1</a>) comp&otilde;e-se de:</font></p>     ^cY#03.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#64#60#article#214#<p><a name="f1"></a></p>  
   ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#65#61#article#214#<p>&nbsp;</p>     ^cY#03.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#66#62#article#214#<p align="center"><img src
="/img/revistas/aob/v19n1/03f01.jpg"></p>     ^cY#03.htm##
00251000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002900069002000700098#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#67#63#article#214#<p>&nbsp;</p> <ul>       ^
cY#03.htm##
00672000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704045000069002000700519#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#68#64#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Dispositivo      de impacto (haste de 10g 
a 12,5mm de altura pr&eacute;-determinada para contus&atilde;o      leve, tubo g
uia e sistema de monitora&ccedil;&atilde;o de posi&ccedil;&atilde;o,      veloci
dade de queda, instante de contato, per&iacute;odo de contato, deforma&ccedil;&a
tilde;o      da coluna e deforma&ccedil;&atilde;o absoluta e relativa da medula)
;</font></li>       ^cY#03.htm##
00377000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704015500069002000700224#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#69#65#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Dispositivos      de interfaceamento (inst
rumenta&ccedil;&atilde;o);</font></li>       ^cY#03.htm##
00355000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704013300069002000700202#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#70#66#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Microcomputador      IBM-PC compat&iacute;
vel;</font></li>       ^cY#03.htm##
00339000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011700069002000700186#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#71#67#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">V&iacute;deo      monitor VGA;</font></li>
       ^cY#03.htm##
00372000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704015000069002000700219#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#72#68#article#214#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Placa de interface      com sa&iacute;da p
aralela e temporizador.</font></li>     ^cY#03.htm##
00236000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704001400069002000700083#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#73#69#article#214#</ul>     ^cY#03.htm##
00886000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704066400069002000700733#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#74#70#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Ap&oacute;s a les&atilde;o,    o rato foi c
olocado em uma superf&iacute;cie aquecida, n&atilde;o excedendo    a temperatura
 de 38°C. Inspecionou-se o s&iacute;tio da les&atilde;o da contus&atilde;o.    N
a presen&ccedil;a de hemorragia realizava-se a hemostasia. Em seguida, lavou-se 
   o s&iacute;tio da contus&atilde;o com solu&ccedil;&atilde;o fisiol&oacute;gic
a    de cloreto de s&oacute;dio a temperatura ambiente. Realizou-se a aproxima&c
cedil;&atilde;o    dos planos teciduais musculares e fasciais e da pele com sutu
ra de pontos simples    com fio nylon monofilamentado 2.0.</font></p>     ^cY#03
.htm##
00887000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704066500069002000700734#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#75#71#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Os ratos foram    submetidos a antibioticot
erapia para prevenir e/ou reduzir a infec&ccedil;&atilde;o    na ferida cir&uacu
te;rgica nas vias urin&aacute;rias. Administrou-se, subcutaneamente,    25mg/kg 
de cefalotina (Keflin Neutro<sup>&reg;</sup> - Ely Lilly) imediatamente    ap&oa
cute;s a les&atilde;o e uma vez ao dia durante os sete dias seguintes.    Naquel
es que apresentassem infec&ccedil;&atilde;o estender-se-ia o tratamento    at&ea
cute; o 10º dia e caso n&atilde;o surtisse efeito o rato seria submetido    &agr
ave; eutan&aacute;sia (crit&eacute;rio de exclus&atilde;o).</font></p>     ^cY#0
3.htm##
01142000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704092000069002000700989#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#76#72#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Utilizou-se uma    c&acirc;mara hiperb&aacu
te;rica tubular com 770mm de comprimento, 180mm de di&acirc;metro    interno e a
ltura &uacute;til de 150mm (entre a plataforma e a parede superior)    especialm
ente dimensionada para ratos, com paredes de acr&iacute;lico transparente    de 
10mm de espessura. A c&acirc;mara hiperb&aacute;rica dispunha de uma v&aacute;lv
ula    de controle na entrada, de um man&ocirc;metro diferencial (kgf/cm<sup>2</
sup>)    (bar&ocirc;metro aner&oacute;ide) para controle da press&atilde;o inter
na, de    um flux&iacute;metro na sa&iacute;da (l/min calibrado a 3,5kgf/cm<sup>
2</sup>    ou 345kPa e 21°C) e de term&ocirc;metro (°C). O fluxo de oxig&ecirc;n
io (O<sub>2</sub>)    provinha de um cilindro atrav&eacute;s de tubula&ccedil;&a
tilde;o flex&iacute;vel    (pl&aacute;stico). (<a href="#f2">Figura 2</a>)</font
></p>     ^cY#03.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#77#73#article#214#<p><a name="f2"></a></p>  
   ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#78#74#article#214#<p>&nbsp;</p>     ^cY#03.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#79#75#article#214#<p align="center"><img src
="/img/revistas/aob/v19n1/03f02.jpg"></p>     ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#80#76#article#214#<p>&nbsp;</p>     ^cY#03.h
tm##
00502000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704028000069002000700349#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#81#77#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A recupera&ccedil;&atilde;o    da capacidad
e locomotora ap&oacute;s les&atilde;o medular foi medida pela escala    BBB (BAS
SO; BEATTIE; BRESNAHAN) de avalia&ccedil;&atilde;o funcional.<sup>12</sup></font
></p>     ^cY#03.htm##
00593000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704037100069002000700440#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#82#78#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A escala BBB de    avalia&ccedil;&atilde;o 
funcional baseia-se em crit&eacute;rios observacionais    espec&iacute;ficos, de
fini&ccedil;&otilde;es simples e n&atilde;o amb&iacute;guas    dos termos e perm
ite uma r&aacute;pida e precisa descri&ccedil;&atilde;o da    performance locomo
tora.</font></p>     ^cY#03.htm##
00547000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704032500069002000700394#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#83#79#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Esta escala foi    adotada pelas institui&c
cedil;&otilde;es que integram o MASCIS e pelo LETRAN.    Decidiu-se pela avalia&
ccedil;&atilde;o visual por time treinado (dois observadores),    &agrave;s cega
s e pela menor avalia&ccedil;&atilde;o.</font></p>     ^cY#03.htm##
00457000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704023500069002000700304#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#84#80#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Todos os ratos    dos grupos Controle e Oxi
g&ecirc;nio Hiperb&aacute;rico foram avaliados no 2º,    9º, 16º, 23º e 30º dia 
p&oacute;s-operat&oacute;rio.</font></p>     ^cY#03.htm##
00659000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704043700069002000700506#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#85#81#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A avalia&ccedil;&atilde;o    consistiu em c
olocar o rato no centro de uma caixa de observa&ccedil;&atilde;o    de 80x80cm e
 borda com 17cm de altura forrada com um campo cir&uacute;rgico    azul turquesa
 (escuro) para maior contraste durante o per&iacute;odo de observa&ccedil;&atild
e;o    (ratos brancos, fundo azul escuro). (<a href="#f3">Figura 3</a>)</font></
p>     ^cY#03.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#86#82#article#214#<p><a name="f3"></a></p>  
   ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#87#83#article#214#<p>&nbsp;</p>     ^cY#03.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#88#84#article#214#<p align="center"><img src
="/img/revistas/aob/v19n1/03f03.jpg"></p>     ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#89#85#article#214#<p>&nbsp;</p>     ^cY#03.h
tm##
00895000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704067300069002000700742#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#90#86#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Avaliou-se a capacidade    locomotora do ra
to. As observa&ccedil;&otilde;es sobre o movimento das articula&ccedil;&otilde;e
s    da pata posterior (quadril, joelho e tornozelo), a posi&ccedil;&atilde;o do
    tronco, do abdome, o deslocamento da pata (balan&ccedil;o) e o modo de conta
to    da pata com o solo, a coordena&ccedil;&atilde;o, os dedos, o contato e a l
ibera&ccedil;&atilde;o    da pata com o solo, a instabilidade do tronco e a posi
&ccedil;&atilde;o relativa    da cauda, em rela&ccedil;&atilde;o ao lado direito
 e esquerdo, foram anotadas    em formul&aacute;rio pr&oacute;prio.</font></p>  
   ^cY#03.htm##
00630000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704040800069002000700477#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#91#87#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O formul&aacute;rio    permitiu o registro 
da identidade, do n&uacute;mero de dias p&oacute;s-operat&oacute;rio    e dos co
ment&aacute;rios, e facilitou a descri&ccedil;&atilde;o do movimento    e a defi
ni&ccedil;&atilde;o da pontua&ccedil;&atilde;o. A escala BBB varia de    0 a 21 
pontos para cada lado, esquerdo e direito.</font></p>     ^cY#03.htm##
00537000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704031500069002000700384#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#92#88#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A avalia&ccedil;&atilde;o    de cada rato f
oi realizada por dois observadores simult&acirc;neos, adequadamente    treinados
, neutros, sem conhecimento do grupo de origem do rato, de maneira    a n&atilde
;o interferir nos resultados.</font></p>     ^cY#03.htm##
00473000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704025100069002000700320#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#93#89#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Caso o rato, posicionado    no centro da ca
ixa, permanecesse im&oacute;vel por 15 a 20s, era estimulado    a movimentar-se 
atrav&eacute;s de toques com um l&aacute;pis.</font></p>     ^cY#03.htm##
00507000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704028500069002000700354#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#94#90#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A avalia&ccedil;&atilde;o    da capacidade 
locomotora do rato demorou de 4 a 5 minutos durante os quais anotaram-se,    no 
respectivo formul&aacute;rio, as caracter&iacute;sticas do movimento executado.<
/font></p>     ^cY#03.htm##
00522000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704030000069002000700369#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#95#91#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Anotaram-se as    caracter&iacute;sticas de
 consenso entre os observadores. Caso houvesse discord&acirc;ncia,    decidiu-se
 pela anota&ccedil;&atilde;o da pior caracter&iacute;stica (menor    pontua&cced
il;&atilde;o).</font></p>     ^cY#03.htm##
00655000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704043300069002000700502#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#96#92#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Ao final do per&iacute;odo    de experiment
a&ccedil;&atilde;o todos os ratos foram submetidos &agrave; eutan&aacute;sia    
conforme legisla&ccedil;&atilde;o em vigor e seguindo os preceitos do Col&eacute
;gio    Brasileiro de Experimenta&ccedil;&atilde;o Animal - COBEA;<sup>17</sup> 
utilizou-se    dose letal de pentobarbital por via intraperitoneal.</font></p>  
   ^cY#03.htm##
00482000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704026000069002000700329#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#97#93#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Para a retirada    da coluna vertebral, rea
lizou-se uma nova incis&atilde;o dorsal extensa, exp&ocirc;s-se    a coluna e co
rtou-se com uma tesoura um segmento dede TVIII a TXII.</font></p>     ^cY#03.htm
##
00482000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704026000069002000700329#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#98#94#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Com um micro sacabocados    retiraram-se cu
idadosamente todas as estruturas &oacute;sseas e de partes moles    adjacentes &
agrave; medula at&eacute; exp&ocirc;-la completamente.</font></p>     ^cY#03.htm
##
00525000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704030300069002000700372#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#99#95#article#214#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Realizou-se uma    avalia&ccedil;&atilde;o 
visual macrosc&oacute;pica da medula no local da contus&atilde;o    para verific
ar-se qualquer anomalia (crit&eacute;rio de exclus&atilde;o). N&atilde;o    se e
ncontrou nenhuma.</font></p>     ^cY#03.htm##
00641000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704041800070002000700488#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#100#96#article#214#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A seguir a medula    retirada foi encaminh
ada em frascos, devidamente identificados, com solu&ccedil;&atilde;o    de forma
lde&iacute;do (10%) para o Servi&ccedil;o de Anatomia Patol&oacute;gica    do In
stituto de Ortopedia e Traumatologia do Hospital das Cl&iacute;nicas da    Facul
dade de Medicina da Universidade de S&atilde;o Paulo.</font></p>     ^cY#03.htm#
#
00469000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704024600070002000700316#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#101#97#article#214#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O estudo anatomopatol&oacute;gico    consi
stiu de uma an&aacute;lise microsc&oacute;pica (&oacute;ptica) de l&acirc;minas 
   coradas pela hematoxilina-eosina (HE).</font></p>     ^cY#03.htm##
00427000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704020400070002000700274#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#102#98#article#214#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O Servi&ccedil;o    de Patologia avaliou e
 graduou (ausente, discreto, moderado e acentuado) os    casos quanto a:</font><
/p> <ul>       ^cY#03.htm##
00320000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704009700070002000700167#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#103#99#article#214#<li><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Hiperemia;</font></li>       ^cY#03.htm##
00370000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704014600071002000700217#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#104#100#article#214#<li><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Degenera&ccedil;&atilde;o      da Subst&
acirc;ncia Nervosa;</font></li>       ^cY#03.htm##
00319000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009500071002000700166#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#105#101#article#214#<li><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Necrose;</font></li>       ^cY#03.htm##
00328000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704010400071002000700175#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#106#102#article#214#<li><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Infiltrado Celular.</font></li>     ^cY#
03.htm##
00238000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704001400071002000700085#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#107#103#article#214#</ul>     ^cY#03.htm##
00452000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704022800071002000700299#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#108#104#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Os patologistas    n&atilde;o foram infor
mados quanto ao grupo de origem a que pertenciam as medulas    dos ratos (avalia
&ccedil;&atilde;o cega).</font></p>     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#109#105#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00324000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704010000071002000700171#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#110#106#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>     ^cY#03.h
tm##
00595000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704037100071002000700442#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#111#107#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">No 2º dia p&oacute;s-operat&oacute;rio,  
  o grupo n&atilde;o tratado com oxigenoterapia hiperb&aacute;rica (grupo contro
le)    apresentou a m&eacute;dia de 2,4 pontos na escala BBB, enquanto o grupo t
ratado    apresentou m&eacute;dia de 5,9 pontos na escala. (<a href="#f4">Figura
 4</a>)</font></p>     ^cY#03.htm##
00257000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003300071002000700104#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#112#108#article#214#<p><a name="f4"></a></p>
     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#113#109#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00300000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704007600071002000700147#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#114#110#article#214#<p align="center"><img s
rc="/img/revistas/aob/v19n1/03f04.jpg"></p>     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#115#111#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00611000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704038700071002000700458#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#116#112#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">No 9º dia p&oacute;s-operat&oacute;rio,  
  a diferen&ccedil;a entre os grupos diminuiu na escala de avalia&ccedil;&atilde
;o    motora, com o grupo controle apresentando 9,9 pontos, e o grupo tratado co
m    oxigenoterapia hiperb&aacute;rica tendo 11,9 pontos na escala BBB. (<a href
="#f5">Figura    5</a>)</font></p>     ^cY#03.htm##
00257000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003300071002000700104#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#117#113#article#214#<p><a name="f5"></a></p>
     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#118#114#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00300000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704007600071002000700147#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#119#115#article#214#<p align="center"><img s
rc="/img/revistas/aob/v19n1/03f05.jpg"></p>     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#120#116#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00550000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704032600071002000700397#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#121#117#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">No 16º dia p&oacute;s-operat&oacute;rio, 
   o grupo controle com oxigenoterapia apresentava 12,6 pontos, enquanto que o  
  grupo submetido a c&acirc;mara hiperb&aacute;rica apresentava 14,4 pontos na  
  escala BBB. (<a href="#f6">Figura 6</a>)</font></p>     ^cY#03.htm##
00257000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003300071002000700104#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#122#118#article#214#<p><a name="f6"></a></p>
     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#123#119#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00300000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704007600071002000700147#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#124#120#article#214#<p align="center"><img s
rc="/img/revistas/aob/v19n1/03f06.jpg"></p>     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#125#121#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00463000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704023900071002000700310#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#126#122#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">No 23º dia, o grupo    controle apresenta
va 13,8 pontos, contra 15,9 do grupo que recebeu oxigenoterapia    hiperb&aacute
;rica. (<a href="#f7">Figura 7</a>)</font></p>     ^cY#03.htm##
00257000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003300071002000700104#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#127#123#article#214#<p><a name="f7"></a></p>
     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#128#124#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00300000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704007600071002000700147#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#129#125#article#214#<p align="center"><img s
rc="/img/revistas/aob/v19n1/03f07.jpg"></p>     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#130#126#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00542000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704031800071002000700389#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#131#127#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Por fim, no 30º    dia p&oacute;s operat&
oacute;rio, a avalia&ccedil;&atilde;o constatou que o    grupo controle apresent
ou 15,6 pontos na escala BBB, enquanto que o grupo tratado    apresentou 17,4 po
ntos. (<a href="#f8">Figura 8</a>)</font></p>     ^cY#03.htm##
00257000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003300071002000700104#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#132#128#article#214#<p><a name="f8"></a></p>
     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#133#129#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00300000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704007600071002000700147#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#134#130#article#214#<p align="center"><img s
rc="/img/revistas/aob/v19n1/03f08.jpg"></p>     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#135#131#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00760000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704053600071002000700607#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#136#132#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Em rela&ccedil;&atilde;o    &agrave; hipe
remia encontrada, no grupo controle evidenciou-se que 55,6% dos    ratos apresen
tou hiperemia em grau moderado, e 44,4% em grau acentuado, n&atilde;o    sendo n
otados indiv&iacute;duos com graus discretos; j&aacute; no grupo que    recebeu 
oxigenoterapia hiperb&aacute;rica, metade apresentou hiperemia em grau    acentu
ado, &frac14; em grau moderado, e &frac14; em grau discreto. (<a href="#f9">Figu
ra    9</a>)</font></p>     ^cY#03.htm##
00257000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003300071002000700104#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#137#133#article#214#<p><a name="f9"></a></p>
     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#138#134#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00300000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704007600071002000700147#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#139#135#article#214#<p align="center"><img s
rc="/img/revistas/aob/v19n1/03f09.jpg"></p>     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#140#136#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00640000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704041600071002000700487#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#141#137#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Quanto &agrave;    degenera&ccedil;&atild
e;o de subst&acirc;ncia nervosa, no grupo controle ocorreu    degenera&ccedil;&a
tilde;o acentuada em 100% dos indiv&iacute;duos, enquanto    no grupo tratado, o
bservou-se degenera&ccedil;&atilde;o moderada em 37,5% e    acentuada em 62,5% d
os indiv&iacute;duos. (<a href="#f10">Figura 10</a>)</font></p>     ^cY#03.htm##
00258000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003400071002000700105#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#142#138#article#214#<p><a name="f10"></a></p
>     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#143#139#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00300000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704007600071002000700147#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#144#140#article#214#<p align="center"><img s
rc="/img/revistas/aob/v19n1/03f10.jpg"></p>     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#145#141#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00675000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704045100071002000700522#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#146#142#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Na avalia&ccedil;&atilde;o    de necrose 
tecidual, o grupo controle apresentou resultados semelhantes a hiperemia    enco
ntrada, com necrose acentuada em 44,4%, e moderada em 55,6% dos indiv&iacute;duo
s.    J&aacute; no grupo tratado, 62,5% dos indiv&iacute;duos apresentaram necro
se    acentuada, 25% moderada, e 12,5% sinais discretos. (<a href="#f11">Figura 
11</a>)</font></p>     ^cY#03.htm##
00258000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003400071002000700105#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#147#143#article#214#<p><a name="f11"></a></p
>     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#148#144#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00300000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704007600071002000700147#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#149#145#article#214#<p align="center"><img s
rc="/img/revistas/aob/v19n1/03f11.jpg"></p>     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#150#146#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00705000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704048100071002000700552#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#151#147#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Por fim, na avalia&ccedil;&atilde;o    qu
anto ao infiltrado celular, os achados do grupo controle se deram com 33,3%    d
e forma acentuada, 55,6% moderada e 11,1% ausente. No grupo que recebeu terapia 
   em c&acirc;mara hiperb&aacute;rica, em 37,5% observou-se sinais acentuados,  
  25% sinais moderados, e 37,5% sinais discretos de infiltrado inflamat&oacute;r
io.    (<a href="#f12">Figura 12</a>)</font></p>     ^cY#03.htm##
00258000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003400071002000700105#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#152#148#article#214#<p><a name="f12"></a></p
>     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#153#149#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00300000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704007600071002000700147#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#154#150#article#214#<p align="center"><img s
rc="/img/revistas/aob/v19n1/03f12.jpg"></p>     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#155#151#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00330000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704010600071002000700177#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#156#152#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font></p>     ^c
Y#03.htm##
01079000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704085500071002000700926#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#157#153#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Para a avalia&ccedil;&atilde;o    da recu
pera&ccedil;&atilde;o locomotora dos membros posteriores procedeu-se    inicialm
ente mensura&ccedil;&otilde;es em separado dos lados direito e esquerdo,    dos 
grupos Controle e Oxig&ecirc;nio Hiperb&aacute;rico, no 2º, 9º, 16º, 23º    e 30
º dia p&oacute;s-operat&oacute;rio. O fato de n&atilde;o se ter comprovado    di
feren&ccedil;as funcionais estatisticamente significativas, permitiu o agrupamen
to    dos resultados da fun&ccedil;&atilde;o dos membros direito e esquerdo de c
ada    grupo. Isto facilitou a interpreta&ccedil;&atilde;o absoluta dos resultad
os.    (<a href="#f4">Figuras 4 a 12</a>) Compararam-se, assim, as diferen&ccedi
l;as    entre os resultados gerais dos grupos Controle e Oxig&ecirc;nio Hiperb&a
acute;rico.</font></p>     ^cY#03.htm##
00777000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704055300071002000700624#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#158#154#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Ap&oacute;s a eutan&aacute;sia,    amostr
as dos tecidos medulares foram retirados do s&iacute;tio da les&atilde;o    e su
bmetidos ao exame anatomopatol&oacute;gico, pelo m&eacute;todo de colora&ccedil;
&atilde;o    de hematoxilina e eosina, com a finalidade de comprovar estigmas da
 les&atilde;o    tecidual. Este estudo se fez necess&aacute;rio para certifica&c
cedil;&atilde;o    de que o traumatismo fora efetivo na produ&ccedil;&atilde;o d
a contus&atilde;o    medular.</font></p>     ^cY#03.htm##
00973000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704074900071002000700820#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#159#155#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Os resultados da    capacidade locomotora
, obtidos pela escala BBB, do grupo Oxig&ecirc;nio Hiperb&aacute;rico    foi 59,
3% superior ao do grupo Controle no 2º dia p&oacute;s-operat&oacute;rio    (<a h
ref="#f4">Figura 4</a>) e 20,2% superior no 9º dia. (<a href="#f5">Figura    5</
a>) No 16º dia a diferen&ccedil;a n&atilde;o foi comprovada. (<a href="#f6">Figu
ra    6</a>) Novamente, no 23º dia o resultado da capacidade locomotora dos rato
s    do grupo Oxig&ecirc;nio Hiperb&aacute;rico foi de 15,2% superior ao do grup
o    Controle (<a href="#f7">Figura 7</a>). No 30º dia p&oacute;s-operat&oacute;
rio    os resultados equivaleram-se. (<a href="#f8">Figura 8</a>)</font></p>    
 ^cY#03.htm##
00970000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704074600071002000700817#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#160#156#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Atrav&eacute;s    destes dados, constatou
-se recupera&ccedil;&atilde;o da capacidade locomotora    de forma acentuada e a
celerada nos ratos tratados com oxigenoterapia hiperb&aacute;rica    at&eacute; 
o 9º dia p&oacute;s-operat&oacute;rio. A partir da&iacute;, neste    grupo, a pr
ogress&atilde;o funcional decresceu gradualmente at&eacute; o 16º    dia. A dife
ren&ccedil;a funcional foi novamente retomada em favor do grupo oxig&ecirc;nio  
  hiperb&aacute;rico no 23º dia e subsequente decr&eacute;scimo para o n&iacute;
vel    de equival&ecirc;ncia que ocorre no 30º dia, quando se deu a estabiliza&c
cedil;&atilde;o    e equipara&ccedil;&atilde;o dos resultados.</font></p>     ^c
Y#03.htm##
00593000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704036900071002000700440#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#161#157#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Constatou-se por    estes resultados que 
do ponto de vista histol&oacute;gico n&atilde;o se provou    o benef&iacute;cio 
da terapia com oxig&ecirc;nio hiperb&aacute;rico, nos quesitos:    hiperemia, de
genera&ccedil;&atilde;o da subst&acirc;ncia nervosa, necrose e    infiltrado cel
ular.</font></p>     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#162#158#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00331000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704010700071002000700178#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#163#159#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="3"><b>CONCLUS&Otilde;ES</b></font></p>     ^
cY#03.htm##
00453000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704022900071002000700300#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#164#160#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">1. O exame anatomopatol&oacute;gico    co
mprovou as altera&ccedil;&otilde;es estruturais da medula espinal de maneira    
uniforme nos dois grupos.</font></p>     ^cY#03.htm##
00486000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704026200071002000700333#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#165#161#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">2. A avalia&ccedil;&atilde;o    funcional
 do d&eacute;ficit neurol&oacute;gico mostrou-se semelhante ap&oacute;s    o m&e
acute;todo de contus&atilde;o por impacto nos dois grupos.</font></p>     ^cY#03
.htm##
00509000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704028500071002000700356#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#166#162#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">3. A avalia&ccedil;&atilde;o    da recupe
ra&ccedil;&atilde;o da capacidade locomotora pela escala BBB, mostrou-se    efic
az na interpreta&ccedil;&atilde;o do efeito da oxigenoterapia hiperb&aacute;rica
.</font></p>     ^cY#03.htm##
00514000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704029000071002000700361#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#167#163#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">4. A les&atilde;o    medular leve provoca
da nos ratos evoluiu de maneira diferente no grupo da oxigenoterapia    hiperb&a
acute;rica comparativamente ao grupo controle, na fase inicial (efeito    aceler
ador).</font></p>     ^cY#03.htm##
01024000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704080000071002000700871#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#168#164#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">A contribui&ccedil;&atilde;o    dessa pes
quisa experimental foi a demonstra&ccedil;&atilde;o do efeito acelerador    na f
ase inicial da recupera&ccedil;&atilde;o da capacidade locomotora dos ratos.    
A partir destes achados, a oxigenoterapia hiperb&aacute;rica passa a ser ferrame
nta    &uacute;til no arsenal terap&ecirc;utico para a solu&ccedil;&atilde;o da 
intrincada    patologia que &eacute; o traumatismo medular, entretanto, a comple
menta&ccedil;&atilde;o    com recursos biol&oacute;gicos e celulares dever&atild
e;o constituir os pr&oacute;ximos    passos a serem trilhados. Ficam suspensas q
uest&otilde;es como tempo de aplica&ccedil;&atilde;o,    press&atilde;o ideal e 
os mecanismos de a&ccedil;&atilde;o.</font></p>     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#169#165#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00331000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704010700071002000700178#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#170#166#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font></p>     ^
cY#03.htm##
00391000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704015300073002000700226#v19
n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#p#171#167#article#214#1#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">1. Weinstein JN,    Mclain 
RF. Primary tumors of the spine. Spine. 1987;12:843-51.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#172#168#article#214#</font></p>     ^cY#03.h
tm##
00510000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704027200073002000700345#v19
n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#p#173#169#article#214#2#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">2. Gupta A, Taly    AB, Sri
vastava A, Murali T. Non-traumatic spinal cord lesions: epidemiology,    complic
ations, neurological and functional outcome of rehabilitation. Spinal    Cord. 2
009;47:307-11.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#174#170#article#214#</font></p>     ^cY#03.h
tm##
00483000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704024500073002000700318#v19
n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#p#175#171#article#214#3#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">3. Jorge FF, Balbani    APS
, Barros Filho TEP. Trauma raquimedular: aspectos epidemiol&oacute;gicos,    imp
acto social e preven&ccedil;&atilde;o. Acta Ortop Bras. 1995;3:1-4.    ^cY#03.ht
m##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#176#172#article#214#</font></p>     ^cY#03.h
tm##
00511000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704027300073002000700346#v19
n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#p#177#173#article#214#4#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">4. Barros Filho    TE. Camp
anha "Cuidado ao Mergulhar". Campanha de preven&ccedil;&atilde;o das    fraturas
 de coluna provocadas pro mergulho. Folha de Ortopedia e Traumatologia;    1999,
 ano XI, n. 32.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#178#174#article#214#</font></p>     ^cY#03.h
tm##
00489000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704025100073002000700324#v19
n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#p#179#175#article#214#5#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">5. D'Andrea Greve    JM. Tr
aumatismos raquimedulares nos acidentes de tr&acirc;nsito e uso de equipamentos 
   de seguran&ccedil;a. Diagn&oacute;stico &amp; Tratamento. 1997;2:10-3.    ^cY
#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#180#176#article#214#</font></p>     ^cY#03.h
tm##
00402000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704016400073002000700237#v19
n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#p#181#177#article#214#6#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">6. Raineteau O.    Plastic 
responses to spinal cord injury. Behav Brain Res. 2008;192:114-23.    ^cY#03.htm
##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#182#178#article#214#</font></p>     ^cY#03.h
tm##
00535000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704029700073002000700370#v19
n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#p#183#179#article#214#7#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">7. Brissot R, Gallien    P,
 Le Bot MP, Beaubras A, Laisne D, Beillot J et al. Clinical experience with    f
unctional electrical stimulation-assisted gait with Parastep in spinal cord-inju
red    patients. Spine. 2000; 25:501-8.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#184#180#article#214#</font></p>     ^cY#03.h
tm##
00470000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704023200073002000700305#v19
n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#p#185#181#article#214#8#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">8. Leypold BG,    Flanders 
AE, Schwartz ED, Burns AS. The impact of methylprednisolone on lesion    severit
y following spinal cord injury. Spine. 2007; 32:373-8.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#186#182#article#214#</font></p>     ^cY#03.h
tm##
00384000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704014600073002000700219#v19
n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#p#187#183#article#214#9#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">9. Biddle C. Oxygen:    the
 two-faced elixir of life. AANA J. 2008;76:61-8.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#188#184#article#214#</font></p>     ^cY#03.h
tm##
00605000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704036600074002000700440#v19
n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#p#189#185#article#214#10#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Bunge RP, Puckett    W
R, Becerra JL, Marcillo A, Quencer RM. Observations on the pathology of human   
 spinal cord injury: a review and classification of 22 new cases with details   
 in from a case of chronic cord compression with extensive focal demyelination. 
   Adv Neurol. 1993;59:75-89.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#190#186#article#214#</font></p>     ^cY#03.h
tm##
00485000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024600074002000700320#v19
n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#p#191#187#article#214#11#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Allen AR. Surgery    o
f experimental lesion of spinal cord equivalent to crush injury fracture disloca
tion    of spinal column: a preliminary report. JAMA. 1911;57:878-80.    ^cY#03.
htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#192#188#article#214#</font></p>     ^cY#03.h
tm##
00464000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022500074002000700299#v19
n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#p#193#189#article#214#12#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Basso DM, Beattie    M
S, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field 
   testing in rats. J Neurotrauma. 1995;12:1-21.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#194#190#article#214#</font></p>     ^cY#03.h
tm##
00405000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704016600074002000700240#v19
n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#p#195#191#article#214#13#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Balentine JD.    Patho
logy of experirnental spinal cord trauma. Lab Invest. 1978;39:236-53.    ^cY#03.
htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#196#192#article#214#</font></p>     ^cY#03.h
tm##
00465000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022600074002000700300#v19
n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#p#197#193#article#214#14#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">14. New York University,  
  Medical Center. Impactor. NYU Spinal cord contusion system. Operation manual. 
   Impactor software version 7.0. New York; 1993.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#198#194#article#214#</font></p>     ^cY#03.h
tm##
00505000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026600074002000700340#v19
n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#p#199#195#article#214#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Rodrigues NR.    Padro
niza&ccedil;&atilde;o da les&atilde;o medular espinal em ratos Wistar &#91;tese&
#93;.    S&atilde;o Paulo: Faculdade de Medicina, Universidade de S&atilde;o Pau
lo; 1999.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#200#196#article#214#</font></p>     ^cY#03.h
tm##
00388000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704014900074002000700223#v19
n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#p#201#197#article#214#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Young W. Spinal    cor
d contusion models. Prog Brain Res. 2002;137:231-55;    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#202#198#article#214#</font></p>     ^cY#03.h
tm##
00578000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033900074002000700413#v19
n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#p#203#199#article#214#17#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Col&eacute;gio    Bras
ileiro de Experimenta&ccedil;&atilde;o Animal - COBEA. Legisla&ccedil;&atilde;o 
   e &Eacute;tica, 1999. Dispon&iacute;vel em URL: <a href="http://www.meusite.c
om.br/COBEA/etica.htm;" target="_blank">http://www.meusite.com.br/COBEA/etica.ht
m;    ^cY#03.htm##
00248000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002400071002000700095#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#204#200#article#214#</a></font></p>     ^cY#
03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#205#201#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#206#202#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00430000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704020600071002000700277#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#207#203#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top"><img sr
c="/img/revistas/aob/v19n1/seta.jpg" border="0"></a>    <b>Endereço para Corresp
ondência:</b>     ^cY#03.htm##
00272000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004800071002000700119#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#208#204#article#214#<br>   Alexandre Foga&cc
edil;a Cristante    ^cY#03.htm##
00289000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704006500071002000700136#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#209#205#article#214#<br>   Rua Ov&iacute;dio
 Pires de Campos, 333 - 3º. Andar    ^cY#03.htm##
00253000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002900071002000700100#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#210#206#article#214#<br>   CEP: 05403-010   
 ^cY#03.htm##
00261000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003700071002000700108#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#211#207#article#214#<br>   Cerqueira C&eacut
e;sar    ^cY#03.htm##
00263000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003900071002000700110#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#212#208#article#214#<br>   S&atilde;o Paulo.
 Brasil    ^cY#03.htm##
00325000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704010100071002000700172#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#213#209#article#214#<br>   E-mail: <a href="
mailto:aacristante@uol.com.br">aacristante@uol.com.br</a></font></p>     ^cY#03.
htm##
00359000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013500071002000700206#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#214#210#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Artigo recebido    em 17/09/09, aprovado 
em 23/11/09</font></p>     ^cY#03.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#215#211#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#216#212#article#214#<p>&nbsp;</p>     ^cY#03
.htm##
00359000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013500071002000700206#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#217#213#article#214#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Trabalho realizado    no Instituto de Ort
opedia e Traumatologia.    ^cY#03.htm##
00361000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013700071002000700208#v19n1#V:\SciELO
\serial\aob\v19n1\markup\03.htm#S#p#218#214#article#214#<br>   Todos os autores 
declaram n&atilde;o haver nenhum potencial conflito de interesses    referente a
 este artigo.</font></p>     ^cY#03.htm##
00479000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100020000700100017000900120
03200107030000600139065000900145064000500154031000300159014000700162865000900169
002000700178035001000185801000600195#v19n1#V:\SciELO\serial\aob\v19n1\markup\03.
htm#S#c#219#1#article#17#1#^rND^sWeinstein^nJN#^rND^sMclain^nRF#Primary tumors o
f the spine^len#Spine#19870000#1987#12#843-51#20110000#03.htm#0362-2436#SPINE##
00604000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100015000700100015000850100
02000100010001700120012012200137030001300259710000200272065000900274064000500283
031000300288014000700291865000900298002000700307#v19n1#V:\SciELO\serial\aob\v19n
1\markup\03.htm#S#c#220#2#article#17#2#^rND^sGupta^nA#^rND^sTaly^nAB#^rND^sSriva
stava^nA#^rND^sMurali^nT.#Non-traumatic spinal cord lesions: epidemiology, compl
ications, neurological and functional outcome of rehabilitation^len#Spinal Cord.
#2#20090000#2009#47#307-11#20110000#03.htm##
00540000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100019000860100
02400105012007800129030001700207710000200224065000900226064000500235031000200240
014000400242865000900246002000700255#v19n1#V:\SciELO\serial\aob\v19n1\markup\03.
htm#S#c#221#3#article#17#3#^rND^sJorge^nFF#^rND^sBalbani^nAPS#^rND^sBarros Filho
^nTEP#Trauma raquimedular: aspectos epidemiológicos, impacto social e prevenção^
lpt#Acta Ortop Bras.#2#19950000#1995#3#1-4#20110000#03.htm##
00512000000000241000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100024000700120106000940300
03500200710000200235065000900237064000500246032000300251865000900254002000700263
#v19n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#c#222#4#article#17#4#^rND^sBar
ros Filho^nTE.#Campanha "Cuidado ao Mergulhar": Campanha de prevenção das fratur
as de coluna provocadas pro mergulho^lpt#Folha de Ortopedia e Traumatologia#2#19
990000#1999#32#20110000#03.htm##
00507000000000253000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100026000700120093000960300
02500189710000200214065000900216064000500225031000200230014000500232865000900237
002000700246#v19n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#c#223#5#article#17
#5#^rND^sD'Andrea Greve^nJM.#Traumatismos raquimedulares nos acidentes de trânsi
to e uso de equipamentos de segurança^lpt#Diagnóstico & Tratamento#2#19970000#19
97#2#10-3#20110000#03.htm##
00448000000000253000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100020000700120044000900300
01700134710000200151065000900153064000500162031000400167014000700171865000900178
002000700187#v19n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#c#224#6#article#17
#6#^rND^sRaineteau^nO.#Plastic responses to spinal cord injury^len#Behav Brain R
es.#2#20080000#2008#192#114-23#20110000#03.htm##
00701000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100017000870100
01700104010001800121010001600139010001700155810000700172012012300179030000600302
06500090030806400050031703100030032201400060032586500090033100200070034003500100
0347801000600357#v19n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#c#225#7#articl
e#17#7#^rND^sBrissot^nR#^rND^sGallien^nP#^rND^sLe Bot^nMP#^rND^sBeaubras^nA#^rND
^sLaisne^nD#^rND^sBeillot^nJ#et al.#Clinical experience with functional electric
al stimulation-assisted gait with Parastep in spinal cord-injured patients^len#S
pine#20000000#2000#25#501-8#20110000#03.htm#0362-2436#SPINE##
00590000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100019000880100
01900107010001600126012008500142030000600227065000900233064000500242031000300247
014000600250865000900256002000700265035001000272801000600282#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\03.htm#S#c#226#8#article#17#8#^rND^sLeypold^nBG#^rND^sFland
ers^nAE#^rND^sSchwartz^nED#^rND^sBurns^nAS#The impact of methylprednisolone on l
esion severity following spinal cord injury^len#Spine#20070000#2007#32#373-8#201
10000#03.htm#0362-2436#SPINE##
00430000000000253000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700120041000870300
00800128710000200136065000900138064000500147031000300152014000500155865000900160
002000700169#v19n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#c#227#9#article#17
#9#^rND^sBiddle^nC.#Oxygen: the two-faced elixir of life^len#AANA J.#2#20080000#
2008#76#61-8#20110000#03.htm##
00713000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100018000880100
01800106010001800124010001800142012019800160030001200358710000200370065000900372
064000500381031000300386014000600389865000900395002000700404#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\03.htm#S#c#228#10#article#17#10#^rND^sBunge^nRP#^rND^sPucke
tt^nWR#^rND^sBecerra^nJL#^rND^sMarcillo^nA#^rND^sQuencer^nRM#Observations on the
 pathology of human spinal cord injury: a review and classification of 22 new ca
ses with details in from a case of chronic cord compression with extensive focal
 demyelination^len#Adv Neurol.#2#19930000#1993#59#75-89#20110000#03.htm##
00552000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720120137000890300
00500226065000900231064000500240031000300245014000700248865000900255002000700264
035001000271801000500281#v19n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#c#229#
11#article#17#11#^rND^sAllen^nAR.#Surgery of experimental lesion of spinal cord 
equivalent to crush injury fracture dislocation of spinal column: a preliminary 
report^len#JAMA#19110000#1911#57#878-80#20110000#03.htm#0098-7484#JAMA##
00543000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100018000880100
02100106012008300127030001500210710000200225065000900227064000500236031000300241
014000500244865000900249002000700258#v19n1#V:\SciELO\serial\aob\v19n1\markup\03.
htm#S#c#230#12#article#17#12#^rND^sBasso^nDM#^rND^sBeattie^nMS#^rND^sBresnahan^n
JC.#A sensitive and reliable locomotor rating scale for open field testing in ra
ts^len#J Neurotrauma.#2#19950000#1995#12#1-21#20110000#03.htm##
00451000000000253000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720120050000930300
01200143710000200155065000900157064000500166031000300171014000700174865000900181
002000700190#v19n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#c#231#13#article#1
7#13#^rND^sBalentine^nJD.#Pathology of experirnental spinal cord trauma^len#Lab 
Invest.#2#19780000#1978#39#236-53#20110000#03.htm##
00461000000000217000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690170036000720180096001080660
00900204065000900213064000500222865000900227002000700236#v19n1#V:\SciELO\serial\
aob\v19n1\markup\03.htm#S#c#232#14#article#17#14#New York University^dMedical Ce
nter#Impactor. NYU Spinal cord contusion system: Operation manual. Impactor soft
ware version 7.0^len#New York#19930000#1993#20110000#03.htm##
00470000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160021000720180058000930660
01000151062004900161065000900210064000500219865000900224002000700233#v19n1#V:\Sc
iELO\serial\aob\v19n1\markup\03.htm#S#c#233#15#article#17#15#^rND^sRodrigues^nNR
.#Padronização da lesão medular espinal em ratos Wistar^lpt#São Paulo#Faculdade 
de Medicina, Universidade de São Paulo#19990000#1999#20110000#03.htm##
00434000000000253000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720120033000880300
01600121710000200137065000900139064000500148031000400153014000700157865000900164
002000700173#v19n1#V:\SciELO\serial\aob\v19n1\markup\03.htm#S#c#234#16#article#1
7#16#^rND^sYoung^nW.#Spinal cord contusion models^len#Prog Brain Res.#2#20020000
#2002#137#231-55#20110000#03.htm##
00430000000000217000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690170044000720180023001160650
00900139064000500148037004300153865000900196002000700205#v19n1#V:\SciELO\serial\
aob\v19n1\markup\03.htm#S#c#235#17#article#17#17#Colégio Brasileiro de Experimen
tação Animal#Legislação e Ética^lpt#19990000#1999#http://www.meusite.com.br/COBE
A/etica.htm;#20110000#03.htm##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v19n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#o#1#1#article#1#201104
11#111841#04.htm#144##
03416000000000649000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000500083038000400088121000300092049000700095158000300102
03000180010503100030012303200020012606500090012801400090013703500100014601200990
01560120122002550100026003770100041004030100033004440100030004770100036005070100
02500543070003900568083096600607085000801573085002201581085002501603085001901628
08500300164708309340167708500080261108500230261908500250264208500170266708500300
26841170006027140720003027201120009027231110009027321140009027411130009027500020
00702759#v19n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#h#2#1#article#1#oa#pt#
br1.1#1#4.0#ILUS#TAB#04#AOB140#nd#Acta ortop. bras.#19#1#20110000#^f17^l21#1413-
7852#Avaliação da altura patelar em atletas com tendinopatia crônica do aparelho
 extensor do joelho^lpt#Evaluation of the patellar height in athletes with diagn
osed with chronic tendinopathy of the knee extensor mechanism^len#^rND^1A01^nEme
rson^sGarms#^rND^1A01^nRogério Teixeira de^sCarvalho#^rND^1A01^nLeonardo Addeo^s
Ramos#^rND^1A01^nJorge^sSayum Filho#^rND^1A01^nMarcelo Mitsuro^sMatsuda#^rND^1A0
1^nMoisés^sCohen#Universidade Federal de São Paulo^iA01#^lpt^aOBJETIVO: Avaliar 
radiograficamente a altura patelar de atletas com diagnóstico de tendinopatia cr
ônica do aparelho extensor do joelho (TCAE). MÉTODOS: Na amostra foram avaliados
 radiograficamente 65 pacientes (110 joelhos) com idade entre 15 e 40 anos e de 
diferentes modalidades esportivas com e sem diagnóstico de tendinopatia crônica 
do aparelho extensor do joelho (jumper's knee). Os atletas foram divididos em do
is grupos: aqueles com diagnóstico de TCAE (grupo 1: 38 atletas - 56 joelhos) e 
um grupo que denominamos de controle (grupo 2: 27 atletas - 54 joelhos). RESULTA
DOS: No grupo 1 tivemos 18 atletas que apresentavam a doença bilateralmente na o
casião dos exames. Para a medida da altura patelar utilizamos os índices radiogr
áficos de Insall e Salvati e Blackburne e Peel. CONCLUSÃO: A presença de patela 
alta no grupo de atletas com tendinopatia crônica do aparelho extensor do joelho
 foi significante maior do que a observada no grupo controle.#^dnd^i1#^tm^lpt^kA
valiação^i1#^tm^lpt^kTendinopatia^i1#^tm^lpt^kJoelho^i1#^tm^lpt^kLesões em atlet
as^i1#^len^aOBJECTIVES: To carry out a radiographic evaluation of patellar heigh
t in athletes diagnosed with chronic tendinopathy of the knee extensor mechanism
; METHODS: Radiographic assessments were carried out on 65 patients (110 knees) 
aged between 15 and 40 years, who practiced different kinds of sports, some with
 of chronic tendinopathy of the knee extensor mechanism (jumper's knee) and othe
rs without. The athletes were divided into two groups: those with diagnosed "jum
per's knee" (group 1:38 athletes - 56 knees) and a control group (group 2:27 ath
letes - 54 knees). In group 1, 18 of the athletes presented the condition in bot
h knees on examination. The height of the patella was measured using the Insall-
Salvati and Blackburne-Peel x-ray methods. CONCLUSION: The presence of a high pa
tella in the group of athletes with chronic tendinopathy of the knee extensor me
chanism was significantly higher than in the control group.#^dnd^i2#^tm^len^kEva
luation^i2#^tm^len^kTendinopathy^i2#^tm^len^kKnee^i2#^tm^len^kAthletic injuries^
i2#other#16#20090109#09/01/09#20100122#22/01/10#04.htm##
03493000000000649000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000500083038000400088121000300092049000700095158000300102
03000180010503100030012303200020012606500090012801400090013703500100014601201060
01560120129002620100026003910100041004170100033004580100030004910100036005210100
02500557070003900582083100800621085000801629085002201637085002501659085001901684
08500300170308309550173308500080268808500230269608500250271908500170274408500300
27611170006027910720003027971120009028001110009028091140009028181130009028270020
00702836#v19n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#f#3#1#article#1#oa#pt#
br1.1#1#4.0#ILUS#TAB#04#AOB140#nd#Acta ortop. bras.#19#1#20110000#^f17^l21#1413-
7852#<b>Avaliação da altura patelar em atletas com tendinopatia crônica do apare
lho extensor do joelho</b>^lpt#<b>Evaluation of the patellar height in athletes 
with diagnosed with chronic tendinopathy of the knee extensor mechanism</b>^len#
^rND^1A01^nEmerson^sGarms#^rND^1A01^nRogério Teixeira de^sCarvalho#^rND^1A01^nLe
onardo Addeo^sRamos#^rND^1A01^nJorge^sSayum Filho#^rND^1A01^nMarcelo Mitsuro^sMa
tsuda#^rND^1A01^nMoisés^sCohen#Universidade Federal de São Paulo^iA01#^lpt^a<b>O
BJETIVO:</b> Avaliar radiograficamente a altura patelar de atletas com diagnósti
co de tendinopatia crônica do aparelho extensor do joelho (TCAE).<b> MÉTODOS:</b
> Na amostra foram avaliados radiograficamente 65 pacientes (110 joelhos) com id
ade entre 15 e 40 anos e de diferentes modalidades esportivas com e sem diagnóst
ico de tendinopatia crônica do aparelho extensor do joelho (jumper's knee). Os a
tletas foram divididos em dois grupos: aqueles com diagnóstico de TCAE (grupo 1:
 38 atletas - 56 joelhos) e um grupo que denominamos de controle (grupo 2: 27 at
letas - 54 joelhos). <b>RESULTADOS:</b> No grupo 1 tivemos 18 atletas que aprese
ntavam a doença bilateralmente na ocasião dos exames. Para a medida da altura pa
telar utilizamos os índices radiográficos de <i>Insall e Salvati</i> e <i>Blackb
urne e Peel</i>. <b>CONCLUSÃO:</b> A presença de patela alta no grupo de atletas
 com tendinopatia crônica do aparelho extensor do joelho foi significante maior 
do que a observada no grupo controle.#^dnd^i1#^tm^lpt^kAvaliação^i1#^tm^lpt^kTen
dinopatia^i1#^tm^lpt^kJoelho^i1#^tm^lpt^kLesões em atletas^i1#^len^a<b>OBJECTIVE
S:</b> To carry out a radiographic evaluation of patellar height in athletes dia
gnosed with chronic tendinopathy of the knee extensor mechanism; <b>METHODS:</b>
 Radiographic assessments were carried out on 65 patients (110 knees) aged betwe
en 15 and 40 years, who practiced different kinds of sports, some with of chroni
c tendinopathy of the knee extensor mechanism (jumper's knee) and others without
. The athletes were divided into two groups: those with diagnosed "jumper's knee
" (group 1:38 athletes - 56 knees) and a control group (group 2:27 athletes - 54
 knees). In group 1, 18 of the athletes presented the condition in both knees on
 examination. The height of the patella was measured using the Insall-Salvati an
d Blackburne-Peel x-ray methods. <b>CONCLUSION:</b> The presence of a high patel
la in the group of athletes with chronic tendinopathy of the knee extensor mecha
nism was significantly higher than in the control group.#^dnd^i2#^tm^len^kEvalua
tion^i2#^tm^len^kTendinopathy^i2#^tm^len^kKnee^i2#^tm^len^kAthletic injuries^i2#
other#16#20090109#09/01/09#20100122#22/01/10#04.htm##
03537000000000673000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000500090038000400095121000300099049000700102
15800030010903000170011203100030012903200020013206500090013401400090014303500100
01520120099001620120122002610100026003830100041004090100033004500100030004830100
03600513010002500549070004100574083096600615085000801581085002201589085002501611
08500190163608500300165508309340168508500080261908500230262708500250265008500170
26750850030026921170006027220720003027281120009027311110009027401140009027491130
00902758002000702767008008902774#v19n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#
S#l#4#1#article#1#^a2011#oa#pt#br1.1#1#4.0#ilus#tab#04#AOB140#nd#Acta ortop. bra
s#19#1#20110000#^f17^l21#1413-7852#Avaliação da altura patelar em atletas com te
ndinopatia crônica do aparelho extensor do joelho^lpt#Evaluation of the patellar
 height in athletes with diagnosed with chronic tendinopathy of the knee extenso
r mechanism^len#^rND^1A01^nEmerson^sGarms#^rND^1A01^nRogério Teixeira de^sCarval
ho#^rND^1A01^nLeonardo Addeo^sRamos#^rND^1A01^nJorge^sSayum Filho#^rND^1A01^nMar
celo Mitsuro^sMatsuda#^rND^1A01^nMoisés^sCohen#^iA01^1Universidade Federal de Sã
o Paulo#^lpt^aOBJETIVO: Avaliar radiograficamente a altura patelar de atletas co
m diagnóstico de tendinopatia crônica do aparelho extensor do joelho (TCAE). MÉT
ODOS: Na amostra foram avaliados radiograficamente 65 pacientes (110 joelhos) co
m idade entre 15 e 40 anos e de diferentes modalidades esportivas com e sem diag
nóstico de tendinopatia crônica do aparelho extensor do joelho (jumper's knee). 
Os atletas foram divididos em dois grupos: aqueles com diagnóstico de TCAE (grup
o 1: 38 atletas - 56 joelhos) e um grupo que denominamos de controle (grupo 2: 2
7 atletas - 54 joelhos). RESULTADOS: No grupo 1 tivemos 18 atletas que apresenta
vam a doença bilateralmente na ocasião dos exames. Para a medida da altura patel
ar utilizamos os índices radiográficos de Insall e Salvati e Blackburne e Peel. 
CONCLUSÃO: A presença de patela alta no grupo de atletas com tendinopatia crônic
a do aparelho extensor do joelho foi significante maior do que a observada no gr
upo controle.#^dnd^i1#^tm^lpt^kAvaliação^i1#^tm^lpt^kTendinopatia^i1#^tm^lpt^kJo
elho^i1#^tm^lpt^kLesões em atletas^i1#^len^aOBJECTIVES: To carry out a radiograp
hic evaluation of patellar height in athletes diagnosed with chronic tendinopath
y of the knee extensor mechanism; METHODS: Radiographic assessments were carried
 out on 65 patients (110 knees) aged between 15 and 40 years, who practiced diff
erent kinds of sports, some with of chronic tendinopathy of the knee extensor me
chanism (jumper's knee) and others without. The athletes were divided into two g
roups: those with diagnosed "jumper's knee" (group 1:38 athletes - 56 knees) and
 a control group (group 2:27 athletes - 54 knees). In group 1, 18 of the athlete
s presented the condition in both knees on examination. The height of the patell
a was measured using the Insall-Salvati and Blackburne-Peel x-ray methods. CONCL
USION: The presence of a high patella in the group of athletes with chronic tend
inopathy of the knee extensor mechanism was significantly higher than in the con
trol group.#^dnd^i2#^tm^len^kEvaluation^i2#^tm^len^kTendinopathy^i2#^tm^len^kKne
e^i2#^tm^len^kAthletic injuries^i2#other#16#20090109#09/01/09#20100122#22/01/10#
04.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-78
522011000100004##
00343000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704012300067002000700190#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#5#1#article#124#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTIGO    ORIGINAL</b> </fon
t></p>     ^cY#04.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#6#2#article#124#<p>&nbsp;</p>     ^cY#04.htm
##
00448000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704022800067002000700295#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#7#3#article#124#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Avalia&ccedil;&atilde;o 
   da altura patelar em atletas com tendinopatia cr&ocirc;nica do aparelho exten
sor    do joelho</b></font></p>     ^cY#04.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#8#4#article#124#<p>&nbsp;</p>     ^cY#04.htm
##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#9#5#article#124#<p>&nbsp;</p>     ^cY#04.htm
##
00454000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704023300068002000700301#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#10#6#article#124#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Emerson Garms;    Rog&eacute;rio Teixeira
 de Carvalho; Leonardo Addeo Ramos; Jorge Sayum Filho;    Marcelo Mitsuro Matsud
a; Mois&eacute;s Cohen</b></font></p>     ^cY#04.htm##
00347000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704012600068002000700194#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#11#7#article#124#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2">Universidade Federal    de S&atilde;o Paulo<
/font></p>     ^cY#04.htm##
00369000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704014800068002000700216#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#12#8#article#124#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><a href="#back">Endere&ccedil;o    para Corr
espond&ecirc;ncia</a></font></p>     ^cY#04.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#13#9#article#124#<p>&nbsp;</p>     ^cY#04.ht
m##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#14#10#article#124#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#04.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#15#11#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#04.htm##
00464000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704024200069002000700311#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#16#12#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Avaliar radiograficamen
te a altura patelar de atletas com diagn&oacute;stico    de tendinopatia cr&ocir
c;nica do aparelho extensor do joelho (TCAE).<b>    ^cY#04.htm##
00710000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704048800069002000700557#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#17#13#article#124#<br>   M&Eacute;TODOS:</b>
 Na amostra foram avaliados radiograficamente 65 pacientes    (110 joelhos) com 
idade entre 15 e 40 anos e de diferentes modalidades esportivas    com e sem dia
gn&oacute;stico de tendinopatia cr&ocirc;nica do aparelho extensor    do joelho 
(jumper's knee). Os atletas foram divididos em dois grupos: aqueles    com diagn
&oacute;stico de TCAE (grupo 1: 38 atletas - 56 joelhos) e um grupo    que denom
inamos de controle (grupo 2: 27 atletas - 54 joelhos).    ^cY#04.htm##
00509000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704028700069002000700356#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#18#14#article#124#<br>   <b>RESULTADOS:</b> 
No grupo 1 tivemos 18 atletas que apresentavam a doen&ccedil;a    bilateralmente
 na ocasi&atilde;o dos exames. Para a medida da altura patelar    utilizamos os 
&iacute;ndices radiogr&aacute;ficos de <i>Insall e Salvati</i>    e <i>Blackburn
e e Peel</i>.    ^cY#04.htm##
00455000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704023300069002000700302#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#19#15#article#124#<br>   <b>CONCLUS&Atilde;O
:</b> A presen&ccedil;a de patela alta no grupo de atletas    com tendinopatia c
r&ocirc;nica do aparelho extensor do joelho foi significante    maior do que a o
bservada no grupo controle.</font></p>     ^cY#04.htm##
00422000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704020000069002000700269#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#20#16#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Descritores:</b>    Avalia&ccedil;&atild
e;o. Tendinopatia. Joelho. Les&otilde;es em atletas.</font></p> <hr size="1" nos
hade>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#21#17#article#124#<p>&nbsp;</p>     ^cY#04.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#22#18#article#124#<p>&nbsp;</p>     ^cY#04.h
tm##
00336000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011400069002000700183#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#23#19#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b></font></p> 
    ^cY#04.htm##
01343000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704112100069002000701190#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#24#20#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A tendinopatia    cr&ocirc;nica do aparelho
 extensor do joelho ("jumper's knee") &eacute; uma    das afec&ccedil;&otilde;es
 frequentes do joelho em atletas que praticam regularmente    alguma atividade e
sportiva. Em n&iacute;veis competitivos ou recreativos, pode    acarretar les&ot
ilde;es e afastamento tempor&aacute;rio do atleta. Esta afec&ccedil;&atilde;o   
 &eacute; clinicamente definida como uma condi&ccedil;&atilde;o de sobrecarga   
 cr&ocirc;nica do mecanismo extensor do joelho, decorrentes de traumas repetitiv
os.    O paciente apresenta dor anterior no joelho que geralmente melhora com o 
repouso,    e que reaparece com a atividade esportiva.<sup>1,2</sup> A alta inci
d&ecirc;ncia    da tendinopatia do tend&atilde;o patelar em atletas de voleibol 
vem de longa    data.<sup>3</sup> A denomina&ccedil;&atilde;o "jumper's knee" ad
iciona a les&atilde;o    do tend&atilde;o quadricipital e auxilia na classifica&
ccedil;&atilde;o das    tendinopatias do aparelho extensor quanto ao est&aacute;
gio de comprometimento.<sup>4</sup></font></p>     ^cY#04.htm##
00873000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704065100069002000700720#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#25#21#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Uma das hip&oacute;teses    para a g&ecirc;
nese da les&atilde;o &eacute; o atrito repetitivo entre o &aacute;pice    da pat
ela e a face posterior do tend&atilde;o patelar relacionado aos movimentos    co
m desacelera&ccedil;&atilde;o e frenagem, e n&atilde;o somente ao salto como    
descrito previamente.<sup>3,4</sup> Determinadas modalidades esportivas que    e
nvolvem movimentos repetidos como o chute, a corrida, o salto, flex&otilde;es   
 repetidas e rota&ccedil;&atilde;o do joelho podem apresentar fatores que favore
&ccedil;am    o aparecimento da les&atilde;o.</font></p>     ^cY#04.htm##
01000000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704077800069002000700847#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#26#22#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Nos pacientes que    n&atilde;o praticam at
ividade esportiva, os fatores intr&iacute;nsecos considerados    predisponentes 
para a les&atilde;o como: o aumento do &acirc;ngulo quadricipital    (Q), altera
&ccedil;&otilde;es da altura patelar, a tor&ccedil;&atilde;o tibial    externa, 
a tor&ccedil;&atilde;o femoral interna, as instabilidades f&ecirc;muro-patelares
,    a prona&ccedil;&atilde;o do p&eacute;.<sup>5</sup> Em atletas, particularme
nte,    devido aos movimentos repetidos do esporte, a altera&ccedil;&atilde;o da
 altura    patelar &eacute; um fator predisponente ao aparecimento da les&atilde
;o, pois    a biomec&acirc;nica articular nestes casos encontra-se comprometida.
<sup>6</sup></font></p>     ^cY#04.htm##
00574000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704035200069002000700421#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#27#23#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A associa&ccedil;&atilde;o    entre patela 
alta e tendinopatia cr&ocirc;nica do aparelho extensor do joelho,    al&eacute;m
 de ser um fator predisponente causa sintomas e danos no joelho do    atleta mes
mo ap&oacute;s o t&eacute;rmino da carreira esportiva.<sup>7</sup></font></p>   
  ^cY#04.htm##
00554000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704033200069002000700401#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#28#24#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O objetivo desse    estudo transversal cons
iste na avalia&ccedil;&atilde;o radiogr&aacute;fica (incid&ecirc;ncias:    anter
oposterior e perfil a 30 graus) da altura patelar em atletas com tendinopatia   
 cr&ocirc;nica do aparelho extensor do joelho.</font></p>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#29#25#article#124#<p>&nbsp;</p>     ^cY#04.h
tm##
00341000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011900069002000700188#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#30#26#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>MATERIAIS E    M&Eacute;TODOS</b></font>
</p>     ^cY#04.htm##
01276000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704105400069002000701123#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#31#27#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Esse estudo transversal    foi realizado no
 per&iacute;odo entre janeiro de 2006 e julho de 2007 e foi    aprovado pelo com
it&ecirc; de &eacute;tica em pesquisa da institui&ccedil;&atilde;o.    Os atleta
s foram divididos em dois grupos: aqueles com diagn&oacute;stico de    tendinopa
tia cr&ocirc;nica do aparelho extensor, denominamos de grupo de estudo    (grupo
 1: 38 atletas - 56 joelhos) e um grupo controle (grupo 2: 27 atletas,    54 joe
lhos). A amostra apresentava 65 atletas (110 joelhos), com idade que variou    d
e 15 a 36 anos (26,1 ± 5,5 anos) no grupo controle e de 20 a 40 anos (26,7    ± 
5,6 anos) no grupo de estudo. Todos os atletas estavam envolvidos em atividades 
   esportivas regulares, sendo que vinte e oito praticavam atletismo, nove futeb
ol,    cinco basquetebol, cinco muscula&ccedil;&atilde;o, cinco voleibol, quatro
 handebol,    dois t&ecirc;nis de mesa, dois softbol, dois karat&ecirc;, um taek
ondo, um nata&ccedil;&atilde;o    e um capoeira.</font></p>     ^cY#04.htm##
02149000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704192700069002000701996#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#32#28#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Os pacientes tanto    do grupo um quanto do
 grupo dois eram atletas amadores com uma rotina de treinamento    de duas horas
 di&aacute;rias, em m&eacute;dia, por tr&ecirc;s vezes na semana,    excluindo-s
e os campeonatos. O grupo um foi composto por 38 pacientes com diagn&oacute;stic
o    de tendinopatia cr&ocirc;nica do aparelho extensor do joelho, sendo que 18 
deles    apresentavam comprometimento bilateral. O diagn&oacute;stico foi cl&iac
ute;nico    e por imagem(radiografias, ultrasonografia e resson&acirc;ncia magn&
eacute;tica).    Todos os atletas inclu&iacute;dos no estudo apresentavam uma hi
st&oacute;ria    de dor no mecanismo extensor do joelho h&aacute; mais de um m&e
circ;s e de car&aacute;ter    evolutivo. O s&iacute;tio de dor foi determinado p
ela palpa&ccedil;&atilde;o    dolorosa do &aacute;pice da patela, tend&atilde;o 
quadriciptal em sua inser&ccedil;&atilde;o    na patela, corpo do tend&atilde;o 
patelar ou no local de inser&ccedil;&atilde;o    do tend&atilde;o patelar na tub
erosidade da t&iacute;bia, conforme t&eacute;cnica    previamente descrita.<sup>
3</sup> O exame de palpa&ccedil;&atilde;o foi efetuada    pelo mesmo examinador 
(E. G.). O grupo dois, grupo controle, foi composto por    27 atletas sem nenhum
 tipo de queixa de dor na regi&atilde;o do joelho. Foram    exclu&iacute;dos do 
estudo atletas que apresentavam hist&oacute;ria pr&eacute;via    de les&atilde;o
 no joelho documentada por exames de imagem (radiografias), osteocondrites    co
mo a doen&ccedil;a de Osgood-Schlatter, tendinites calcificantes, ou aqueles    
que tenham sido submetidos a tratamento cir&uacute;rgico do joelho. Foi feita   
 avalia&ccedil;&atilde;o radiogr&aacute;fica de 110 joelhos, sendo 56 no grupo  
  de estudo e 54 no grupo controle. Os dados do grupo de estudo s&atilde;o apres
entados    na <a href="#t1">Tabela 1</a>.</font></p>     ^cY#04.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#33#29#article#124#<p><a name="t1"></a></p>  
   ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#34#30#article#124#<p>&nbsp;</p>     ^cY#04.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#35#31#article#124#<p align="center"><img src
="/img/revistas/aob/v19n1/04t01.jpg"></p>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#36#32#article#124#<p>&nbsp;</p>     ^cY#04.h
tm##
01184000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704096200069002000701031#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#37#33#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O diagn&oacute;stico    de tendinopatia cr&
ocirc;nica do aparelho estensor do joelho foi hist&oacute;ria    cl&iacute;nica 
e dor &agrave; palpa&ccedil;&atilde;o no p&oacute;lo inferior    da patela, tend
&atilde;o patelar ou inser&ccedil;&atilde;o do tend&atilde;o    quadricipital. P
ara a realiza&ccedil;&atilde;o das medidas de altura patelar    foram realizadas
 radiografias, na incid&ecirc;ncia de perfil (lateral) dos joelhos    com flex&a
tilde;o de 30º, conforme t&eacute;cnica previamente citada.<sup>4</sup>    (<a h
ref="#f1">Figura 1</a>) A altura patelar foi medida pelo mesmo examinador,    de
 acordo com dois m&eacute;todos: um descrito por Insall e Salvati apud Roels    
<i>et al.</i><sup>4</sup> e outro por Blackburne e Peel,<sup>8</sup> tendo como 
   refer&ecirc;ncia para estabelecer a patela alta os valores acima de 1,2 e 0,9
6,    respectivamente.<sup>4,8</sup></font></p>     ^cY#04.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#38#34#article#124#<p><a name="f1"></a></p>  
   ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#39#35#article#124#<p>&nbsp;</p>     ^cY#04.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#40#36#article#124#<p align="center"><img src
="/img/revistas/aob/v19n1/04f01.jpg"></p>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#41#37#article#124#<p>&nbsp;</p>     ^cY#04.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#42#38#article#124#<p>&nbsp;</p>     ^cY#04.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#43#39#article#124#<p align="center"><img src
="/img/revistas/aob/v19n1/04f02.jpg"></p>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#44#40#article#124#<p>&nbsp;</p>     ^cY#04.h
tm##
00485000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704026300069002000700332#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#45#41#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A an&aacute;lise    estat&iacute;stica foi 
realizada, comparando-se os grupos e foram utilizados    para tal, o teste <i>t 
de Student</i> e o teste do Qui-Quadrado, com p&lt;0,001.</font></p>     ^cY#04.
htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#46#42#article#124#<p>&nbsp;</p>     ^cY#04.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#47#43#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>     ^cY#04.htm
##
00937000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704071500069002000700784#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#48#44#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">No grupo de estudo,    17 (30,4%) joelhos a
presentaram altura normal de patela nos dois &iacute;ndices,    seis (10,7%) joe
lhos apresentaram patela alta, pelo &iacute;ndice de Insall    e Salvati e norma
l pelo &iacute;ndice de Blackburne e Peel, 13 (23,2%) joelhos    apresentaram al
tura normal de patela pelo &iacute;ndice de Insall e Salvati    e presen&ccedil;
a pelo &iacute;ndice de Blackburne e Peel e 20 (35,7%) joelhos    apresentaram p
atela alta nos dois &iacute;ndices. Dessa forma, no grupo de estudo    foram obt
idos 39 (69,6%) joelhos com patela alta determinados por pelo menos    um dos do
is &iacute;ndices utilizados.</font></p>     ^cY#04.htm##
00948000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704072600069002000700795#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#49#45#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">No grupo controle,    42 (77,8%) joelhos ap
resentaram alturas normais das patelas nos dois &iacute;ndices,    tr&ecirc;s (5
,6%) joelhos apresentaram patela alta pelo &iacute;ndice de Insall    e Salvati 
e normal pelo &iacute;ndice de Blackburne e Peel, 7 (13%) joelhos    apresentara
m alturas normais das patelas pelo &iacute;ndice de Insall e Salvati    e presen
&ccedil;a pelo &iacute;ndice de Blackburne e Peel, e dois (3,7%) joelhos    apre
sentaram patela alta pelos dois &iacute;ndices. Dessa forma, no grupo controle  
  foram obtidos 12 (22,2%) joelhos com patela alta determinados por pelo menos  
  um dos dois &iacute;ndices utilizados.</font></p>     ^cY#04.htm##
00433000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704021100069002000700280#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#50#46#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Os dados comparativos    das alturas patela
res s&atilde;o apresentados nas <a href="#t2">Tabelas 2</a>    e <a href="#t3">3
</a>.</font></p>     ^cY#04.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#51#47#article#124#<p><a name="t2"></a></p>  
   ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#52#48#article#124#<p>&nbsp;</p>     ^cY#04.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#53#49#article#124#<p align="center"><img src
="/img/revistas/aob/v19n1/04t02.jpg"></p>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#54#50#article#124#<p>&nbsp;</p>     ^cY#04.h
tm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#55#51#article#124#<p><a name="t3"></a></p>  
   ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#56#52#article#124#<p>&nbsp;</p>     ^cY#04.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#57#53#article#124#<p align="center"><img src
="/img/revistas/aob/v19n1/04t03.jpg"></p>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#58#54#article#124#<p>&nbsp;</p>     ^cY#04.h
tm##
00418000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704019600069002000700265#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#59#55#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Os grupos se mostraram    homog&ecirc;neos 
quanto ao sexo e idade (P&gt;0,05 em ambas compara&ccedil;&otilde;es).</font></p
>     ^cY#04.htm##
00548000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704032600069002000700395#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#60#56#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A m&eacute;dia    de altura patelar, avalia
da pelo &iacute;ndice de <i>Insall e Salvati</i>, do    grupo de estudo foi sign
ificantemente maior que a m&eacute;dia do grupo controle    (p&lt;0,001), 1,175 
± 0,162 e 1,063 ± 0,104 respectivamente.</font></p>     ^cY#04.htm##
00540000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704031800069002000700387#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#61#57#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O grupo de estudo    apresentou patela alta
, segundo o &iacute;ndice de <i>Insall e Salvati</i>,    significantemente maior
 que o grupo controle (p&lt;0,001), com 46,4% de presen&ccedil;a    no grupo de 
estudo e 9,3% no grupo controle.</font></p>     ^cY#04.htm##
00550000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704032800069002000700397#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#62#58#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A m&eacute;dia    de altura patelar, avalia
da pelo &iacute;ndice de <i>Blackburne e Peel</i>,    do grupo de estudo foi sig
nificantemente maior que a m&eacute;dia do grupo controle    (p&lt;0,001), 1,003
 ± 0,159 e 0,883 ± 0,133, respectivamente.</font></p>     ^cY#04.htm##
00571000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704034900069002000700418#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#63#59#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O grupo de estudo    apresentou patela alta
, segundo o &iacute;ndice de <i>Blackburne e Peel</i>,    significantemente maio
r que o grupo controle (p&lt;0,001), com 58,9% de presen&ccedil;a    no grupo de
 estudo e 16,7% no grupo controle. (<a href="#t4">Tabela 4</a>)</font></p>     ^
cY#04.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#64#60#article#124#<p><a name="t4"></a></p>  
   ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#65#61#article#124#<p>&nbsp;</p>     ^cY#04.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#66#62#article#124#<p align="center"><img src
="/img/revistas/aob/v19n1/04t04.jpg"></p>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#67#63#article#124#<p>&nbsp;</p>     ^cY#04.h
tm##
00328000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010600069002000700175#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#68#64#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font></p>     ^cY#
04.htm##
00617000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704039500069002000700464#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#69#65#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Em estudos pr&eacute;vios    sobre tendinop
atias cr&ocirc;nicas do aparelho extensor do joelho em atletas,    existe pouca 
aten&ccedil;&atilde;o referente a altura patelar.<sup>2-4</sup>    Nosso estudo 
procurou correlacionar a altura patelar com a tendinopatia cr&ocirc;nica    do a
parelho extensor dos atletas.</font></p>     ^cY#04.htm##
00991000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704076900069002000700838#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#70#66#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O diagn&oacute;stico    da tendinopatia cr&
ocirc;nica do aparelho extensor do joelho nos atletas do    nosso estudo foi cl&
iacute;nico, baseado na hist&oacute;ria de dor no mecanismo    extensor do joelh
o, de car&aacute;ter evolutivo e limitante e relacionado a    atividades de sobr
ecarga.<sup>1</sup> Al&eacute;m da hist&oacute;ria, a avalia&ccedil;&atilde;o   
 diagn&oacute;stica foi complementada pelo exame f&iacute;sico, que consistia   
 em se localizar o s&iacute;tio da dor pela palpa&ccedil;&atilde;o (&aacute;pice
    da patela, tend&atilde;o quadriciptal, tend&atilde;o patelar e/ou local de i
nser&ccedil;&atilde;o    do tend&atilde;o patelar na tuberosidade da t&iacute;bi
a).</font></p>     ^cY#04.htm##
01262000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704104000069002000701109#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#71#67#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Em outro estudo    com dezessete adolescent
es com diagn&oacute;stico de Osgood-Schlatter, e doze    adolescentes sem dor na
 regi&atilde;o anterior no joelho. O &iacute;ndice utilizado    para a avalia&cc
edil;&atilde;o da altura patelar foi o de Caton-Deschamps, utilizando-se    radi
ografias laterais do joelho. O grupo de jovens com diagn&oacute;stico de    Osgo
od-Schlatter apresentou 58% de patelas altas, contra 17% do grupo sem queixas,  
  demonstrando uma forte associa&ccedil;&atilde;o entre patela alta e doen&ccedi
l;a    de Osgood-Schlatter.<sup>9</sup> Este aumento da altura patelar exige um 
aumento    da for&ccedil;a do quadr&iacute;ceps para alcan&ccedil;ar a extens&at
ilde;o    completa. Este mecanismo poderia ser respons&aacute;vel pela les&atild
e;o da    ap&oacute;fise. Em nosso estudo, a grande maioria dos atletas apresent
avam a    fise de crescimento fechada, n&atilde;o sendo poss&iacute;vel estabele
cer esta    rela&ccedil;&atilde;o.</font></p>     ^cY#04.htm##
00904000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704068200069002000700751#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#72#68#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Num estudo com    cadetes, a altura patelar
, o encurtamento da musculatura posterior da coxa e    do m&uacute;sculo quadr&i
acute;ceps, entre outros fatores, de forma isolada,    n&atilde;o pareceram cont
ribuir para o desencadeamento da dor anterior do joelho.<sup>10</sup>    Dentre 
os in&uacute;meros diagn&oacute;sticos poss&iacute;veis de dor anterior    do jo
elho, selecionamos a tendinopatia cr&ocirc;nica do aparelho extensor e    ao con
tr&aacute;rio do estudo supra-citado, foi encontrada rela&ccedil;&atilde;o    en
tre tendinopatia cr&ocirc;nica do aparelho extensor do joelho e patela alta.</fo
nt></p>     ^cY#04.htm##
01194000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704097200069002000701041#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#73#69#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A rela&ccedil;&atilde;o    entre altura pat
elar e desordens do mecanismo extensor em jovens (doen&ccedil;a    de Osgood-Sch
latter) foi relatada em um estudo com quarenta jogadores de futebol    (oitenta 
joelhos) com seguimento de 02 anos.<sup>11</sup> Nenhum atleta apresentou    pat
ela alta antes da ocorr&ecirc;ncia de qualquer tipo de desordem do mecanismo    
extensor. Dos doze atletas, com diagn&oacute;stico de Osgood-Schlatter, durante 
   o acompanhamento, dez apresentaram patela alta ap&oacute;s o in&iacute;cio do
s    sintomas. Os autores, conclu&iacute;ram, assim, que patela alta &eacute; um
a    consequ&ecirc;ncia da doen&ccedil;a de Osgood-Schlatter em atletas imaturos
.    Nesse estudo, os atletas com diagn&oacute;stico de doen&ccedil;a de Osgood-
Schlatter    foram exclu&iacute;dos, n&atilde;o foi poss&iacute;vel avaliar a po
ssibilidade    dessa correla&ccedil;&atilde;o.</font></p>     ^cY#04.htm##
01355000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704113300069002000701202#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#74#70#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Quanto ao local    de acometimento, a tendi
nopatia cr&ocirc;nica do aparelho extensor do joelho,    afetou em ordem de freq
u&ecirc;ncia, a origem do tend&atilde;o patelar na patela    (&aacute;pice da pa
tela) em 65%, o tend&atilde;o quadricipital (p&oacute;lo    superior da patela) 
em 25% e o tend&atilde;o patelar em 10% das vezes.<sup>12</sup>    Num estudo na
cional, a localiza&ccedil;&atilde;o da dor no &aacute;pice da patela    ocorreu 
em 63,8%, no tend&atilde;o patelar em 25,9%, no tend&atilde;o quadriciptal    em
 6,9% e na inser&ccedil;&atilde;o do tend&atilde;o patelar na t&iacute;bia    em
 3,4% dos casos.<sup>13</sup> Nesse estudo, dos 56 joelhos com diagn&oacute;stic
o    de tendinopatia cr&ocirc;nica do aparelho extensor do joelho, 46 apresentar
am    dor no &aacute;pice da patela (73,7%), quatro no tend&atilde;o patelar (10
,5%),    3 exclusivamente no tend&atilde;o quadriciptal (7,9%) e tr&ecirc;s nos 
tend&otilde;es    patelar e quadricipital concomitantemente (7,9%), o que se apr
oxima dos valores    encontrados na literatura.</font></p>     ^cY#04.htm##
00912000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704069000069002000700759#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#75#71#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A tendinopatia    cr&ocirc;nica do aparelho
 extensor do joelho pode ser avaliada por v&aacute;rios    m&eacute;todos de ima
gem, os quais podem ser radiografias simples, ultrassonografia,    tomografia co
mputadorizada e resson&acirc;ncia nuclear magn&eacute;tica. Com    rela&ccedil;&
atilde;o &agrave;s medidas radiogr&aacute;ficas, foi realizado    um estudo radi
ogr&aacute;fico simples. Os dois &iacute;ndices radiogr&aacute;ficos    utilizad
os nesse estudo s&atilde;o descritos em outros estudos, embora existam    outros
 &iacute;ndices para a determina&ccedil;&atilde;o da altura patelar.<sup>14,15</
sup></font></p>     ^cY#04.htm##
01089000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704086700069002000700936#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#76#72#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Na determina&ccedil;&atilde;o    do &iacute
;ndice de <i>Insall e Salvatti</i> houve dificuldade na localiza&ccedil;&atilde;
o    exata da inser&ccedil;&atilde;o do tend&atilde;o patelar na tuberosidade an
terior    da t&iacute;bia, como descrito previamente.<sup>16</sup> No c&aacute;l
culo do    &iacute;ndice de <i>Blackburne e Peel</i> n&atilde;o houve necessidad
e da localiza&ccedil;&atilde;o    desse ponto de inser&ccedil;&atilde;o do tend&
atilde;o patelar. A medida &eacute;    baseada na menor dist&acirc;ncia entre a 
parte mais distal da patela e a linha    tangente &agrave; superf&iacute;cie art
icular do planalto tibial. (<a href="#f1">Figura    1</a>) N&atilde;o houve vari
a&ccedil;&atilde;o desse &iacute;ndice em fun&ccedil;&atilde;o    do grau de fle
x&atilde;o do joelho.</font></p>     ^cY#04.htm##
00631000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704040900069002000700478#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#77#73#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Quando estudamos    os dois &iacute;ndices,
 houve uma diferen&ccedil;a estat&iacute;stica significante    no grupo de estud
o, em rela&ccedil;&atilde;o ao grupo controle, corroboraram    com outros estudo
s, que observaram haver associa&ccedil;&atilde;o entre patela    alta e dor no m
ecanismo extensor do joelho.<sup>9,11</sup></font></p>     ^cY#04.htm##
00688000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704046600069002000700535#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#78#74#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Nesse estudo houveram    limita&ccedil;&oti
lde;es como a falha em classificar o grau de comprometimento    tendinoso, o per
&iacute;odo de avalia&ccedil;&atilde;o em diferentes est&aacute;gios    de acome
timento e compara&ccedil;&atilde;o de diferentes modalidades esportivas.    Todo
s os atletas que participaram do estudo preencheram o termo de consentimento    
livre e esclarecido.</font></p>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#79#75#article#124#<p>&nbsp;</p>     ^cY#04.h
tm##
00328000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010600069002000700175#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#80#76#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>CONCLUS&Atilde;O</b></font></p>     ^cY#
04.htm##
00678000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704045600069002000700525#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#81#77#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Nesse estudo observou-se    uma rela&ccedil
;&atilde;o direta entre patela alta e a tendinopatia cr&ocirc;nica    do mecanis
mo extensor do joelho, que foi demonstrado pela signific&acirc;ncia    estat&iac
ute;stica entre o grupo de estudo e o grupo controle quando se estudou    a altu
ra patelar pelos &iacute;ndices de <i>Insall e Salvatti</i> e <i>Blackburne    e
 Peel</i>.</font></p>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#82#78#article#124#<p>&nbsp;</p>     ^cY#04.h
tm##
00329000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010700069002000700176#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#83#79#article#124#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font></p>     ^cY
#04.htm##
00428000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704019200071002000700263#v19
n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#p#84#80#article#124#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1. Osbahr DC, Speer    KP. Pa
tellar tendinitis: evaluation and arthroscopic management. Techn Knee    Surg. 2
003;2:160-5.    ^cY#04.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#85#81#article#124#</font></p>     ^cY#04.htm
##
00419000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704018300071002000700254#v19
n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#p#86#82#article#124#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2. Maurizio D.    La tendinit
e rotulea del giocatore di pallavolo. Arch Soc Tosco Umbra Chir.    1963;24:443-
52.    ^cY#04.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#87#83#article#124#</font></p>     ^cY#04.htm
##
00422000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704018600071002000700257#v19
n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#p#88#84#article#124#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">3. Blazina ME,    Kerlan RK, 
Jobe FW, Carter VS, Carlson GJ. Jumper's knee. Orthop Clin North    Am. 1973;4:6
65-78.    ^cY#04.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#89#85#article#124#</font></p>     ^cY#04.htm
##
00426000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704019000071002000700261#v19
n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#p#90#86#article#124#4#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">4. Roels J, Martens    M, Mul
ier JC, Burssens A. Patellar tendinitis (jumper's knee). Am J Sports Med.    197
8;6:362-8.    ^cY#04.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#91#87#article#124#</font></p>     ^cY#04.htm
##
00456000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704022000071002000700291#v19
n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#p#92#88#article#124#5#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">5. Aglietti P,    Insall JN, 
Cerulli G. Patellar pain and incongruence. I: Measurements of incongruence.    C
lin Orthop Relat Res. 1983;(176):217-24.    ^cY#04.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#93#89#article#124#</font></p>     ^cY#04.htm
##
00462000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704022600071002000700297#v19
n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#p#94#90#article#124#6#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">6. Kujala UM, Aalto    T, Ost
erman K, Dahlstr&ouml;m S. The effect of volleyball playing on the knee    exten
sor mechanism. Am J Sports Med. 1989;17:766-9.    ^cY#04.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#95#91#article#124#</font></p>     ^cY#04.htm
##
00478000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704024200071002000700313#v19
n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#p#96#92#article#124#7#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">7. Kettunen JA,    Kvist M, A
lanen E, Kujala UM. Long-term prognosis for jumper's knee in male    athletes. A
 prospective follow-up study. Am J Sports Med. 2002;30:689-92.    ^cY#04.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#97#93#article#124#</font></p>     ^cY#04.htm
##
00416000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704018000071002000700251#v19
n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#p#98#94#article#124#8#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">8. Blackburne JS,    Peel TE.
 A new method of measuring patellar height. J Bone Joint Surg Br. 1977;59:241-2.
    ^cY#04.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#99#95#article#124#</font></p>     ^cY#04.htm
##
00455000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704021800072002000700290#v19
n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#p#100#96#article#124#9#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">9. Aparicio G,    Abril JC, 
Calvo E, Alvarez L. Radiologic study of patellar height in Osgood-Schlatter    d
isease. J Pediatr Orthop. 1997;17:63-6.    ^cY#04.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#101#97#article#124#</font></p>     ^cY#04.ht
m##
00576000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000300070704033800073002000700411#v19
n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#p#102#98#article#124#10#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">10. Percope MA.    A rela&c
cedil;&atilde;o do encurtamento da musculatura posterior da coxa e do    m&uacut
e;sculo quadr&iacute;ceps com a dor anterior do joelho &#91;disserta&ccedil;&ati
lde;o&#93;.    S&atilde;o Paulo: Universidade Federal de S&atilde;o Paulo; 1998.
    ^cY#04.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#103#99#article#124#</font></p>     ^cY#04.ht
m##
00507000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026800074002000700342#v19
n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#p#104#100#article#124#11#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Hirano A, Fukubayashi 
   T, Ishii T, Ochiai N. Relationship between the patellar height and the disord
er    of the knee extensor mechanism in immature athletes. J Pediatr Orthop. 200
1;21:541-4.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#105#101#article#124#</font></p>     ^cY#04.h
tm##
00392000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704015300074002000700227#v19
n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#p#106#102#article#124#12#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Ferretti A.    Epidemi
ology of jumper&acute;s knee. Sports Med. 1986;3:289-95.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#107#103#article#124#</font></p>     ^cY#04.h
tm##
00387000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704014800074002000700222#v19
n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#p#108#104#article#124#13#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Cohen M, Abdalla    RJ
. Tendinite patelar. Rev Bras Ortop. 1989;24:221-5.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#109#105#article#124#</font></p>     ^cY#04.h
tm##
00447000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704020800074002000700282#v19
n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#p#110#106#article#124#14#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Berg EE, Mason    SL, 
Lucas MJ. Patellar height ratios. A comparison of four measurement methods.    A
m J Sports Med. 1996;24:218-21.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#111#107#article#124#</font></p>     ^cY#04.h
tm##
00500000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026100074002000700335#v19
n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#p#112#108#article#124#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Seil R, M&uuml;ller   
 B, Georg T, Kohn D, Rupp S. Reliability and interobserver variability in radiol
ogical    patellar height ratios. Knee Surg Sports Traumatol Arthrosc. 2000;8:23
1-6.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#113#109#article#124#</font></p>     ^cY#04.h
tm##
00424000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704018500074002000700259#v19
n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#p#114#110#article#124#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Kadakia NR,    Ilahi O
A. Interobserver variability of the Insall-Salvati ratio. Orthopedics.    2003;2
6:321-3.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#115#111#article#124#</font></p>     ^cY#04.h
tm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#116#112#article#124#<p>&nbsp;</p>     ^cY#04
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#117#113#article#124#<p>&nbsp;</p>     ^cY#04
.htm##
00430000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704020600071002000700277#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#118#114#article#124#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top"><img sr
c="/img/revistas/aob/v19n1/seta.jpg" border="0"></a>    <b>Endereço para Corresp
ondência:</b>     ^cY#04.htm##
00258000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003400071002000700105#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#119#115#article#124#<br>   Rua Emba&uacute; 
87    ^cY#04.htm##
00254000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003000071002000700101#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#120#116#article#124#<br>   Vila Clementino  
  ^cY#04.htm##
00267000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004300071002000700114#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#121#117#article#124#<br>   S&atilde;o Paulo,
 SP, Brasil    ^cY#04.htm##
00253000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002900071002000700100#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#122#118#article#124#<br>   CEP: 04039-060   
 ^cY#04.htm##
00316000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009200071002000700163#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#123#119#article#124#<br>   E-mail: <a href="
mailto:egarms@uol.com.br">egarms@uol.com.br</a></font> </p>     ^cY#04.htm##
00360000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013600071002000700207#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#124#120#article#124#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Artigo recebido    em 09/01/09, aprovado 
em 22/01/10.</font></p>     ^cY#04.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#125#121#article#124#<p>&nbsp;</p>     ^cY#04
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#126#122#article#124#<p>&nbsp;</p>     ^cY#04
.htm##
00473000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704024900071002000700320#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#127#123#article#124#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Trabalho realizado    no Centro de Trauma
to-Ortopedia do Esporte (CETE) do Departamento de Ortopedia    e Traumatologia d
a Universidade Federal de S&atilde;o Paulo (UNIFESP/EPM).    ^cY#04.htm##
00361000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013700071002000700208#v19n1#V:\SciELO
\serial\aob\v19n1\markup\04.htm#S#p#128#124#article#124#<br>   Todos os autores 
declaram n&atilde;o haver nenhum potencial conflito de interesses    referente a
 este artigo.</font></p>     ^cY#04.htm##
00489000000000265000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100016000870120
06400103030001600167710000200183065000900185064000500194031000200199014000600201
865000900207002000700216#v19n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#c#129#
1#article#16#1#^rND^sOsbahr^nDC#^rND^sSpeer^nKP#Patellar tendinitis: evaluation 
and arthroscopic management^len#Techn Knee Surg#2#20030000#2003#2#160-5#20110000
#04.htm##
00462000000000253000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700120052000880300
02600140710000200166065000900168064000500177031000300182014000700185865000900192
002000700201#v19n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#c#130#2#article#16
#2#^rND^sMaurizio^nD#La tendinite rotulea del giocatore di pallavolo^lit#Arch So
c Tosco Umbra Chir#2#19630000#1963#24#443-52#20110000#04.htm##
00578000000000313000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100017000880100
01500105010001700120010001800137012001800155030002100173065000900194064000500203
031000200208014000700210865000900217002000700226035001000233801002100243#v19n1#V
:\SciELO\serial\aob\v19n1\markup\04.htm#S#c#131#3#article#16#3#^rND^sBlazina^nME
#^rND^sKerlan^nRK#^rND^sJobe^nFW#^rND^sCarter^nVS#^rND^sCarlson^nGJ#Jumper's kne
e^len#Orthop Clin North Am#19730000#1973#4#665-78#20110000#04.htm#0030-5898#Orth
op Clin North Am##
00559000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100015000700100017000850100
01700102010001800119012004000137030001600177065000900193064000500202031000200207
014000600209865000900215002000700224035001000231801001600241#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\04.htm#S#c#132#4#article#16#4#^rND^sRoels^nJ#^rND^sMartens^
nM#^rND^sMulier^nJC#^rND^sBurssens^nA#Patellar tendinitis (jumper's knee)^len#Am
 J Sports Med#19780000#1978#6#362-8#20110000#04.htm#0363-5465#Am J Sports Med##
00533000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100017000880100
01700105012006800122030002200190710000200212065000900214064000500223031000400228
014000700232865000900239002000700248#v19n1#V:\SciELO\serial\aob\v19n1\markup\04.
htm#S#c#133#5#article#16#5#^rND^sAglietti^nP#^rND^sInsall^nJN#^rND^sCerulli^nG#P
atellar pain and incongruence: I: Measurements of incongruence^len#Clin Orthop R
elat Res#2#19830000#1983#176#217-24#20110000#04.htm##
00590000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100015000870100
01800102010001900120012006800139030001600207065000900223064000500232031000300237
014000600240865000900246002000700255035001000262801001600272#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\04.htm#S#c#134#6#article#16#6#^rND^sKujala^nUM#^rND^sAalto^
nT#^rND^sOsterman^nK#^rND^sDahlström^nS#The effect of volleyball playing on the 
knee extensor mechanism^len#Am J Sports Med#19890000#1989#17#766-9#20110000#04.h
tm#0363-5465#Am J Sports Med##
00611000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700100015000890100
01600104010001700120012009000137030001600227065000900243064000500252031000300257
014000700260865000900267002000700276035001000283801001600293#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\04.htm#S#c#135#7#article#16#7#^rND^sKettunen^nJA#^rND^sKvis
t^nM#^rND^sAlanen^nE#^rND^sKujala^nUM#Long-term prognosis for jumper's knee in m
ale athletes: A prospective follow-up study^len#Am J Sports Med#20020000#2002#30
#689-92#20110000#04.htm#0363-5465#Am J Sports Med##
00521000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100021000700100015000910120
04600106030002100152065000900173064000500182031000300187014000600190865000900196
002000700205035001000212801002100222#v19n1#V:\SciELO\serial\aob\v19n1\markup\04.
htm#S#c#136#8#article#16#8#^rND^sBlackburne^nJS#^rND^sPeel^nTE#A new method of m
easuring patellar height^len#J Bone Joint Surg Br#19770000#1977#59#241-2#2011000
0#04.htm#0301-620X#J Bone Joint Surg Br##
00588000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100016000880100
01500104010001700119012006800136030001700204065000900221064000500230031000300235
014000500238865000900243002000700252035001000259801001700269#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\04.htm#S#c#137#9#article#16#9#^rND^sAparicio^nG#^rND^sAbril
^nJC#^rND^sCalvo^nE#^rND^sAlvarez^nL#Radiologic study of patellar height in Osgo
od-Schlatter disease^len#J Pediatr Orthop#19970000#1997#17#63-6#20110000#04.htm#
0271-6798#J Pediatr Orthop##
00510000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160018000720180116000900660
01000206062003400216065000900250064000500259865000900264002000700273#v19n1#V:\Sc
iELO\serial\aob\v19n1\markup\04.htm#S#c#138#10#article#16#10#^rND^sPercope^nMA#A
 relação do encurtamento da musculatura posterior da coxa e do músculo quadrícep
s com a dor anterior do joelho^lpt#São Paulo#Universidade Federal de São Paulo#1
9980000#1998#20110000#04.htm##
00639000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100021000880100
01500109010001600124012011400140030001700254065000900271064000500280031000300285
014000600288865000900294002000700303035001000310801001700320#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\04.htm#S#c#139#11#article#16#11#^rND^sHirano^nA#^rND^sFukub
ayashi^nT#^rND^sIshii^nT#^rND^sOchiai^nN#Relationship between the patellar heigh
t and the disorder of the knee extensor mechanism in immature athletes^len#J Ped
iatr Orthop#20010000#2001#21#541-4#20110000#04.htm#0271-6798#J Pediatr Orthop##
00461000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720120034000900300
01100124065000900135064000500144031000200149014000700151865000900158002000700167
035001000174801001100184#v19n1#V:\SciELO\serial\aob\v19n1\markup\04.htm#S#c#140#
12#article#16#12#^rND^sFerretti^nA#Epidemiology of jumper´s knee^len#Sports Med#
19860000#1986#3#289-95#20110000#04.htm#0112-1642#Sports Med##
00484000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100018000870120
02200105030001500127065000900142064000500151031000300156014000600159865000900165
002000700174035001000181801001500191#v19n1#V:\SciELO\serial\aob\v19n1\markup\04.
htm#S#c#141#13#article#16#13#^rND^sCohen^nM#^rND^sAbdalla^nRJ#Tendinite patelar^
lpt#Rev Bras Ortop#19890000#1989#24#221-5#20110000#04.htm#0486-6401#Rev Bras Ort
op##
00560000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100016000870100
01600103012006900119030001600188065000900204064000500213031000300218014000700221
865000900228002000700237035001000244801001600254#v19n1#V:\SciELO\serial\aob\v19n
1\markup\04.htm#S#c#142#14#article#16#14#^rND^sBerg^nEE#^rND^sMason^nSL#^rND^sLu
cas^nMJ#Patellar height ratios: A comparison of four measurement methods^len#Am 
J Sports Med#19960000#1996#24#218-21#20110000#04.htm#0363-5465#Am J Sports Med##
00664000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100014000720100016000860100
01500102010001400117010001400131012008500145030003600230065000900266064000500275
031000200280014000600282865000900288002000700297035001000304801003600314#v19n1#V
:\SciELO\serial\aob\v19n1\markup\04.htm#S#c#143#15#article#16#15#^rND^sSeil^nR#^
rND^sMüller^nB#^rND^sGeorg^nT#^rND^sKohn^nD#^rND^sRupp^nS#Reliability and intero
bserver variability in radiological patellar height ratios^len#Knee Surg Sports 
Traumatol Arthrosc#20000000#2000#8#231-6#20110000#04.htm#0942-2056#Knee Surg Spo
rts Traumatol Arthrosc##
00515000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100016000900120
05800106030001200164065000900176064000500185031000300190014000600193865000900199
002000700208035001000215801001200225#v19n1#V:\SciELO\serial\aob\v19n1\markup\04.
htm#S#c#144#16#article#16#16#^rND^sKadakia^nNR#^rND^sIlahi^nOA#Interobserver var
iability of the Insall-Salvati ratio^len#Orthopedics#20030000#2003#26#321-3#2011
0000#04.htm#0147-7447#Orthopedics##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v19n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#o#1#1#article#1#201104
11#111846#05.htm#168##
03837000000000637000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000500083038000400088038000400092121000300096049000700099
15800030010603000180010903100030012703200020013006500090013201400090014103500100
01500120095001600120087002550100042003420100034003840100030004180100037004480100
04800485010003700533070004600570083113900616085000801755085002401763085002601787
08500200181308312380183308500080307108500250307908500250310408500160312911700060
3145072000303151112000903154111000903163114000903172113001103181002000703192#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#
ILUS#GRA#TAB#05#AOB140#nd#Acta ortop. bras.#19#1#20110000#^f22^l27#1413-7852#Ach
ados em ressonância magnética artrográfica de indivíduos com lesão do labrum ace
tabular^lpt#Magnetic resonance arthrographic findings in subjects with acetabula
r labral tears^len#^rND^1A01^nAndré Luiz Almeida^sPizzolatti#^rND^1A01^nAlessand
ro^sHaupenthal#^rND^1A01^nAdriano^sMarostika#^rND^1A01^nRichard Prazeres^sCanell
a#^rND^1A01^nAdemar José de Oliveira^sPaes Junior#^rND^1A01^nSérgio Marcondes^sB
rincas#Universidade do Estado de Santa Catarina^iA01#^lpt^aOBJETIVO: Descrever o
s achados em artro RM de sujeitos com suspeita de lesão do labrum acetabular. MÉ
TODO: Foram analisadas 108 artro RM de quadris em 2007/2008. Dois radiologistas 
independentemente analisaram as imagens e foi considerada a resposta comum entre
 eles. Com base em seus pareceres observou-se o local e estadiamento das lesões 
labrais e condrais, as alterações anatômicas, e a presença de tendinite e bursit
e trocantérica. RESULTADO: As lesões labrais grau I ocorreram em 41% dos casos, 
grau II em 31%, e grau III em 29%. O IFA tipo cam foi frequente em 36% dos casos
, tipo pincer em 11%, e IFA misto em 13%, nestes casos 57% apresentaram lesão la
bral grau III, A lesão condral grau I foi observada em 51% acetábulos, as de gra
u II em 13%, e grau III em 18%. CONCLUSÃO: As alterações morfológicas que provoc
am IFA do tipo cam foram as mais prevalentes. Em relação ao grau de lesão labral
 e condral foram predominantes as lesões grau I independente da presença ou do t
ipo de IFA, exceto em IFAs mistos onde houve predomínio de lesão labral grau III
. Não foi observada uma relação entre o grau de lesão labral e condral.#^dnd^i1#
^tm^lpt^kArtrografia^i1#^tm^lpt^kEpidemiologia^i1#^tm^lpt^kQuadril^i1#^len^aOBJE
CTIVE: To describe the MR arthrographic findings in subjects with suspected acet
abular labral tears of the hip. METHOD: 108 hip MRa results were analyzed in 200
7-2008. Two radiologists independently interpreted the images, and the consensua
l answers between them were considered for analysis. Based on their opinions, in
formation was obtained on the location, staging of the chondral and labral lesio
ns, anatomic alterations, and the presence of trochanteric bursitis and tendonit
is. RESULTS: 1st degree labral lesions occurred in 41% of cases, 2nd degree in 3
1%, and 3rd degree in 29%. The cam type FAI was common in 36% of cases, pincer F
AI in 11%, and mixed cam-pincer FAI in 13%; in these cases 57% had grade III lab
ral lesions. 1st degree chondral lesions were observed in 51% of acetabulum, 2nd
 degree in 13%, and 3rd degree in 18%. CONCLUSION: The morphologic alterations t
hat cause cam type FAI were the most common. With respect to the degree of labra
l and chondral lesions, 1st degree lesions were the most common, irrespective of
 the presence or type of FAI, except in mixed cam-pincer FAIs, in which 3rd degr
ee lesions were predominant. No relationship was observed between the degree of 
labral and chondral lesion.#^dnd^i2#^tm^len^kArthrography^i2#^tm^len^kEpidemiolo
gy^i2#^tm^len^kHip^i2#other#21#20090402#02/04/09#20090728#28/07/2009#05.htm##
03977000000000637000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000500083038000400088038000400092121000300096049000700099
15800030010603000180010903100030012703200020013006500090013201400090014103500100
01500120109001600120094002690100042003630100034004050100030004390100037004690100
04800506010003700554070004600591083123000637085000801867085002401875085002601899
08500200192508312660194508500080321108500250321908500250324408500160326911700060
3285072000303291112000903294111000903303114000903312113001103321002000703332#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#
ILUS#GRA#TAB#05#AOB140#nd#Acta ortop. bras.#19#1#20110000#^f22^l27#1413-7852#<b>
Achados em ressonância magnética artrográfica de indivíduos com lesão do <i>labr
um</i> acetabular</b>^lpt#<b>Magnetic resonance arthrographic findings in subjec
ts with acetabular labral tears</b>^len#^rND^1A01^nAndré Luiz Almeida^sPizzolatt
i#^rND^1A01^nAlessandro^sHaupenthal#^rND^1A01^nAdriano^sMarostika#^rND^1A01^nRic
hard Prazeres^sCanella#^rND^1A01^nAdemar José de Oliveira^sPaes Junior#^rND^1A01
^nSérgio Marcondes^sBrincas#Universidade do Estado de Santa Catarina^iA01#^lpt^a
<b>OBJETIVO:</b> Descrever os achados em artro RM de sujeitos com suspeita de le
são do <i>labrum</i> acetabular. <b>MÉTODO:</b> Foram analisadas 108 artro RM de
 quadris em 2007/2008. Dois radiologistas independentemente analisaram as imagen
s e foi considerada a resposta comum entre eles. Com base em seus pareceres obse
rvou-se o local e estadiamento das lesões <i>labrais</i> e condrais, as alteraçõ
es anatômicas, e a presença de tendinite e bursite trocantérica. <b>RESULTADO:</
b> As lesões labrais grau I ocorreram em 41% dos casos, grau II em 31%, e grau I
II em 29%. O IFA tipo <i>cam</i> foi frequente em 36% dos casos, tipo <i>pincer<
/i> em 11%, e IFA misto em 13%, nestes casos 57% apresentaram lesão <i>labral</i
> grau III, A lesão condral grau I foi observada em 51% acetábulos, as de grau I
I em 13%, e grau III em 18%. <b>CONCLUSÃO:</b> As alterações morfológicas que pr
ovocam IFA do tipo <i>cam</i> foram as mais prevalentes. Em relação ao grau de l
esão <i>labral</i> e condral foram predominantes as lesões grau I independente d
a presença ou do tipo de IFA, exceto em IFAs mistos onde houve predomínio de les
ão <i>labral</i> grau III. Não foi observada uma relação entre o grau de lesão <
i>labral</i> e condral.#^dnd^i1#^tm^lpt^kArtrografia^i1#^tm^lpt^kEpidemiologia^i
1#^tm^lpt^kQuadril^i1#^len^a<b>OBJECTIVE:</b> To describe the MR arthrographic f
indings in subjects with suspected acetabular labral tears of the hip. <b>METHOD
:</b> 108 hip MRa results were analyzed in 2007-2008. Two radiologists independe
ntly interpreted the images, and the consensual answers between them were consid
ered for analysis. Based on their opinions, information was obtained on the loca
tion, staging of the chondral and labral lesions, anatomic alterations, and the 
presence of trochanteric bursitis and tendonitis. <b>RESULTS:</b> 1st degree lab
ral lesions occurred in 41% of cases, 2nd degree in 31%, and 3rd degree in 29%. 
The cam type FAI was common in 36% of cases, pincer FAI in 11%, and mixed cam-pi
ncer FAI in 13%; in these cases 57% had grade III labral lesions. 1st degree cho
ndral lesions were observed in 51% of acetabulum, 2nd degree in 13%, and 3rd deg
ree in 18%. <b>CONCLUSION:</b> The morphologic alterations that cause cam type F
AI were the most common. With respect to the degree of labral and chondral lesio
ns, 1st degree lesions were the most common, irrespective of the presence or typ
e of FAI, except in mixed cam-pincer FAIs, in which 3rd degree lesions were pred
ominant. No relationship was observed between the degree of labral and chondral 
lesion.#^dnd^i2#^tm^len^kArthrography^i2#^tm^len^kEpidemiology^i2#^tm^len^kHip^i
2#other#21#20090402#02/04/09#20090728#28/07/2009#05.htm##
04118000000000661000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000500090038000400095038000400099121000300103
04900070010615800030011303000170011603100030013303200020013606500090013801400090
01470350010001560120095001660120087002610100042003480100034003900100030004240100
03700454010004800491010003700539070004800576083122900624085000801853085002401861
08500260188508500200191108313080193108500080323908500250324708500250327208500160
32971170006033130720003033191120009033221110009033311140009033401130011033490020
00703360008008903367#v19n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#l#4#1#arti
cle#1#^a2011#oa#pt#br1.1#1#4.0#ilus#gra#tab#05#AOB140#nd#Acta ortop. bras#19#1#2
0110000#^f22^l27#1413-7852#Achados em ressonância magnética artrográfica de indi
víduos com lesão do labrum acetabular^lpt#Magnetic resonance arthrographic findi
ngs in subjects with acetabular labral tears^len#^rND^1A01^nAndré Luiz Almeida^s
Pizzolatti#^rND^1A01^nAlessandro^sHaupenthal#^rND^1A01^nAdriano^sMarostika#^rND^
1A01^nRichard Prazeres^sCanella#^rND^1A01^nAdemar José de Oliveira^sPaes Junior#
^rND^1A01^nSérgio Marcondes^sBrincas#^iA01^1Universidade do Estado de Santa Cata
rina#^lpt^aOBJETIVO: Descrever os achados em artro RM de sujeitos com suspeita d
e lesão do labrum acetabular. MÉTODO: Foram analisadas 108 artro RM de quadris e
m 2007/2008. Dois radiologistas independentemente analisaram as imagens e foi co
nsiderada a resposta comum entre eles. Com base em seus pareceres observou-se o 
local e estadiamento das lesões labrais e condrais, as alterações anatômicas, e 
a presença de tendinite e bursite trocantérica. RESULTADO: As lesões labrais gra
u I ocorreram em 41 por cento dos casos, grau II em 31 por cento, e grau III em 
29 por cento. O IFA tipo cam foi frequente em 36 por cento dos casos, tipo pince
r em 11 por cento, e IFA misto em 13 por cento, nestes casos 57 por cento aprese
ntaram lesão labral grau III, A lesão condral grau I foi observada em 51 por cen
to acetábulos, as de grau II em 13 por cento, e grau III em 18 por cento. CONCLU
SÃO: As alterações morfológicas que provocam IFA do tipo cam foram as mais preva
lentes. Em relação ao grau de lesão labral e condral foram predominantes as lesõ
es grau I independente da presença ou do tipo de IFA, exceto em IFAs mistos onde
 houve predomínio de lesão labral grau III. Não foi observada uma relação entre 
o grau de lesão labral e condral.#^dnd^i1#^tm^lpt^kArtrografia^i1#^tm^lpt^kEpide
miologia^i1#^tm^lpt^kQuadril^i1#^len^aOBJECTIVE: To describe the MR arthrographi
c findings in subjects with suspected acetabular labral tears of the hip. METHOD
: 108 hip MRa results were analyzed in 2007-2008. Two radiologists independently
 interpreted the images, and the consensual answers between them were considered
 for analysis. Based on their opinions, information was obtained on the location
, staging of the chondral and labral lesions, anatomic alterations, and the pres
ence of trochanteric bursitis and tendonitis. RESULTS: 1st degree labral lesions
 occurred in 41 percent of cases, 2nd degree in 31 percent, and 3rd degree in 29
 percent. The cam type FAI was common in 36 percent of cases, pincer FAI in 11 p
ercent, and mixed cam-pincer FAI in 13 percent; in these cases 57 percent had gr
ade III labral lesions. 1st degree chondral lesions were observed in 51 percent 
of acetabulum, 2nd degree in 13 percent, and 3rd degree in 18 percent. CONCLUSIO
N: The morphologic alterations that cause cam type FAI were the most common. Wit
h respect to the degree of labral and chondral lesions, 1st degree lesions were 
the most common, irrespective of the presence or type of FAI, except in mixed ca
m-pincer FAIs, in which 3rd degree lesions were predominant. No relationship was
 observed between the degree of labral and chondral lesion.#^dnd^i2#^tm^len^kArt
hrography^i2#^tm^len^kEpidemiology^i2#^tm^len^kHip^i2#other#21#20090402#02/04/09
#20090728#28/07/2009#05.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci
_arttext&pid=S1413-78522011000100005##
00343000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704012300067002000700190#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#5#1#article#143#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTIGO    ORIGINAL</b> </fon
t></p>     ^cY#05.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#6#2#article#143#<p>&nbsp;</p>     ^cY#05.htm
##
00465000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704024500067002000700312#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#7#3#article#143#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Achados    em resson&aci
rc;ncia magn&eacute;tica artrogr&aacute;fica de indiv&iacute;duos    com les&ati
lde;o do <i>labrum</i> acetabular</b></font></p>     ^cY#05.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#8#4#article#143#<p>&nbsp;</p>     ^cY#05.htm
##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#9#5#article#143#<p>&nbsp;</p>     ^cY#05.htm
##
00501000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704028000068002000700348#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#10#6#article#143#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Andr&eacute;    Luiz Almeida Pizzolatti; 
Alessandro Haupenthal; Adriano Marostika; Richard Prazeres    Canella; Ademar Jo
s&eacute; de Oliveira Paes Junior; S&eacute;rgio Marcondes    Brincas</b></font>
</p>     ^cY#05.htm##
00355000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704013400068002000700202#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#11#7#article#143#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2">Universidade do    Estado de Santa Catarina 
- UDESC</font></p>     ^cY#05.htm##
00369000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704014800068002000700216#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#12#8#article#143#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><a href="#back">Endere&ccedil;o    para Corr
espond&ecirc;ncia</a></font></p>     ^cY#05.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#13#9#article#143#<p>&nbsp;</p>     ^cY#05.ht
m##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#14#10#article#143#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#05.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#15#11#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#05.htm##
00418000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704019600069002000700265#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#16#12#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Descrever os achados em
 artro RM de sujeitos com suspeita de les&atilde;o do    <i>labrum</i> acetabula
r.    ^cY#05.htm##
00652000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704043000069002000700499#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#17#13#article#143#<br>   <b>M&Eacute;TODO:</
b> Foram analisadas 108 artro RM de quadris em 2007/2008.    Dois radiologistas 
independentemente analisaram as imagens e foi considerada    a resposta comum en
tre eles. Com base em seus pareceres observou-se o local    e estadiamento das l
es&otilde;es <i>labrais</i> e condrais, as altera&ccedil;&otilde;es    anat&ocir
c;micas, e a presen&ccedil;a de tendinite e bursite trocant&eacute;rica.        
^cY#05.htm##
00640000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704041800069002000700487#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#18#14#article#143#<br>   <b>RESULTADO:</b> A
s les&otilde;es labrais grau I ocorreram em 41% dos casos,    grau II em 31%, e 
grau III em 29%. O IFA tipo <i>cam</i> foi frequente em 36%    dos casos, tipo <
i>pincer</i> em 11%, e IFA misto em 13%, nestes casos 57% apresentaram    les&at
ilde;o <i>labral</i> grau III, A les&atilde;o condral grau I foi observada    em
 51% acet&aacute;bulos, as de grau II em 13%, e grau III em 18%.    ^cY#05.htm##
00766000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704054400069002000700613#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#19#15#article#143#<br>   <b>CONCLUS&Atilde;O
:</b> As altera&ccedil;&otilde;es morfol&oacute;gicas que    provocam IFA do tip
o <i>cam</i> foram as mais prevalentes. Em rela&ccedil;&atilde;o    ao grau de l
es&atilde;o <i>labral</i> e condral foram predominantes as les&otilde;es    grau
 I independente da presen&ccedil;a ou do tipo de IFA, exceto em IFAs mistos    o
nde houve predom&iacute;nio de les&atilde;o <i>labral</i> grau III. N&atilde;o  
  foi observada uma rela&ccedil;&atilde;o entre o grau de les&atilde;o <i>labral
</i>    e condral.</font></p>     ^cY#05.htm##
00386000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704016400069002000700233#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#20#16#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Descritores:</b>    Artrografia. Epidemi
ologia. Quadril.</font></p> <hr size="1" noshade>     ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#21#17#article#143#<p>&nbsp;</p>     ^cY#05.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#22#18#article#143#<p>&nbsp;</p>     ^cY#05.h
tm##
00336000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011400069002000700183#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#23#19#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b></font></p> 
    ^cY#05.htm##
00706000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704048400069002000700553#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#24#20#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O <i>labrum</i>    acetabular &eacute; uma 
estrutura fibrocartilaginosa fixada &agrave; orla acetabular    que possui impor
tante fun&ccedil;&atilde;o para a estabilidade do quadril. O    <i>labrum</i> &e
acute; respons&aacute;vel por aumentar a congru&ecirc;ncia articular    e melhor
ar a distribui&ccedil;&atilde;o das cargas entre a cabe&ccedil;a do    f&ecirc;m
ur e o acet&aacute;bulo.<sup>1,2</sup></font></p>     ^cY#05.htm##
00923000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704070100069002000700770#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#25#21#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As les&otilde;es    <i>labrais</i> s&atilde
;o causas de dor cr&ocirc;nica incapacitante, de car&aacute;ter    insidioso, e 
geralmente de natureza microtraum&aacute;tica associada a anormalidades    estru
turais do quadril.<sup>1</sup> Com a elevada acur&aacute;cia da artroresson&acir
c;ncia    magn&eacute;tica (artro RM) para a detec&ccedil;&atilde;o e estadiamen
to das    les&otilde;es <i>labrais</i> e condrais,<sup>3-5</sup> bem como das al
tera&ccedil;&otilde;es    anat&ocirc;micas do quadril, t&ecirc;m-se melhorado o 
entendimento do quadro    cl&iacute;nico e da patomec&acirc;nica da les&atilde;o
 <i>labral</i>.</font></p>     ^cY#05.htm##
01151000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704092900069002000700998#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#26#22#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Altera&ccedil;&otilde;es    na rela&ccedil;
&atilde;o anat&ocirc;mica entre o f&ecirc;mur e o acet&aacute;bulo    s&atilde;o
 os principais fatores etiol&oacute;gicos para a les&atilde;o <i>labral</i>    p
or provocarem o impacto femoroacetabular (IFA). Este impacto pode ser do tipo   
 <i>cam</i>, onde h&aacute; a perda da jun&ccedil;&atilde;o normal esf&eacute;ri
ca    entre a cabe&ccedil;a e o colo do f&ecirc;mur,<sup>1,6-8</sup> ou do tipo 
<i>pincer</i>    ocasionado pelo aumento da cobertura acetabular decorrente de c
oxa profunda    ou retrovers&atilde;o acetabular.<sup>7,8</sup> Menos frequente,
 as displasias    de quadril provocam instabilidade e consequentemente o desloca
mento anterosuperior    excessivo do f&ecirc;mur, isto gera um trauma cr&ocirc;n
ico sobre o <i>labrum</i>,    causando sua degenera&ccedil;&atilde;o.<sup>1,9</s
up></font></p>     ^cY#05.htm##
00838000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704061600069002000700685#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#27#23#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Os diferentes fatores    etiol&oacute;gicos
 podem, no entanto, provocar les&otilde;es <i>labrais</i>    com caracter&iacute
;sticas morfol&oacute;gicas inerentes e que ocorrem em por&ccedil;&otilde;es    
espec&iacute;ficas do <i>labrum</i>.<sup>9-11</sup> Todavia, tanto as altera&cce
dil;&otilde;es    anat&ocirc;micas quanto as les&otilde;es <i>labrais</i> parece
m aumentar as    press&otilde;es de contato articular do quadril e provocar inst
abilidade, predispondo    ao desenvolvimento de osteoartrite do quadril.<sup>1,1
2-14</sup></font></p>     ^cY#05.htm##
00443000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704022100069002000700290#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#28#24#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Dessa forma, este    estudo tem por objetiv
o descrever os achados em artro RM de sujeitos com les&atilde;o    do <i>labrum<
/i> acetabular.</font></p>     ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#29#25#article#143#<p>&nbsp;</p>     ^cY#05.h
tm##
00336000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011400069002000700183#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#30#26#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>MATERIAL E M&Eacute;TODO</b></font></p> 
    ^cY#05.htm##
00320000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009800069002000700167#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#31#27#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Sujeitos</b></font></p>     ^cY#05.htm##
00973000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704075100069002000700820#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#32#28#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Foram realizados,    durante o per&iacute;o
do de janeiro de 2007 a setembro de 2008, 108 exames de    artro RM em 96 pacien
tes atendidos por um ortopedista, com suspeita de les&atilde;o    <i>labral</i> 
por meio do sinal cl&iacute;nico de McCarthy positivo ao exame    f&iacute;sico 
e queixa &aacute;lgica na regi&atilde;o inguinal. Os exames de    imagem realiza
dos na Cl&iacute;nica Imagem Centro Diagn&oacute;stico, Florian&oacute;polis/SC.
    Dentre os pacientes, 37 indiv&iacute;duos eram do sexo masculino (m&eacute;d
ia    de idade de 39,3 anos; amplitude de 18 a 63 anos) e 56 do sexo feminino (m
&eacute;dia    de idade de 41,3 anos; amplitude de 20 a 73 anos).</font></p>    
 ^cY#05.htm##
00320000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009800069002000700167#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#33#29#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Artro RM</b></font></p>     ^cY#05.htm##
00571000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704034900069002000700418#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#34#30#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Todos os exames    foram feitos por meio de
 equipamentos <i>MRI Giroscan T5 0,5T</i><sup>&reg;</sup>    (Phillips, Holanda)
 ou <i>MRI Eclipse 1,5T</i><sup>&reg;</sup> (Picker, EUA),    utilizando bobinas
 flex&iacute;veis dedicadas &agrave; articula&ccedil;&atilde;o.</font></p>     ^
cY#05.htm##
00844000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704062200069002000700691#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#35#31#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O protocolo de    exame de artro RM incluiu
 sequ&ecirc;ncias spin-eco axiais e coronais ponderadas    em T1, com par&acirc;
metros TR/TE de 500-625/12-15, assim como sequ&ecirc;ncias    axiais, coronais e
 sagitais ponderadas em DP (densidade de pr&oacute;tons) com    satura&ccedil;&a
tilde;o de gordura e STIR (<i>inversion recovery</i>), com par&acirc;metros    T
R/TE de 2500-3500/ 40-45. A matriz utilizada foi de 256 x 256, com campo de    v
is&atilde;o (fov) entre 23 e 30cm. N&uacute;mero de excita&ccedil;&otilde;es    
(nex) de 1 ou 2.</font></p>     ^cY#05.htm##
00840000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704061800069002000700687#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#36#32#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Nos exames de artro    RM, foi realizado pr
eparo com protocolo de inje&ccedil;&atilde;o intra-articular    de solu&ccedil;&
atilde;o composta por 0,02ml de contraste paramagn&eacute;tico    (gadol&iacute;
nio), 4,0ml de contraste iodado n&atilde;o-i&ocirc;nico e 3,0ml    de bupivaca&i
acute;na 0,5%, sem vasoconstritor, dilu&iacute;dos em 10,0ml de    soro fisiol&o
acute;gico 0,9%. Em todos os casos o acesso foi realizado por via    anterior, n
o n&iacute;vel do colo do f&ecirc;mur, com agulha fina (22G), monitorado    por 
radioscopia.</font></p>     ^cY#05.htm##
00354000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704013200069002000700201#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#37#33#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Interpreta&ccedil;&atilde;o    das image
ns</b></font></p>     ^cY#05.htm##
00474000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704025200069002000700321#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#38#34#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As imagens foram    analisadas prospectivam
ente por dois m&eacute;dicos radiologistas com mais de    8 anos de experi&ecirc
;ncia em radiologia musculoesquel&eacute;tica.</font></p>     ^cY#05.htm##
00714000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704049200069002000700561#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#39#35#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Para a an&aacute;lise    da localiza&ccedil
;&atilde;o da les&atilde;o <i>labral</i> e da cartilagem acetabular    foram uti
lizados sequ&ecirc;ncias de imagens em plano sagital. A &aacute;rea    de carga 
do acet&aacute;bulo foi dividida em tr&ecirc;s por&ccedil;&otilde;es,    segundo
 Nishii <i>et al.</i>:<sup>15</sup> anterosuperior (AS), superior (SU)    e post
erosuperior (PS). (<a href="#f1">Figura 1</a>)</font></p>     ^cY#05.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#40#36#article#143#<p><a name="f1"></a></p>  
   ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#41#37#article#143#<p>&nbsp;</p>     ^cY#05.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#42#38#article#143#<p align="center"><img src
="/img/revistas/aob/v19n1/05f01.jpg"></p>     ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#43#39#article#143#<p>&nbsp;</p>     ^cY#05.h
tm##
01410000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704118800069002000701257#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#44#40#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Utilizou-se para    avaliar o grau de les&a
tilde;o <i>labral</i> o sistema de classifica&ccedil;&atilde;o    descrito por C
zerny <i>et al</i>.,<sup>3</sup> n&atilde;o se considerando as    subdivis&otild
e;es A e B. Na aus&ecirc;ncia de les&atilde;o, ou Grau 0, o <i>labrum</i>    pos
sui intensidade de sinal baixa e homog&ecirc;nea, forma triangular, e fixa&ccedi
l;&atilde;o    cont&iacute;nua &agrave; orla acetabular sem a exist&ecirc;ncia d
e corte ou    sulco. No Grau I o <i>labrum</i> acetabular apresenta aumento da i
ntensidade    do sinal se estendendo a margem <i>labral</i>, manuten&ccedil;&ati
lde;o da forma    triangular e fixa&ccedil;&atilde;o cont&iacute;nua &agrave; or
la acetabular    sem a exist&ecirc;ncia de corte ou sulco. No Grau II ocorre a e
xtens&atilde;o    do contraste para dentro do <i>labrum,</i> mas sem desinser&cc
edil;&atilde;o    da orla acetabular, n&atilde;o se levando em considera&ccedil;
&atilde;o o espessamento    ou a presen&ccedil;a ou n&atilde;o de recesso <i>lab
ral</i>. Na les&atilde;o    Grau III h&aacute; espessamento e desinser&ccedil;&a
tilde;o <i>labral</i>.</font></p>     ^cY#05.htm##
01012000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704079000069002000700859#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#45#41#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Para a classifica&ccedil;&atilde;o    do gr
au de degenera&ccedil;&atilde;o da cartilagem acetabular utilizou-se os    segui
ntes par&acirc;metros radiol&oacute;gicos: Grau 0, intensidade do sinal    norma
l sem irregularidades da superf&iacute;cie condral. Grau I, aumento da    intens
idade do sinal entre o baixo sinal da fibrocartilagem e o sinal intermedi&aacute
;rio    da cartilagem articular hialina, com pequena irregularidade da superf&ia
cute;cie.    Grau II, eros&atilde;o condral ou separa&ccedil;&atilde;o imediatam
ente adjacente    &agrave; fixa&ccedil;&atilde;o <i>labral</i>. Grau III, perda 
total da espessura    da cartilagem com &aacute;reas de exposi&ccedil;&atilde;o 
&oacute;ssea subcondral.</font></p>     ^cY#05.htm##
00466000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704024400069002000700313#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#46#42#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O estadiamento    do grau de les&atilde;o <
i>labral</i> e condral foi realizado atrav&eacute;s    da descri&ccedil;&atilde;
o em laudos de ambos os radiologistas.</font></p>     ^cY#05.htm##
00348000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012600069002000700195#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#47#43#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>An&aacute;lise    estat&iacute;stica</b>
</font></p>     ^cY#05.htm##
00402000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704018000069002000700249#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#48#44#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A an&aacute;lise    estat&iacute;stica foi 
feita por meio de an&aacute;lise descritiva dos dados.</font></p>     ^cY#05.htm
##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#49#45#article#143#<p>&nbsp;</p>     ^cY#05.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#50#46#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>     ^cY#05.htm
##
00971000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704074900069002000700818#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#51#47#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Dos 108 quadris    analisados observou-se q
ue em 42 (39%) quadris n&atilde;o houve ind&iacute;cios    de qualquer tipo de a
ltera&ccedil;&atilde;o anat&ocirc;mica como displasias    e IFAs. Em 39 (36%) qu
adris constatou-se IFA do tipo <i>cam</i>, em 12 (11%)    quadris IFA do tipo <i
>pincer</i>, e em 14 (13%) quadris ambos os tipos de IFA,    chamados aqui de mi
sto. No sexo masculino o IFA do tipo <i>cam</i> ocorreu em    29 (67%) quadris, 
enquanto que no sexo feminino a aus&ecirc;ncia de IFA ocorreu    em 35 (54%) qua
dris. (<a href="#f2">Figura 2</a>) Dos indiv&iacute;duos com    IFA do tipo <i>p
incer</i> 10 s&atilde;o do sexo feminino e 2 do sexo masculino.</font></p>     ^
cY#05.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#52#48#article#143#<p><a name="f2"></a></p>  
   ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#53#49#article#143#<p>&nbsp;</p>     ^cY#05.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#54#50#article#143#<p align="center"><img src
="/img/revistas/aob/v19n1/05f02.jpg"></p>     ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#55#51#article#143#<p>&nbsp;</p>     ^cY#05.h
tm##
00589000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704036700069002000700436#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#56#52#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Das causas de IFA    tipo <i>pincer</i> a r
etrovers&atilde;o acetabular foi evidenciada em 21 (19%)    e o acet&aacute;bulo
 profundo em 5 (5%) dos 108 quadris. Ambas foram observadas    em conjunto em ap
enas um caso. (Caso 75, <a href="/img/revistas/aob/v19n1/05t01.jpg">Tabela 1</a>
)</font></p>     ^cY#05.htm##
00448000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704022600069002000700295#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#57#53#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O acet&aacute;bulo    raso foi observado em
 somente 2 (2%) quadris. (Caso 60 e 66, <a href="/img/revistas/aob/v19n1/05t01.j
pg">Tabela    1</a>)</font></p>     ^cY#05.htm##
01519000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704129700069002000701366#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#58#54#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Em 24 quadris a    les&atilde;o ocorreu em 
apenas uma por&ccedil;&atilde;o do <i>labrum</i>. A    por&ccedil;&atilde;o AS f
oi acometida em 59 (40%) quadris, a por&ccedil;&atilde;o    SU em 38 (26%), a PS
 em 5 (3%), e o <i>labrum</i> foi lesionado como um todo    em 45 (31%) quadris.
 No sexo feminino, 40% (n = 39) das les&otilde;es ocorreram    em toda a por&cce
dil;&atilde;o <i>labral</i>. J&aacute; no sexo masculino a    por&ccedil;&atilde
;o mais acometida foi a AS em 42% (n = 25) dos casos. Dos    quadris com IFA do 
tipo <i>cam</i> 14 (36%) possu&iacute;am les&atilde;o <i>labral</i>    AS e SU, 
13 (33%) possu&iacute;am les&atilde;o em todo o <i>labrum</i>, 8 (21%)    apenas
 na por&ccedil;&atilde;o AS, 2 (5%) na por&ccedil;&atilde;o SU, e 2 (5%)    nas 
por&ccedil;&otilde;es AS e PS do <i>labrum</i>. Nos casos com IFA do tipo    <i>
pincer</i> 6 (50%) apresentavam les&atilde;o total do <i>labrum</i>, 3 (25%)    
na por&ccedil;&atilde;o AS e SU, 2 (17%) na por&ccedil;&atilde;o AS, e 1 (8%)   
 somente na parte PS. Em IFA do tipo misto 7 (50%) possu&iacute;am les&atilde;o 
   total do <i>labrum</i>, 6 (46%) na por&ccedil;&atilde;o AS e SU do <i>labrum<
/i>,    e 1 (7%) apenas na por&ccedil;&atilde;o AS.</font></p>     ^cY#05.htm##
01820000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704159800069002000701667#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#59#55#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Com rela&ccedil;&atilde;o    ao estadiament
o das les&otilde;es <i>labrais</i> observou-se que as les&otilde;es    de grau I
 ocorreram em 44 (41%) quadris, as les&otilde;es de grau II em 33 (31%),    e as
 les&otilde;es de grau III em 31 (29%) quadris. No sexo feminino as les&otilde;e
s    grau I foram as mais prevalentes sendo observadas em 27 (42%) quadris. No s
exo    masculino as les&otilde;es em grau I e grau II tiveram frequ&ecirc;ncias 
iguais    de 40% cada, isto &eacute;, 17 quadris para cada grau. Analisando apen
as as    les&otilde;es grau III estas foram mais frequentes em mulheres (71%; n 
= 22)    do que em homens (29%; n = 9). Dos sujeitos com IFA do tipo <i>cam</i> 
20 (51%)    possu&iacute;am les&atilde;o <i>labral</i> grau I, 12 (31%) les&atil
de;o grau    II e 7 (18%) les&atilde;o grau III. Dos indiv&iacute;duos com IFA d
o tipo <i>pincer</i>    6 (50%) apresentavam les&atilde;o <i>labral</i> grau I e
 6 (50%) grau III. Nenhum    caso apresentou les&atilde;o <i>labral</i> grau II.
 Nos casos com IFA do tipo    misto, 8 (57%) apresentaram les&atilde;o <i>labral
</i> grau III, e as les&otilde;es    grau I e grau II representaram 3 (21%) quad
ris cada. Nos quadris sem IFA 15    (35%) apresentavam les&atilde;o <i>labral</i
> grau I, 18 (42%) les&atilde;o    grau II e 10 (23%) les&atilde;o grau III. (<a
 href="#f3">Figura 3</a>) O grau    de les&atilde;o <i>labral</i> por por&ccedil
;&atilde;o do <i>labrum</i> est&aacute;    descrito na <a href="/img/revistas/ao
b/v19n1/05t01.jpg">Tabela 1</a>.</font></p>     ^cY#05.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#60#56#article#143#<p><a name="f3"></a></p>  
   ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#61#57#article#143#<p>&nbsp;</p>     ^cY#05.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#62#58#article#143#<p align="center"><img src
="/img/revistas/aob/v19n1/05f03.jpg"></p>     ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#63#59#article#143#<p>&nbsp;</p>     ^cY#05.h
tm##
00737000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704051500069002000700584#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#64#60#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Em rela&ccedil;&atilde;o    &agrave;s les&o
tilde;es condrais, estas ocorreram em 88 (81%) acet&aacute;bulos    e foram ause
ntes em 20 (19%). Em 46 (44%) quadris as les&otilde;es condrais    foram observa
das em toda a zona de carga, em 36 (35%) acet&aacute;bulos apenas    na por&cced
il;&atilde;o AS, em 22 (21%) na por&ccedil;&atilde;o SU, e nenhuma    les&atilde
;o foi observada somente na por&ccedil;&atilde;o PS da zona de carga.</font></p>
     ^cY#05.htm##
01490000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704126800069002000701337#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#65#61#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A les&atilde;o    condral grau I foi observ
ada em 55 (51%) acet&aacute;bulos, as les&otilde;es    grau II em 14 (13%), e gr
au III em 19 (18%). Em rela&ccedil;&atilde;o ao grau    de les&atilde;o da carti
lagem acetabular em indiv&iacute;duos com IFA do tipo    <i>cam</i> 24 (62%) ace
t&aacute;bulos possu&iacute;am les&atilde;o condral do    tipo grau I, 6 (15%) a
cet&aacute;bulos com les&atilde;o grau III, 2 (5%) com    les&atilde;o grau II e
 7 (18%) com grau 0. Nos acet&aacute;bulos com IFA do    tipo <i>pincer</i> 6 (5
0%) apresentavam les&atilde;o condral grau I, 3 (25%)    quadris com les&atilde;
o grau III, 3 (25%) quadris com grau 0, e em nenhum acet&aacute;bulo    foi obse
rvado les&atilde;o condral grau II. Em sujeitos com IFA do tipo misto    5 (36%)
 acet&aacute;bulos possu&iacute;am les&atilde;o condral grau I, 4 (29%)    acet&
aacute;bulos les&atilde;o grau II, e em 3 (21%) quadris les&atilde;o grau    III
. Em 2 (14%) acet&aacute;bulos n&atilde;o havia les&atilde;o condral. (<a href="
#f4">Figura    4</a>) O grau de les&atilde;o condral por por&ccedil;&atilde;o do
 acet&aacute;bulo    est&aacute; descrito na <a href="/img/revistas/aob/v19n1/05
t01.jpg">Tabela 1</a>.</font></p>     ^cY#05.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#66#62#article#143#<p><a name="f4"></a></p>  
   ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#67#63#article#143#<p>&nbsp;</p>     ^cY#05.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#68#64#article#143#<p align="center"><img src
="/img/revistas/aob/v19n1/05f04.jpg"></p>     ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#69#65#article#143#<p>&nbsp;</p>     ^cY#05.h
tm##
00474000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704025200069002000700321#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#70#66#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">N&atilde;o foi    observada rela&ccedil;&at
ilde;o entre o grau de les&atilde;o <i>labral</i> e    o grau de les&atilde;o co
ndral acetabular. (<a href="#t2">Tabela 2</a>)</font></p>     ^cY#05.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#71#67#article#143#<p><a name="t2"></a></p>  
   ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#72#68#article#143#<p>&nbsp;</p>     ^cY#05.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#73#69#article#143#<p align="center"><img src
="/img/revistas/aob/v19n1/05t02.jpg"></p>     ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#74#70#article#143#<p>&nbsp;</p>     ^cY#05.h
tm##
00439000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704021700069002000700286#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#75#71#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A tendinite dos    m&uacute;sculos gl&uacut
e;teos estava presente em 27 (25%) quadris. Destes,    23 (85%) ocorreram no sex
o feminino.</font></p>     ^cY#05.htm##
00437000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704021500069002000700284#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#76#72#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A frequ&ecirc;ncia    de bursite trocant&ea
cute;rica foi de 28 (26%) casos. Destes, 25 (89%) foram    evidenciados no sexo 
feminino.</font></p>     ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#77#73#article#143#<p>&nbsp;</p>     ^cY#05.h
tm##
00328000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010600069002000700175#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#78#74#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font></p>     ^cY#
05.htm##
01149000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704092700069002000700996#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#79#75#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As les&otilde;es    <i>labrais</i> ocasiona
das por altera&ccedil;&otilde;es anat&ocirc;micas como    IFAs e displasias ocor
reram em 61% dos quadris, e em 39% n&atilde;o houve ind&iacute;cios    de qualqu
er altera&ccedil;&atilde;o &agrave; artro RM. Os IFAs do tipo <i>pincer</i>    e
 misto ocorreram em apenas 23% dos quadris e a maior preval&ecirc;ncia de IFA   
 do tipo <i>pincer</i> ocorreu em mulheres. Dentre as altera&ccedil;&otilde;es  
  morfol&oacute;gicas causadoras do IFA do tipo <i>pincer,</i> a retrovers&atild
e;o    acetabular foi mais prevalente do que o acet&aacute;bulo profundo. Os IFA
s do    tipo <i>cam</i> foram os mais prevalentes e em 67% dos casos eram do sex
o masculino,    o que est&aacute; de acordo com os estudos de Ito <i>et al.</i><
sup>6</sup>,    Beck <i>et al</i>.<sup>9</sup> e Ganz <i>et al</i>.<sup>12</sup>
.</font></p>     ^cY#05.htm##
00724000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704050200069002000700571#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#80#76#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As les&otilde;es    <i>labrais</i> sem apar
ente fator etiol&oacute;gico &agrave; artro RM podem    estar relacionadas a fat
ores biomec&acirc;nicos que aumentam a adu&ccedil;&atilde;o    e rota&ccedil;&at
ilde;o interna do f&ecirc;mur como, por exemplo, retro p&eacute;    varo, joelho
 valgo, discrep&acirc;ncias de comprimento de membros inferiores,    retrovers&a
tilde;o femoral<sup>16</sup> ou por traumas.<sup>8</sup></font></p>     ^cY#05.h
tm##
01031000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704080900069002000700878#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#81#77#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Entretanto, as    diferentes morfologias do
 quadril podem estar relacionadas a les&otilde;es <i>labrais</i>    com caracter
&iacute;sticas especificas. Nosso estudo demonstrou que a maior    parte das les
&otilde;es <i>labrais</i> ocorre na por&ccedil;&atilde;o AS do    <i>labrum</i> 
e est&aacute; de acordo com a literatura<sup>3,4,9,13,14,17,18</sup>,    apesar 
de observamos uma elevada frequ&ecirc;ncia (31%) de les&atilde;o total    do <i>
labrum</i>, principalmente no sexo feminino. De acordo com Lewis e Sahrmann<sup>
19</sup>,    a preval&ecirc;ncia de les&otilde;es AS se deve por esta regi&atild
e;o estar    sujeita a elevada for&ccedil;as direcionadas anteriormente e a fraq
ueza mec&acirc;nica    desta regi&atilde;o.</font></p>     ^cY#05.htm##
01204000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704098200069002000701051#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#82#78#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Segundo Beck <i>et    al</i>.<sup>9</sup> e
 Pfirmann <i>et al.<sup>14</sup></i>, em quadris com IFA    do tipo <i>cam</i> a
s les&otilde;es <i>labrais</i> ocorrem principalmente na    por&ccedil;&atilde;o
 AS devido &agrave; perda da esfericidade anterior da cabe&ccedil;a    do f&ecir
c;mur. Isto n&atilde;o ocorre em casos de IFA do tipo <i>pincer</i>    onde as l
es&otilde;es tendem a ser mais distribu&iacute;das, no entanto com    predom&iac
ute;nio na por&ccedil;&atilde;o SU.<sup>9</sup> Nossos achados v&atilde;o    ao 
encontro desses autores. Contudo, ressaltamos que houve uma elevada frequ&ecirc;
ncia    (33%) de les&atilde;o total do <i>labrum</i> em quadris com IFA do tipo 
<i>cam</i>    e em dois casos nas por&ccedil;&otilde;es AS e PS. J&aacute; em qu
adris do tipo    misto, observamos uma maior incid&ecirc;ncia de les&otilde;es e
m toda a por&ccedil;&atilde;o    do <i>labrum</i> (50%).</font></p>     ^cY#05.h
tm##
01146000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704092400069002000700993#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#83#79#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Em rela&ccedil;&atilde;o    ao estadiamento
 das les&otilde;es <i>labrais</i> observamos maior frequ&ecirc;ncia    de les&ot
ilde;es grau I, seguidas de les&otilde;es grau II e grau III. Na literatura    e
xiste bastante varia&ccedil;&atilde;o quanto ao grau de maior incid&ecirc;ncia. 
   Czerny <i>et al</i>.<sup>3</sup> observaram a mesma ordem com 24 les&otilde;e
s    <i>labrais</i> grau I, 19 les&otilde;es grau II e 8 les&otilde;es grau III.
    Por&eacute;m em estudo posterior, Czerny <i>et al</i>.<sup>4</sup> evidencia
ram    24 les&otilde;es <i>labrais</i> grau III, 7 les&otilde;es grau II e 4 les
&otilde;es    grau I. J&aacute; Blankenbaker <i>et al</i>.<sup>18</sup> observar
am 42 casos    de les&otilde;es <i>labrais</i> grau II e 23 de les&otilde;es gra
u III, n&atilde;o    havendo nenhum caso de les&atilde;o <i>labral</i> grau I.</
font></p>     ^cY#05.htm##
01393000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704117100069002000701240#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#84#80#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Tanto as les&otilde;es    <i>labrais</i> qu
anto o IFA e a displasia de quadril s&atilde;o poss&iacute;veis    fatores etiol
&oacute;gicos para a osteoartrite de quadril.<sup>1,3,12</sup>    Acredita-se qu
e a les&atilde;o <i>labral</i> aumenta em duas vezes o risco de    les&atilde;o 
condral.<sup>1</sup> Diante disso, estudos por videoartroscopia    e artro RM t&
ecirc;m relatado uma associa&ccedil;&atilde;o entre les&atilde;o    <i>labral</i
> e condral que varia de 52,7%<sup>5</sup> a 73%.<sup>1</sup> J&aacute;    em su
jeitos com IFA, as les&otilde;es condrais estiveram presentes em 88%<sup>20</sup
>    e 95%.<sup>7</sup> Em nosso estudo as les&otilde;es condrais acetabulares e
stiveram    presentes em 81% dos quadris com les&atilde;o <i>labral</i>. Geralme
nte as les&otilde;es    condrais s&atilde;o adjacentes &agrave;s les&otilde;es <
i>labrais</i> e ocorrem    em sua maioria na por&ccedil;&atilde;o AS do acet&aac
ute;bulo.<sup>1,7,9,20</sup>    Em contrapartida, observamos que apenas 35% ocor
reram somente na por&ccedil;&atilde;o    AS e 44% em toda a zona de carga acetab
ular.</font></p>     ^cY#05.htm##
01077000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704085500069002000700924#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#85#81#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Apesar da elevada    associa&ccedil;&atilde
;o entre a les&atilde;o <i>labral</i> e condral, o grau    de les&atilde;o condr
al provavelmente n&atilde;o est&aacute; relacionado ao    grau de les&atilde;o <
i>labral</i>. Nossos achados demonstraram que mesmo em    casos de les&otilde;es
 <i>labrais</i> grau II e grau III, a frequ&ecirc;ncia    de les&otilde;es condr
ais acetabulares grau I foi de 55% e 58%, respectivamente.    (<a href="#t2">Tab
ela 2</a>) Cirurgicamente, Ito <i>et al.</i><sup>21</sup>    avaliaram as caract
er&iacute;stica histopatol&oacute;gicas do <i>labrum</i>    e morfol&oacute;gica
s da cartilagem acetabular e n&atilde;o observaram rela&ccedil;&atilde;o    entr
e as caracter&iacute;sticas do <i>labrum</i> com a severidade da les&atilde;o   
 condral.</font></p>     ^cY#05.htm##
01370000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704114800069002000701217#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#86#82#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Por outro lado,    a conforma&ccedil;&atild
e;o &oacute;ssea anat&ocirc;mica pode estar relacionada    ao grau de les&atilde
;o <i>labral</i> e condral. As altera&ccedil;&otilde;es    anat&ocirc;micas dos 
quadris com IFA do tipo <i>cam</i> provocam extensa les&atilde;o    condral com 
exposi&ccedil;&atilde;o &oacute;ssea subcondral e desinser&ccedil;&atilde;o    <
i>labral.</i> No entanto, as les&otilde;es condrais tendem a ser mais limitas   
 e de menor gravidade nos IFAs do tipo <i>pincer</i>.<sup>9,12</sup> James <i>et
    al.<sup>13</sup></i> evidenciaram focos de exposi&ccedil;&atilde;o &oacute;s
sea    e desinser&ccedil;&atilde;o <i>labral</i> em 50% dos sujeitos com IFA do 
tipo    <i>cam</i>. Nosso estudo observou que 51% dos sujeitos com IFA do tipo <
i>cam</i>    apresentam les&atilde;o <i>labral</i> grau I, e apenas 23% com les&
atilde;o    <i>labral</i> grau III. Com rela&ccedil;&atilde;o &agrave; les&atild
e;o condral    observamos que apenas 15% dos quadris com IFA do tipo <i>cam</i> 
apresentam    les&atilde;o grau III e 62% les&atilde;o grau I.</font></p>     ^c
Y#05.htm##
01368000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704114600069002000701215#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#87#83#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As tendinites dos    m&uacute;sculos abduto
res do quadril, em especifico o gl&uacute;teo m&eacute;dio,    e a bursite troca
nt&eacute;rica s&atilde;o respons&aacute;veis por dor em regi&atilde;o    gl&uac
ute;tea e no entorno do troc&acirc;nter, ocasionada por atividades que    exigem
 flex&atilde;o do quadril como na marcha, descida de degrau, ou ao permanecer   
 sentado. Este quadro clinico &eacute; semelhante ao observado em indiv&iacute;d
uos    com les&atilde;o labral, e, portanto, &eacute; visto como um dos diagn&oa
cute;sticos    diferenciais. Todavia, a associa&ccedil;&atilde;o entre estas les
&otilde;es    n&atilde;o &eacute; relatada na literatura. Em nossos achados as t
endinites    dos m&uacute;sculos gl&uacute;teos estava presente em 27 (25%) quad
ris, sendo    que destes 85% ocorreram no sexo feminino. A frequ&ecirc;ncia de b
ursite trocant&eacute;rica    foi de 28 (26%) casos e em 89% foram evidenciados 
no sexo feminino. Esta condi&ccedil;&atilde;o    ocorreu em associa&ccedil;&atil
de;o &agrave; tendinite dos gl&uacute;teos em    18 quadris.</font></p>     ^cY#
05.htm##
01006000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704078400069002000700853#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#88#84#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Nosso estudo apresenta    como limita&ccedi
l;&atilde;o a falta de mensura&ccedil;&atilde;o quantitativa    acerca da morfol
ogia do quadril. Nem todos os casos foram utilizados o &acirc;ngulo    </font><f
ont size="2">&#945;</font><font face="Verdana, Arial, Helvetica, sans-serif" siz
e="2">    para quantificar a altera&ccedil;&atilde;o da jun&ccedil;&atilde;o cab
e&ccedil;a-colo    do f&ecirc;mur, &acirc;ngulo de Wiberg que descreve a rela&cc
edil;&atilde;o    do f&ecirc;mur e acet&aacute;bulo, e &acirc;ngulo de cobertura
 acetabular. Outro    fator limitante &eacute; a subjetividade para o estadiamen
to do grau de les&atilde;o    <i>labral</i> diante da t&eacute;cnica radiol&oacu
te;gica empregada.</font></p>     ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#89#85#article#143#<p>&nbsp;</p>     ^cY#05.h
tm##
00328000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010600069002000700175#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#90#86#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>CONCLUS&Atilde;O</b></font></p>     ^cY#
05.htm##
01219000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704099700069002000701066#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#91#87#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Observamos que    o segmento <i>labral</i> 
AS e toda a cartilagem da zona de carga acetabular    foram as por&ccedil;&otild
e;es mais acometidas. Em casos de IFA do tipo <i>pincer</i>    as les&otilde;es 
em todo o <i>labro</i> foram mais prevalentes, j&aacute; em    IFA do tipo <i>ca
m</i> a por&ccedil;&atilde;o AS foram mais frequentes. Em rela&ccedil;&atilde;o 
   ao grau de les&atilde;o <i>labral</i> e condral foram predominantes as les&ot
ilde;es    grau I independente da presen&ccedil;a ou do tipo de IFA, exceto em I
FAs do    tipo misto onde houve predom&iacute;nio de les&atilde;o <i>labral</i> 
grau III.    N&atilde;o observamos uma poss&iacute;vel rela&ccedil;&atilde;o ent
re o grau    de les&atilde;o <i>labral</i> e condral. A frequ&ecirc;ncia de retr
overs&atilde;o    acetabular, displasia, cistos paralabrais, tendinite dos m&uac
ute;sculos gl&uacute;teos    e bursite trocant&eacute;rica foi pequena.</font></
p>     ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#92#88#article#143#<p>&nbsp;</p>     ^cY#05.h
tm##
00329000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010700069002000700176#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#93#89#article#143#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font></p>     ^cY
#05.htm##
00493000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704025700071002000700328#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#94#90#article#143#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1. McCarthy J,    Noble P, Al
uisio FV, Schuck M, Wright J, Lee J. The role of labral lesions to    developmen
t of early degenerative hip desease. Clin Orthop Relat Res. 2001;(393);25-31.   
 ^cY#05.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#95#91#article#143#</font></p>     ^cY#05.htm
##
00491000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704025500071002000700326#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#96#92#article#143#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2. Crawford MJ,    Dy CJ, Ale
xander JW, Thompson M, Schroder SJ, Vega CE et al. The biomechanics    of hip la
brum and the stability of the hip. Clin Orthop Relat Res. 2007;(465):12-22.    ^
cY#05.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#97#93#article#143#</font></p>     ^cY#05.htm
##
00519000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704028300071002000700354#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#98#94#article#143#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">3. Czerny C, Hofmann    S, Ne
uhold A, Tschauner C, Engel A, Recht MP et al. Lesions of the acetabular    labr
um: accuracy of MR imaging and MR arthrography in detection and staging.    Radi
ology. 1996;200:225-30.    ^cY#05.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#99#95#article#143#</font></p>     ^cY#05.htm
##
00538000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704030100072002000700373#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#100#96#article#143#4#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">4. Czerny C, Hofmann    S, U
rban M, Tschauner C, Neuhold A, Pretterklieber M, et al. MR arthrography    of t
he adult acetabular capsular-labral complex: correlation with surgery and    ana
tomy. AJR Am J Roentgenol. 1999;173;345-9.    ^cY#05.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#101#97#article#143#</font></p>     ^cY#05.ht
m##
00609000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704037200072002000700444#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#102#98#article#143#5#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">5. Contreras MEK,    Brincas
 SM, Paes J&uacute;nior AJ, Oliveira GR, La Rosa FJ. A resson&acirc;ncia    magn
&eacute;tica e a artrorresson&acirc;ncia magn&eacute;tica na les&atilde;o    lab
ral e condral do quadril: compara&ccedil;&atilde;o com achados na artroscopia.  
  Rev Bras Ortop. 2008;43:217-24.    ^cY#05.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#103#99#article#143#</font></p>     ^cY#05.ht
m##
00532000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704029400073002000700367#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#104#100#article#143#6#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">6. Ito K, Minka-II    M.-A.
, Leunig M, Werlen S, Ganz R. Femoroacetabular impingement and the cam-effect.  
  A MRI-based quantitative anatomical study of the femoral head-neck offset. J  
  Bone Joint Surg Br. 2001;83:171-6.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#105#101#article#143#</font></p>     ^cY#05.h
tm##
00510000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704027200073002000700345#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#106#102#article#143#7#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">7. Kassarjian,    A.; Yoon 
LS; Belzile E; Connolly SA; Millis MB; Palmer WE. Triad of MR arthrographic    f
indings in patients with cam-type femoroacetabular impingement. Radiology.    20
05;236:588-92.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#107#103#article#143#</font></p>     ^cY#05.h
tm##
00471000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704023300073002000700306#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#108#104#article#143#8#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">8. Martin RL, Enseki    KR,
 Draovitch P, Trapuzzano T, Philippon MJ. Acetabular labral tears of the    hip:
 examination and diagnostic challenges. 2006;36:503-15.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#109#105#article#143#</font></p>     ^cY#05.h
tm##
00547000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704030900073002000700382#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#110#106#article#143#9#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">9. Beck M, Kalhor    M, Leu
nig M, Ganz R. Hip morphology influences the pattern of damage to the    acetabu
lar cartilage: femoroacetabular impingement as a cause of early osteoarthritis  
  of the hip. J Bone Joint Surg Br. 2005;87-1012-8.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#111#107#article#143#</font></p>     ^cY#05.h
tm##
00500000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026100074002000700335#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#112#108#article#143#10#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Leunig M, Podeszwa    
D, Beck M, Werlen S, Ganz R. Magnetic resonance arthrography of labral disorders
    in hips with dysplasia and impingement. Clin Orthop Relat Res. 2004;(418):74
-80.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#113#109#article#143#</font></p>     ^cY#05.h
tm##
00460000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022100074002000700295#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#114#110#article#143#11#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Haene RA, Bradley    M
, Villar RN. Hip dysplasia and the torn acetabular labrum an inexact relationshi
p.    J Bone Joint Surg Br. 2007;89:1289-92.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#115#111#article#143#</font></p>     ^cY#05.h
tm##
00488000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024900074002000700323#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#116#112#article#143#12#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Ganz R, Parvizi    J, 
Beck M, Leunig M, Hubert N, Siebenrck KA. Femoroacetabular impingement: a    cau
se for osteoarthritis of the hip. J Bone Joint Surg Br. 2003;417:112-20.    ^cY#
05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#117#113#article#143#</font></p>     ^cY#05.h
tm##
00460000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022100074002000700295#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#118#114#article#143#13#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">13. James SL, Ali    K, Ma
lara F, Young D, O'Donnell J, Connell DA. MRI findings of femoroacetabular    im
pingement. Am J Roentgenol. 2006;187:1412-9.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#119#115#article#143#</font></p>     ^cY#05.h
tm##
00518000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027900074002000700353#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#120#116#article#143#14#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Pfirmann CW;    Mengia
rdi B; Dora C; Kalberer F, Zanetti M, Hodler J. Cam and pincer femoroacetabular 
   impingment: characteristic MR arthrographic findings in 50 pacients. Radiolog
y.    2006;204:778-85.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#121#117#article#143#</font></p>     ^cY#05.h
tm##
00541000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030200074002000700376#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#122#118#article#143#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Nishii T, Tanaka    H,
 Nakanishi K, Sugano N, Miki H, Yoshikawa H. Fat-Suppressed 3D Spoiled Gradient-
Echo    MRI and MDCT Arthrography of Articular Cartilage in Patients with Hip Dy
splasia.    Am J Roentgenol. 2005;185:379-85.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#123#119#article#143#</font></p>     ^cY#05.h
tm##
00485000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024600074002000700320#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#124#120#article#143#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Riegger-Krugh    C, Ke
ysor JJ. Skeletal malalignments of the lower quarter: correlated and compensator
y    motions and postures. J Orthop Sports Phys Ther. 1996;23:164-70.    ^cY#05.
htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#125#121#article#143#</font></p>     ^cY#05.h
tm##
00542000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030300074002000700377#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#126#122#article#143#17#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Noguchi Y,    Miura H,
 Takasugi S, Iwamot Y. Cartilage and labrum degeneration in the dysplastic    hi
p generally originates in the anterosuperiorweight-bearing area: an arthroscopic
    observation. Arthroscopy. 1999;15:496-506.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#127#123#article#143#</font></p>     ^cY#05.h
tm##
00459000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022000074002000700294#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#128#124#article#143#18#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Blankenbaker    DG, De
 Smet AA, Keene JS, Fine JP. Classification and localization of acetabular    la
bral tears. Skeletal Radiol. 2007;36:391-7.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#129#125#article#143#</font></p>     ^cY#05.h
tm##
00391000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704015200074002000700226#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#130#126#article#143#19#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Lewis CL, Sahrmann    
AS. Acetabular labral tears. Phys Ther. 2006;86:110-21.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#131#127#article#143#</font></p>     ^cY#05.h
tm##
00478000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704023900074002000700313#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#132#128#article#143#20#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Schmid MR,    N&ouml;t
zli HP, Zanetti M, Wyss TF, Hodler J. Cartilage lesions in the hip:    diagnosti
c effectiveness of MR arthrography. Radiology. 2003;226:382-6.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#133#129#article#143#</font></p>     ^cY#05.h
tm##
00473000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704023400074002000700308#v19
n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#p#134#130#article#143#21#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Ito K, MD,    Leunig M
, Ganz R. Histopathologic features of the acetabular labrum in femoroacetabular 
   impingement. Clin Orthop Relat Res. 2004;(429):262-71.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#135#131#article#143#</font></p>     ^cY#05.h
tm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#136#132#article#143#<p>&nbsp;</p>     ^cY#05
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#137#133#article#143#<p>&nbsp;</p>     ^cY#05
.htm##
00430000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704020600071002000700277#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#138#134#article#143#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top"><img sr
c="/img/revistas/aob/v19n1/seta.jpg" border="0"></a>    <b>Endereço para Corresp
ondência:</b>     ^cY#05.htm##
00289000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704006500071002000700136#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#139#135#article#143#<br>   R. Jos&eacute; Fr
ancisco Dias Areias 335, Trindade    ^cY#05.htm##
00271000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004700071002000700118#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#140#136#article#143#<br>   Florian&oacute;po
lis, SC. Brasil    ^cY#05.htm##
00253000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002900071002000700100#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#141#137#article#143#<br>   CEP: 88036-120   
 ^cY#05.htm##
00330000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704010600071002000700177#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#142#138#article#143#<br>   Email: <a href="m
ailto:rpizzolatti@terra.com.br">rpizzolatti@terra.com.br</a></font>  </p>     ^c
Y#05.htm##
00362000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013800071002000700209#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#143#139#article#143#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Artigo recebido    em 02/04/09, aprovado 
em 28/07/2009.</font></p>     ^cY#05.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#144#140#article#143#<p>&nbsp;</p>     ^cY#05
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#145#141#article#143#<p>&nbsp;</p>     ^cY#05
.htm##
00406000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704018200071002000700253#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#146#142#article#143#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Trabalho realizado    na Cl&iacute;nica I
magem Centro Diagn&oacute;stico - Florian&oacute;polis, SC,    Brasil.    ^cY#05
.htm##
00361000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013700071002000700208#v19n1#V:\SciELO
\serial\aob\v19n1\markup\05.htm#S#p#147#143#article#143#<br>   Todos os autores 
declaram n&atilde;o haver nenhum potencial conflito de interesses    referente a
 este artigo.</font></p>     ^cY#05.htm##
00626000000000313000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100015000880100
01800103010001600121010001600137010001400153012008000167030002300247710000200270
065000900272064000500281032000400286014000600290865000900296002000700305#v19n1#V
:\SciELO\serial\aob\v19n1\markup\05.htm#S#c#148#1#article#21#1#^rND^sMcCarthy^nJ
#^rND^sNoble^nP#^rND^sAluisio^nFV#^rND^sSchuck^nM#^rND^sWright^nJ#^rND^sLee^nJ.#
The role of labral lesions to development of early degenerative hip desease^len#
Clin Orthop Relat Res.#2#20010000#2001#393#25-31#20110000#05.htm##
00636000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700100013000890100
02000102010001800122010001900140010001500159810000700174012006400181030002300245
71000020026806500090027006400050027903200040028401400060028886500090029400200070
0303#v19n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#c#149#2#article#21#2#^rND^
sCrawford^nMJ#^rND^sDy^nCJ#^rND^sAlexander^nJW#^rND^sThompson^nM#^rND^sSchroder^
nSJ#^rND^sVega^nCE#et al.#The biomechanics of hip labrum and the stability of th
e hip^len#Clin Orthop Relat Res.#2#20070000#2007#465#12-22#20110000#05.htm##
00692000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100017000860100
01700103010001900120010001500139010001600154810000700170012010600177030001000283
06500090029306400050030203100040030701400070031186500090031800200070032703500100
0334801001000344#v19n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#c#150#3#articl
e#21#3#^rND^sCzerny^nC#^rND^sHofmann^nS#^rND^sNeuhold^nA#^rND^sTschauner^nC#^rND
^sEngel^nA#^rND^sRecht^nMP#et al.#Lesions of the acetabular labrum: accuracy of 
MR imaging and MR arthrography in detection and staging^len#Radiology#19960000#1
996#200#225-30#20110000#05.htm#0033-8419#Radiology##
00680000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100017000860100
01500103010001900118010001700137010002400154810000700178012010600185030002100291
71000020031206500090031406400050032303100040032801400060033286500090033800200070
0347#v19n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#c#151#4#article#21#4#^rND^
sCzerny^nC#^rND^sHofmann^nS#^rND^sUrban^nM#^rND^sTschauner^nC#^rND^sNeuhold^nA#^
rND^sPretterklieber^nM#et al.#MR arthrography of the adult acetabular capsular-l
abral complex: correlation with surgery and anatomy^len#AJR Am J Roentgenol.#2#1
9990000#1999#173#345-9#20110000#05.htm##
00664000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100021000700100018000910100
02200109010001900131010001800150012013600168030001600304710000200320065000900322
064000500331031000300336014000700339865000900346002000700355#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\05.htm#S#c#152#5#article#21#5#^rND^sContreras^nMEK#^rND^sBr
incas^nSM#^rND^sPaes Júnior^nAJ#^rND^sOliveira^nGR#^rND^sLa Rosa^nFJ#A ressonânc
ia magnética e a artrorressonância magnética na lesão labral e condral do quadri
l: comparação com achados na artroscopia^lpt#Rev Bras Ortop.#2#20080000#2008#43#
217-24#20110000#05.htm##
00644000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100013000700100022000830100
01600105010001600121010001500137012012700152030002200279710000200301065000900303
064000500312031000300317014000600320865000900326002000700335#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\05.htm#S#c#153#6#article#21#6#^rND^sIto^nK#^rND^sMinka-II^n
M.-A.#^rND^sLeunig^nM#^rND^sWerlen^nS#^rND^sGanz^nR.#Femoroacetabular impingemen
t and the cam-effect: A MRI-based quantitative anatomical study of the femoral h
ead-neck offset^len#J Bone Joint Surg Br.#2#20010000#2001#83#171-6#20110000#05.h
tm##
00668000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100021000700100015000910100
01700106010001900123010001700142010001800159012009400177030001000271065000900281
06400050029003100040029501400070029986500090030600200070031503500100032280100100
0332#v19n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#c#154#7#article#21#7#^rND^
sKassarjian^nA.#^rND^sYoon^nLS#^rND^sBelzile^nE#^rND^sConnolly^nSA#^rND^sMillis^
nMB#^rND^sPalmer^nWE.#Triad of MR arthrographic findings in patients with cam-ty
pe femoroacetabular impingement^len#Radiology#20050000#2005#236#588-92#20110000#
05.htm#0033-8419#Radiology##
00559000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680160017000700160017000870160
01900104016002000123016002000143018007800163065000900241064000500250031000300255
014000700258865000900265002000700274#v19n1#V:\SciELO\serial\aob\v19n1\markup\05.
htm#S#c#155#8#article#21#8#^rND^sMartin^nRL#^rND^sEnseki^nKR#^rND^sDraovitch^nP#
^rND^sTrapuzzano^nT#^rND^sPhilippon^nMJ#Acetabular labral tears of the hip: exam
ination and diagnostic challenges^len#20060000#2006#36#503-15#20110000#05.htm##
00641000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100014000700100016000840100
01600100010001500116012015600131030002200287710000200309065000900311064000500320
031000300325014000700328865000900335002000700344#v19n1#V:\SciELO\serial\aob\v19n
1\markup\05.htm#S#c#156#9#article#21#9#^rND^sBeck^nM#^rND^sKalhor^nM#^rND^sLeuni
g^nM#^rND^sGanz^nR.#Hip morphology influences the pattern of damage to the aceta
bular cartilage: femoroacetabular impingement as a cause of early osteoarthritis
 of the hip^len#J Bone Joint Surg Br.#2#20050000#2005#87#1012-8#20110000#05.htm#
#
00612000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100018000880100
01400106010001600120010001400136012009500150030002300245710000200268065000900270
064000500279032000400284014000600288865000900294002000700303#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\05.htm#S#c#157#10#article#21#10#^rND^sLeunig^nM#^rND^sPodes
zwa^nD#^rND^sBeck^nM#^rND^sWerlen^nS#^rND^sGanz^nR#Magnetic resonance arthrograp
hy of labral disorders in hips with dysplasia and impingement^len#Clin Orthop Re
lat Res.#2#20040000#2004#418#74-80#20110000#05.htm##
00538000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100017000880100
01700105012007300122030002200195710000200217065000900219064000500228031000300233
014000800236865000900244002000700253#v19n1#V:\SciELO\serial\aob\v19n1\markup\05.
htm#S#c#158#11#article#21#11#^rND^sHaene^nRA#^rND^sBradley^nM#^rND^sVillar^nRN#H
ip dysplasia and the torn acetabular labrum an inexact relationship^len#J Bone J
oint Surg Br.#2#20070000#2007#89#1289-92#20110000#05.htm##
00620000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100014000720100017000860100
01400103010001600117010001600133010002000149012007200169030002200241710000200263
065000900265064000500274031000400279014000700283865000900290002000700299#v19n1#V
:\SciELO\serial\aob\v19n1\markup\05.htm#S#c#159#12#article#21#12#^rND^sGanz^nR#^
rND^sParvizi^nJ#^rND^sBeck^nM#^rND^sLeunig^nM#^rND^sHubert^nN#^rND^sSiebenrck^nK
A#Femoroacetabular impingement: a cause for osteoarthritis of the hip^len#J Bone
 Joint Surg Br.#2#20030000#2003#417#112-20#20110000#05.htm##
00592000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100013000880100
01600101010001500117010001900132010001800151012004900169030001700218710000200235
065000900237064000500246031000400251014000700255865000900262002000700271#v19n1#V
:\SciELO\serial\aob\v19n1\markup\05.htm#S#c#160#13#article#21#13#^rND^sJames^nSL
#^rND^sAli^nK#^rND^sMalara^nF#^rND^sYoung^nD#^rND^sO'Donnell^nJ#^rND^sConnell^nD
A#MRI findings of femoroacetabular impingement^len#Am J Roentgenol.#2#20060000#2
006#187#1412-9#20110000#05.htm##
00677000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100019000910100
01400110010001800124010001700142010001700159012010400176030001000280065000900290
06400050029903100040030401400070030886500090031500200070032403500100033180100100
0341#v19n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#c#161#14#article#21#14#^rN
D^sPfirmann^nCW#^rND^sMengiardi^nB#^rND^sDora^nC#^rND^sKalberer^nF#^rND^sZanetti
^nM#^rND^sHodler^nJ.#Cam and pincer femoroacetabular impingment: characteristic 
MR arthrographic findings in 50 pacients^len#Radiology#20060000#2006#204#778-85#
20110000#05.htm#0033-8419#Radiology##
00670000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100016000880100
01900104010001600123010001400139010001900153012012400172030001700296710000200313
065000900315064000500324031000400329014000700333865000900340002000700349#v19n1#V
:\SciELO\serial\aob\v19n1\markup\05.htm#S#c#162#15#article#21#15#^rND^sNishii^nT
#^rND^sTanaka^nH#^rND^sNakanishi^nK#^rND^sSugano^nN#^rND^sMiki^nH#^rND^sYoshikaw
a^nH#Fat-Suppressed 3D Spoiled Gradient-Echo MRI and MDCT Arthrography of Articu
lar Cartilage in Patients with Hip Dysplasia^len#Am J Roentgenol.#2#20050000#200
5#185#379-85#20110000#05.htm##
00546000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100023000720100018000950120
09800113030002700211710000200238065000900240064000500249031000300254014000700257
865000900264002000700273#v19n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#c#163#
16#article#21#16#^rND^sRiegger-Krugh^nC#^rND^sKeysor^nJJ.#Skeletal malalignments
 of the lower quarter: correlated and compensatory motions and postures^len#J Or
thop Sports Phys Ther.#2#19960000#1996#23#164-70#20110000#05.htm##
00666000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100015000890100
01800104010001600122012015100138030001200289065000900301064000500310031000300315
014000800318865000900326002000700335035001000342801001200352#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\05.htm#S#c#164#17#article#21#17#^rND^sNoguchi^nY#^rND^sMiur
a^nH#^rND^sTakasugi^nS#^rND^sIwamot^nY#Cartilage and labrum degeneration in the 
dysplastic hip generally originates in the anterosuperiorweight-bearing area: an
 arthroscopic observation^len#Arthroscopy#19990000#1999#15#496-506#20110000#05.h
tm#0749-8063#Arthroscopy##
00555000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100023000720100018000950100
01600113010001500129012006300144030001700207710000200224065000900226064000500235
031000300240014000600243865000900249002000700258#v19n1#V:\SciELO\serial\aob\v19n
1\markup\05.htm#S#c#165#18#article#21#18#^rND^sBlankenbaker^nDG#^rND^sDe Smet^nA
A#^rND^sKeene^nJS#^rND^sFine^nJP#Classification and localization of acetabular l
abral tears^len#Skeletal Radiol.#2#20070000#2007#36#391-7#20110000#05.htm##
00454000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100019000880120
02800107030001100135710000200146065000900148064000500157031000300162014000700165
865000900172002000700181#v19n1#V:\SciELO\serial\aob\v19n1\markup\05.htm#S#c#166#
19#article#21#19#^rND^sLewis^nCL#^rND^sSahrmann^nAS#Acetabular labral tears^len#
Phys Ther.#2#20060000#2006#86#110-21#20110000#05.htm##
00617000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100017000890100
01700106010001500123010001700138012007800155030001000233065000900243064000500252
031000400257014000600261865000900267002000700276035001000283801001000293#v19n1#V
:\SciELO\serial\aob\v19n1\markup\05.htm#S#c#167#20#article#21#20#^rND^sSchmid^nM
R#^rND^sNötzli^nHP#^rND^sZanetti^nM#^rND^sWyss^nTF#^rND^sHodler^nJ.#Cartilage le
sions in the hip: diagnostic effectiveness of MR arthrography^len#Radiology#2003
0000#2003#226#382-6#20110000#05.htm#0033-8419#Radiology##
00548000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100016000880100
01400104012008600118030002300204710000200227065000900229064000500238032000400243
014000700247865000900254002000700263#v19n1#V:\SciELO\serial\aob\v19n1\markup\05.
htm#S#c#168#21#article#21#21#^rND^sIto K^nMD#^rND^sLeunig^nM#^rND^sGanz^nR#Histo
pathologic features of the acetabular labrum in femoroacetabular impingement^len
#Clin Orthop Relat Res.#2#20040000#2004#429#262-71#20110000#05.htm##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v19n1#V:\SciELO\serial\aob\v19n1\markup\06.htm#S#o#1#1#article#1#201104
11#111850#06.htm#129##
04202000000000601000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000500083121000300088049000700091158000300098030001800101
03100030011903200020012206500090012401400090013303500100014201200940015201200850
02460100047003310100031003780100035004090100033004440100034004770700092005110831
34600603085000801949085002901957085002701986085002402013083143002037085000803467
08500260347508500230350108500250352411700060354907200020355511200090355711100090
3566114000903575113000903584002000703593#v19n1#V:\SciELO\serial\aob\v19n1\markup
\06.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#06#AOB140#nd#Acta ortop. bras.#
19#1#20110000#^f28^l31#1413-7852#Novo sistema para acoplamento de parafusos de i
nterferência: ensaio biomecânico de torção^lpt#New coupling system for interfere
nce screws: biomechanical resistance to torsion^len#^rND^1A01^nAloísio Fernandes
^sBonavides Júnior#^rND^1A01^nRodrigo César^sRosa#^rND^1A01^nAntônio Carlos^sShi
mano#^rND^1A01^nJosé Baptista^sVolpon#^rND^1A01^nMaurício^sKfuri Júnior#Universi
dade de São Paulo^iA01^1Faculdade de Medicina de Ribeirão Preto^cRibeirão Preto^
sSP#^lpt^aOBJETIVO: Apresentar um novo sistema de acoplamento solidário entre ch
ave e parafuso de interferência, assim como ensaios biomecânicos que avaliem a s
egurança de sua utilização. MÉTODOS: O novo sistema foi submetido a ensaios biom
ecânicos de torção. Foram realizados dois tipos de análise: torque máximo de ins
erção manual dos parafusos em osso bovino; ensaios destrutivos de torção do sist
ema em máquina INSTRON 55MT. Os mesmos testes foram realizados em um grupo contr
ole utilizando um sistema de acoplamento já disponível no mercado. (Acufex®) RES
ULTADOS: Nos ensaios de inserção em fêmures bovinos as médias de valores aferido
s com torquímetro digital foram 1,958 N/m para Acufex® e 2,563 N/m para FMRP. Co
nsiderando p<0,05, não houve diferença significativa (p=0,02) nos valores de tor
que máximo de inserção nos dois sistemas estudados. Os valores médios de torque 
máximo para deformar o parafuso foram de 15 N/m para o parafuso Acufex® e 13 N/m
 para o parafuso FMRP, portanto, sem diferença estatística (p&gt;0,05). Ao avali
ar a deformação angular, não houve diferença significativa entre os grupos de pa
rafuso (p=0,15). CONCLUSÃO: O novo sistema de acoplamento para parafusos de inte
rferência desenvolvido na FMRP-USP revelou resistência à torção comparável a sis
tema já disponível no mercado e regulamentado para uso internacional.#^dnd^i1#^t
m^lpt^kJoelho^i1^scirurgia#^tm^lpt^kParafuso ósseo^i1#^tm^lpt^kBiomecânica^i1#^l
en^aOBJECTIVE: To introduce a new coupling system between screw driver and inter
ference screw, and biomechanical tests that validate the safety of its applicati
on. METHODS: The new system was submitted to biomechanical torsion assays. Two t
ypes of analysis were performed: maximum torque of manual insertion of the screw
s into bovine bone; destructive assays of torsion of the system using an INSTRON
 55MT machine. The same tests were also performed on a control group, using a co
mmercially available interference screw coupling system (Acufex®). RESULTS: In t
he tests on manual insertion of screws in bovine femurs, the average values foun
d with a digital torque meter were 1.958 N/m for Acufex® and 2.563 N/m for FMRP.
 Considering p>0.05, there were no statistical differences between the two group
s (p=0.02) in the values for maximum torque of insertion, in the two systems stu
died. The average values for maximum torque of torsion resisted by the screw wer
e 15N/m for the Acufex® screw and 13N/m for the FMRP screw, again with no statis
tical differences between the two groups (p>0.05). In the evaluation of angular 
deformation, there was also no significant difference between the two screw type
s (p=0.15). CONCLUSION: The new coupling system for interference screws develope
d at FMRP-USP revealed a torsion resistance that is comparable with the system a
lready available on the market and regulated for international use.#^dnd^i2#^tm^
len^kKnee^i2^ssurgery#^tm^len^kBone screw^i2#^tm^len^kBiomechanics^i2#other#8#20
090922#22/09/09#20101126#26/11/10#06.htm##
04361000000000601000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000500083121000300088049000700091158000300098030001800101
03100030011903200020012206500090012401400090013303500100014201201080015201200990
02600100047003590100031004060100035004370100033004720100034005050700092005390831
41000631085000802041085002902049085002702078085002402105083149702129085000803626
08500260363408500230366008500250368311700060370807200020371411200090371611100090
3725114000903734113000903743002000703752#v19n1#V:\SciELO\serial\aob\v19n1\markup
\06.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#06#AOB140#nd#Acta ortop. bras.#
19#1#20110000#^f28^l31#1413-7852#<b>Novo sistema para acoplamento de parafusos d
e interferência</b>: <b>ensaio biomecânico de torção</b>^lpt#<b>New coupling sys
tem for interference screws</b>: <b>biomechanical resistance to torsion</b>^len#
^rND^1A01^nAloísio Fernandes^sBonavides Júnior#^rND^1A01^nRodrigo César^sRosa#^r
ND^1A01^nAntônio Carlos^sShimano#^rND^1A01^nJosé Baptista^sVolpon#^rND^1A01^nMau
rício^sKfuri Júnior#Universidade de São Paulo^iA01^1Faculdade de Medicina de Rib
eirão Preto^cRibeirão Preto^sSP#^lpt^a<b>OBJETIVO:</b> Apresentar um novo sistem
a de acoplamento solidário entre chave e parafuso de interferência, assim como e
nsaios biomecânicos que avaliem a segurança de sua utilização. <b>MÉTODOS:</b> O
 novo sistema foi submetido a ensaios biomecânicos de torção. Foram realizados d
ois tipos de análise: torque máximo de inserção manual dos parafusos em osso bov
ino; ensaios destrutivos de torção do sistema em máquina INSTRON 55MT. Os mesmos
 testes foram realizados em um grupo controle utilizando um sistema de acoplamen
to já disponível no mercado. (Acufex<sup>®</sup>) <b>RESULTADOS:</b> Nos ensaios
 de inserção em fêmures bovinos as médias de valores aferidos com torquímetro di
gital foram 1,958 N/m para Acufex<sup>®</sup> e 2,563 N/m para FMRP. Considerand
o p&lt;0,05, não houve diferença significativa (p=0,02) nos valores de torque má
ximo de inserção nos dois sistemas estudados. Os valores médios de torque máximo
 para deformar o parafuso foram de 15 N/m para o parafuso Acufex<sup>®</sup> e 1
3 N/m para o parafuso FMRP, portanto, sem diferença estatística (p&gt;0,05). Ao 
avaliar a deformação angular, não houve diferença significativa entre os grupos 
de parafuso (p=0,15). <b>CONCLUSÃO:</b> O novo sistema de acoplamento para paraf
usos de interferência desenvolvido na FMRP-USP revelou resistência à torção comp
arável a sistema já disponível no mercado e regulamentado para uso internacional
.#^dnd^i1#^tm^lpt^kJoelho^i1^scirurgia#^tm^lpt^kParafuso ósseo^i1#^tm^lpt^kBiome
cânica^i1#^len^a<b>OBJECTIVE:</b> To introduce a new coupling system between scr
ew driver and interference screw, and biomechanical tests that validate the safe
ty of its application. <b>METHODS:</b> The new system was submitted to biomechan
ical torsion assays. Two types of analysis were performed: maximum torque of man
ual insertion of the screws into bovine bone; destructive assays of torsion of t
he system using an INSTRON 55MT machine. The same tests were also performed on a
 control group, using a commercially available interference screw coupling syste
m (Acufex<sup>®</sup>). <b>RESULTS:</b> In the tests on manual insertion of scre
ws in bovine femurs, the average values found with a digital torque meter were 1
.958 N/m for Acufex<sup>®</sup> and 2.563 N/m for FMRP. Considering p&gt;0.05, t
here were no statistical differences between the two groups (p=0.02) in the valu
es for maximum torque of insertion, in the two systems studied. The average valu
es for maximum torque of torsion resisted by the screw were 15N/m for the Acufex
<sup>®</sup> screw and 13N/m for the FMRP screw, again with no statistical diffe
rences between the two groups (p&gt;0.05). In the evaluation of angular deformat
ion, there was also no significant difference between the two screw types (p=0.1
5). <b>CONCLUSION:</b> The new coupling system for interference screws developed
 at FMRP-USP revealed a torsion resistance that is comparable with the system al
ready available on the market and regulated for international use.#^dnd^i2#^tm^l
en^kKnee^i2^ssurgery#^tm^len^kBone screw^i2#^tm^len^kBiomechanics^i2#other#8#200
90922#22/09/09#20101126#26/11/10#06.htm##
04323000000000625000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000500090121000300095049000700098158000300105
03000170010803100030012503200020012806500090013001400090013903500100014801200940
01580120085002520100047003370100031003840100035004150100033004500100034004830700
09400517083134600611085000801957085002901965085002701994085002402021083143002045
08500080347508500260348308500230350908500250353211700060355707200020356311200090
3565111000903574114000903583113000903592002000703601008008903608#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#l#4#1#article#1#^a2011#oa#pt#br1.1#1#4.0#ilus#
06#AOB140#nd#Acta ortop. bras#19#1#20110000#^f28^l31#1413-7852#Novo sistema para
 acoplamento de parafusos de interferência: ensaio biomecânico de torção^lpt#New
 coupling system for interference screws: biomechanical resistance to torsion^le
n#^rND^1A01^nAloísio Fernandes^sBonavides Júnior#^rND^1A01^nRodrigo César^sRosa#
^rND^1A01^nAntônio Carlos^sShimano#^rND^1A01^nJosé Baptista^sVolpon#^rND^1A01^nM
aurício^sKfuri Júnior#^iA01^1Universidade de São Paulo^2Faculdade de Medicina de
 Ribeirão Preto^cRibeirão Preto^sSP#^lpt^aOBJETIVO: Apresentar um novo sistema d
e acoplamento solidário entre chave e parafuso de interferência, assim como ensa
ios biomecânicos que avaliem a segurança de sua utilização. MÉTODOS: O novo sist
ema foi submetido a ensaios biomecânicos de torção. Foram realizados dois tipos 
de análise: torque máximo de inserção manual dos parafusos em osso bovino; ensai
os destrutivos de torção do sistema em máquina INSTRON 55MT. Os mesmos testes fo
ram realizados em um grupo controle utilizando um sistema de acoplamento já disp
onível no mercado. (Acufex®) RESULTADOS: Nos ensaios de inserção em fêmures bovi
nos as médias de valores aferidos com torquímetro digital foram 1,958 N/m para A
cufex® e 2,563 N/m para FMRP. Considerando p<0,05, não houve diferença significa
tiva (p=0,02) nos valores de torque máximo de inserção nos dois sistemas estudad
os. Os valores médios de torque máximo para deformar o parafuso foram de 15 N/m 
para o parafuso Acufex® e 13 N/m para o parafuso FMRP, portanto, sem diferença e
statística (p&gt;0,05). Ao avaliar a deformação angular, não houve diferença sig
nificativa entre os grupos de parafuso (p=0,15). CONCLUSÃO: O novo sistema de ac
oplamento para parafusos de interferência desenvolvido na FMRP-USP revelou resis
tência à torção comparável a sistema já disponível no mercado e regulamentado pa
ra uso internacional.#^dnd^i1#^tm^lpt^kJoelho^i1^scirurgia#^tm^lpt^kParafuso óss
eo^i1#^tm^lpt^kBiomecânica^i1#^len^aOBJECTIVE: To introduce a new coupling syste
m between screw driver and interference screw, and biomechanical tests that vali
date the safety of its application. METHODS: The new system was submitted to bio
mechanical torsion assays. Two types of analysis were performed: maximum torque 
of manual insertion of the screws into bovine bone; destructive assays of torsio
n of the system using an INSTRON 55MT machine. The same tests were also performe
d on a control group, using a commercially available interference screw coupling
 system (Acufex®). RESULTS: In the tests on manual insertion of screws in bovine
 femurs, the average values found with a digital torque meter were 1.958 N/m for
 Acufex® and 2.563 N/m for FMRP. Considering p>0.05, there were no statistical d
ifferences between the two groups (p=0.02) in the values for maximum torque of i
nsertion, in the two systems studied. The average values for maximum torque of t
orsion resisted by the screw were 15N/m for the Acufex® screw and 13N/m for the 
FMRP screw, again with no statistical differences between the two groups (p>0.05
). In the evaluation of angular deformation, there was also no significant diffe
rence between the two screw types (p=0.15). CONCLUSION: The new coupling system 
for interference screws developed at FMRP-USP revealed a torsion resistance that
 is comparable with the system already available on the market and regulated for
 international use.#^dnd^i2#^tm^len^kKnee^i2^ssurgery#^tm^len^kBone screw^i2#^tm
^len^kBiomechanics^i2#other#8#20090922#22/09/09#20101126#26/11/10#06.htm#Interne
t^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-7852201100010000
6##
00342000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704012200067002000700189#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#5#1#article#117#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTIGO    ORIGINAL</b></font
></p>     ^cY#06.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#6#2#article#117#<p>&nbsp;</p>     ^cY#06.htm
##
00449000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704022900067002000700296#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#7#3#article#117#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Novo    sistema para aco
plamento de parafusos de interfer&ecirc;ncia: ensaio biomec&acirc;nico    de tor
&ccedil;&atilde;o</b></font></p>     ^cY#06.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#8#4#article#117#<p>&nbsp;</p>     ^cY#06.htm
##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#9#5#article#117#<p>&nbsp;</p>     ^cY#06.htm
##
00488000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704026700068002000700335#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#10#6#article#117#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Alo&iacute;sio    Fernandes Bonavides J&u
acute;nior; Rodrigo C&eacute;sar Rosa; Ant&ocirc;nio    Carlos Shimano; Jos&eacu
te; Baptista Volpon; Maur&iacute;cio Kfuri J&uacute;nior</b></font></p>     ^cY#
06.htm##
00427000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704020600068002000700274#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#11#7#article#117#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2">Faculdade de Medicina    de Ribeir&atilde;o 
Preto da Universidade de S&atilde;o Paulo - USP - Ribeir&atilde;o    Preto (SP)<
/font></p>     ^cY#06.htm##
00369000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704014800068002000700216#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#12#8#article#117#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><a href="#back">Endere&ccedil;o    para Corr
espond&ecirc;ncia</a></font></p>     ^cY#06.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#13#9#article#117#<p>&nbsp;</p>     ^cY#06.ht
m##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#14#10#article#117#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#06.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#15#11#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#06.htm##
00526000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704030400069002000700373#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#16#12#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Apresentar um novo sist
ema de acoplamento solid&aacute;rio entre chave e parafuso    de interfer&ecirc;
ncia, assim como ensaios biomec&acirc;nicos que avaliem a    seguran&ccedil;a de
 sua utiliza&ccedil;&atilde;o.    ^cY#06.htm##
00732000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704051000069002000700579#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#17#13#article#117#<br>   <b>M&Eacute;TODOS:<
/b> O novo sistema foi submetido a ensaios biomec&acirc;nicos    de tor&ccedil;&
atilde;o. Foram realizados dois tipos de an&aacute;lise: torque    m&aacute;ximo
 de inser&ccedil;&atilde;o manual dos parafusos em osso bovino;    ensaios destr
utivos de tor&ccedil;&atilde;o do sistema em m&aacute;quina INSTRON    55MT. Os 
mesmos testes foram realizados em um grupo controle utilizando um sistema    de 
acoplamento j&aacute; dispon&iacute;vel no mercado. (Acufex<sup>&reg;</sup>)    
^cY#06.htm##
01008000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704078600069002000700855#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#18#14#article#117#<br>   <b>RESULTADOS:</b> 
Nos ensaios de inser&ccedil;&atilde;o em f&ecirc;mures bovinos    as m&eacute;di
as de valores aferidos com torqu&iacute;metro digital foram 1,958    N/m para Ac
ufex<sup>&reg;</sup> e 2,563 N/m para FMRP. Considerando p&lt;0,05,    n&atilde;
o houve diferen&ccedil;a significativa (p=0,02) nos valores de torque    m&aacut
e;ximo de inser&ccedil;&atilde;o nos dois sistemas estudados. Os valores    m&ea
cute;dios de torque m&aacute;ximo para deformar o parafuso foram de 15 N/m    pa
ra o parafuso Acufex<sup>&reg;</sup> e 13 N/m para o parafuso FMRP, portanto,   
 sem diferen&ccedil;a estat&iacute;stica (p&gt;0,05). Ao avaliar a deforma&ccedi
l;&atilde;o    angular, n&atilde;o houve diferen&ccedil;a significativa entre os
 grupos de    parafuso (p=0,15).    ^cY#06.htm##
00538000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704031600069002000700385#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#19#15#article#117#<br>   <b>CONCLUS&Atilde;O
:</b> O novo sistema de acoplamento para parafusos de interfer&ecirc;ncia    des
envolvido na FMRP-USP revelou resist&ecirc;ncia &agrave; tor&ccedil;&atilde;o   
 compar&aacute;vel a sistema j&aacute; dispon&iacute;vel no mercado e regulament
ado    para uso internacional.</font></p>     ^cY#06.htm##
00408000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704018600069002000700255#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#20#16#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Descritores:</b>    Joelho/cirurgia. Par
afuso &oacute;sseo. Biomec&acirc;nica.</font></p> <hr size="1" noshade>     ^cY#
06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#21#17#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#22#18#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00336000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011400069002000700183#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#23#19#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b></font></p> 
    ^cY#06.htm##
00980000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704075800069002000700827#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#24#20#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As les&otilde;es    do ligamento cruzado an
terior (LCA) tem uma import&acirc;ncia significativa    na pr&aacute;tica clinic
a. Do ponto de vista cl&iacute;nico, a les&atilde;o    pode promover instabilida
de e les&otilde;es secund&aacute;rias na articula&ccedil;&atilde;o,    proporcio
nando ao ortopedista um desafio em busca do melhor tratamento e do    mais r&aac
ute;pido retorno de seu paciente ao esporte. Uma das t&eacute;cnicas    mais usa
das para as reconstru&ccedil;&otilde;es ligamentares &eacute; a que    associa o
 uso de parafuso de interfer&ecirc;ncia com o ter&ccedil;o central    do ligamen
to patelar com osso em suas extremidades como substituto do LCA rompido.</font><
/p>     ^cY#06.htm##
02018000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704179600069002000701865#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#25#21#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">V&aacute;rios fatores    concorrem para que
 o uso do enxerto de ligamento patelar seja muito popular    entre os ortopedist
as. Entre eles est&atilde;o: a localiza&ccedil;&atilde;o    subcut&acirc;nea do 
enxerto, fato que facilita sua retirada; a rigidez da fixa&ccedil;&atilde;o    i
nicial com a utiliza&ccedil;&atilde;o de parafusos de interfer&ecirc;ncia e    a
 possibilidade de uma cicatriza&ccedil;&atilde;o mediante consolida&ccedil;&atil
de;o    &oacute;ssea do bloco &oacute;sseo do enxerto no t&uacute;nel de inser&c
cedil;&atilde;o    ligamentar. Apesar das vantagens te&oacute;ricas associadas a
o uso do enxerto    de ligamento patelar fixado por meio de parafusos de interfe
r&ecirc;ncia, alguns    problemas s&atilde;o descritos com o uso desta t&eacute;
cnica, tais como: desconex&atilde;o    da chave no ato da inser&ccedil;&atilde;o
 ou retirada do parafuso, com a consequente    perda do parafuso na regi&atilde;
o intra-articular; a lacera&ccedil;&atilde;o    iatrog&ecirc;nica parcial ou tot
al das fibras do enxerto ou do ligamento cruzado    posterior no ato da fixa&cce
dil;&atilde;o do enxerto; interposi&ccedil;&atilde;o    da gordura de Hoffa e da
 sinovial no momento da penetra&ccedil;&atilde;o do    parafuso, impossibilitand
o a visibilidade no ato da fixa&ccedil;&atilde;o femoral;    quebra e deformidad
e no pino guia com a impossibilidade de retir&aacute;-lo    e a diverg&ecirc;nci
a ou converg&ecirc;ncia da dire&ccedil;&atilde;o do parafuso    em rela&ccedil;&
atilde;o ao t&uacute;nel &oacute;sseo, levando &agrave; fixa&ccedil;&atilde;o   
 insuficiente do enxerto e a n&atilde;o visibilidade do enxerto no t&uacute;nel 
   no ato da inser&ccedil;&atilde;o do parafuso femoral.<sup>1,2</sup></font></p
>     ^cY#06.htm##
00740000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704051800069002000700587#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#26#22#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Estes fatores complicadores    determinam u
m aumento no tempo cir&uacute;rgico, maior morbidade ao paciente    e estresse i
ntra-operat&oacute;rio para a equipe cir&uacute;rgica. A percep&ccedil;&atilde;o
    destas dificuldades pr&aacute;ticas fez com que busc&aacute;ssemos alternati
vas    para facilitar a utiliza&ccedil;&atilde;o de parafusos de interfer&ecirc;
ncia    na cirurgia ligamentar do joelho assistida por videoartroscopia.</font><
/p>     ^cY#06.htm##
00756000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704053400069002000700603#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#27#23#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Um dos autores    deste trabalho (MKJ) idea
lizou um modo de acoplamento solid&aacute;rio entre    o parafuso de interfer&ec
irc;ncia e sua respectiva chave. A hip&oacute;tese    &eacute; de que este desen
volvimento resulte em maior controle durante o procedimento    de inser&ccedil;&
atilde;o ou remo&ccedil;&atilde;o do parafuso na articula&ccedil;&atilde;o,    i
mpedindo que o mesmo se solte inadvertidamente ou seja perdido no interior    do
 joelho.</font></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#28#24#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00320000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009800069002000700167#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#29#25#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>OBJETIVO</b></font></p>     ^cY#06.htm##
00590000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704036800069002000700437#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#30#26#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O objetivo deste    trabalho &eacute; o de 
apresentar um novo sistema de acoplamento chave-parafuso    de interferencia, as
sim como a seguran&ccedil;a de sua utiliza&ccedil;&atilde;o,    tomando como par
&acirc;metros ensaios biomec&acirc;nicos torcionais realizados    <i>in vitro</i
>.</font></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#31#27#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00341000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011900069002000700188#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#32#28#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>MATERIAIS E    M&Eacute;TODOS</b></font>
</p>     ^cY#06.htm##
00321000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009900069002000700168#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#33#29#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>MATERIAIS</b></font></p>     ^cY#06.htm#
#
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#34#30#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>1. Implantes</b></font></p>     ^cY#06.h
tm##
00327000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010500069002000700174#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#35#31#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>A. Sistema FMRP</b></font></p>     ^cY#0
6.htm##
00629000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704040700069002000700476#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#36#32#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Os parafusos e    o sistema de acoplamento 
com a chave foram desenvolvidos na Faculdade de Medicina    de Ribeir&atilde;o P
reto da Universidade de S&atilde;o Paulo - FMRP-USP. Foram    produzidos pela em
presa Trautec<sup>&reg;</sup> - Equipamentos Cir&uacute;rgicos    Ltda (Ribeir&a
tilde;o Preto, S&atilde;o Paulo, Brasil).</font></p>     ^cY#06.htm##
02936000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704271400069002000702783#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#37#33#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O parafuso de tit&acirc;nio    FMRP apresen
ta caracter&iacute;sticas similares aos parafusos de interfer&ecirc;ncia    exis
tentes no mercado, exceto pela sua cabe&ccedil;a, que foi redesenhada para    se
r sujeitada de maneira solid&aacute;ria &agrave; chave de inser&ccedil;&atilde;o
.    Trata-se de um parafuso canulado, c&ocirc;nico em sua por&ccedil;&atilde;o 
distal,    com bordas proximais rombas, rosca externa &agrave; direita. Sua cabe
&ccedil;a    consiste em um hex&aacute;gono externo com rosca interna &agrave; e
squerda.    Esta rosca interna do parafuso &eacute; que permite o acoplamento so
lid&aacute;rio    &agrave; chave como ser&aacute; mostrado a seguir. No tocante 
&agrave; mat&eacute;ria    prima, o parafuso &eacute; composto de Liga de Tit&ac
irc;nio (Ti-6Al-4V) de    Classifica&ccedil;&atilde;o ASTMS 136. (<a href="#f1">
Figura 1</a>) A chave    correspondente apresenta um formato em T, com hex&aacut
e;gono distal interno,    comprimento total controlado, e trajeto canulado por o
nde passa o elemento de    interfixa&ccedil;&atilde;o. (<a href="#f2">Figura 2</
a>) Este &eacute; um dispositivo    fixador chave-parafuso que realiza a conex&a
tilde;o solid&aacute;ria. Trata-se    de uma haste reta, lisa e canulada, com um
a rosca externa para a esquerda e    possuindo em sua extremidade proximal um ma
nipulador fixo de formato hexagonal.    (<a href="#f3">Figura 3</a>) Os tr&ecirc
;s formam o sistema FMRP de fixa&ccedil;&atilde;o    integrada. A extremidade di
stal da chave em T, ou seja, a sua ponta, &eacute;    composta de a&ccedil;o ino
xid&aacute;vel austen&iacute;tico endurecido por choque    t&eacute;rmico de Cla
ssifica&ccedil;&atilde;o AISI 455. O restante da chave,    bem como o elemento d
e interfixa&ccedil;&atilde;o, s&atilde;o compostos de a&ccedil;o    inoxid&aacut
e;vel martens&iacute;tico endurecido por encruamento (trefila&ccedil;&atilde;o) 
   de Classifica&ccedil;&atilde;o AISI 304. O mecanismo de sujei&ccedil;&atilde;
o    do parafuso ao dispositivo introdutor &eacute; desta forma realizado: o hex
&aacute;gono    interno da chave em "T" &eacute; acoplado ao hex&aacute;gono ext
erno do parafuso,    e &eacute; introduzido o "elemento de interfixa&ccedil;&ati
lde;o" rosqueando    at&eacute; o final, atentando para que n&atilde;o haja folg
a entre a chave e    o parafuso. Todo este dispositivo descrito &eacute; canulad
o para a passagem    do pino guia. O modelo &eacute; solid&aacute;rio, fix&aacut
e;vel de modo tempor&aacute;rio    &agrave; chave de introdu&ccedil;&atilde;o, m
as preserva a possibilidade de    continuar utilizando o tradicional pino guia. 
(<a href="#f4">Figura 4</a>)</font></p>     ^cY#06.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#38#34#article#117#<p><a name="f1"></a></p>  
   ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#39#35#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#40#36#article#117#<p align="center"><img src
="/img/revistas/aob/v19n1/06f01.jpg"></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#41#37#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#42#38#article#117#<p><a name="f2"></a></p>  
   ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#43#39#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#44#40#article#117#<p align="center"><img src
="/img/revistas/aob/v19n1/06f02.jpg"></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#45#41#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#46#42#article#117#<p><a name="f3"></a></p>  
   ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#47#43#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#48#44#article#117#<p align="center"><img src
="/img/revistas/aob/v19n1/06f03.jpg"></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#49#45#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#50#46#article#117#<p><a name="f4"></a></p>  
   ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#51#47#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#52#48#article#117#<p align="center"><img src
="/img/revistas/aob/v19n1/06f04.jpg"></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#53#49#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00336000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011400069002000700183#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#54#50#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>B. Sistema Padr&atilde;o</b></font></p> 
    ^cY#06.htm##
00468000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704024600069002000700315#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#55#51#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Utilizamos como    controle parafusos da ma
rca Acufex<sup>&reg;</sup> (Smith &amp; Nephew, EUA)    e sua respectiva chave i
ntrodutora. (<a href="#f5">Figura 5</a>)</font></p>     ^cY#06.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#56#52#article#117#<p><a name="f5"></a></p>  
   ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#57#53#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#58#54#article#117#<p align="center"><img src
="/img/revistas/aob/v19n1/06f05.jpg"></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#59#55#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00333000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011100069002000700180#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#60#56#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>2. Corpos de    Prova</b></font></p>    
 ^cY#06.htm##
01164000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704094200069002000701011#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#61#57#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">20 (vinte) pe&ccedil;as    de f&ecirc;mur e
squerdo de bovino "in natura" (idade estimada dos bovinos entre    dois e tr&eci
rc;s anos na &eacute;poca do abate), as quais foram conseguidas    no Frigor&iac
ute;fico Barra Mansa da cidade de Ribeir&atilde;o Preto (SP). As    pe&ccedil;as
 j&aacute; desarticuladas da t&iacute;bia foram inicialmente dissecadas,    send
o retiradas as partes moles e cortado o osso com o uso de serra el&eacute;trica 
   no ter&ccedil;o distal supracondiliano na regi&atilde;o metafis&aacute;ria do
    f&ecirc;mur. Realizados cortes padronizados e obtidos blocos &oacute;sseos c
orrespondentes    ao c&ocirc;ndilo femoral lateral. Feitas perfura&ccedil;&otild
e;es para a confec&ccedil;&atilde;o    de orif&iacute;cios 10x25mm em cada bloco
 &oacute;sseo. Retirados cilindros    &oacute;sseos 9x25mm para preencherem os o
rif&iacute;cios.</font></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#62#58#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00326000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010400069002000700173#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#63#59#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>M&Eacute;TODOS</b></font></p>     ^cY#06
.htm##
02928000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704270600069002000702775#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#64#60#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Foram realizados    20(vinte) ensaios de to
r&ccedil;&atilde;o dos parafusos em ossos de bovino.    Separamos 10(dez) parafu
sos 7x25mm novos FMRP e 10(dez) parafusos 7x30mm controle    Acufex<sup>&reg;</s
up>. As pe&ccedil;as j&aacute; desarticuladas da t&iacute;bia    foram inicialme
nte dissecadas, sendo retiradas as partes moles e cortado o osso    com o uso de
 serra el&eacute;trica no ter&ccedil;o distal supracondiliano na    regi&atilde;
o metafis&aacute;ria do f&ecirc;mur e levadas ao Laborat&oacute;rio    de Endocr
inologia do Hospital das Clinicas da Faculdade de Medicina de Ribeir&atilde;o   
 Preto-USP para exame densitom&eacute;trico. A BMD (densidade mineral &oacute;ss
ea)    dos f&ecirc;mures de bovino foi determinada pelo exame de densitometria p
ara    absor&ccedil;&atilde;o de raios X de dupla energia (DEXA) e sistema QDR c
om    <i>software</i> vers&atilde;o 11-2:5 (Hologic 4500 W, Waltham, MA, USA). A
daptamos    um torqu&iacute;metro digital (<i>software</i> MK, Vers&atilde;o 1.0
.0.6/2004)    &agrave;s respectivas chaves de introdu&ccedil;&atilde;o dos paraf
usos para    avaliar os valores m&aacute;ximos do torque de inser&ccedil;&atilde
;o de cada    parafuso de interfer&ecirc;ncia. O dispositivo e m&eacute;todo de 
aferi&ccedil;&atilde;o    de torque foi desenvolvido no Laborat&oacute;rio de Bi
oengenharia da Faculdade    de Medicina de Ribeir&atilde;o Preto<sup>3</sup>. (<
a href="#f6">Figura 6</a>)    O torque de inser&ccedil;&atilde;o de cada parafus
o representou o momento de    for&ccedil;a angular para a inser&ccedil;&atilde;o
 do implante. O valor m&aacute;ximo    do torque de inser&ccedil;&atilde;o foi o
btido para cada parafuso, ao ser introduzido    atrav&eacute;s de pega manual ex
ecutada pelo mesmo avaliador por mecanismo torcional    no torquimetro adaptado 
&agrave; chave. Assim, o implante foi avan&ccedil;ado    de forma padronizada em
 &acirc;ngulo perpendicular com a superf&iacute;cie &oacute;ssea    e colocado n
a interface entre o enxerto e o t&uacute;nel do f&ecirc;mur. Alem    dos ensaios
 em f&ecirc;mures bovinos realizamos ensaios destrutivos de tor&ccedil;&atilde;o
,    utilizando apenas os parafusos. Foram submetidos a ensaios de tor&ccedil;&a
tilde;o    10 (dez) parafusos, sendo cinco (cinco) parafusos FMRP 7x30mm e cinco
 parafusos    controle Acufex<sup>&reg;</sup> 7x30mm. Avaliamos no ensaio de tor
&ccedil;&atilde;o    o torque m&aacute;ximo de ruptura (Nm) e a deformidade angu
lar (graus). O ensaio    usou como base a norma ASTM F543:2007 (<i>Standard Spec
ification and Test Methods    for Determining the Torsional Properties of Metall
ic Bone Screws</i>).</font></p>     ^cY#06.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#65#61#article#117#<p><a name="f6"></a></p>  
   ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#66#62#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#67#63#article#117#<p align="center"><img src
="/img/revistas/aob/v19n1/06f06.jpg"></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#68#64#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
01107000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704088500069002000700954#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#69#65#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O equipamento de    ensaio consistiu da m&a
acute;quina INSTRON 55MT, pertencente ao Laborat&oacute;rio    de Bioengenharia 
da Faculdade de Medicina de Ribeir&atilde;o Preto-USP. A velocidade    de ensaio
 foi de 2 rpm (=720 graus/min), temperatura de 22 graus centigrados    (ambiente
), escala de 21x110 e v&atilde;o livre (L) de 6,5mm. (<a href="#f7">Figura    7<
/a>) Para os parafusos Acufex ficaram tr&ecirc;s fios de rosca expostos, e    pa
ra os parafusos FMRP ficou 1 (um) fio de rosca exposto. Antes dos ensaios    de 
tor&ccedil;&atilde;o, em todos os corpos de prova foram realizadas avalia&ccedil
;&otilde;es    dimensionais com paqu&iacute;metro digital Mitutoyo, interessando
 di&acirc;metro    externo, di&acirc;metro interno, profundidade de rosca, compr
imento de rosca    e comprimento total.</font></p>     ^cY#06.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#70#66#article#117#<p><a name="f7"></a></p>  
   ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#71#67#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#72#68#article#117#<p align="center"><img src
="/img/revistas/aob/v19n1/06f07.jpg"></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#73#69#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00348000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012600069002000700195#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#74#70#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>AN&Aacute;LISE    ESTAT&Iacute;STICA</b>
</font></p>     ^cY#06.htm##
00821000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704059900069002000700668#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#75#71#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Na an&aacute;lise    estat&iacute;stica dos
 resultados dos valores do torque m&aacute;ximo de inser&ccedil;&atilde;o    no 
osso bovino, utilizamos testes n&atilde;o-param&eacute;tricos nas compara&ccedil
;&otilde;es    entre as duas marcas de parafuso (Teste de Mann-Whitney). Nos ens
aios de tor&ccedil;&atilde;o,    foi usado o Teste de Kruskal-Wallis. O n&iacute
;vel de signific&acirc;ncia p    <u><</u> 0,05 foi adotado. Os testes estat&iacu
te;sticos foram realizados no    SPSS<sup>&reg;</sup> vers&atilde;o 15.0.</font>
</p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#76#72#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#77#73#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>     ^cY#06.htm
##
00826000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704060400069002000700673#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#78#74#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Avaliamos os valores    do torque m&aacute;
ximo de inser&ccedil;&atilde;o (N.m) dos parafusos FMRP 7x25mm    e Acufex<sup>&
reg;</sup> 7x30mm, com M&eacute;dia e Desvio Padr&atilde;o. As    m&eacute;dias 
de nossos valores encontrados foram 1,958 Nm para Acufex<sup>&reg;</sup>    e 2,
563 Nm para FMRP. Considerando p&lt;0,05, n&atilde;o houve diferen&ccedil;a    s
ignificativa (p=0,02) ao usar o torquimetro digital para quantificar o valor    
de torque m&aacute;ximo de inser&ccedil;&atilde;o nos dois sistemas estudados.</
font></p>     ^cY#06.htm##
00839000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704061700069002000700686#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#79#75#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Nos ensaios de    tor&ccedil;&atilde;o, con
siderando p&lt;0,05 ao avaliar o torque m&aacute;ximo,    n&atilde;o houve difer
en&ccedil;a estat&iacute;stica entre o parafuso Acufex<sup>&reg;</sup>    7x30mm
 e o parafuso FMRP 7x30mm. Os valores m&eacute;dios de torque m&aacute;ximo    p
ara deformar o parafuso foram de 15 N/m para o parafuso Acufex<sup>&reg;</sup>  
  e 13 N/m para o parafuso FMRP. Ao avaliar a deforma&ccedil;&atilde;o angular, 
   n&atilde;o houve diferen&ccedil;a significativa entre os grupos de parafuso  
  (p=0,15).</font></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#80#76#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00328000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010600069002000700175#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#81#77#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font></p>     ^cY#
06.htm##
00649000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704042700069002000700496#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#82#78#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Na escolha do esp&eacute;cime    para servi
r como modelo experimental no estudo do torque de inser&ccedil;&atilde;o    do p
arafuso, optamos pelo f&ecirc;mur bovino, pois de acordo com os achados    de Br
own <i>et al</i>.<sup>4</sup>, ele apresenta densidade &oacute;ssea mais    simi
lar e compat&iacute;vel com o osso de adultos humanos jovens.</font></p>     ^cY
#06.htm##
00889000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704066700069002000700736#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#83#79#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Decidimos pelo    estudo do torque de inser
&ccedil;&atilde;o visto que a principal diferen&ccedil;a    entre o novo sistema
 e os sistemas j&aacute; em uso &eacute; a adapta&ccedil;&atilde;o    entre o pa
rafusos e sua chave de inser&ccedil;&atilde;o. Desej&aacute;vamos    saber se o 
novo modo de acoplamento &eacute; seguro ao torque, n&atilde;o levando    a rupt
uras por fadiga ou estresse torcional na cabe&ccedil;a do parafuso durante    a 
inser&ccedil;&atilde;o. Utilizamos como refer&ecirc;ncia um sistema j&aacute;   
 consolidado e amplamente utilizado no mercado internacional.</font></p>     ^cY
#06.htm##
02570000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704234800069002000702417#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#84#80#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Para a inser&ccedil;&atilde;o    de parafus
os, Browner<sup>5</sup> relata que o torque normalmente aplicado pelos    ortope
distas nas cirurgias varia de 2,95 Nm a 5,98 Nm. &Eacute; importante que    o to
rque em condi&ccedil;&otilde;es habituais permita uma boa fixa&ccedil;&atilde;o 
   e n&atilde;o cause nenhum dano estrutural ao parafuso a ser implantado. Optam
os    por avaliar o torque m&aacute;ximo de inser&ccedil;&atilde;o manual de um 
mesmo    cirurgi&atilde;o aferido por um torqu&iacute;metro digital. Isso foi mo
tivado    pela praticidade da mensura&ccedil;&atilde;o e j&aacute; que pode have
r uma    varia&ccedil;&atilde;o significativa de torques medidos com torquimetro
 convencional.    N&atilde;o houve diferen&ccedil;a significativa entre os valor
es m&aacute;ximos    de torque de inser&ccedil;&atilde;o quando comparamos os pa
rafusos FMRP e Acufex<sup>&reg;</sup>.    As m&eacute;dias de nossos valores enc
ontrados foram 1,958 Nm para Acufex<sup>&reg;</sup>    e 2,563 Nm para FMRP. Bro
wn <i>et al</i>.<sup>4</sup> acharam uma correla&ccedil;&atilde;o    positiva mo
derada entre o torque de inser&ccedil;&atilde;o e a for&ccedil;a    de arrancame
nto para parafusos com 7 e 9mm usados em ossos de bovinos. Daftari    <i>et al</
i>.<sup>6</sup> tamb&eacute;m acharam essa mesma correla&ccedil;&atilde;o    com
 a aplica&ccedil;&atilde;o de certos parafusos usados na cirurgia de coluna    e
m corpos vertebrais de carneiro. Zdeblick <i>et al</i>.<sup>7</sup> encontraram 
   achados id&ecirc;nticos a favor da correla&ccedil;&atilde;o entre torque de  
  inser&ccedil;&atilde;o e a for&ccedil;a de arrancamento usando parafusos pedic
ulares.    Outros autores n&atilde;o encontraram correla&ccedil;&atilde;o entre 
o torque    de inser&ccedil;&atilde;o e a for&ccedil;a de arrancamento para v&aa
cute;rios    tipos de parafusos aplicados em ossos de cad&aacute;ver humano.<sup
>7,8</sup>    Pela poss&iacute;vel rela&ccedil;&atilde;o do torque de inser&cced
il;&atilde;o    dos parafusos de interfer&ecirc;ncia com propriedades mec&acirc;
nicas importantes    como for&ccedil;a de arrancamento e rigidez, acreditamos qu
e estudos biomec&acirc;nicos    posteriores devam ser planejados para aferir a s
eguran&ccedil;a do emprego do    novo sistema <i>in vitro</i>.</font></p>     ^c
Y#06.htm##
00685000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704046300069002000700532#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#85#81#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Em nosso estudo    n&atilde;o ocorreu nenhu
m caso de dano ao implante ou fratura no bloco &oacute;sseo    durante a inser&c
cedil;&atilde;o dos parafusos em f&ecirc;mures bovinos. Os    torques m&aacute;x
imos de ruptura dos implantes foram muito superiores aos torques    m&aacute;xim
os necess&aacute;rios para a inser&ccedil;&atilde;o &oacute;ssea    nos esp&eacu
te;cimes bovinos.</font></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#86#82#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00329000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010700069002000700176#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#87#83#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>CONCLUS&Otilde;ES</b></font></p>     ^cY
#06.htm##
00848000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704062600069002000700695#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#88#84#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Apresentamos um    novo sistema para acopla
mento entre chave e parafuso de interfer&ecirc;ncia.    Ensaios preliminares de 
tor&ccedil;&atilde;o realizados em esp&eacute;cimes    bovinos revelam que o nov
o sistema tem resist&ecirc;ncia ao torque compar&aacute;vel    a sistemas j&aacu
te; dispon&iacute;veis no mercado e aprovados segundo regulamenta&ccedil;&atilde
;o    internacional. Novos estudos biomec&acirc;nicos dever&atilde;o confirmar a
 seguran&ccedil;a    do uso do novo sistema, para que estudos cl&iacute;nicos po
ssam ser desenhados.</font></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#89#85#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00329000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010700069002000700176#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#90#86#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font></p>     ^cY
#06.htm##
00562000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704032600071002000700397#v19
n1#V:\SciELO\serial\aob\v19n1\markup\06.htm#S#p#91#87#article#117#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1. Brand J Jr,    Hamilton D,
 Selby J, Pienkowski D, Caborn DN, Johnson DL. Biomechanical comparison    of qu
adriceps tendon fixation with patellar tendon bone plug interference fixation   
 in cruciate ligament reconstruction. Arthroscopy. 2000;16:805-12.    ^cY#06.htm
##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#92#88#article#117#</font></p>     ^cY#06.htm
##
00470000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704023400071002000700305#v19
n1#V:\SciELO\serial\aob\v19n1\markup\06.htm#S#p#93#89#article#117#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2. Matthews LS,    Soffer SR.
 Pitfalls in the use of interference screws for anterior cruciate    ligament re
construction: brief report. Arthroscopy. 1989;5:225-6.    ^cY#06.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#94#90#article#117#</font></p>     ^cY#06.htm
##
00466000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704023000071002000700301#v19
n1#V:\SciELO\serial\aob\v19n1\markup\06.htm#S#p#95#91#article#117#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">3. Shimano AC,    Defino HLA,
 Rosa RC, Silva P, inventores. Dispositivo e m&eacute;todo para aferi&ccedil;&at
ilde;o    de torque. (Patente PI 0803449-4, 2009).    ^cY#06.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#96#92#article#117#</font></p>     ^cY#06.htm
##
00622000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704038600071002000700457#v19
n1#V:\SciELO\serial\aob\v19n1\markup\06.htm#S#p#97#93#article#117#4#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">4. Brown GA, Pe&ntilde;a    F
, Gr&oslash;ntvedt T, Labadie D, Engebretsen L. Fixation strength of interferenc
e    screw fixation in bovine, young human, and elderly human cadaver knees: inf
luence    of insertion torque, tunnel-bone block gap, and interference. Knee Sur
g Sports    Traumatol Arthrosc. 1996;3:238-44.    ^cY#06.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#98#94#article#117#</font></p>     ^cY#06.htm
##
00427000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704019100071002000700262#v19
n1#V:\SciELO\serial\aob\v19n1\markup\06.htm#S#p#99#95#article#117#5#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">5. Browner BC.    Skeletal tr
auma basic science, management and reconstruction. 3th ed. Philadelphia:    Saun
ders; 2003.    ^cY#06.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#100#96#article#117#</font></p>     ^cY#06.ht
m##
00488000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704025100072002000700323#v19
n1#V:\SciELO\serial\aob\v19n1\markup\06.htm#S#p#101#97#article#117#6#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">6. Daftari TK,    Horton WC,
 Hutton WC. Correlations between screw hole preparation, torque of    insertion,
 and pullout strength for spinal screws. J Spinal Disord. 1994;7:139-45.    ^cY#
06.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#102#98#article#117#</font></p>     ^cY#06.ht
m##
00466000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704022900072002000700301#v19
n1#V:\SciELO\serial\aob\v19n1\markup\06.htm#S#p#103#99#article#117#7#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">7. Zdeblick TA,    Warden KE
, Zou D, McAfee PC, Abitbol JJ. Anterior spinal fixators. A biomechanical    in 
vitro study. Spine (Phila Pa 1976). 1993;18:513-7.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#104#100#article#117#</font></p>     ^cY#06.h
tm##
00517000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704027900073002000700352#v19
n1#V:\SciELO\serial\aob\v19n1\markup\06.htm#S#p#105#101#article#117#8#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">8. Kwok AW, Finkelstein    
JA, Woodside T, Hearn TC, Hu RW. Insertional torque and pull-out strengths of   
 conical and cylindrical pedicle screws in cadaveric bone. Spine (Phila Pa 1976)
.    1996;21:2429-34.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#106#102#article#117#</font></p>     ^cY#06.h
tm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#107#103#article#117#<p>&nbsp;</p>     ^cY#06
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#108#104#article#117#<p>&nbsp;</p>     ^cY#06
.htm##
00430000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704020600071002000700277#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#109#105#article#117#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top"><img sr
c="/img/revistas/aob/v19n1/seta.jpg" border="0"></a>    <b>Endereço para Corresp
ondência:</b>     ^cY#06.htm##
00260000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003600071002000700107#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#110#106#article#117#<br>   Av. Bandeirantes 
3900    ^cY#06.htm##
00270000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004600071002000700117#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#111#107#article#117#<br>   Hospital das Clin
icas 11º Andar    ^cY#06.htm##
00265000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004100071002000700112#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#112#108#article#117#<br>   Depto de Biomec&a
circ;nica    ^cY#06.htm##
00298000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704007400071002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#113#109#article#117#<br>   Medicina e Reabil
ita&ccedil;&atilde;o do Aparelho Locomotor    ^cY#06.htm##
00273000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004900071002000700120#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#114#110#article#117#<br>   Ribeir&atilde;o P
reto (SP), Brasil    ^cY#06.htm##
00252000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002800071002000700099#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#115#111#article#117#<br>   CEP 14048-900    
^cY#06.htm##
00339000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704011500071002000700186#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#116#112#article#117#<br>   E-mail: <a href="
mailto:aloisiobonavides@hotmail.com">aloisiobonavides@hotmail.com</a></font>  </
p>     ^cY#06.htm##
00360000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013600071002000700207#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#117#113#article#117#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Artigo recebido    em 22/09/09, aprovado 
em 26/11/10.</font></p>     ^cY#06.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#118#114#article#117#<p>&nbsp;</p>     ^cY#06
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#119#115#article#117#<p>&nbsp;</p>     ^cY#06
.htm##
00491000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704026700071002000700338#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#120#116#article#117#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Trabalho realizado    no Laborat&oacute;r
io de Bioengenharia da Faculdade de Medicina de Ribeir&atilde;o    Preto da Univ
ersidade de S&atilde;o Paulo - USP - Ribeir&atilde;o Preto (SP),    Brasil.    ^
cY#06.htm##
00361000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013700071002000700208#v19n1#V:\SciELO
\serial\aob\v19n1\markup\06.htm#S#p#121#117#article#117#<br>   Todos os autores 
declaram n&atilde;o haver nenhum potencial conflito de interesses    referente a
 este artigo.</font></p>     ^cY#06.htm##
00723000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080002000651180002000670100018000690100018000870100
01500105010002000120010001700140010001800157012014800175030001200323065000900335
06400050034403100030034901400070035286500090035900200070036803500100037580100120
0385#v19n1#V:\SciELO\serial\aob\v19n1\markup\06.htm#S#c#122#1#article#8#1#^rND^s
Brand J^nJr#^rND^sHamilton^nD#^rND^sSelby^nJ#^rND^sPienkowski^nD#^rND^sCaborn^nD
N#^rND^sJohnson^nDL#Biomechanical comparison of quadriceps tendon fixation with 
patellar tendon bone plug interference fixation in cruciate ligament reconstruct
ion^len#Arthroscopy#20000000#2000#16#805-12#20110000#06.htm#0749-8063#Arthroscop
y##
00562000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080002000651180002000670100019000690100017000880120
10700105030001200212065000900224064000500233031000200238014000600240865000900246
002000700255035001000262801001200272#v19n1#V:\SciELO\serial\aob\v19n1\markup\06.
htm#S#c#123#2#article#8#2#^rND^sMatthews^nLS#^rND^sSoffer^nSR#Pitfalls in the us
e of interference screws for anterior cruciate ligament reconstruction: brief re
port^len#Arthroscopy#19890000#1989#5#225-6#20110000#06.htm#0749-8063#Arthroscopy
##
00430000000000217000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080002000651180002000670160018000690160018000870160
01500105016001500120018006100135865000900196002000700205#v19n1#V:\SciELO\serial\
aob\v19n1\markup\06.htm#S#c#124#3#article#8#3#^rND^sShimano^nAC#^rND^sDefino^nHL
A#^rND^sRosa^nRC#^rND^sSilva^nP#inventores: Dispositivo e método para aferição d
e torque^lpt#20110000#06.htm##
00772000000000313000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080002000651180002000670100016000690100014000850100
01900099010001700118010002100135012018100156030003600337065000900373064000500382
031000200387014000700389865000900396002000700405035001000412801003600422#v19n1#V
:\SciELO\serial\aob\v19n1\markup\06.htm#S#c#125#4#article#8#4#^rND^sBrown^nGA#^r
ND^sPeña^nF#^rND^sGrøntvedt^nT#^rND^sLabadie^nD#^rND^sEngebretsen^nL#Fixation st
rength of interference screw fixation in bovine, young human, and elderly human 
cadaver knees: influence of insertion torque, tunnel-bone block gap, and interfe
rence^len#Knee Surg Sports Traumatol Arthrosc#19960000#1996#3#238-44#20110000#06
.htm#0942-2056#Knee Surg Sports Traumatol Arthrosc##
00448000000000241000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080002000651180002000670160018000690180065000870630
00200152066001300154062000900167065000900176064000500185865000900190002000700199
#v19n1#V:\SciELO\serial\aob\v19n1\markup\06.htm#S#c#126#5#article#8#5#^rND^sBrow
ner^nBC#Skeletal trauma basic science, management and reconstruction^len#3#Phila
delphia#Saunders#20030000#2003#20110000#06.htm##
00601000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080002000651180002000670100018000690100017000870100
01700104012010900121030001600230065000900246064000500255031000200260014000700262
865000900269002000700278035001000285801001600295#v19n1#V:\SciELO\serial\aob\v19n
1\markup\06.htm#S#c#127#6#article#8#6#^rND^sDaftari^nTK#^rND^sHorton^nWC#^rND^sH
utton^nWC#Correlations between screw hole preparation, torque of insertion, and 
pullout strength for spinal screws^len#J Spinal Disord#19940000#1994#7#139-45#20
110000#06.htm#0895-0385#J Spinal Disord##
00589000000000313000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080002000651180002000670100019000690100017000880100
01300105010001700118010001800135012006100153030000600214065000900220064000500229
031000300234014000600237865000900243002000700252035001000259801000600269#v19n1#V
:\SciELO\serial\aob\v19n1\markup\06.htm#S#c#128#7#article#8#7#^rND^sZdeblick^nTA
#^rND^sWarden^nKE#^rND^sZou^nD#^rND^sMcAfee^nPC#^rND^sAbitbol^nJJ#Anterior spina
l fixators: A biomechanical in vitro study^len#Spine#19930000#1993#18#513-7#2011
0000#06.htm#0362-2436#SPINE##
00636000000000313000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080002000651180002000670100015000690100022000840100
01800106010001600124010001300140012010600153030000600259065000900265064000500274
031000300279014000800282865000900290002000700299035001000306801000600316#v19n1#V
:\SciELO\serial\aob\v19n1\markup\06.htm#S#c#129#8#article#8#8#^rND^sKwok^nAW#^rN
D^sFinkelstein^nJA#^rND^sWoodside^nT#^rND^sHearn^nTC#^rND^sHu^nRW#Insertional to
rque and pull-out strengths of conical and cylindrical pedicle screws in cadaver
ic bone^len#Spine#19960000#1996#21#2429-34#20110000#06.htm#0362-2436#SPINE##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#o#1#1#article#1#201104
11#111855#07.htm#223##
03547000000000589000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083121000300087049000700090158000300097030001800100
03100030011803200020012106500090012301400090013203500100014101200970015101200780
02480100039003260100041003650700038004060831133004440850008015770850025015850850
02301610085001901633085003801652083110901690085000802799085002502807085002302832
08500170285508500330287211700060290507200030291111200090291411100090292311400090
2932113000902941002000702950#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#h#
2#1#article#1#oa#pt#br1.1#1#4.0#TAB#07#AOB140#nd#Acta ortop. bras.#19#1#20110000
#^f32^l36#1413-7852#Avaliação da perda sanguínea na artroplastia total do joelho
 com e sem soltura do torniquete^lpt#Blood loss in total knee arthroplasty with 
and without tourniquet release^len#^rND^1A01^nJosé Wanderley^sVasconcelos#^rND^1
A01^nGerusa de Arruda^sVasconcelos#Universidade Federal do Maranhão^iA01#^lpt^aO
BJETIVO: Avaliar a perda sanguínea em pacientes submetidos à artroplastia total 
cimentada do joelho com e sem soltura trans-operatória do torniquete pneumático 
para a hemostasia. MÉTODOS: Foram estudados 72 pacientes submetidos à artroplast
ia total, num total de 80 joelhos, divididos em dois grupos: Grupo 1 onde se man
teve o torniquete pneumático até a sutura e curativo da ferida operatória, e Gru
po 2 onde foi realizada a soltura do torniquete pneumático após a cimentação da 
prótese, com realização de hemostasia direta, antes da sutura e curativo. Os pac
ientes foram avaliados quanto ao sangramento pelo dreno de sucção e à contagem d
e hemoglobina e hematócrito, considerando os intervalos de duas, 24 e 48 horas d
e pós-operatório. RESULTADOS: Não houve diferença significante entre os dois gru
pos quanto ao sangramento pós-operatório e decréscimo dos parâmetros hematimétri
cos. Somente um paciente do Grupo 2 necessitou transfusão de concentrado de hemá
ceas no pós-operatório. CONCLUSÃO: O sangramento pós-operatório na ATJ mostrou-s
e igual com e sem a soltura do torniquete pneumático para a realização da hemost
asia.#^dnd^i1#^tm^lpt^kArtroplastia^i1#^tm^lpt^kHemostasia^i1#^tm^lpt^kJoelho^i1
#^tm^lpt^kPerda sanguínea cirúrgica^i1#^len^aOBJECTIVE: To evaluate blood loss i
n patients submitted to cemented total knee arthroplasty with and without periop
erative tourniquet release for hemostasis. METHODS: Seventy-two patients (eighty
 knees) were submitted to total knee arthroplasty, allocated into two groups: in
 Group 1, in which the pneumatic tourniquet was maintained until suture and dres
sing of the operated wound, and Group 2, in which the pneumatic tourniquet was r
eleased intraoperatively after cementing the prosthesis, with direct hemostasis,
 before the suture and dressing. The patients were evaluated for blood loss by t
he suction drain, and hemoglobin and hematocrit counts, at intervals of 2, 24 an
d 48 hours in the postoperative period tube. RESULTS: There was no significant d
ifference between the groups in terms of postoperative blood loss or decrease in
 hemoglobin and hematocrit parameters. Only one patient, from Group 2, required 
a blood transfusion in the postoperative period. CONCLUSION: Postoperative blood
 loss in TKA was similar with and without perioperative release of the pneumatic
 tourniquet for hemostasis.#^dnd^i2#^tm^len^kArthroplasty^i2#^tm^len^kHemostasis
^i2#^tm^len^kKnee^i2#^tm^len^kBlood loss, surgical^i2#other#34#20080830#30/08/08
#20090629#29/06/09#07.htm##
03617000000000589000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083121000300087049000700090158000300097030001800100
03100030011803200020012106500090012301400090013203500100014101201040015101200850
02550100039003400100041003790700038004200831161004580850008016190850025016270850
02301652085001901675085003801694083113701732085000802869085002502877085002302902
08500170292508500330294211700060297507200030298111200090298411100090299311400090
3002113000903011002000703020#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#f#
3#1#article#1#oa#pt#br1.1#1#4.0#TAB#07#AOB140#nd#Acta ortop. bras.#19#1#20110000
#^f32^l36#1413-7852#<b>Avaliação da perda sanguínea na artroplastia total do joe
lho com e sem soltura do torniquete</b>^lpt#<b>Blood loss in total knee arthropl
asty with and without tourniquet release</b>^len#^rND^1A01^nJosé Wanderley^sVasc
oncelos#^rND^1A01^nGerusa de Arruda^sVasconcelos#Universidade Federal do Maranhã
o^iA01#^lpt^a<b>OBJETIVO:</b> Avaliar a perda sanguínea em pacientes submetidos 
à artroplastia total cimentada do joelho com e sem soltura trans-operatória do t
orniquete pneumático para a hemostasia. <b>MÉTODOS:</b> Foram estudados 72 pacie
ntes submetidos à artroplastia total, num total de 80 joelhos, divididos em dois
 grupos: Grupo 1 onde se manteve o torniquete pneumático até a sutura e curativo
 da ferida operatória, e Grupo 2 onde foi realizada a soltura do torniquete pneu
mático após a cimentação da prótese, com realização de hemostasia direta, antes 
da sutura e curativo. Os pacientes foram avaliados quanto ao sangramento pelo dr
eno de sucção e à contagem de hemoglobina e hematócrito, considerando os interva
los de duas, 24 e 48 horas de pós-operatório. <b>RESULTADOS:</b> Não houve difer
ença significante entre os dois grupos quanto ao sangramento pós-operatório e de
créscimo dos parâmetros hematimétricos. Somente um paciente do Grupo 2 necessito
u transfusão de concentrado de hemáceas no pós-operatório. <b>CONCLUSÃO:</b> O s
angramento pós-operatório na ATJ mostrou-se igual com e sem a soltura do torniqu
ete pneumático para a realização da hemostasia.#^dnd^i1#^tm^lpt^kArtroplastia^i1
#^tm^lpt^kHemostasia^i1#^tm^lpt^kJoelho^i1#^tm^lpt^kPerda sanguínea cirúrgica^i1
#^len^a<b>OBJECTIVE:</b> To evaluate blood loss in patients submitted to cemente
d total knee arthroplasty with and without perioperative tourniquet release for 
hemostasis. <b>METHODS:</b> Seventy-two patients (eighty knees) were submitted t
o total knee arthroplasty, allocated into two groups: in Group 1, in which the p
neumatic tourniquet was maintained until suture and dressing of the operated wou
nd, and Group 2, in which the pneumatic tourniquet was released intraoperatively
 after cementing the prosthesis, with direct hemostasis, before the suture and d
ressing. The patients were evaluated for blood loss by the suction drain, and he
moglobin and hematocrit counts, at intervals of 2, 24 and 48 hours in the postop
erative period tube. <b>RESULTS:</b> There was no significant difference between
 the groups in terms of postoperative blood loss or decrease in hemoglobin and h
ematocrit parameters. Only one patient, from Group 2, required a blood transfusi
on in the postoperative period. <b>CONCLUSION:</b> Postoperative blood loss in T
KA was similar with and without perioperative release of the pneumatic tournique
t for hemostasis.#^dnd^i2#^tm^len^kArthroplasty^i2#^tm^len^kHemostasis^i2#^tm^le
n^kKnee^i2#^tm^len^kBlood loss, surgical^i2#other#34#20080830#30/08/08#20090629#
29/06/09#07.htm##
03668000000000613000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000400090121000300094049000700097158000300104
03000170010703100030012403200020012706500090012901400090013803500100014701200970
01570120078002540100039003320100041003710700040004120831133004520850008015850850
02501593085002301618085001901641085003801660083110901698085000802807085002502815
08500230284008500170286308500330288011700060291307200030291911200090292211100090
2931114000902940113000902949002000702958008008902965#v19n1#V:\SciELO\serial\aob\
v19n1\markup\07.htm#S#l#4#1#article#1#^a2011#oa#pt#br1.1#1#4.0#tab#07#AOB140#nd#
Acta ortop. bras#19#1#20110000#^f32^l36#1413-7852#Avaliação da perda sanguínea n
a artroplastia total do joelho com e sem soltura do torniquete^lpt#Blood loss in
 total knee arthroplasty with and without tourniquet release^len#^rND^1A01^nJosé
 Wanderley^sVasconcelos#^rND^1A01^nGerusa de Arruda^sVasconcelos#^iA01^1Universi
dade Federal do Maranhão#^lpt^aOBJETIVO: Avaliar a perda sanguínea em pacientes 
submetidos à artroplastia total cimentada do joelho com e sem soltura trans-oper
atória do torniquete pneumático para a hemostasia. MÉTODOS: Foram estudados 72 p
acientes submetidos à artroplastia total, num total de 80 joelhos, divididos em 
dois grupos: Grupo 1 onde se manteve o torniquete pneumático até a sutura e cura
tivo da ferida operatória, e Grupo 2 onde foi realizada a soltura do torniquete 
pneumático após a cimentação da prótese, com realização de hemostasia direta, an
tes da sutura e curativo. Os pacientes foram avaliados quanto ao sangramento pel
o dreno de sucção e à contagem de hemoglobina e hematócrito, considerando os int
ervalos de duas, 24 e 48 horas de pós-operatório. RESULTADOS: Não houve diferenç
a significante entre os dois grupos quanto ao sangramento pós-operatório e decré
scimo dos parâmetros hematimétricos. Somente um paciente do Grupo 2 necessitou t
ransfusão de concentrado de hemáceas no pós-operatório. CONCLUSÃO: O sangramento
 pós-operatório na ATJ mostrou-se igual com e sem a soltura do torniquete pneumá
tico para a realização da hemostasia.#^dnd^i1#^tm^lpt^kArtroplastia^i1#^tm^lpt^k
Hemostasia^i1#^tm^lpt^kJoelho^i1#^tm^lpt^kPerda sanguínea cirúrgica^i1#^len^aOBJ
ECTIVE: To evaluate blood loss in patients submitted to cemented total knee arth
roplasty with and without perioperative tourniquet release for hemostasis. METHO
DS: Seventy-two patients (eighty knees) were submitted to total knee arthroplast
y, allocated into two groups: in Group 1, in which the pneumatic tourniquet was 
maintained until suture and dressing of the operated wound, and Group 2, in whic
h the pneumatic tourniquet was released intraoperatively after cementing the pro
sthesis, with direct hemostasis, before the suture and dressing. The patients we
re evaluated for blood loss by the suction drain, and hemoglobin and hematocrit 
counts, at intervals of 2, 24 and 48 hours in the postoperative period tube. RES
ULTS: There was no significant difference between the groups in terms of postope
rative blood loss or decrease in hemoglobin and hematocrit parameters. Only one 
patient, from Group 2, required a blood transfusion in the postoperative period.
 CONCLUSION: Postoperative blood loss in TKA was similar with and without periop
erative release of the pneumatic tourniquet for hemostasis.#^dnd^i2#^tm^len^kArt
hroplasty^i2#^tm^len^kHemostasis^i2#^tm^len^kKnee^i2#^tm^len^kBlood loss, surgic
al^i2#other#34#20080830#30/08/08#20090629#29/06/09#07.htm#Internet^ihttp://www.s
cielo.br/scielo.php?script=sci_arttext&pid=S1413-78522011000100007##
00342000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704012200067002000700189#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#5#1#article#185#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTIGO    ORIGINAL</b></font
></p>     ^cY#07.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#6#2#article#185#<p>&nbsp;</p>     ^cY#07.htm
##
00447000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704022700067002000700294#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#7#3#article#185#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Avalia&ccedil;&atilde;o 
   da perda sangu&iacute;nea na artroplastia total do joelho com e sem soltura  
  do torniquete</b></font></p>     ^cY#07.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#8#4#article#185#<p>&nbsp;</p>     ^cY#07.htm
##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#9#5#article#185#<p>&nbsp;</p>     ^cY#07.htm
##
00377000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704015600068002000700224#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#10#6#article#185#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Jos&eacute;    Wanderley Vasconcelos; Ger
usa de Arruda Vasconcelos</b></font></p>     ^cY#07.htm##
00353000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704013200068002000700200#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#11#7#article#185#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2">Universidade Federal    do Maranh&atilde;o -
 UFMA</font></p>     ^cY#07.htm##
00369000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704014800068002000700216#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#12#8#article#185#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><a href="#back">Endere&ccedil;o    para Corr
espond&ecirc;ncia</a></font></p>     ^cY#07.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#13#9#article#185#<p>&nbsp;</p>     ^cY#07.ht
m##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#14#10#article#185#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#07.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#15#11#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#07.htm##
00516000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704029400069002000700363#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#16#12#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Avaliar a perda sangu&i
acute;nea em pacientes submetidos &agrave; artroplastia    total cimentada do jo
elho com e sem soltura trans-operat&oacute;ria do torniquete    pneum&aacute;tic
o para a hemostasia.    ^cY#07.htm##
00952000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704073000069002000700799#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#17#13#article#185#<br>   <b>M&Eacute;TODOS:<
/b> Foram estudados 72 pacientes submetidos &agrave; artroplastia    total, num 
total de 80 joelhos, divididos em dois grupos: Grupo 1 onde se manteve    o torn
iquete pneum&aacute;tico at&eacute; a sutura e curativo da ferida operat&oacute;
ria,    e Grupo 2 onde foi realizada a soltura do torniquete pneum&aacute;tico a
p&oacute;s    a cimenta&ccedil;&atilde;o da pr&oacute;tese, com realiza&ccedil;&
atilde;o de    hemostasia direta, antes da sutura e curativo. Os pacientes foram
 avaliados    quanto ao sangramento pelo dreno de suc&ccedil;&atilde;o e &agrave
; contagem    de hemoglobina e hemat&oacute;crito, considerando os intervalos de
 duas, 24    e 48 horas de p&oacute;s-operat&oacute;rio.    ^cY#07.htm##
00574000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704035200069002000700421#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#18#14#article#185#<br>   <b>RESULTADOS:</b> 
N&atilde;o houve diferen&ccedil;a significante entre os dois    grupos quanto ao
 sangramento p&oacute;s-operat&oacute;rio e decr&eacute;scimo    dos par&acirc;m
etros hematim&eacute;tricos. Somente um paciente do Grupo 2 necessitou    transf
us&atilde;o de concentrado de hem&aacute;ceas no p&oacute;s-operat&oacute;rio.  
  ^cY#07.htm##
00445000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704022300069002000700292#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#19#15#article#185#<br>   <b>CONCLUS&Atilde;O
:</b> O sangramento p&oacute;s-operat&oacute;rio na ATJ mostrou-se    igual com 
e sem a soltura do torniquete pneum&aacute;tico para a realiza&ccedil;&atilde;o 
   da hemostasia.</font></p>     ^cY#07.htm##
00424000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704020200069002000700271#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#20#16#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Descritores:</b>    Artroplastia. Hemost
asia. Joelho. Perda sangu&iacute;nea cir&uacute;rgica.</font></p> <hr size="1" n
oshade>     ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#21#17#article#185#<p>&nbsp;</p>     ^cY#07.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#22#18#article#185#<p>&nbsp;</p>     ^cY#07.h
tm##
00336000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011400069002000700183#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#23#19#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b></font></p> 
    ^cY#07.htm##
00489000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704026700069002000700336#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#24#20#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A artroplastia    total do joelho (ATJ) pod
e ser causa de perda sangu&iacute;nea importante e    diversos trabalhos demonst
ram uma elevada incid&ecirc;ncia transfusional.<sup>1-4</sup></font></p>     ^cY
#07.htm##
00942000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704072000069002000700789#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#25#21#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As transfus&otilde;es    hom&oacute;logas e
st&atilde;o relacionadas a um grande n&uacute;mero de complica&ccedil;&otilde;es
    como eleva&ccedil;&atilde;o na incid&ecirc;ncia de infec&ccedil;&otilde;es d
a    ferida<sup>5</sup>, sobrecarga h&iacute;drica, aumento do tempo de hospital
iza&ccedil;&atilde;o,<sup>6</sup>    infec&ccedil;&otilde;es virais, imunodepres
s&atilde;o, rea&ccedil;&otilde;es    hemol&iacute;ticas e les&otilde;es teciduai
s inflamat&oacute;rias,<sup>7,8</sup>    al&eacute;m dos riscos inerentes de con
tamina&ccedil;&atilde;o por HIV, hepatite    C, dentre outras enfermidades de tr
ansmiss&atilde;o sangu&iacute;nea.</font></p>     ^cY#07.htm##
00797000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704057500069002000700644#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#26#22#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A autotransfus&atilde;o    (aut&oacute;loga
) com sangue de pr&eacute;-dep&oacute;sito atrav&eacute;s do    sistema de estoc
agem sangu&iacute;nea tem sido defendida na ATJ na tentativa    de evitar as com
plica&ccedil;&otilde;es das transfus&otilde;es hom&oacute;logas.<sup>9-11</sup> 
   As transfus&otilde;es aut&oacute;logas, entretanto, s&atilde;o caras, n&atild
e;o    isentas de complica&ccedil;&otilde;es,<sup>12</sup> e nem sempre podem se
r utilizadas    em pacientes idosos.<sup>13</sup></font></p>     ^cY#07.htm##
01014000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704079200069002000700861#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#27#23#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Visando diminuir    o n&uacute;mero de tran
sfus&otilde;es sanguineas em ATJ, alguns cuidados t&ecirc;m    sido descritos pa
ra a minimiza&ccedil;&atilde;o do sangramento trans e p&oacute;s-operat&oacute;r
io,    como a oclus&atilde;o do orif&iacute;cio de frezagem femoral com enxerto 
&oacute;sseo,<sup>14</sup>    o uso de torniquete pneum&aacute;tico e do dreno d
e suc&ccedil;&atilde;o,<sup>13</sup>    a melhoria da t&eacute;cnica cir&uacute;
rgica<sup>15</sup>, a utiliza&ccedil;&atilde;o    do &aacute;cido tranex&acirc;m
ico,<sup>16</sup> a infus&atilde;o local com norepinefrina<sup>17</sup>    e mai
s recentemente a coloca&ccedil;&atilde;o de gel com plaquetas na ferida    opera
t&oacute;ria.<sup>18</sup></font></p>     ^cY#07.htm##
00865000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704064300069002000700712#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#28#24#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A utiliza&ccedil;&atilde;o    do torniquete
 pneum&aacute;tico no trans-operat&oacute;rio permite ao cirurgi&atilde;o    um 
campo exangue at&eacute; a coloca&ccedil;&atilde;o dos componentes, melhorando  
  ainda a t&eacute;cnica de cimenta&ccedil;&atilde;o. O momento de sua retirada,
    entretanto, &eacute; motivo de controv&eacute;rsias na literatura, podendo s
er    realizada no trans-operat&oacute;rio, logo ap&oacute;s a cimenta&ccedil;&a
tilde;o    da pr&oacute;tese para a hemostasia direta da ferida, ou ap&oacute;s 
a sutura    e o curativo compressivo.</font></p>     ^cY#07.htm##
00909000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704068700069002000700756#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#29#25#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O primeiro estudo    comparando os dois m&e
acute;todos foi realizado por Newman <i>et al</i>.,<sup>19</sup>    com oitenta 
pacientes submetidos &agrave; artroplastias cimentadas. Os autores    referiram 
uma menor perda sangu&iacute;nea quando o torniquete foi retirado    ap&oacute;s
 a sutura e o curativo. Page <i>et al</i>.,<sup>20</sup> entretanto,    em um es
tudo n&atilde;o randomizado, referiram melhores resultados em pacientes    com s
oltura trans-operat&oacute;ria do torniquete para a hemostasia direta.    Apesar
 da redu&ccedil;&atilde;o encontrada todos os seus pacientes foram transfundidos
.</font></p>     ^cY#07.htm##
00698000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704047600069002000700545#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#30#26#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Desde ent&atilde;o    estudos t&ecirc;m sid
o publicados com resultados discordantes. Jorn <i>et al</i>.<sup>21</sup>    e I
shii e Matsuda<sup>22</sup> encontraram um sangramento significativamente    men
or no grupo de pacientes onde o torniquete foi retirado ap&oacute;s o fechamento
    da ferida operat&oacute;ria e o curativo, concordando com o relato de Newman
    <i>et al</i>.<sup>19</sup></font></p>     ^cY#07.htm##
00544000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704032200069002000700391#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#31#27#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Widman e Isacson,<sup>23</sup>    Schuh <i>
et al</i>.<sup>24</sup> e Hersekli <i>et al</i>.<sup>25</sup> n&atilde;o    enco
ntraram diferen&ccedil;a na perda sangu&iacute;nea quanto ao momento da    retir
ada do torniquete pneum&aacute;tico.</font></p>     ^cY#07.htm##
00528000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704030600069002000700375#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#32#28#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O objetivo deste    estudo &eacute; avaliar
 a perda sangu&iacute;nea total em pacientes submetidos    &agrave; artroplastia
 total cimentada do joelho com e sem a soltura do torniquete    pneum&aacute;tic
o para a hemostasia.</font></p>     ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#33#29#article#185#<p>&nbsp;</p>     ^cY#07.h
tm##
00336000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011400069002000700183#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#34#30#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>MATERIAL E M&Eacute;TODO</b></font></p> 
    ^cY#07.htm##
01032000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704081000069002000700879#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#35#31#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Foram estudados    72 pacientes submetidos 
&agrave; ATJ, num total de 80 joelhos, operados no Hospital    Universit&aacute;
rio Presidente Dutra, da Universidade Federal do Maranh&atilde;o,    no per&iacu
te;odo de junho de 2005 a dezembro de 2006. O estudo foi do tipo    prospectivo,
 aprovado pelo Comit&ecirc; de &Eacute;tica em Pesquisa. Todos os    pacientes r
ealizaram exames de rotina pr&eacute;-operat&oacute;rios, sendo o    hemograma i
ndispens&aacute;vel. O uso de anti-coagulantes foi suspenso em tr&ecirc;s    pac
ientes com dez dias de anteced&ecirc;ncia da cirurgia. Todos os pacientes    for
am informados do estudo, e s&oacute; participaram mediante autoriza&ccedil;&atil
de;o    do termo de consentimento informado.</font></p>     ^cY#07.htm##
00756000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704053400069002000700603#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#36#32#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Os crit&eacute;rios    de exclus&atilde;o f
oram pacientes que apresentavam alguma forma de discrasia    sangu&iacute;nea, a
queles com cirurgias pr&eacute;vias no joelho a ser operado    ou quando o proce
dimento cir&uacute;rgico teve que ser alargado por tenotomia    do quadr&iacute;
ceps ou osteotomia da tuberosidade tibial. Como crit&eacute;rio    pr&eacute;-op
erat&oacute;rio de inclus&atilde;o a hemoglobina m&iacute;nima    aceita foi de 
11 g/dL.</font></p>     ^cY#07.htm##
00575000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704035300069002000700422#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#37#33#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Setenta e um joelhos    foram operados por 
artrose prim&aacute;ria, seis por artrite reumat&oacute;ide,    um por sequela d
e gota, um por artrose secund&aacute;ria a condromatose sinovial    avan&ccedil;
ada e um por sequela traum&aacute;tica e joelho semi-r&iacute;gido.</font></p>  
   ^cY#07.htm##
00479000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704025700069002000700326#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#38#34#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Os pacientes foram    divididos em dois gru
pos, sendo os primeiros quarenta joelhos operados pertencentes    ao Grupo 1 e o
s quarenta subsequentes alocados no Grupo 2.</font></p> <ul>       ^cY#07.htm##
00543000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704032100069002000700390#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#39#35#article#185#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Grupo 1 (35      pacientes, 40 joelhos) on
de foi realizada a sutura da ferida e o curativo      compressivo, com bandagens
 sucessivas de crepom e algod&atilde;o ortop&eacute;dico,      antes da soltura 
do torniquete pneum&aacute;tico.</font></li>       ^cY#07.htm##
00543000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704032100069002000700390#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#40#36#article#185#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Grupo 2 (37      pacientes, 40 joelhos) on
de foi realizada a retirada do torniquete pneum&aacute;tico      logo ap&oacute;
s a cimenta&ccedil;&atilde;o da pr&oacute;tese e hemostasia      aberta antes da
 sutura e do curativo compressivo.</font></li>     ^cY#07.htm##
00236000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704001400069002000700083#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#41#37#article#185#</ul>     ^cY#07.htm##
00631000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704040900069002000700478#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#42#38#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Os pacientes que    realizaram artroplastia
s bilaterais n&atilde;o o fizeram a um s&oacute; tempo.    Os mesmos receberam a
lta hospitalar e s&oacute; foram submetidos ao segundo    procedimento ap&oacute
;s a realiza&ccedil;&atilde;o de novos exames com normaliza&ccedil;&atilde;o    
dos par&acirc;metros hematim&eacute;tricos.</font></p>     ^cY#07.htm##
00916000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704069400069002000700763#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#43#39#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Todos os pacientes    seguiram a rotina est
abelecida para ATJ, com antibioticoterapia profil&aacute;tica    conforme normas
 da Comiss&atilde;o de Controle de Infec&ccedil;&atilde;o Hospitalar    (CCIH). 
O antibi&oacute;tico utilizado foi a cefazolina nas doses de um grama    trinta 
minutos antes da incis&atilde;o, seguindo-se por um grama endovenoso    a cada o
ito horas at&eacute; o segundo dia de p&oacute;s-operat&oacute;rio.    A utiliza
&ccedil;&atilde;o de heparina de baixo peso molecular se iniciou ap&oacute;s    
18 horas de p&oacute;s-operat&oacute;rio e foi mantida at&eacute; a alta do    p
aciente.</font></p>     ^cY#07.htm##
00539000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704031700069002000700386#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#44#40#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Todos os pacientes    foram operados pela m
esma equipe cir&uacute;rgica e os dados pr&eacute; e p&oacute;s-operat&oacute;ri
os    colhidos pela pr&oacute;pria pesquisadora e equipe e anotados em uma ficha
 de    avalia&ccedil;&atilde;o.</font></p>     ^cY#07.htm##
01192000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704097000069002000701039#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#45#41#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O procedimento    cir&uacute;rgico foi real
izado atrav&eacute;s de via de acesso parapatelar medial,    seguindo-se de ever
s&atilde;o e luxa&ccedil;&atilde;o lateral da patela, ressec&ccedil;&atilde;o   
 dos meniscos e ligamento cruzado anterior, cortes femoral e tibial conforme    
t&eacute;cnica padronizada para as artroplastias do joelho. Os cortes femorais  
  foram realizados com guia intramedular e os tibiais com extra-medular. O ligam
ento    cruzado posterior foi preservado em sessenta e quatro joelhos. A patela 
foi    preservada em todos os pacientes. Em 18 joelhos do Grupo 1 e 20 do Grupo 
2 foi    realizada a libera&ccedil;&atilde;o do retin&aacute;culo lateral da pat
ela,    com cauteriza&ccedil;&atilde;o da art&eacute;ria retinacular s&uacute;pe
ro-lateral.    Todas as pr&oacute;teses foram cimentadas e o orif&iacute;cio fem
oral obliterado    com enxerto &oacute;sseo.</font></p>     ^cY#07.htm##
00777000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704055500069002000700624#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#46#42#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Nos pacientes do    Grupo 2, logo ap&oacute
;s a soltura do torniquete pneum&aacute;tico, foi realizada    a compress&atilde
;o da ferida operat&oacute;ria com compressas e ataduras de    crepom e eleva&cc
edil;&atilde;o do membro por sete minutos. Ap&oacute;s esse    per&iacute;odo se
 procedeu &agrave; retirada progressiva e cautelosa das compressas    e &agrave;
 inspe&ccedil;&atilde;o dos tecidos moles com subsequente cauteriza&ccedil;&atil
de;o    dos vasos sangrantes.</font></p>     ^cY#07.htm##
00646000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704042400069002000700493#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#47#43#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A sutura da ferida    operat&oacute;ria foi
 realizada por planos, com joelho em flex&atilde;o de 60°,    e colocado dreno d
e suc&ccedil;&atilde;o intra-articular com sa&iacute;da para    a regi&atilde;o 
medial e proximal da perna. Foi realizado curativo com camadas    sucessivas de 
bandagens compressivas e algod&atilde;o ortop&eacute;dico.</font></p>     ^cY#07
.htm##
00579000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704035700069002000700426#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#48#44#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Nos pacientes do    Grupo 1, ap&oacute;s a 
realiza&ccedil;&atilde;o do curativo compressivo e a    soltura do torniquete, v
erificou-se a presen&ccedil;a de pulso da art&eacute;ria    pediosa e da tibial 
posterior, para avalia&ccedil;&atilde;o da perfus&atilde;o    vascular.</font></
p>     ^cY#07.htm##
00991000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704076900069002000700838#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#49#45#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Todos os pacientes    permaneceram no p&oac
ute;s-operat&oacute;rio imediato na sala de recupera&ccedil;&atilde;o    p&oacut
e;s-anest&eacute;sica nas duas primeiras horas, com monitoriza&ccedil;&atilde;o 
   card&iacute;aca, oximetria de pulso e aferi&ccedil;&atilde;o dos sinais vitai
s,    sendo realizado a primeira medi&ccedil;&atilde;o da perda sangu&iacute;nea
 e    coletado o hemograma. Ap&oacute;s duas horas, na depend&ecirc;ncia das con
di&ccedil;&otilde;es    cl&iacute;nicas, eram encaminhados &agrave; enfermaria d
o Servi&ccedil;o de    Ortopedia, onde eram anotados os sinais vitais a cada sei
s horas, colhido o    hemograma e medida a perda sangu&iacute;nea de 24 e 48 hor
as.</font></p>     ^cY#07.htm##
01035000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704081300069002000700882#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#50#46#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Adotamos no p&oacute;s-operat&oacute;rio   
 os crit&eacute;rios de transfus&atilde;o do <i>American College of Surgeons</i>
    (<a href="#t1">Tabela 1</a>), citado por Cangiani <i>et al</i>.,<sup>26</sup
>    bem como a medida da hemoglobina p&oacute;s-operat&oacute;ria. Realizamos a
    reposi&ccedil;&atilde;o vol&ecirc;mica com cristal&oacute;ides em rela&ccedi
l;&atilde;o    de 3:1 para as perdas sangu&iacute;neas medidas pelo dreno succto
r, e aceitamos    n&iacute;veis m&iacute;nimos de hemoglobina de 7,5 g/dL. A dec
is&atilde;o de    transfus&atilde;o, entretanto, cabia sempre ao cirurgi&atilde;
o, no trans ou    p&oacute;s-operat&oacute;rio, baseado no estado cl&iacute;nico
 e quadro hematol&oacute;gico    dos pacientes.</font></p>     ^cY#07.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#51#47#article#185#<p><a name="t1"></a></p>  
   ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#52#48#article#185#<p>&nbsp;</p>     ^cY#07.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#53#49#article#185#<p align="center"><img src
="/img/revistas/aob/v19n1/07t01.jpg"></p>     ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#54#50#article#185#<p>&nbsp;</p>     ^cY#07.h
tm##
00694000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704047200069002000700541#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#55#51#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">No primeiro dia    de p&oacute;s-operat&oac
ute;rio os pacientes eram estimulados a realizar exerc&iacute;cios    de contra&
ccedil;&atilde;o isom&eacute;trica do quadr&iacute;ceps e de flexo-extens&atilde
;o    ativa do joelho, progressiva, conforme os limiares dolorosos. N&atilde;o f
oram    utilizados aparelhos de movimenta&ccedil;&atilde;o cont&iacute;nua passi
va em    nossos pacientes.</font></p>     ^cY#07.htm##
00859000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704063700069002000700706#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#56#52#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O controle foi    realizado atrav&eacute;s 
da medi&ccedil;&atilde;o da perda sangu&iacute;nea    pelo esvaziamento do dreno
 succtor e as medidas da hemoglobina e hemat&oacute;crito    ap&oacute;s duas, 2
4 e 48 horas de p&oacute;s-operat&oacute;rio. O sangramento    da ferida operat&
oacute;ria no Grupo 2, ap&oacute;s a retirada do torniquete    pneum&aacute;tico
, foi considerado desprez&iacute;vel neste estudo. Foram anotadas    as complica
&ccedil;&otilde;es at&eacute; 48 horas de p&oacute;s-operat&oacute;rio,    tanto
 local quanto sist&ecirc;micas.</font></p>     ^cY#07.htm##
00719000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704049700069002000700566#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#57#53#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Foi realizado o    c&aacute;lculo do tamanh
o da amostra para se detectar uma diferen&ccedil;a de    200 ml na perda sangu&i
acute;nea assumindo-se que o grupo de menor perda tenha    a m&eacute;dia de 750
 ml, e que o desvio padr&atilde;o dos dois grupos seja    igual a 250 ml, com po
der de 80% em n&iacute;vel alfa de 0,05 para um teste    bilateral, para isso se
riam necess&aacute;rios 25 pacientes em cada grupo.</font></p>     ^cY#07.htm##
00795000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704057300069002000700642#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#58#54#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Os dados foram    analisados utilizando-se 
o programa <i>SPSS for Windows 10.0</i><sup>&reg;</sup>    (1999). Para avalia&c
cedil;&atilde;o dos par&acirc;metros hematim&eacute;tricos    (hemoglobina e hem
at&oacute;crito) e da perda sangu&iacute;nea foi aplicado    o teste <i>t</i> de
 <i>Student</i> para amostras independentes (vari&aacute;veis    quantitativas).
 Em todos os testes o n&iacute;vel de signific&acirc;ncia <i>p</i>    para se re
jeitar a hip&oacute;tese de nulidade foi de 5%.</font></p>     ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#59#55#article#185#<p>&nbsp;</p>     ^cY#07.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#60#56#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>     ^cY#07.htm
##
00536000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704031400069002000700383#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#61#57#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Quarenta e nove    pacientes (68%) eram do 
sexo feminino e vinte e tr&ecirc;s (32%) do masculino.    A m&eacute;dia de idad
e &agrave; &eacute;poca da cirurgia foi de 69,3 anos,    sendo a m&iacute;nima 5
4 e a m&aacute;xima 79 anos.</font></p>     ^cY#07.htm##
00943000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704072100069002000700790#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#62#58#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A perda sangu&iacute;nea    foi maior nas p
rimeiras duas horas de p&oacute;s-operat&oacute;rio (45,33% do    sangramento to
tal no Grupo 1 e 42,85% no Grupo 2) e de duas a 24 horas em ambos    os grupos (
40,37% do sangramento total no Grupo 1 e 43,42% no Grupo 2), havendo    um decr&
eacute;scimo ap&oacute;s 24 at&eacute; 48 horas. A perda sangu&iacute;nea    m&e
acute;dia foi de 747,25 ml no Grupo 1 (m&iacute;nima de 156 e m&aacute;xima    d
e 1.219 ml) e de 838,38 ml no Grupo 2 (m&iacute;nima de 243 e m&aacute;xima    d
e 1.493 ml), sem diferen&ccedil;a estat&iacute;stica significativa entre os    g
rupos. (<a href="#t2">Tabela 2</a>)</font></p>     ^cY#07.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#63#59#article#185#<p><a name="t2"></a></p>  
   ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#64#60#article#185#<p>&nbsp;</p>     ^cY#07.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#65#61#article#185#<p align="center"><img src
="/img/revistas/aob/v19n1/07t02.jpg"></p>     ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#66#62#article#185#<p>&nbsp;</p>     ^cY#07.h
tm##
00716000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704049400069002000700563#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#67#63#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Na avalia&ccedil;&atilde;o    da contagem d
a hemoglobina a perda m&eacute;dia no Grupo 1 foi de 3,29 g/dL    (m&iacute;nima
 0,9 e m&aacute;xima 5,6 g/dL) e no Grupo 2 foi de 3,69 g/dL (m&iacute;nima    1
,1 e m&aacute;xima 8,0 g/dL) com um decr&eacute;scimo constante nas contagens   
 de duas, 24 e 48 horas. (<a href="#t3">Tabela 3</a>) N&atilde;o ocorreu diferen
&ccedil;a    significativa entre os dois grupos.</font></p>     ^cY#07.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#68#64#article#185#<p><a name="t3"></a></p>  
   ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#69#65#article#185#<p>&nbsp;</p>     ^cY#07.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#70#66#article#185#<p align="center"><img src
="/img/revistas/aob/v19n1/07t03.jpg"></p>     ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#71#67#article#185#<p>&nbsp;</p>     ^cY#07.h
tm##
00665000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704044300069002000700512#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#72#68#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Na avalia&ccedil;&atilde;o    do hemat&oacu
te;crito a perda foi de 9,865 pontos no Grupo 1 (m&iacute;nimo    de um e m&aacu
te;ximo de 20,3) e de 10,433 no Grupo 2 (m&iacute;nimo 3 e m&aacute;ximo    de 2
2,1), sem diferen&ccedil;a estat&iacute;stica significativa, ocorrendo um    dec
r&eacute;scimo constante em duas, 24 e 48 horas. (<a href="#t4">Tabela 4</a>)</f
ont></p>     ^cY#07.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#73#69#article#185#<p><a name="t4"></a></p>  
   ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#74#70#article#185#<p>&nbsp;</p>     ^cY#07.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#75#71#article#185#<p align="center"><img src
="/img/revistas/aob/v19n1/07t04.jpg"></p>     ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#76#72#article#185#<p>&nbsp;</p>     ^cY#07.h
tm##
00687000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704046500069002000700534#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#77#73#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Somente um paciente    (1,25%) do Grupo 2 f
oi submetido &agrave; transfus&atilde;o de concentrado de    hem&aacute;ceas no 
segundo dia de p&oacute;s-operat&oacute;rio, pois apresentava    hemoglobina aba
ixo de 7,5 g/dL. Nenhum paciente apresentou sintomas de anemia    aguda, como di
spn&eacute;ia, estado let&aacute;rgico ou taquicardia, no trans    ou p&oacute;s
-operat&oacute;rio.</font></p>     ^cY#07.htm##
00565000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704034300069002000700412#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#78#74#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">At&eacute; o segundo    dia de p&oacute;s-o
perat&oacute;rio nenhum dos pacientes apresentou trombose    venosa profunda ou 
embolia pulmonar. Um paciente do Grupo 1 apresentou derrame    intra-articular a
p&oacute;s 24 horas e outro do Grupo 1 flictenas de pele.</font></p>     ^cY#07.
htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#79#75#article#185#<p>&nbsp;</p>     ^cY#07.h
tm##
00328000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010600069002000700175#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#80#76#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font></p>     ^cY#
07.htm##
00762000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704054000069002000700609#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#81#77#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A utiliza&ccedil;&atilde;o    de torniquete
 pneum&aacute;tico em ATJ permite um campo exangue, o que facilita    a dissec&c
cedil;&atilde;o de partes moles e a realiza&ccedil;&atilde;o dos cortes    &oacu
te;sseos, melhorando ainda a cimenta&ccedil;&atilde;o da pr&oacute;tese.<sup>13,
22</sup>    O momento da retirada do torniquete como melhor op&ccedil;&atilde;o 
na preserva&ccedil;&atilde;o    do estoque sangu&iacute;neo, entretanto, &eacute
; controverso.</font></p>     ^cY#07.htm##
01032000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704081000069002000700879#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#82#78#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A retirada trans-operat&oacute;ria    pode,
 segundo Jorn <i>et al</i>.,<sup>21</sup> levar a uma grande perda devido    ao 
sangramento imediato que ocorre na ferida, decorrente dos vasos n&atilde;o    ca
uterizados ou das superf&iacute;cies de corte &oacute;sseo, dando prefer&ecirc;n
cia    assim &agrave; soltura do torniquete ap&oacute;s a sutura e o curativo co
mpressivo.    J&aacute; Page <i>et al.</i><sup>20</sup> afirmaram que, quando o 
torniquete    &eacute; liberado mais tardiamente, existe a possibilidade de les&
atilde;o de    vasos maiores que n&atilde;o puderam ser verificados no trans-ope
rat&oacute;rio,    e a possibilidade de sangramento da ferida apesar da realiza&
ccedil;&atilde;o    do curativo compressivo.</font></p>     ^cY#07.htm##
01499000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704127700069002000701346#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#83#79#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Em nosso estudo    n&atilde;o houve diferen
&ccedil;a significativa quanto ao sangramento p&oacute;s-operat&oacute;rio    qu
ando o torniquete pneum&aacute;tico foi retirado no trans-operat&oacute;rio    o
u ap&oacute;s a sutura da ferida e curativo compressivo, concordando com os    r
esultados de Widman e Isacson,<sup>23</sup> Schuh <i>et al.</i><sup>24</sup>    
e Hersekli <i>et al.</i><sup>25</sup> Pelo observado em nossa s&eacute;rie deve-
se    esperar, com a retirada ou n&atilde;o do torniquete no trans-operat&oacute
;rio,    uma perda sangu&iacute;nea nas duas primeiras horas praticamente igual 
&agrave;    perda de duas at&eacute; 24 horas, constituindo aproximadamente 80% 
da perda    total. A perda ap&oacute;s 24 at&eacute; 48 horas foi de aproximadam
ente 20%,    sendo retirado o dreno neste momento. Burkart <i>et al.</i><sup>27<
/sup> relataram    a falta de drenagem sangu&iacute;nea pelo dreno de suc&ccedil
;&atilde;o ap&oacute;s    48 horas, recomendando sua retirada para reduzir a pos
sibilidade de coloniza&ccedil;&atilde;o    bacteriana. N&atilde;o ocorreu difere
n&ccedil;a significativa quanto ao decr&eacute;scimo    da hemoglobina e do hema
t&oacute;crito nos dois grupos.</font></p>     ^cY#07.htm##
01110000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704088800069002000700957#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#84#80#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">N&atilde;o consideramos    relevante, nos p
acientes em que o torniquete foi retirado no trans-operat&oacute;rio    (Grupo 2
), o sangramento que ocorre no campo cir&uacute;rgico logo ap&oacute;s    a solt
ura do torniquete, havendo controv&eacute;rsias na literatura quanto &agrave;   
 sua mensura&ccedil;&atilde;o. Christodoulou <i>et al.</i><sup>13</sup> determin
avam    a perda trans-operat&oacute;ria pela pesagem de compressas e pela quanti
dade    de l&iacute;quido aspirado. Burkart <i>et al.</i><sup>27</sup> recomenda
vam    a mensura&ccedil;&atilde;o do l&iacute;quido aspirado e n&atilde;o proced
iam    &agrave; pesagem das compressas. Hersekli <i>et al.</i><sup>25</sup> n&at
ilde;o    realizavam nenhuma medi&ccedil;&atilde;o da perda trans-operat&oacute;
ria, considerando-a    desprez&iacute;vel.</font></p>     ^cY#07.htm##
01024000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704080200069002000700871#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#85#81#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Em nossa experi&ecirc;ncia    observamos qu
e a compress&atilde;o firme da ferida operat&oacute;ria eleva&ccedil;&atilde;o  
  do membro operado por um per&iacute;odo m&iacute;nimo de sete minutos, seguida
    de uma hemostasia cuidadosa, leva a uma perda muita pequena de sangue, que &
eacute;    dif&iacute;cil de mensurar. N&atilde;o utilizamos aspirador quando da
 soltura    do torniquete pneum&aacute;tico para hemostasia nos pacientes do Gru
po 2, por    considerarmos que h&aacute; um aumento na quantidade de sangue perd
ido pela    aspira&ccedil;&atilde;o. Retiramos gradativamente as compressas e, d
e maneira    cuidadosa, realizamos a cauteriza&ccedil;&atilde;o dos vasos t&atil
de;o logo    eles comecem a sangrar.</font></p>     ^cY#07.htm##
01034000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704081200069002000700881#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#86#82#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">&Eacute; importante    ressaltarmos que o c
irurgi&atilde;o deve ter um bom conhecimento da anatomia    vascular do joelho e
 proceda, quando do procedimento com o torniquete pneum&aacute;tico    insuflado
, &agrave; cauteriza&ccedil;&atilde;o dos vasos mais importantes durante    o at
o operat&oacute;rio, para que n&atilde;o ocorra sangramento dos mesmos quando   
 da retirada trans ou p&oacute;s-operat&oacute;ria do torniquete.<sup>15,28</sup
>    Em especial devem ser cauterizados os vasos retinaculares infero-laterais, 
quando    da ressec&ccedil;&atilde;o do menisco lateral, e os retinaculares s&ua
cute;pero-laterais    quando da necessidade de libera&ccedil;&atilde;o do retin&
aacute;culo lateral    da patela.<sup>28</sup></font></p>     ^cY#07.htm##
01136000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704091400069002000700983#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#87#83#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Vale ressaltar    ainda a import&acirc;ncia
 da palpa&ccedil;&atilde;o do pulso pedioso e da art&eacute;ria    tibial poster
ior nos pacientes do Grupo 1, ap&oacute;s a soltura do torniquete    pneum&aacut
e;tico. A les&atilde;o de grandes vasos em ATJ &eacute; muito rara,<sup>25</sup>
    por&eacute;m pode ser diagnosticada pela palpa&ccedil;&atilde;o do pulso art
erial,    em especial quando da libera&ccedil;&atilde;o mais tardia do torniquet
e, quando    n&atilde;o se pode realizar a inspe&ccedil;&atilde;o direta da feri
da e dos    vasos sangrantes. Rand<sup>29</sup> relatou tr&ecirc;s complica&cced
il;&otilde;es    vasculares em 9.022 pacientes operados, por&eacute;m relacionad
as ao quadro    de doen&ccedil;a ateroescler&oacute;tica da art&eacute;ria popl&
iacute;tea e    n&atilde;o a trauma durante o ato operat&oacute;rio.</font></p> 
    ^cY#07.htm##
00832000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704061000069002000700679#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#88#84#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Alguns estudos    referem um maior sangrame
nto quando do uso de pr&oacute;teses n&atilde;o cimentadas    em rela&ccedil;&at
ilde;o &agrave;s cimentadas.<sup>21,27</sup> A utiliza&ccedil;&atilde;o    do ci
mento ortop&eacute;dico diminui o sangramento em ATJ devido &agrave;s propriedad
es    mec&acirc;nicas sobre os cortes &oacute;sseos bem como &agrave;s proprieda
des    qu&iacute;micas e t&eacute;rmicas da cimenta&ccedil;&atilde;o.<sup>13,25<
/sup>    Em nossa s&eacute;rie todas as pr&oacute;teses utilizadas foram cimenta
das.</font></p>     ^cY#07.htm##
01177000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704095500069002000701024#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#89#85#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Outro fator relatado    na literatura que p
ode influenciar a perda sangu&iacute;nea em ATJ &eacute;    um programa de reabi
lita&ccedil;&atilde;o precoce, principalmente pela utiliza&ccedil;&atilde;o    d
e aparelhos de movimenta&ccedil;&atilde;o passiva cont&iacute;nua, relacionada  
  a aumento de sangramento p&oacute;s-operat&oacute;rio.<sup>25,28</sup> Em noss
os    casos n&atilde;o utilizamos a movimenta&ccedil;&atilde;o passiva cont&iacu
te;nua.    O nosso programa de reabilita&ccedil;&atilde;o inicia-se precocemente
, por&eacute;m    com exerc&iacute;cios ativos, realizados pelos pr&oacute;prios
 pacientes, e    que v&atilde;o at&eacute; o limiar da dor dos mesmos. A reabili
ta&ccedil;&atilde;o    precoce &eacute; importante para evitar-se rigidez articu
lar e melhorar as condi&ccedil;&otilde;es    circulat&oacute;rias, prevenindo o 
tromboembolismo.<sup>28</sup></font></p>     ^cY#07.htm##
00565000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704034300069002000700412#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#90#86#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Somente um paciente    de nossa s&eacute;ri
e (1,25%) foi submetido &agrave; transfus&atilde;o sangu&iacute;nea,    o que n&
atilde;o est&aacute; de acordo com a maioria dos artigos pesquisados,    que ref
erem um n&uacute;mero mais elevado de transfus&otilde;es.</font></p>     ^cY#07.
htm##
01014000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704079200069002000700861#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#91#87#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Rosencher <i>et    al.</i><sup>30</sup>, em
 um estudo multic&ecirc;ntrico de 225 servi&ccedil;os    na Europa com 3.996 pac
ientes submetidos &agrave; artroplastias de joelho e    quadril, referiu 69% de 
transfus&otilde;es. Santana <i>et al.</i><sup>10</sup>    estudaram 107 paciente
s submetidos &agrave; ATJ onde foram realizadas 98 transfus&otilde;es    (91,6%)
. Gabriel <i>et al.</i><sup>31</sup> avaliaram 30 pacientes e apresentaram    pe
rda m&eacute;dia de 550 ml no p&oacute;s-operat&oacute;rio, com incid&ecirc;ncia
    de transfus&atilde;o em 50%. Estes estudos, entretanto, n&atilde;o apresenta
ram    crit&eacute;rios pr&eacute;-estabelecidos para a realiza&ccedil;&atilde;o
 de    transfus&otilde;es.</font></p>     ^cY#07.htm##
01024000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704080200069002000700871#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#92#88#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Spencer <i>et al.</i><sup>32</sup>    chama
ram a aten&ccedil;&atilde;o para a falta de crit&eacute;rios definidos    nas tr
ansfus&otilde;es trans e p&oacute;s-operat&oacute;rias de artroplastias    do me
mbro inferior (quadril e joelho), muitas vezes realizadas rotineiramente    sem 
benef&iacute;cios para os pacientes. Ao estudarem 151 pacientes encontraram    8
4% de transfus&otilde;es realizadas mesmo em pacientes com hemoglobina acima    
de 10 g/dL, ou durante o ato operat&oacute;rio, baseado somente na previs&atilde
;o    de sangramento. Tellisi <i>et al.</i><sup>4</sup>, ao estudarem 85 ATJ, re
feriram,    por falta de um protocolo definido, transfus&otilde;es em pacientes 
com hemoglobina    acima de 10 g/dL.</font></p>     ^cY#07.htm##
00897000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704067500069002000700744#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#93#89#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Hadjianastassiou    <i>et al.</i><sup>6</su
p> apresentaram 169 operados onde 34% foram transfundidos,    sendo 60% destes n
o trans-operat&oacute;rio. Os autores chamam a aten&ccedil;&atilde;o    para a f
alta de diretrizes nestas transfus&otilde;es. N&atilde;o encontraram    diferen&
ccedil;a pr&eacute;-operat&oacute;ria na hemoglobina dos pacientes submetidos   
 ou n&atilde;o a transfus&otilde;es, n&atilde;o houve ado&ccedil;&atilde;o de   
 um n&iacute;vel m&iacute;nimo que a justificasse, bem como somente 10% dos tran
sfundidos    apresentaram algum grau de instabilidade cardiovascular.</font></p>
     ^cY#07.htm##
00817000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704059500069002000700664#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#94#90#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O estabelecimento    de uma rotina com prot
ocolos definidos pode diminuir significativamente o n&uacute;mero    de transfus
&otilde;es.<sup>15</sup> Ballantyne <i>et al.</i><sup>15</sup> com    um protoco
lo onde a ado&ccedil;&atilde;o de hemoglobina pr&eacute;-operat&oacute;ria    m&
iacute;nima de 11g/dL para a realiza&ccedil;&atilde;o da cirurgia, e transfus&at
ilde;o    no p&oacute;s-operat&oacute;rio somente com hemoglobina abaixo 8,5g/dL
 reduziu    de 31 para 11,9% as transfus&otilde;es realizadas em ATJ.</font></p>
     ^cY#07.htm##
00887000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704066500069002000700734#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#95#91#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Pierson <i>et al.</i><sup>33</sup>    elabo
raram um protocolo para artroplastias de quadril e joelho, onde o paciente    re
cebia eritropoetina no pr&eacute;-operat&oacute;rio com ado&ccedil;&atilde;o    
de crit&eacute;rios p&oacute;s-operat&oacute;rios para a transfus&atilde;o de   
 elementos do sangue. De 500 pacientes operados distribu&iacute;dos em dois grup
os    (433 que seguiram o protocolo estabelecido e 67 sem a ado&ccedil;&atilde;o
 do    mesmo), somente 2,1% (nove pacientes) do primeiro grupo foram submetidos 
&agrave;    transfus&atilde;o, contra 16,4% do outro grupo.</font></p>     ^cY#0
7.htm##
00898000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704067600069002000700745#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#96#92#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Kourtzis <i>et    al.</i><sup>34</sup> tamb
&eacute;m sugeriram um protocolo com a utiliza&ccedil;&atilde;o    de eritropoet
ina, ferro e &aacute;cido f&oacute;lico no trans-operat&oacute;rio,    manuten&c
cedil;&atilde;o da volemia, t&eacute;cnica operat&oacute;ria meticulosa    e ace
ita&ccedil;&atilde;o de n&iacute;veis hematim&eacute;tricos mais baixos    para 
a transfus&atilde;o. Os autores referem uma redu&ccedil;&atilde;o de 94%    nas 
transfus&otilde;es realizadas com o novo protocolo, em compara&ccedil;&atilde;o 
   aos pacientes operados antes da implanta&ccedil;&atilde;o do mesmo.</font></p
>     ^cY#07.htm##
00776000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704055400069002000700623#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#97#93#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Creditamos nossa    baixa taxa de transfus&
atilde;o &agrave; ado&ccedil;&atilde;o de crit&eacute;rios    bem estabelecidos,
 com uma racionaliza&ccedil;&atilde;o na indica&ccedil;&atilde;o    destas trans
fus&otilde;es e emprego de t&eacute;cnica de dissec&ccedil;&atilde;o    cuidados
a e conhecimento da anatomia vascular, seguindo-se a cauteriza&ccedil;&atilde;o 
   dos vasos mais importantes durante a cirurgia, como recomendado por Burkart  
  <i>et al.</i><sup>27</sup></font></p>     ^cY#07.htm##
00742000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704052000069002000700589#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#98#94#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Outro cuidado tomado    foi em rela&ccedil;
&atilde;o a pacientes com indica&ccedil;&atilde;o de ATJ    bilateral. A realiza
&ccedil;&atilde;o de um procedimento de cada vez, em &eacute;pocas    distintas,
 e somente ap&oacute;s a normaliza&ccedil;&atilde;o do quadro hematim&eacute;tri
co,    contribuiu para uma menor incid&ecirc;ncia de transfus&otilde;es, o que p
rovavelmente    ocorreria se as cirurgias fossem feitas concomitantemente.</font
></p>     ^cY#07.htm##
01268000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704104600069002000701115#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#99#95#article#185#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Conforme estabelecido    pelo Servi&ccedil;
o de Ortopedia do hospital, s&oacute; &eacute; indicada a    cirurgia de ATJ em 
pacientes com hemoglobina pr&eacute;-operat&oacute;ria acima    de 11 g/dL. Ball
antyne <i>et al.</i><sup>5</sup> referiram um aumento significativo    no n&uacu
te;mero de transfus&otilde;es em pacientes submetidos a ATJ com hemoglobina    a
baixo de 11 g/dL em rela&ccedil;&atilde;o &agrave;queles operados com &iacute;nd
ice    acima de 11 g/dL. No p&oacute;s-operat&oacute;rio adotamos uma estrat&eac
ute;gia    transfusional restritiva: aceita&ccedil;&atilde;o de hemoglobina p&oa
cute;s-operat&oacute;ria    de at&eacute; 7,5 g/dL, desde que o paciente encontr
e-se sem altera&ccedil;&otilde;es    cl&iacute;nicas importantes, reposi&ccedil;
&atilde;o da volemia com cristal&oacute;ides    em rela&ccedil;&atilde;o de 3:1 
e retardo na utiliza&ccedil;&atilde;o de heparina    de baixo peso molecular (18
 horas de p&oacute;s-operat&oacute;rio).</font></p>     ^cY#07.htm##
01090000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704086700070002000700937#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#100#96#article#185#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A estrat&eacute;gia    restritiva transfus
ional, com redu&ccedil;&atilde;o do limiar critico da hemoglobina,    deve ser u
tilizada com o objetivo de minimizar a morbidade e mortalidade em    paciente de
 diferentes situa&ccedil;&otilde;es cl&iacute;nicas, podendo ser    aceita hemog
lobina de at&eacute; 7 g/dL em pacientes sem sintomatologia importante.<sup>7,8<
/sup>    Cangiani <i>et al.</i><sup>26</sup> referem que, em condi&ccedil;&otild
e;es    basais, s&atilde;o necess&aacute;rios somente 4 g/dL para satisfazer as 
necessidades    do ser humano. Em pacientes cir&uacute;rgicos recomendam uma hem
oglobina m&iacute;nima    de 7 g/dL, mas a reposi&ccedil;&atilde;o poder&aacute;
 ser realizada com n&iacute;veis    maiores se a oxigena&ccedil;&atilde;o n&atil
de;o estiver adequada.</font></p>     ^cY#07.htm##
00922000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704069900070002000700769#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#101#97#article#185#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">N&atilde;o encontramos,    na literatura p
esquisada, nenhum artigo onde a hemoglobina aceita para necessidades    transfus
ionais em ATJ fosse de 7,5 g/dL ou menos. A maioria dos autores estudados,    co
mo visto acima, utilizaram como par&acirc;metros transfusionais taxas mais    el
evadas, acima de 8,5 g/dL. Em nossa s&eacute;rie n&atilde;o ocorreram complica&c
cedil;&otilde;es,    e concordamos que 7,5 g/dL &eacute; um n&iacute;vel seguro,
 desde que o paciente    encontre-se sob vigil&acirc;ncia de outros par&acirc;me
tros cl&iacute;nicos    e n&atilde;o apresente altera&ccedil;&otilde;es decorren
tes da anemia.</font></p>     ^cY#07.htm##
00817000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704059400070002000700664#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#102#98#article#185#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Como continuidade    deste estudo iremos p
ropor, em nosso servi&ccedil;o, um protocolo de transfus&atilde;o    sangu&iacut
e;nea em ATJ, com monitoriza&ccedil;&atilde;o mais precisa dos par&acirc;metros 
   cl&iacute;nicos at&eacute; o terceiro dia de p&oacute;s-operat&oacute;rio, pa
ra    verifica&ccedil;&atilde;o da seguran&ccedil;a destes n&iacute;veis mais re
stritivos    de hemoglobina. Para tal contaremos com colabora&ccedil;&atilde;o d
o Servi&ccedil;o    de Anestesiologia e o de Hematologia do hospital.</font></p>
     ^cY#07.htm##
00245000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002200070002000700092#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#103#99#article#185#<p>&nbsp;</p>     ^cY#07.
htm##
00330000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704010600071002000700177#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#104#100#article#185#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="3"><b>CONCLUS&Atilde;O</b></font></p>     ^c
Y#07.htm##
00801000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704057700071002000700648#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#105#101#article#185#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">N&atilde;o encontramos    diferen&ccedil;
a na perda sangu&iacute;nea nem no decr&eacute;scimo da hemoglobina    e do hema
t&oacute;crito, em ATJ cimentadas, entre a retirada trans ou p&oacute;s-operat&o
acute;ria    do torniquete pneum&aacute;tico. A retirada do torniquete para a re
aliza&ccedil;&atilde;o    da hemostasia n&atilde;o contribuiu para a diminui&cce
dil;&atilde;o do sangramento    p&oacute;s-operat&oacute;rio nem para o decr&eac
ute;scimo da hemoglobina ou    do hemat&oacute;crito.</font></p>     ^cY#07.htm#
#
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#106#102#article#185#<p>&nbsp;</p>     ^cY#07
.htm##
00331000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704010700071002000700178#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#107#103#article#185#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font></p>     ^
cY#07.htm##
00435000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704019700073002000700270#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#108#104#article#185#1#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">1. Berman AT, Geissele    A
E, Bosacco SJ. Blood loss with total knee arthroplasty. Clin Orthop Relat Res.  
  1988;(234):137-8.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#109#105#article#185#</font></p>     ^cY#07.h
tm##
00420000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704018200073002000700255#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#110#106#article#185#2#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">2. Cushner FD,    Friedman 
RJ. Blood loss in total knee arthroplasty. Clin Orthop Relat Res. 1991;(269):98-
101.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#111#107#article#185#</font></p>     ^cY#07.h
tm##
00472000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704023400073002000700307#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#112#108#article#185#3#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">3. Seyfert C, Schulz    K, 
Pap G. Einfluss des Drainagesoges auf den postoperativen Verlauf nach Knieendopr
othesen-Implantation.    Zentralbl Chir. 2002;127:886-9.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#113#109#article#185#</font></p>     ^cY#07.h
tm##
00500000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704026200073002000700335#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#114#110#article#185#4#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">4. Teellisi N,    Kakwani R
, Hulse N, Abusitta G, Ashammakhi N, Wahab KA. Autologous blood transfusion    f
ollowing total knee arthroplasty: is it always necessary? Int Orthop. 2006;30:41
2-4.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#115#111#article#185#</font></p>     ^cY#07.h
tm##
00590000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704035200073002000700425#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#116#112#article#185#5#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">5. Innerhofer P,    Klingle
r A, Klimmer C, Fries D, Nussbaumer W. Risk for postoperative infection    after
 transfusion of white blood cell-filtered allogeneic or autologous blood    comp
onents in orthopedic patients undergoing primary arthroplasty. Transfusion.    2
005;45:103-10.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#117#113#article#185#</font></p>     ^cY#07.h
tm##
00501000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704026300073002000700336#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#118#114#article#185#6#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">6. Hadjianastassiou    VG, 
Virich G, Lennox IA. Transfusion practice in primary unilateral total knee    re
placement arthroplasty; the need for guidelines. Ann Chir Gynaecol. 2001;90:    
23-7.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#119#115#article#185#</font></p>     ^cY#07.h
tm##
00493000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704025500073002000700328#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#120#116#article#185#7#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">7. Ferreira JS,    Ferreira
 VLPC, Pelandr&eacute; GL. Transfus&atilde;o de concentrado de hem&aacute;cias  
  em unidade de terapia intensiva. Rev Bras Hematol Hemoter. 2005;27: 179-82.   
 ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#121#117#article#185#</font></p>     ^cY#07.h
tm##
00453000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704021500073002000700288#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#122#118#article#185#8#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">8. Hajjar LA, Auler    Juni
or JOC, Santos L, Galas F. Blood tranfusion in critically ill patients:    state
 of the art. Clinics. 2007;62:507-24.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#123#119#article#185#</font></p>     ^cY#07.h
tm##
00493000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704025500073002000700328#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#124#120#article#185#9#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">9. Malta MC, Motta    G, Ba
rretto JM, Lopes MAS. Incid&ecirc;ncia de hemotransfus&atilde;o na artroplastia 
   total prim&aacute;ria unilateral do joelho. Rev Bras Ortop. 2000;35:416-8.   
 ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#125#121#article#185#</font></p>     ^cY#07.h
tm##
00611000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704037200074002000700446#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#126#122#article#185#10#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Santana M,    Mart&iac
ute;nez E, Herrera E, Tatsidis P, P&eacute;rez M, Rodriguez F. Efectividad    de
 la autotransfusi&oacute;n postoperatoria em la cirurg&iacute;a prot&eacute;sica
    de rodilla. Influencia del valor de la hemoglobina preoperatoria. Rev Esp An
estesiol    Reanim. 2005;52:315-20.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#127#123#article#185#</font></p>     ^cY#07.h
tm##
00510000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027100074002000700345#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#128#124#article#185#11#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Cohen M, Abdalla    RI
, Amaro JTO, Ejinisman B, Filardi MS, Ribeiro AAF, Takatu PM. Autotransfus&auml;
o    intra-operat&oacute;ria em artroplastia totais de joelho. Acta Ortop Bras. 
1996;4:149-54.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#129#125#article#185#</font></p>     ^cY#07.h
tm##
00489000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704025000074002000700324#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#130#126#article#185#12#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Muller U, R&ouml;der  
  C, Pisan M, Orler R, El-Kerdi A, Eggli S. Autologous blood donation in total  
  knee arthroplasties is not necessary. Acta Orthop Scand. 2004;75:66-70.    ^cY
#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#131#127#article#185#</font></p>     ^cY#07.h
tm##
00539000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030000074002000700374#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#132#128#article#185#13#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Christodoulou    AG, P
loumis AL, Terzidis IP, Chantzidis P, Metsovitis SR, Nikiforos DG. The    role o
f timing of tourniquet release and cementing on perioperative blood loss    in t
otal knee replacement. Knee. 2004;11:313-7.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#133#129#article#185#</font></p>     ^cY#07.h
tm##
00521000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028200074002000700356#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#134#130#article#185#14#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Kumar N, Saleh    J, G
ardiner E, Devadoss VG, Howell FR. Plugging the intramedullary canal of    the f
emur in total knee arthroplasty: reduction in postoperative blood loss.    J Art
hroplasty. 2000;15:947-9.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#135#131#article#185#</font></p>     ^cY#07.h
tm##
00516000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027700074002000700351#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#136#132#article#185#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Ballantyne    A, Walms
ley P, Brenkel I. Reduction of blood transfusion rates in unilateral    total kn
ee arthroplasty by the introduction of a simple blood transfusion protocol.    K
nee. 2003;10:379-84.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#137#133#article#185#</font></p>     ^cY#07.h
tm##
00533000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029400074002000700368#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#138#134#article#185#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Cid J, Lozano    M. Tr
anexamic acid reduces allogeneic red cell transfusions in patients undergoing   
 total knee arthroplasty: results of a meta-analysis of randomized controlled   
 trials. Transfusion. 2005;45:1302-7.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#139#135#article#185#</font></p>     ^cY#07.h
tm##
00523000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028400074002000700358#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#140#136#article#185#17#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Gasparini G,    Papale
o P, Pola P, Cerciello S, Pola E, Fabbriciani C. Local infusion of norepinephrin
e    reduces blood losses and need of transfusion in total knee arthroplasty. In
t    Orthop. 2006;30:253-6.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#141#137#article#185#</font></p>     ^cY#07.h
tm##
00578000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033900074002000700413#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#142#138#article#185#18#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Gardner MJ,    Demetra
kopoulos D, Klepchick PR, Mooar PA. The Efficacy of autologous platelet    gel i
n pain control and blood loss in total knee arthroplasty. An analysis of    the 
haemoglobin, narcotic requirement and range of motion. Int Orthop. 2007;31:309-1
3.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#143#139#article#185#</font></p>     ^cY#07.h
tm##
00432000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704019300074002000700267#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#144#140#article#185#19#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Newman JH,    Jackson 
JP, Waugh W. Timing of tourniquet removal after knee replacement. J    R Soc Med
. 1979;72:492-3.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#145#141#article#185#</font></p>     ^cY#07.h
tm##
00431000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704019200074002000700266#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#146#142#article#185#20#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Page MH, Shepard    BD
, Harrisson JM. Reduction of blood loss in knee arthroplasty. Aust NZ J Surg.   
 1984;54:141-4.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#147#143#article#185#</font></p>     ^cY#07.h
tm##
00492000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704025300074002000700327#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#148#144#article#185#21#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Jorn LP, Lindstrand   
 A, Toksvig-Larsen S. Tourniquet release for hemostasis increases bleeding. A   
 randomized study of 77 knee replacements. Acta Orthop Scand. 1999;70:265-7.    
^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#149#145#article#185#</font></p>     ^cY#07.h
tm##
00529000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029000074002000700364#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#150#146#article#185#22#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Ishii Y, Matsuda    Y.
 Effect of the timing of tourniquet release on perioperative blood loss associat
ed    with cementless total knee arthroplasty: a prospective randomized study. J
 Arthroplasty.    2005;20:977-83.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#151#147#article#185#</font></p>     ^cY#07.h
tm##
00518000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027900074002000700353#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#152#148#article#185#23#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Widman J, Isacson    J
. Surgical hemostasis after tourniquet release does not reduce blood loss in    
knee replacement. A prospective randomized study of 81 patients. Acta Orthop    
Scand. 1999;70:268-70.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#153#149#article#185#</font></p>     ^cY#07.h
tm##
00471000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704023200074002000700306#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#154#150#article#185#24#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Schuh A, Hausel    M, 
Salminen S. Die Auswirkung der Oberschenkelblutsperre auf den Blutverlust    in 
der Knieendoprothetik. Zentralbl Chir. 2003;128:866-70.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#155#151#article#185#</font></p>     ^cY#07.h
tm##
00513000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027400074002000700348#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#156#152#article#185#25#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Hersekli MA,    Akpina
r S, Ozkoc G, Ozalay M, Uysal M, Cesur N et al. The timing of tourniquet    rele
ase and its influence on blood loss after total knee arthroplasty. Int Orthop.  
  2004;28:138-41.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#157#153#article#185#</font></p>     ^cY#07.h
tm##
00452000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704021300074002000700287#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#158#154#article#185#26#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Cangiani LM,    Posso 
IP, Pot&eacute;rio PO, Braga GM, Nogueira CS. Tratado de Anestesiologia.    6a. 
ed. S&atilde;o Paulo: Atheneu; 2006.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#159#155#article#185#</font></p>     ^cY#07.h
tm##
00505000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026600074002000700340#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#160#156#article#185#27#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Burkart BC,    Bourne 
RB, Rorabeck CH, Kirk PG, Nott L. The efficacy of tourniquet release    in blood
 conservation after total knee arthroplasty. Clin Orthop Relat Res.    1994;(299
):147-52.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#161#157#article#185#</font></p>     ^cY#07.h
tm##
00401000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704016200074002000700236#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#162#158#article#185#28#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Lotke PA, Lonner    JH
. Artroplastia do Joelho. 2a. ed. Rio de Janeiro: Revinter; 2007.    ^cY#07.htm#
#
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#163#159#article#185#</font></p>     ^cY#07.h
tm##
00432000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704019300074002000700267#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#164#160#article#185#29#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Rand JA. Vascular    c
omplications of total knee arthroplasty. Report of three cases. J Arthroplasty. 
   1987;2:89-93.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#165#161#article#185#</font></p>     ^cY#07.h
tm##
00574000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033500074002000700409#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#166#162#article#185#30#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Rosencher N,    Kerkka
mp HE, Macheras G, Munuera LM, Menichella G, Barton DM et al. Orthopedic    Surg
ery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management   
 in elective knee and hip arthroplasty in Europe. Transfusion, 2003;43:459-69.  
  ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#167#163#article#185#</font></p>     ^cY#07.h
tm##
00562000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032300074002000700397#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#168#164#article#185#31#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Gabriel SP,    Mestrin
er LA, Masiero D. Avalia&ccedil;&auml;o da perda sangu&iacute;nea p&oacute;s-ope
rat&oacute;ria    em pacientes submetidos &agrave; artroplastia total do joelho 
com drenagem de    suc&ccedil;&atilde;o. Folha Med. 1997;114:71-5.    ^cY#07.htm
##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#169#165#article#185#</font></p>     ^cY#07.h
tm##
00535000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029600074002000700370#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#170#166#article#185#32#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Spencer J,    Thomas S
R, Yard G, Mukundan C, Barrington R. Are we overusing blood transfusing    after
 elective joint replacement? A simple method to reduce the use of a scarce    re
source. Ann R Coll Engl. 2005;87:28-30.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#171#167#article#185#</font></p>     ^cY#07.h
tm##
00490000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704025100074002000700325#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#172#168#article#185#33#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Pierson JL,    Hannon 
TJ, Earles DR. A blood-conservation algorithm to reduce blood transfusions    af
ter total hip and knee arthroplasty. J Bone Joint Surg Am. 2004;86:1512-8.    ^c
Y#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#173#169#article#185#</font></p>     ^cY#07.h
tm##
00441000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704020200074002000700276#v19
n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#p#174#170#article#185#34#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Kourtzis N,    Pafilas
 D, Kasimatis G. Blood saving protocol in elective total knee arthroplasty.    A
m J Surg. 2004;187:261-7.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#175#171#article#185#</font></p>     ^cY#07.h
tm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#176#172#article#185#<p>&nbsp;</p>     ^cY#07
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#177#173#article#185#<p>&nbsp;</p>     ^cY#07
.htm##
00430000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704020600071002000700277#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#178#174#article#185#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top"><img sr
c="/img/revistas/aob/v19n1/seta.jpg" border="0"></a>    <b>Endereço para Corresp
ondência:</b>     ^cY#07.htm##
00268000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004400071002000700115#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#179#175#article#185#<br>   Av. dos Holandese
s, quadra 19    ^cY#07.htm##
00267000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004300071002000700114#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#180#176#article#185#<br>   Residencial Monet
, apto 1202    ^cY#07.htm##
00267000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004300071002000700114#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#181#177#article#185#<br>   Bairro do Olho d'
&aacute;gua    ^cY#07.htm##
00253000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002900071002000700100#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#182#178#article#185#<br>   CEP 65.065-180   
 ^cY#07.htm##
00273000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004900071002000700120#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#183#179#article#185#<br>   S&atilde;o Lu&iac
ute;s, MA, Brasil    ^cY#07.htm##
00322000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009800071002000700169#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#184#180#article#185#<br>   E-mail:<a href="m
ailto:jjwander@terra.com.br">jjwander@terra.com.br</a></font></p>     ^cY#07.htm
##
00360000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013600071002000700207#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#185#181#article#185#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Artigo recebido    em 30/08/08, aprovado 
em 29/06/09.</font></p>     ^cY#07.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#186#182#article#185#<p>&nbsp;</p>     ^cY#07
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#187#183#article#185#<p>&nbsp;</p>     ^cY#07
.htm##
00452000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704022800071002000700299#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#188#184#article#185#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Trabalho realizado    no Servi&ccedil;o d
e Traumato-Ortopedia do Hospital Universit&aacute;rio da    Universidade Federal
 do Maranh&atilde;o HU-UFMA, Brasil.    ^cY#07.htm##
00361000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013700071002000700208#v19n1#V:\SciELO
\serial\aob\v19n1\markup\07.htm#S#p#189#185#article#185#<br>   Todos os autores 
declaram n&atilde;o haver nenhum potencial conflito de interesses    referente a
 este artigo.</font></p>     ^cY#07.htm##
00511000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100019000870100
01800106012004400124030002300168710000200191065000900193064000500202032000400207
014000600211865000900217002000700226#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.
htm#S#c#190#1#article#34#1#^rND^sBerman^nAT#^rND^sGeissele^nAE#^rND^sBosacco^nSJ
#Blood loss with total knee arthroplasty^len#Clin Orthop Relat Res.#2#19880000#1
988#234#137-8#20110000#07.htm##
00482000000000265000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100020000880120
04200108030002300150710000200173065000900175064000500184032000400189014000700193
865000900200002000700209#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#c#191#
2#article#34#2#^rND^sCushner^nFD#^rND^sFriedman^nRJ.#Blood loss in total knee ar
throplasty^len#Clin Orthop Relat Res.#2#19910000#1991#269#98-101#20110000#07.htm
##
00550000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100016000870100
01300103012009800116030001600214710000200230065000900232064000500241031000400246
014000600250865000900256002000700265#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.
htm#S#c#192#3#article#34#3#^rND^sSeyfert^nC#^rND^sSchulz^nK#^rND^sPap^nG#Einflus
s des Drainagesoges auf den postoperativen Verlauf nach Knieendoprothesen-Implan
tation^len#Zentralbl Chir.#2#20020000#2002#127#886-9#20110000#07.htm##
00633000000000313000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100017000880100
01500105010001800120010002000138010001600158012009200174030001200266710000200278
065000900280064000500289031000300294014000600297865000900303002000700312#v19n1#V
:\SciELO\serial\aob\v19n1\markup\07.htm#S#c#193#4#article#34#4#^rND^sTeellisi^nN
#^rND^sKakwani^nR#^rND^sHulse^nN#^rND^sAbusitta^nG#^rND^sAshammakhi^nN#^rND^sWah
ab^nKA#Autologous blood transfusion following total knee arthroplasty: is it alw
ays necessary?^len#Int Orthop.#2#20060000#2006#30#412-4#20110000#07.htm##
00729000000000313000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100020000700100018000900100
01700108010001500125010002000140012018100160030001200341065000900353064000500362
031000300367014000700370865000900377002000700386035001000393801001200403#v19n1#V
:\SciELO\serial\aob\v19n1\markup\07.htm#S#c#194#5#article#34#5#^rND^sInnerhofer^
nP#^rND^sKlingler^nA#^rND^sKlimmer^nC#^rND^sFries^nD#^rND^sNussbaumer^nW#Risk fo
r postoperative infection after transfusion of white blood cell-filtered allogen
eic or autologous blood components in orthopedic patients undergoing primary art
hroplasty^len#Transfusion#20050000#2005#45#103-10#20110000#07.htm#0041-1132#Tran
sfusion##
00576000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100027000700100016000970100
01800113012010800131030001900239710000200258065000900260064000500269031000300274
014000500277865000900282002000700291#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.
htm#S#c#195#6#article#34#6#^rND^sHadjianastassiou^nVG#^rND^sVirich^nG#^rND^sLenn
ox^nIA.#Transfusion practice in primary unilateral total knee replacement arthro
plasty: the need for guidelines^len#Ann Chir Gynaecol.#2#20010000#2001#90#23-7#2
0110000#07.htm##
00550000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700100021000890100
02000110012007400130030002600204710000200230065000900232064000500241031000300246
014000700249865000900256002000700265#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.
htm#S#c#196#7#article#34#7#^rND^sFerreira^nJS#^rND^sFerreira^nVLPC#^rND^sPelandr
é^nGL.#Transfusão de concentrado de hemácias em unidade de terapia intensiva^lpt
#Rev Bras Hematol Hemoter.#2#20050000#2005#27#179-82#20110000#07.htm##
00577000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100024000870100
01600111010001600127012006600143030000800209065000900217064000500226031000300231
014000700234865000900241002000700250035001000257801000800267#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\07.htm#S#c#197#8#article#34#8#^rND^sHajjar^nLA#^rND^sAuler 
Junior^nJOC#^rND^sSantos^nL#^rND^sGalas^nF.#Blood tranfusion in critically ill p
atients: state of the art^len#Clinics#20070000#2007#62#507-24#20110000#07.htm#18
07-5932#Clinics##
00569000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100015000860100
01900101010001700120012008500137030001600222710000200238065000900240064000500249
031000300254014000600257865000900263002000700272#v19n1#V:\SciELO\serial\aob\v19n
1\markup\07.htm#S#c#198#9#article#34#9#^rND^sMalta^nMC#^rND^sMotta^nG#^rND^sBarr
etto^nJM#^rND^sLopes^nMAS#Incidência de hemotransfusão na artroplastia total pri
mária unilateral do joelho^lpt#Rev Bras Ortop.#2#20000000#2000#35#416-8#20110000
#07.htm##
00703000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100018000890100
01700107010001800124010001500142010002000157012014300177030002700320710000200347
065000900349064000500358031000300363014000700366865000900373002000700382#v19n1#V
:\SciELO\serial\aob\v19n1\markup\07.htm#S#c#199#10#article#34#10#^rND^sSantana^n
M#^rND^sMartínez^nE#^rND^sHerrera^nE#^rND^sTatsidis^nP#^rND^sPérez^nM#^rND^sRodr
iguez^nF.#Efectividad de la autotransfusión postoperatoria em la cirurgía protés
ica de rodilla: Influencia del valor de la hemoglobina preoperatoria^les#Rev Esp
 Anestesiol Reanim.#2#20050000#2005#52#315-20#20110000#07.htm##
00648000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100018000870100
01700105010001900122010001800141010001900159010001700178012006900195030001700264
71000020028106500090028306400050029203100020029701400070029986500090030600200070
0315#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#c#200#11#article#34#11#^rN
D^sCohen^nM#^rND^sAbdalla^nRI#^rND^sAmaro^nJTO#^rND^sEjinisman^nB#^rND^sFilardi^
nMS#^rND^sRibeiro^nAAF#^rND^sTakatu^nPM#Autotransfusäo intra-operatória em artro
plastia totais de joelho^lpt#Acta Ortop Bras.#2#19960000#1996#4#149-54#20110000#
07.htm##
00617000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100015000880100
01500103010001500118010001800133010001600151012007600167030001900243710000200262
065000900264064000500273031000300278014000600281865000900287002000700296#v19n1#V
:\SciELO\serial\aob\v19n1\markup\07.htm#S#c#201#12#article#34#12#^rND^sMuller^nU
#^rND^sRöder^nC#^rND^sPisan^nM#^rND^sOrler^nR#^rND^sEl-Kerdi^nA#^rND^sEggli^nS.#
Autologous blood donation in total knee arthroplasties is not necessary^len#Acta
 Orthop Scand.#2#20040000#2004#75#66-70#20110000#07.htm##
00692000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100024000720100018000960100
01900114010002000133010002100153010002000174012011300194030000500307065000900312
06400050032103100030032601400060032986500090033500200070034403500100035180100050
0361#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#c#202#13#article#34#13#^rN
D^sChristodoulou^nAG#^rND^sPloumis^nAL#^rND^sTerzidis^nIP#^rND^sChantzidis^nP#^r
ND^sMetsovitis^nSR#^rND^sNikiforos^nDG#The role of timing of tourniquet release 
and cementing on perioperative blood loss in total knee replacement^len#Knee#200
40000#2004#11#313-7#20110000#07.htm#0968-0160#KNEE##
00632000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100015000870100
01800102010001900120010001700139012011700156030001600273710000200289065000900291
064000500300031000300305014000600308865000900314002000700323#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\07.htm#S#c#203#14#article#34#14#^rND^sKumar^nN#^rND^sSaleh^
nJ#^rND^sGardiner^nE#^rND^sDevadoss^nVG#^rND^sHowell^nFR#Plugging the intramedul
lary canal of the femur in total knee arthroplasty: reduction in postoperative b
lood loss^len#J Arthroplasty.#2#20000000#2000#15#947-9#20110000#07.htm##
00615000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100018000920100
01700110012013800127030000500265065000900270064000500279031000300284014000700287
865000900294002000700303035001000310801000500320#v19n1#V:\SciELO\serial\aob\v19n
1\markup\07.htm#S#c#204#15#article#34#15#^rND^sBallantyne^nA#^rND^sWalmsley^nP#^
rND^sBrenkel^nI#Reduction of blood transfusion rates in unilateral total knee ar
throplasty by the introduction of a simple blood transfusion protocol^len#Knee#2
0030000#2003#10#379-84#20110000#07.htm#0968-0160#KNEE##
00622000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100013000720100017000850120
16800102030001200270065000900282064000500291031000300296014000700299865000900306
002000700315035001000322801001200332#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.
htm#S#c#205#16#article#34#16#^rND^sCid^nJ#^rND^sLozano^nM.#Tranexamic acid reduc
es allogeneic red cell transfusions in patients undergoing total knee arthroplas
ty: results of a meta-analysis of randomized controlled trials^len#Transfusion#2
0050000#2005#45#1302-7#20110000#07.htm#0041-1132#Transfusion##
00652000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100017000910100
01400108010001900122010001400141010002100155012010900176030001200285710000200297
065000900299064000500308031000300313014000600316865000900322002000700331#v19n1#V
:\SciELO\serial\aob\v19n1\markup\07.htm#S#c#206#17#article#34#17#^rND^sGasparini
^nG#^rND^sPapaleo^nP#^rND^sPola^nP#^rND^sCerciello^nS#^rND^sPola^nE#^rND^sFabbri
ciani^nC#Local infusion of norepinephrine reduces blood losses and need of trans
fusion in total knee arthroplasty^len#Int Orthop.#2#20060000#2006#30#253-6#20110
000#07.htm##
00672000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100025000900100
02000115010001700135012017600152030001200328710000200340065000900342064000500351
031000300356014000700359865000900366002000700375#v19n1#V:\SciELO\serial\aob\v19n
1\markup\07.htm#S#c#207#18#article#34#18#^rND^sGardner^nMJ#^rND^sDemetrakopoulos
^nD#^rND^sKlepchick^nPR#^rND^sMooar^nPA.#The Efficacy of autologous platelet gel
 in pain control and blood loss in total knee arthroplasty: An analysis of the h
aemoglobin, narcotic requirement and range of motion^len#Int Orthop.#2#20070000#
2007#31#309-13#20110000#07.htm##
00510000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100018000890100
01500107012005600122030001300178710000200191065000900193064000500202031000300207
014000600210865000900216002000700225#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.
htm#S#c#208#19#article#34#19#^rND^sNewman^nJH#^rND^sJackson^nJP#^rND^sWaugh^nW#T
iming of tourniquet removal after knee replacement^len#J R Soc Med.#2#19790000#1
979#72#492-3#20110000#07.htm##
00509000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100018000870100
02000105012004900125030001600174710000200190065000900192064000500201031000300206
014000600209865000900215002000700224#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.
htm#S#c#209#20#article#34#20#^rND^sPage^nMH#^rND^sShepard^nBD#^rND^sHarrisson^nJ
M#Reduction of blood loss in knee arthroplasty^len#Aust NZ J Surg.#2#19840000#19
84#54#141-4#20110000#07.htm##
00571000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100020000870100
02500107012010100132030001900233710000200252065000900254064000500263031000300268
014000600271865000900277002000700286#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.
htm#S#c#210#21#article#34#21#^rND^sJorn^nLP#^rND^sLindstrand^nA#^rND^sToksvig-La
rsen^nS.#Tourniquet release for hemostasis increases bleeding: A randomized stud
y of 77 knee replacements^len#Acta Orthop Scand.#2#19990000#1999#70#265-7#201100
00#07.htm##
00587000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100018000870120
15800105030001600263710000200279065000900281064000500290031000300295014000700298
865000900305002000700314#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#c#211#
22#article#34#22#^rND^sIshii^nY#^rND^sMatsuda^nY.#Effect of the timing of tourni
quet release on perioperative blood loss associated with cementless total knee a
rthroplasty: a prospective randomized study^len#J Arthroplasty.#2#20050000#2005#
20#977-83#20110000#07.htm##
00576000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100018000880120
14300106030001900249710000200268065000900270064000500279031000300284014000700287
865000900294002000700303#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#c#212#
23#article#34#23#^rND^sWidman^nJ#^rND^sIsacson^nJ.#Surgical hemostasis after tou
rniquet release does not reduce blood loss in knee replacement: A prospective ra
ndomized study of 81 patients^len#Acta Orthop Scand.#2#19990000#1999#70#268-70#2
0110000#07.htm##
00550000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100016000870100
01900103012009100122030001600213710000200229065000900231064000500240031000400245
014000700249865000900256002000700265#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.
htm#S#c#213#24#article#34#24#^rND^sSchuh^nA#^rND^sHausel^nM#^rND^sSalminen^nS.#D
ie Auswirkung der Oberschenkelblutsperre auf den Blutverlust in der Knieendoprot
hetik^len#Zentralbl Chir.#2#20030000#2003#128#866-70#20110000#07.htm##
00655000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100017000910100
01500108010001600123010001500139010001500154810000700169012009900176030001200275
71000020028706500090028906400050029803100030030301400070030686500090031300200070
0322#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#c#214#25#article#34#25#^rN
D^sHersekli^nMA#^rND^sAkpinar^nS#^rND^sOzkoc^nG#^rND^sOzalay^nM#^rND^sUysal^nM#^
rND^sCesur^nN#et al.#The timing of tourniquet release and its influence on blood
 loss after total knee arthroplasty^len#Int Orthop.#2#20040000#2004#28#138-41#20
110000#07.htm##
00532000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160019000720160016000910160
01800107016001600125016002000141018003000161063000300191066001000194062000800204
065000900212064000500221865000900226002000700235#v19n1#V:\SciELO\serial\aob\v19n
1\markup\07.htm#S#c#215#26#article#34#26#^rND^sCangiani^nLM#^rND^sPosso^nIP#^rND
^sPotério^nPO#^rND^sBraga^nGM#^rND^sNogueira^nCS.#Tratado de Anestesiologia^lpt#
6a#São Paulo#Atheneu#20060000#2006#20110000#07.htm##
00615000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100017000900100
01900107010001500126010001500141012009100156030002300247710000200270065000900272
064000500281032000400286014000700290865000900297002000700306#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\07.htm#S#c#216#27#article#34#27#^rND^sBurkart^nBC#^rND^sBou
rne^nRB#^rND^sRorabeck^nCH#^rND^sKirk^nPG#^rND^sNott^nL.#The efficacy of tourniq
uet release in blood conservation after total knee arthroplasty^len#Clin Orthop 
Relat Res.#2#19940000#1994#299#147-52#20110000#07.htm##
00444000000000253000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160016000720160018000880180
02700106063000300133066001500136062000900151065000900160064000500169865000900174
002000700183#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#c#217#28#article#3
4#28#^rND^sLotke^nPA#^rND^sLonner^nJH.#Artroplastia do Joelho^lpt#2a#Rio de Jane
iro#Revinter#20070000#2007#20110000#07.htm##
00475000000000253000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720120077000880300
01600165710000200181065000900183064000500192031000200197014000600199865000900205
002000700214#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#c#218#29#article#3
4#29#^rND^sRand^nJA.#Vascular complications of total knee arthroplasty: Report o
f three cases^len#J Arthroplasty.#2#19870000#1987#2#89-93#20110000#07.htm##
00747000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100019000910100
01800110010001800128010002000146010001700166810000700183012014500190030001200335
06500090034706400050035603100030036101400070036486500090037100200070038003500100
0387801001200397#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.htm#S#c#219#30#artic
le#34#30#^rND^sRosencher^nN#^rND^sKerkkamp^nHE#^rND^sMacheras^nG#^rND^sMunuera^n
LM#^rND^sMenichella^nG#^rND^sBarton^nDM#et al.#Orthopedic Surgery Transfusion He
moglobin European Overview (OSTHEO) study: blood management in elective knee and
 hip arthroplasty in Europe^len#Transfusion#20030000#2003#43#459-69#20110000#07.
htm#0041-1132#Transfusion##
00583000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100020000900100
01700110012012600127030001100253710000200264065000900266064000500275031000400280
014000500284865000900289002000700298#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.
htm#S#c#220#31#article#34#31#^rND^sGabriel^nSP#^rND^sMestriner^nLA#^rND^sMasiero
^nD#Avaliaçäo da perda sanguínea pós-operatória em pacientes submetidos à artrop
lastia total do joelho com drenagem de sucção^lpt#Folha Med.#2#19970000#1997#114
#71-5#20110000#07.htm##
00648000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100017000890100
01400106010001800120010002100138012012900159030001700288710000200305065000900307
064000500316031000300321014000600324865000900330002000700339#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\07.htm#S#c#221#32#article#34#32#^rND^sSpencer^nJ#^rND^sThom
as^nSR#^rND^sYard^nG#^rND^sMukundan^nC#^rND^sBarrington^nR.#Are we overusing blo
od transfusing after elective joint replacement?: A simple method to reduce the 
use of a scarce resource^len#Ann R Coll Engl.#2#20050000#2005#87#28-30#20110000#
07.htm##
00568000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100017000900100
01700107012010200124030002200226710000200248065000900250064000500259031000300264
014000700267865000900274002000700283#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.
htm#S#c#222#33#article#34#33#^rND^sPierson^nJL#^rND^sHannon^nTJ#^rND^sEarles^nDR
#A blood-conservation algorithm to reduce blood transfusions after total hip and
 knee arthroplasty^len#J Bone Joint Surg Am.#2#20040000#2004#86#1512-8#20110000#
07.htm##
00519000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100017000900100
01900107012006200126030001100188710000200199065000900201064000500210031000400215
014000600219865000900225002000700234#v19n1#V:\SciELO\serial\aob\v19n1\markup\07.
htm#S#c#223#34#article#34#34#^rND^sKourtzis^nN#^rND^sPafilas^nD#^rND^sKasimatis^
nG#Blood saving protocol in elective total knee arthroplasty^len#Am J Surg.#2#20
040000#2004#187#261-7#20110000#07.htm##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#o#1#1#article#1#201104
11#111901#08.htm#210##
04452000000000661000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000500083038000400088038000400092121000300096049000700099
15800030010603000180010903100030012703200020013006500090013201400090014103500100
01500120076001600120071002360100038003070100025003450100048003700100041004180100
03800459070007300497070007800570070006200648070005800710083140900768085000802177
08500190218508500190220408500360222308314040225908500080366308500170367108500200
36880850030037081170006037380720003037441120009037471110009037561140009037651130
00903774002000703783#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#h#2#1#arti
cle#1#oa#pt#br1.1#1#4.0#ILUS#GRA#TAB#08#AOB140#nd#Acta ortop. bras.#19#1#2011000
0#^f37^l40#1413-7852#Avaliação dos fatores predisponentes nas instabilidades fem
oropatelares^lpt#Avaliation of predisposing factors in patellofemoral instabilit
ies^len#^rND^1A01 A03^nRicardo Carli^sBurmann#^rND^1A02^nRenato^sLocks#^rND^1A01
 A03 A04^nJoão Fernando Argento^sPozzi#^rND^1A03 A04^nEwerton Renato^sKonkewicz#
^rND^1A03 A04^nMarcos Paulo de^sSouza#Hospital Beneficência Portuguesa de Porto 
Alegre^iA01^cRio Grande do Sul#Hospital Cristo Redentor (Grupo Hospitalar Concei
ção)^iA02^cRio Grande do Sul#ULBRA^iA03^1Hospital Universitário^cCanoas^pRio Gra
nde do Sul#Serviço de Ortopedia Independente^iA04^cRio Grande do Sul#^lpt^aOBJET
IVO: Avaliar a prevalência dos fatores predisponentes à instabilidade femoropate
lar (displasia de tróclea, patela alta, TAGT, báscula patelar) em um grupo de pa
cientes acompanhados em nível ambulatorial. MÉTODOS: Avaliou-se 70 pacientes, se
ndo 52 do sexo feminino (74,28%) e 18 (25,72%) do sexo masculino, num total de 1
27 joelhos, com uma média de idade de 17,71 anos. A avaliação por imagem foi rea
lizada através de radiografias e tomografia computadorizada. As instabilidades f
emoropatelares foram classificadas seguindo-se a classificação de Henri Dejour (
instabilidade maior, objetiva e potencial). Enquadraram-se as displasias troclea
res de acordo com a classificação de David Dejour (tipo A, B, C, D). RESULTADOS:
 Observou-se displasia troclear em 118 (92,91%) joelhos, sendo 91 (77,11%) joelh
os dos tipos A e B. A altura patelar apresentou uma média de 1,23, com 44 (34,64
%) consideradas patela alta e 83 (65,36%) normais. A báscula patelar alterada fo
i encontrada em 92 (72,44%) joelhos e a elevação da TAGT em 63 (49,60%) joelhos.
 Obteve-se predominância de instabilidades objetivas 89 (70,07%) joelhos, Quanto
 a associação de fatores predisponentes,, 117 (92,13%) joelhos apresentaram mais
 quem um fator. CONCLUSÕES: A instabilidade femoropatelar é uma doença multifato
rial, os distúrbios trocleares são mais prevalentes e há uma forte associação en
tre 2 ou mais fatores predisponentes.#^dnd^i1#^tm^lpt^kJoelho^i1#^tm^lpt^kPatela
^i1#^tm^lpt^kInstabilidade articular^i1#^len^aOBJECTIVE: To evaluate the prevale
nce of predisposing factors for femoropatelar instability (dysplasia of the troc
hlea, high patella, TTTG, and patellar tilt) in a group of patients in outpatien
t follow-up. METHODS: 70 patients were evaluated; 52 (74.28 %) female and 18 (25
.72 %) male, with an average age of 17.71 years and a total of 127 knees. The ev
aluation by imaging was carried out through radiologic examination and computeri
zed tomography. The femoropatelar instabilities were classified according to Hen
ri Dejour's classification (major, objective and potential instability). The tro
chlear dysplasia was classified according to David Dejour's classification (type
 A, B, C, D). RESULTS: Trochlear dysplasia was observed in 118 knees (92.91%), w
ith 91 knees (77.11%) being of type A and B. The average for patellar height was
 1.23, with 44 (34.64%) considered high patellas and 83 (65.36%) within the norm
al range. Abnormal patellae tilt was found in 92 knees (72.44%) and an elevation
 of TTTG in 63 knees (49.60%). The was a prevalence of objective instabilities w
ith 89 knees (70.07%). In relation to the association of predisposing factors, 1
17 knees (92.13%) presented more than one factor. CONCLUSIONS: Femoropatelar ins
tability is a multifactorial disease, with trochlear disorders being the most fr
equent, and there is a strong association between two or more predisposing facto
rs.#^dnd^i2#^tm^len^kKnee^i2#^tm^len^kPatella^i2#^tm^len^kJoint instability^i2#o
ther#28#20091025#25/10/09#20100507#07/05/10#08.htm##
04522000000000661000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000500083038000400088038000400092121000300096049000700099
15800030010603000180010903100030012703200020013006500090013201400090014103500100
01500120083001600120078002430100038003210100025003590100048003840100041004320100
03800473070007300511070007800584070006200662070005800724083143700782085000802219
08500190222708500190224608500360226508314320230108500080373308500170374108500200
37580850030037781170006038080720003038141120009038171110009038261140009038351130
00903844002000703853#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#f#3#1#arti
cle#1#oa#pt#br1.1#1#4.0#ILUS#GRA#TAB#08#AOB140#nd#Acta ortop. bras.#19#1#2011000
0#^f37^l40#1413-7852#<b>Avaliação dos fatores predisponentes nas instabilidades 
femoropatelares</b>^lpt#<b>Avaliation of predisposing factors in patellofemoral 
instabilities</b>^len#^rND^1A01 A03^nRicardo Carli^sBurmann#^rND^1A02^nRenato^sL
ocks#^rND^1A01 A03 A04^nJoão Fernando Argento^sPozzi#^rND^1A03 A04^nEwerton Rena
to^sKonkewicz#^rND^1A03 A04^nMarcos Paulo de^sSouza#Hospital Beneficência Portug
uesa de Porto Alegre^iA01^cRio Grande do Sul#Hospital Cristo Redentor (Grupo Hos
pitalar Conceição)^iA02^cRio Grande do Sul#ULBRA^iA03^1Hospital Universitário^cC
anoas^pRio Grande do Sul#Serviço de Ortopedia Independente^iA04^cRio Grande do S
ul#^lpt^a<b>OBJETIVO:</b> Avaliar a prevalência dos fatores predisponentes à ins
tabilidade femoropatelar (displasia de tróclea, patela alta, TAGT, báscula patel
ar) em um grupo de pacientes acompanhados em nível ambulatorial. <b>MÉTODOS:</b>
 Avaliou-se 70 pacientes, sendo 52 do sexo feminino (74,28%) e 18 (25,72%) do se
xo masculino, num total de 127 joelhos, com uma média de idade de 17,71 anos. A 
avaliação por imagem foi realizada através de radiografias e tomografia computad
orizada. As instabilidades femoropatelares foram classificadas seguindo-se a cla
ssificação de Henri Dejour (instabilidade maior, objetiva e potencial). Enquadra
ram-se as displasias trocleares de acordo com a classificação de David Dejour (t
ipo A, B, C, D). <b>RESULTADOS:</b> Observou-se displasia troclear em 118 (92,91
%) joelhos, sendo 91 (77,11%) joelhos dos tipos A e B. A altura patelar apresent
ou uma média de 1,23, com 44 (34,64%) consideradas patela alta e 83 (65,36%) nor
mais. A báscula patelar alterada foi encontrada em 92 (72,44%) joelhos e a eleva
ção da TAGT em 63 (49,60%) joelhos. Obteve-se predominância de instabilidades ob
jetivas 89 (70,07%) joelhos, Quanto a associação de fatores predisponentes,, 117
 (92,13%) joelhos apresentaram mais quem um fator. <b>CONCLUSÕES:</b> A instabil
idade femoropatelar é uma doença multifatorial, os distúrbios trocleares são mai
s prevalentes e há uma forte associação entre 2 ou mais fatores predisponentes.#
^dnd^i1#^tm^lpt^kJoelho^i1#^tm^lpt^kPatela^i1#^tm^lpt^kInstabilidade articular^i
1#^len^a<b>OBJECTIVE:</b> To evaluate the prevalence of predisposing factors for
 femoropatelar instability (dysplasia of the trochlea, high patella, TTTG, and p
atellar tilt) in a group of patients in outpatient follow-up. <b>METHODS:</b> 70
 patients were evaluated; 52 (74.28 %) female and 18 (25.72 %) male, with an ave
rage age of 17.71 years and a total of 127 knees. The evaluation by imaging was 
carried out through radiologic examination and computerized tomography. The femo
ropatelar instabilities were classified according to Henri Dejour's classificati
on (major, objective and potential instability). The trochlear dysplasia was cla
ssified according to David Dejour's classification (type A, B, C, D). <b>RESULTS
:</b> Trochlear dysplasia was observed in 118 knees (92.91%), with 91 knees (77.
11%) being of type A and B. The average for patellar height was 1.23, with 44 (3
4.64%) considered high patellas and 83 (65.36%) within the normal range. Abnorma
l patellae tilt was found in 92 knees (72.44%) and an elevation of TTTG in 63 kn
ees (49.60%). The was a prevalence of objective instabilities with 89 knees (70.
07%). In relation to the association of predisposing factors, 117 knees (92.13%)
 presented more than one factor. <b>CONCLUSIONS:</b> Femoropatelar instability i
s a multifactorial disease, with trochlear disorders being the most frequent, an
d there is a strong association between two or more predisposing factors.#^dnd^i
2#^tm^len^kKnee^i2#^tm^len^kPatella^i2#^tm^len^kJoint instability^i2#other#28#20
091025#25/10/09#20100507#07/05/10#08.htm##
04739000000000685000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000500090038000400095038000400099121000300103
04900070010615800030011303000170011603100030013303200020013606500090013801400090
01470350010001560120076001660120071002420100038003130100025003510100048003760100
04100424010003800465070007500503070008000578070006400658070006000722083149900782
08500080228108500190228908500190230808500360232708314740236308500080383708500170
38450850020038620850030038821170006039120720003039181120009039211110009039301140
00903939113000903948002000703957008008903964#v19n1#V:\SciELO\serial\aob\v19n1\ma
rkup\08.htm#S#l#4#1#article#1#^a2011#oa#pt#br1.1#1#4.0#ilus#gra#tab#08#AOB140#nd
#Acta ortop. bras#19#1#20110000#^f37^l40#1413-7852#Avaliação dos fatores predisp
onentes nas instabilidades femoropatelares^lpt#Avaliation of predisposing factor
s in patellofemoral instabilities^len#^rND^1A01 A03^nRicardo Carli^sBurmann#^rND
^1A02^nRenato^sLocks#^rND^1A01 A03 A04^nJoão Fernando Argento^sPozzi#^rND^1A03 A
04^nEwerton Renato^sKonkewicz#^rND^1A03 A04^nMarcos Paulo de^sSouza#^iA01^1Hospi
tal Beneficência Portuguesa de Porto Alegre^cRio Grande do Sul#^iA02^1Hospital C
risto Redentor (Grupo Hospitalar Conceição)^cRio Grande do Sul#^iA03^1ULBRA^2Hos
pital Universitário^cCanoas^pRio Grande do Sul#^iA04^1Serviço de Ortopedia Indep
endente^cRio Grande do Sul#^lpt^aOBJETIVO: Avaliar a prevalência dos fatores pre
disponentes à instabilidade femoropatelar (displasia de tróclea, patela alta, TA
GT, báscula patelar) em um grupo de pacientes acompanhados em nível ambulatorial
. MÉTODOS: Avaliou-se 70 pacientes, sendo 52 do sexo feminino (74,28 por cento) 
e 18 (25,72 por cento) do sexo masculino, num total de 127 joelhos, com uma médi
a de idade de 17,71 anos. A avaliação por imagem foi realizada através de radiog
rafias e tomografia computadorizada. As instabilidades femoropatelares foram cla
ssificadas seguindo-se a classificação de Henri Dejour (instabilidade maior, obj
etiva e potencial). Enquadraram-se as displasias trocleares de acordo com a clas
sificação de David Dejour (tipo A, B, C, D). RESULTADOS: Observou-se displasia t
roclear em 118 (92,91 por cento) joelhos, sendo 91 (77,11 por cento) joelhos dos
 tipos A e B. A altura patelar apresentou uma média de 1,23, com 44 (34,64 por c
ento) consideradas patela alta e 83 (65,36 por cento) normais. A báscula patelar
 alterada foi encontrada em 92 (72,44 por cento) joelhos e a elevação da TAGT em
 63 (49,60 por cento) joelhos. Obteve-se predominância de instabilidades objetiv
as 89 (70,07 por cento) joelhos, Quanto a associação de fatores predisponentes,,
 117 (92,13 por cento) joelhos apresentaram mais quem um fator. CONCLUSÕES: A in
stabilidade femoropatelar é uma doença multifatorial, os distúrbios trocleares s
ão mais prevalentes e há uma forte associação entre 2 ou mais fatores predispone
ntes.#^dnd^i1#^tm^lpt^kJoelho^i1#^tm^lpt^kPatela^i1#^tm^lpt^kInstabilidade artic
ular^i1#^len^aOBJECTIVE: To evaluate the prevalence of predisposing factors for 
femoropatelar instability (dysplasia of the trochlea, high patella, TTTG, and pa
tellar tilt) in a group of patients in outpatient follow-up. METHODS: 70 patient
s were evaluated; 52 (74.28  percent) female and 18 (25.72  percent) male, with 
an average age of 17.71 years and a total of 127 knees. The evaluation by imagin
g was carried out through radiologic examination and computerized tomography. Th
e femoropatelar instabilities were classified according to Henri Dejour's classi
fication (major, objective and potential instability). The trochlear dysplasia w
as classified according to David Dejour's classification (type A, B, C, D). RESU
LTS: Trochlear dysplasia was observed in 118 knees (92.91 percent), with 91 knee
s (77.11 percent) being of type A and B. The average for patellar height was 1.2
3, with 44 (34.64 percent) considered high patellas and 83 (65.36 percent) withi
n the normal range. Abnormal patellae tilt was found in 92 knees (72.44 percent)
 and an elevation of TTTG in 63 knees (49.60 percent). The was a prevalence of o
bjective instabilities with 89 knees (70.07 percent). In relation to the associa
tion of predisposing factors, 117 knees (92.13 percent) presented more than one 
factor. CONCLUSIONS: Femoropatelar instability is a multifactorial disease, with
 trochlear disorders being the most frequent, and there is a strong association 
between two or more predisposing factors.#^dnd^i2#^tm^len^kKnee^i2#^tm^len^kPate
lla^i2#^tm^len^kJoint instability^i2#other#28#20091025#25/10/09#20100507#07/05/1
0#08.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-
78522011000100008##
00343000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704012300067002000700190#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#5#1#article#178#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTIGO    ORIGINAL</b> </fon
t></p>     ^cY#08.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#6#2#article#178#<p>&nbsp;</p>     ^cY#08.htm
##
00416000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704019600067002000700263#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#7#3#article#178#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Avalia&ccedil;&atilde;o 
   dos fatores predisponentes nas instabilidades femoropatelares</b></font></p> 
    ^cY#08.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#8#4#article#178#<p>&nbsp;</p>     ^cY#08.htm
##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#9#5#article#178#<p>&nbsp;</p>     ^cY#08.htm
##
00527000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704030600068002000700374#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#10#6#article#178#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Ricardo Carli    Burmann<sup>I, III</sup>
; Renato Locks<sup>II</sup>; Jo&atilde;o Fernando Argento    Pozzi<sup>I, III, I
V</sup>; Ewerton Renato Konkewicz<sup>III, IV</sup>; Marcos    Paulo de Souza<su
p>III, IV</sup></b></font></p>     ^cY#08.htm##
00380000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704015900068002000700227#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#11#7#article#178#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><sup>I</sup>Hospital    Benefic&ecirc;ncia P
ortuguesa de Porto Alegre, Rio Grande do Sul    ^cY#08.htm##
00352000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704013100068002000700199#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#12#8#article#178#<br>   <sup>II</sup>Hospita
l Cristo Redentor (Grupo Hospitalar Concei&ccedil;&atilde;o),    Porto Alegre, R
io Grande do Sul    ^cY#08.htm##
00314000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704009300068002000700161#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#13#9#article#178#<br>   <sup>III</sup>Hospit
al Universit&aacute;rio da ULBRA, Canoas/Rio Grande do Sul    ^cY#08.htm##
00379000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704015700069002000700226#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#14#10#article#178#<br>   <sup>IV</sup>Servi&
ccedil;o de Ortopedia Independente (SOTI - Independent Orthopedics    Service), 
Porto Alegre, Rio Grande do Sul</font></p>     ^cY#08.htm##
00370000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704014800069002000700217#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#15#11#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#back">Endere&ccedil;o    para Cor
respond&ecirc;ncia</a></font></p>     ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#16#12#article#178#<p>&nbsp;</p>     ^cY#08.h
tm##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#17#13#article#178#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#08.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#18#14#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#08.htm##
00551000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704032900069002000700398#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#19#15#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Avaliar a preval&ecirc;
ncia dos fatores predisponentes &agrave; instabilidade    femoropatelar (displas
ia de tr&oacute;clea, patela alta, TAGT, b&aacute;scula    patelar) em um grupo 
de pacientes acompanhados em n&iacute;vel ambulatorial.    ^cY#08.htm##
00829000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704060700069002000700676#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#20#16#article#178#<br>   <b>M&Eacute;TODOS:<
/b> Avaliou-se 70 pacientes, sendo 52 do sexo feminino (74,28%)    e 18 (25,72%)
 do sexo masculino, num total de 127 joelhos, com uma m&eacute;dia    de idade d
e 17,71 anos. A avalia&ccedil;&atilde;o por imagem foi realizada atrav&eacute;s 
   de radiografias e tomografia computadorizada. As instabilidades femoropatelar
es    foram classificadas seguindo-se a classifica&ccedil;&atilde;o de Henri Dej
our    (instabilidade maior, objetiva e potencial). Enquadraram-se as displasias
 trocleares    de acordo com a classifica&ccedil;&atilde;o de David Dejour (tipo
 A, B, C, D).    ^cY#08.htm##
00816000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704059400069002000700663#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#21#17#article#178#<br>   <b>RESULTADOS:</b> 
Observou-se displasia troclear em 118 (92,91%) joelhos, sendo    91 (77,11%) joe
lhos dos tipos A e B. A altura patelar apresentou uma m&eacute;dia    de 1,23, c
om 44 (34,64%) consideradas patela alta e 83 (65,36%) normais. A b&aacute;scula 
   patelar alterada foi encontrada em 92 (72,44%) joelhos e a eleva&ccedil;&atil
de;o    da TAGT em 63 (49,60%) joelhos. Obteve-se predomin&acirc;ncia de instabi
lidades    objetivas 89 (70,07%) joelhos, Quanto a associa&ccedil;&atilde;o de f
atores    predisponentes,, 117 (92,13%) joelhos apresentaram mais quem um fator.
    ^cY#08.htm##
00499000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704027700069002000700346#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#22#18#article#178#<br>   <b>CONCLUS&Otilde;E
S:</b> A instabilidade femoropatelar &eacute; uma doen&ccedil;a    multifatorial
, os dist&uacute;rbios trocleares s&atilde;o mais prevalentes e    h&aacute; uma
 forte associa&ccedil;&atilde;o entre 2 ou mais fatores predisponentes.</font></
p>     ^cY#08.htm##
00390000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704016800069002000700237#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#23#19#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Descritores:</b>    Joelho. Patela. Inst
abilidade articular.</font></p> <hr size="1" noshade>     ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#24#20#article#178#<p>&nbsp;</p>     ^cY#08.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#25#21#article#178#<p>&nbsp;</p>     ^cY#08.h
tm##
00336000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011400069002000700183#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#26#22#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b></font></p> 
    ^cY#08.htm##
00619000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704039700069002000700466#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#27#23#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As afec&ccedil;&otilde;es    da articula&cc
edil;&atilde;o femoropatelar s&atilde;o, certamente, das que mais    trazem frus
tra&ccedil;&otilde;es ao ortopedista, tanto pela sua alta preval&ecirc;ncia    c
omo pelo grande n&uacute;mero de casos insol&uacute;veis, principalmente em    a
dolescentes jovens.<sup>1</sup></font></p>     ^cY#08.htm##
00864000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704064200069002000700711#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#28#24#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Essa articula&ccedil;&atilde;o    &eacute; 
local de in&uacute;meras patologias, principalmente pelas suas caracter&iacute;s
ticas    anat&ocirc;micas. &Eacute; uma articula&ccedil;&atilde;o que centraliza
 for&ccedil;as    do quadr&iacute;ceps no comando de grande alavanca respons&aac
ute;vel pela posi&ccedil;&atilde;o    ereta. Seu equil&iacute;brio estrutural &e
acute; fr&aacute;gil, e qualquer dist&uacute;rbio    na sua estabilidade pode re
presentar altera&ccedil;&atilde;o funcional capaz    de produzir sintomas, algum
as vezes incapacitantes.<sup>2</sup></font></p>     ^cY#08.htm##
00856000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704063400069002000700703#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#29#25#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Durante a realiza&ccedil;&atilde;o    da hi
st&oacute;ria e do exame f&iacute;sico &eacute; importante que conhe&ccedil;amos
    os fatores predisponentes associados &agrave; instabilidade femoropatelar. E
stes    fatores s&atilde;o respons&aacute;veis pela fisiopatologia da instabilid
ade    da patela. S&atilde;o eles: displasias trocleares, patela alta, desvios r
otacionais    e angulares dos membros inferiores, displasia muscular (vasto medi
al obliquo),    displasia retinacular, fatores heredit&aacute;rios e hist&oacute
;ria familiar.<sup>2,3</sup></font></p>     ^cY#08.htm##
00710000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704048800069002000700557#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#30#26#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Estes fatores foram    classificados por De
jour <i>et al.</i><sup>4</sup> de acordo com a sua import&acirc;ncia:    Fatores
 prim&aacute;rios (Patela alta, Displasia troclear, Displasia VMO (quadr&iacute;
ceps),    Lateraliza&ccedil;&atilde;o da TAT, Insufici&ecirc;ncia do ligamento p
atelofemoral    medial (LPFM)) e Fatores secund&aacute;rios (Desvios rotacionais
 dos MsIs, Geno    Recurvato, Geno valgo).</font></p>     ^cY#08.htm##
01038000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704081600069002000700885#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#31#27#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Cada um destes    fatores pode ser identifi
cado em exames complementares, sendo para tal selecionado    a radiografia e a t
omografia computadorizada, segundo um protocolo espec&iacute;fico    idealizado 
por Dejour <i>et al</i>.<sup>4</sup> Desta maneira, a radiografia    permite ava
liar e identificar a patela alta e a displasia troclear. A Tomografia    Computa
dorizada permite identificar e mensurar a displasia do VMO (vasto medial    obl&
iacute;quo) e a insufici&ecirc;ncia do LPFM atrav&eacute;s da b&aacute;scula    
ou inclina&ccedil;&atilde;o patelar e a lateraliza&ccedil;&atilde;o da TAT atrav
&eacute;s    da medi&ccedil;&atilde;o da TAGT. A TC tamb&eacute;m auxilia na ide
ntifica&ccedil;&atilde;o    da displasia troclear.</font></p>     ^cY#08.htm##
00499000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704027700069002000700346#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#32#28#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O objetivo do presente    estudo &eacute; a
valiar a preval&ecirc;ncia destes fatores prim&aacute;rios,    em um grupo de pa
cientes com queixa de dor e/ou instabilidade femoropatelar.<sup>4</sup></font></
p>     ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#33#29#article#178#<p>&nbsp;</p>     ^cY#08.h
tm##
00337000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011500069002000700184#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#34#30#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>MATERIAL E M&Eacute;TODOS</b></font></p>
     ^cY#08.htm##
00486000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704026400069002000700333#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#35#31#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Foram avaliados    pacientes portadores de 
instabilidade femoropatelar em acompanhamento no ambulat&oacute;rio    de joelho
 com queixas femoropatelares em pelo menos um dos joelhos.</font></p>     ^cY#08
.htm##
00503000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704028100069002000700350#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#36#32#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Foram inclu&iacute;dos    70 pacientes port
adores de instabilidade femoropatelar, sendo 52 pacientes (74,28%)    do sexo fe
minino e 18 (25,72%) do sexo masculino, num total de 127 joelhos avaliados.</fon
t></p>     ^cY#08.htm##
00491000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704026900069002000700338#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#37#33#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Deste total, 99    joelhos eram sintom&aacu
te;ticos (77,95%) e 28 eram assintom&aacute;ticos (22,05%).    A idade dos pacie
ntes variou dos 10 aos 40 anos, com m&eacute;dia de 17,71 anos.</font></p>     ^
cY#08.htm##
00456000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704023400069002000700303#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#38#34#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A identifica&ccedil;&atilde;o    da TA-GT e
 da b&aacute;scula patelar foi realizado por Tomografia Computadorizada    (TC) 
segundo o protocolo de Lyon.</font></p>     ^cY#08.htm##
00515000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704029300069002000700362#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#39#35#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O valor normal    para a TAGT situa-se entr
e 10 e 15 mm. TAGT significa a dist&acirc;ncia entre    a tuberosidade anterior 
da t&iacute;bia (TA) e a garganta da tr&oacute;clea    (GT) dentro de um plano s
agital.</font></p>     ^cY#08.htm##
00762000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704054000069002000700609#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#40#36#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A b&aacute;scula    patelar &eacute; calcul
ada pela m&eacute;dia de tr&ecirc;s posi&ccedil;&otilde;es    diferentes: joelho
 em extens&atilde;o total com contra&ccedil;&atilde;o do quadr&iacute;ceps    (p
osi&ccedil;&atilde;o 1), joelho em extens&atilde;o total com relaxamento do    q
uadr&iacute;ceps (posi&ccedil;&atilde;o 2) e joelho em 15° de flex&atilde;o    c
om relaxamento do quadr&iacute;ceps (posi&ccedil;&atilde;o 3). (<a href="#f1">Fi
gura    1</a>)</font></p>     ^cY#08.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#41#37#article#178#<p><a name="f1"></a></p>  
   ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#42#38#article#178#<p>&nbsp;</p>     ^cY#08.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#43#39#article#178#<p align="center"><img src
="/img/revistas/aob/v19n1/08f01.jpg"></p>     ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#44#40#article#178#<p>&nbsp;</p>     ^cY#08.h
tm##
00602000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704038000069002000700449#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#45#41#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O valor normal    para a b&aacute;scula pat
elar &eacute; de 0 a 20°. A altura patelar foi mensurada    pela radiografia em 
perfil estrito a 30º de flex&atilde;o, pelo m&eacute;todo    de Caton-Deschamps.
 Os valores considerados normais est&atilde;o entre 0,8 e    1,2. (<a href="#f2"
>Figura 2</a>)</font></p>     ^cY#08.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#46#42#article#178#<p><a name="f2"></a></p>  
   ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#47#43#article#178#<p>&nbsp;</p>     ^cY#08.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#48#44#article#178#<p align="center"><img src
="/img/revistas/aob/v19n1/08f02.jpg"></p>     ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#49#45#article#178#<p>&nbsp;</p>     ^cY#08.h
tm##
00565000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704034300069002000700412#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#50#46#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A displasia troclear    foi avaliada por ra
diografia e por TC. Foi adotada a classifica&ccedil;&atilde;o    Dejour,<sup>5</
sup> modificada por David Dejour,<sup>6</sup> que diferencia    em tipos A, B, C
 e D. (<a href="#f3">Figuras 3</a> e <a href="#f4">4</a>)</font></p>     ^cY#08.
htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#51#47#article#178#<p><a name="f3"></a></p>  
   ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#52#48#article#178#<p>&nbsp;</p>     ^cY#08.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#53#49#article#178#<p align="center"><img src
="/img/revistas/aob/v19n1/08f03.jpg"></p>     ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#54#50#article#178#<p>&nbsp;</p>     ^cY#08.h
tm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#55#51#article#178#<p><a name="f4"></a></p>  
   ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#56#52#article#178#<p>&nbsp;</p>     ^cY#08.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#57#53#article#178#<p align="center"><img src
="/img/revistas/aob/v19n1/08f04.jpg"></p>     ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#58#54#article#178#<p>&nbsp;</p>     ^cY#08.h
tm##
00526000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704030400069002000700373#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#59#55#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Al&eacute;m disto,    os pacientes foram di
vididos em grupos, segundo a classifica&ccedil;&atilde;o    de Henri Dejour, par
a as tr&ecirc;s apresenta&ccedil;&otilde;es cl&iacute;nicas    das instabilidade
s femoropatelares:</font></p>     ^cY#08.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002400069002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#60#56#article#178#<blockquote>        ^cY#08
.htm##
00341000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011900069002000700188#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#61#57#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">- Instabilidade      Patelar Maior</font></
p>       ^cY#08.htm##
00344000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012200069002000700191#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#62#58#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">- Instabilidade      Patelar Objetiva</font
></p>       ^cY#08.htm##
00357000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704013500069002000700204#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#63#59#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">- Instabilidade      Patelar Potencial</fon
t></p> </blockquote>     ^cY#08.htm##
00477000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704025500069002000700324#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#64#60#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Foram exclu&iacute;dos    os pacientes port
adores de les&otilde;es associadas e pacientes submetidos a    procedimentos cir
&uacute;rgicos pr&eacute;vios no joelho avaliado.</font></p>     ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#65#61#article#178#<p>&nbsp;</p>     ^cY#08.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#66#62#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>     ^cY#08.htm
##
00370000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704014800069002000700217#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#67#63#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Na amostra deste    estudo foi encontrado (
total de 127 joelhos):</font></p>     ^cY#08.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002400069002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#68#64#article#178#<blockquote>        ^cY#08
.htm##
00522000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704030000069002000700369#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#69#65#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">1. Displasia      troclear em 118 joelhos (
92, 91%), sendo 61 joelhos do tipo A (51,69%), 30      joelhos do tipo B (25,42%
), 20 joelhos do tipo C (16,95%) e apenas 07 joelhos      classificados como tip
o D (5,93%).</font></p>       ^cY#08.htm##
00511000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704028900069002000700358#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#70#66#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">2. Quarenta e      quatro (44) patelas alta
s (34,64%) e 83 patelas com altura dentro da normalidade      (65,36%). N&atilde
;o foram detectados casos de patela baixa. A m&eacute;dia      geral foi de 1,23
.</font></p>       ^cY#08.htm##
00470000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704024800069002000700317#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#71#67#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">3. Noventa e      dois (92) joelhos apresen
taram b&aacute;scula patelar acima de 20°(72,44%),      enquanto que 35 joelhos 
(27,56%) tinham a b&aacute;scula normal.</font></p>       ^cY#08.htm##
00401000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704017900069002000700248#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#72#68#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">4. Sessenta e      tr&ecirc;s (63) joelhos 
apresentaram a TAGT aumentada (49,60%).</font></p> </blockquote>     ^cY#08.htm#
#
00537000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704031500069002000700384#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#73#69#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A associa&ccedil;&atilde;o    de fatores pr
im&aacute;rios de instabilidade, em um mesmo joelho, &eacute; demonstrada    na 
<a href="#f5">Figura 5</a> e a preval&ecirc;ncia dos tipos de instabilidade    n
a <a href="#t1">Tabela 1</a>.</font></p>     ^cY#08.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#74#70#article#178#<p><a name="t1"></a></p>  
   ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#75#71#article#178#<p>&nbsp;</p>     ^cY#08.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#76#72#article#178#<p align="center"><img src
="/img/revistas/aob/v19n1/08t01.jpg"></p>     ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#77#73#article#178#<p>&nbsp;</p>     ^cY#08.h
tm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#78#74#article#178#<p><a name="f5"></a></p>  
   ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#79#75#article#178#<p>&nbsp;</p>     ^cY#08.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#80#76#article#178#<p align="center"><img src
="/img/revistas/aob/v19n1/08f05.jpg"></p>     ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#81#77#article#178#<p>&nbsp;</p>     ^cY#08.h
tm##
00328000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010600069002000700175#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#82#78#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font></p>     ^cY#
08.htm##
00748000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704052600069002000700595#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#83#79#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A luxa&ccedil;&atilde;o    da patela &eacut
e; uma experi&ecirc;ncia dolorosa que ocorre subitamente, com    o primeiro epis
&oacute;dio, afetando principalmente pacientes jovens. Existe    uma s&eacute;ri
e de fatores que podem resultar em instabilidade patelar objetiva.    Na tentati
va de identificar alguns desses fatores, definiram-se caracter&iacute;sticas    
radiogr&aacute;ficas e tomogr&aacute;ficas da instabilidade patelar.<sup>7</sup>
</font></p>     ^cY#08.htm##
00693000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704047100069002000700540#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#84#80#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A literatura tem    mostrado maior frequ&ec
irc;ncia das instabilidades femoropatelar no sexo feminino    (58%)<sup>8</sup>.
 Na amostra estudada encontrou-se tamb&eacute;m uma preval&ecirc;ncia    maior n
o sexo feminino (74,28%). Com rela&ccedil;&atilde;o &agrave; idade, teve-se    u
ma preval&ecirc;ncia na segunda d&eacute;cada, semelhante &agrave; relatada    n
a literatura.<sup>9</sup></font></p>     ^cY#08.htm##
00670000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704044800069002000700517#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#85#81#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Displasia troclear    tem sido considerada 
como um fator de instabilidade patelar desde 1915, quando    Albee prop&ocirc;s 
sua corre&ccedil;&atilde;o por uma osteotomia superolateral    da tr&oacute;clea
.<sup>10</sup> Brattstr&ouml;m<sup>11</sup> foi o primeiro    a estudar a displa
sia troclear na radiografia na incid&ecirc;ncia axial com    30º de flex&atilde;
o.</font></p>     ^cY#08.htm##
00469000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704024700069002000700316#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#86#82#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Maldague e Malghem<sup>12</sup>    foram os
 primeiros a definir a import&acirc;ncia do perfil verdadeiro de joelho    no es
tudo da tr&oacute;clea e suas displasias.</font></p>     ^cY#08.htm##
00761000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704053900069002000700608#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#87#83#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Em estudo de Dejour    <i>et al.</i><sup>4<
/sup> foi identificado o sinal do cruzamento em 96% dos    joelhos com instabili
dade patelar, sendo que 85% dos joelhos com instabilidade    apresentavam um esp
or&atilde;o troclear. Neste trabalho de Dejour <i>et al.</i><sup>4</sup>,    foi
 estudado uma amostra total de 143 joelhos com instabilidade objetiva, e    dest
es somente 0,7% n&atilde;o apresentaram crit&eacute;rios para displasia    de tr
&oacute;clea.</font></p>     ^cY#08.htm##
00531000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704030900069002000700378#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#88#84#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Entretanto a displasia    troclear &eacute;
 uma constante (patognom&ocirc;nica) de instabilidade patelar.    A frequ&ecirc;
ncia de bilateralidade foi de 92,5%, o que faz acreditar em anormalidade    cons
titucional.<sup>4</sup></font></p>     ^cY#08.htm##
00916000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704069400069002000700763#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#89#85#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Em trabalho de    Dejour e Le Coultre,<sup>
13</sup> encontrou-se displasia troclear em 96% dos    pacientes com hist&oacute
;ria verdadeira de luxa&ccedil;&atilde;o patelar.<sup>13</sup>    No estudo em q
uest&atilde;o, foi encontrada presen&ccedil;a de displasia troclear    em 92,91%
 dos joelhos avaliados, o que ratifica a alta preval&ecirc;ncia de    displasia 
troclear na instabilidade femoropatelar. Provavelmente este percentual    um pou
co abaixo da m&eacute;dia da literatura, deveu-se ao fato de que, neste    traba
lho foram inclu&iacute;dos joelhos com diagn&oacute;stico de instabilidade    po
tencial.</font></p>     ^cY#08.htm##
00433000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704021100069002000700280#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#90#86#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Hughston <i>et    al</i>.<sup>14</sup> e In
sall <i>et al.</i><sup>15</sup> estudaram em especial    a displasia do vasto me
dial.</font></p>     ^cY#08.htm##
00782000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704056000069002000700629#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#91#87#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Hughston <i>et    al</i>.<sup>14</sup> acre
ditavam que o vasto medial era composto por dois m&uacute;sculos    independente
s, vasto medial longo e o vasto medial obl&iacute;quo (VMO), cuja    maioria das
 fibras distais tem orienta&ccedil;&atilde;o horizontal e a inser&ccedil;&atilde
;o    ao longo do bordo superomedial da patela. As fibras do vasto medial obl&ia
cute;quo    exercem uma for&ccedil;a de medializa&ccedil;&atilde;o durante os pr
imeiros    graus de flex&atilde;o.</font></p>     ^cY#08.htm##
00512000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704029000069002000700359#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#92#88#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Dejour <i>et al.</i><sup>4</sup>    encontr
aram associa&ccedil;&atilde;o de displasia do VMO com a instabilidade    patelar
, em que 83% dos casos de instabilidade apresentavam displasia do quadr&iacute;c
eps.</font></p>     ^cY#08.htm##
00543000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704032100069002000700390#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#93#89#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O ligamento patelo-femoral    medial &eacut
e; o principal estabilizador est&aacute;tico na preven&ccedil;&atilde;o    do de
slocamento lateral da patela e a primeira estrutura a ser lesada na sua    luxa&
ccedil;&atilde;o aguda.<sup>4</sup></font></p>     ^cY#08.htm##
00674000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704045200069002000700521#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#94#90#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Al&eacute;m deste    ligamento, destaca-se 
a import&acirc;ncia do m&uacute;sculo vasto medial obl&iacute;quo    (VMO) na es
tabilidade patelar<sup>7</sup>. Na amostra estudada, utilizou-se    a avalia&cce
dil;&atilde;o da b&aacute;scula patelar m&eacute;dia como par&acirc;metro    par
a a displasia do VMO, sendo encontrada altera&ccedil;&atilde;o em 72,44%    dos 
casos.</font></p>     ^cY#08.htm##
00886000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704066400069002000700733#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#95#91#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O contato entre    o f&ecirc;mur e a patela
 tem caracter&iacute;sticas vari&aacute;veis de acordo    com o grau de flex&ati
lde;o do joelho. A 0° de flex&atilde;o n&atilde;o h&aacute;    contato da superf
&iacute;cie articular da patela com a tr&oacute;clea femoral.    A 30º de flex&a
tilde;o, a por&ccedil;&atilde;o inferior da patela articula-se    com a por&cced
il;&atilde;o mais superior dos c&ocirc;ndilos femorais.<sup>16</sup>    &Eacute;
 importante, para a estabilidade articular, que haja um encaixe correto    da pa
tela na tr&oacute;clea femoral enquanto o joelho flexiona.</font></p>     ^cY#08
.htm##
00692000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704047000069002000700539#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#96#92#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A exist&ecirc;ncia    de patela alta &eacut
e; um fator que pode predispor a falha deste encaixe patelar.    Em estudo reali
zado por Galli <i>et al</i>.,<sup>17</sup> em pacientes portadores    de subluxa
&ccedil;&atilde;o femoropatelar em extens&atilde;o, n&atilde;o foi    encontrado
 nenhum caso como patela baixa, 45 casos (45%) apresentaram-se como    normais e
 em 55 (55%) como altas.</font></p>     ^cY#08.htm##
00550000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704032800069002000700397#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#97#93#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Insall <i>e</i>    Salvatti <sup>18</sup> e
 Blackburne e Peel<sup>19</sup> j&aacute; tinham demonstrado    o papel da patel
a alta na instabilidade patelar. Uma patela alta anormal &eacute;    um pr&eacut
e;-requisito para a luxa&ccedil;&atilde;o.</font></p>     ^cY#08.htm##
00806000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704058400069002000700653#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#98#94#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Trabalhos como    o de Dejour <i>et al</i>.
,<sup>4</sup> encontrou este achado em 24% dos joelhos    avaliados com instabil
idade patelar objetiva. Neste estudo utilizou-se o m&eacute;todo    de Caton-Des
champs para avaliar a altura patelar, sendo encontrada altera&ccedil;&atilde;o  
  em 34% dos joelhos avaliados, um valor acima dos encontrados na literatura,   
 talvez por n&atilde;o ter-se individualizado a preval&ecirc;ncia de patela alta
    de acordo com os tipos de instabilidade femoropatelar.</font></p>     ^cY#08
.htm##
00718000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704049600069002000700565#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#99#95#article#178#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A altera&ccedil;&atilde;o    na TA-GT, pato
l&oacute;gica quando superior a 20mm, pode aparecer como um fator    espec&iacut
e;fico na instabilidade femoro-patelar. A literatura mostra uma presen&ccedil;a 
   de 56% deste fator nos casos de instabilidade patelar. A medida tomogr&aacute
;fica    de TA-GT foi considerada anormal quando superior a 15mm, apresentando-s
e alterada    em 49,60% dos casos.<sup>20,21</sup></font></p>     ^cY#08.htm##
00495000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704027200070002000700342#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#100#96#article#178#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A associa&ccedil;&atilde;o    de no m&iacu
te;nimo, dois fatores predisponentes foi encontrada em 92,13% dos    joelhos est
udados, reafirmando o car&aacute;ter multifatorial desta patologia.</font></p>  
   ^cY#08.htm##
00797000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704057400070002000700644#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#101#97#article#178#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Encontrou-se 70,07%    de instabilidades f
emoropatelares objetivas. Esta predomin&acirc;ncia talvez    possa ser explicada
 pelo fato de que a instabilidade objetiva apresenta sintomas    debilitantes ma
is precocemente, quando comparados &agrave;s instabilidades potenciais,    que e
m m&eacute;dia, iniciam seus sintomas mais tardiamente e em algumas vezes    che
gam a ser assintom&aacute;ticas at&eacute; a quarta ou quinta d&eacute;cadas    
de vida, quando sobrevem a artrose femoropatelar.</font></p>     ^cY#08.htm##
00245000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002200070002000700092#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#102#98#article#178#<p>&nbsp;</p>     ^cY#08.
htm##
00329000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704010600070002000700176#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#103#99#article#178#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>CONCLUS&Atilde;O</b></font></p>     ^cY
#08.htm##
00591000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704036700071002000700438#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#104#100#article#178#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">A instabilidade    femoropatelar &eacute;
 determinada pela associa&ccedil;&atilde;o de, no m&iacute;nimo,    dois ou mais
 fatores de instabilidade. Dentre os fatores, o mais frequente &eacute;    a dis
plasia troclear, presente em mais de 90% dos casos. (<a href="#f6">Figura    6</
a>)</font></p>     ^cY#08.htm##
00257000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003300071002000700104#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#105#101#article#178#<p><a name="f6"></a></p>
     ^cY#08.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#106#102#article#178#<p>&nbsp;</p>     ^cY#08
.htm##
00300000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704007600071002000700147#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#107#103#article#178#<p align="center"><img s
rc="/img/revistas/aob/v19n1/08f06.jpg"></p>     ^cY#08.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#108#104#article#178#<p>&nbsp;</p>     ^cY#08
.htm##
00494000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704027000071002000700341#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#109#105#article#178#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Pela ordem de frequ&ecirc;ncia,    ap&oac
ute;s a displasia troclear vem a b&aacute;scula patelar (70% dos casos),    segu
ida do TAGT elevada (49% dos casos) e patela alta (34% dos casos).</font></p>   
  ^cY#08.htm##
00434000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704021000071002000700281#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#110#106#article#178#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">A instabilidade    objetiva, de acordo co
m a classifica&ccedil;&atilde;o de Dejour, &eacute; a    mais comum com 70% dos 
casos.</font></p>     ^cY#08.htm##
00460000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704023600071002000700307#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#111#107#article#178#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">A nossa casu&iacute;stica    demonstrou s
er mais frequente a associa&ccedil;&atilde;o de 3 fatores de instabilidade,    e
m quase 50% dos casos avaliados.</font></p>     ^cY#08.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#112#108#article#178#<p>&nbsp;</p>     ^cY#08
.htm##
00331000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704010700071002000700178#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#113#109#article#178#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font></p>     ^
cY#08.htm##
00530000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704029200073002000700365#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#114#110#article#178#1#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">1. Mainine S. Tratamento   
 da luxa&ccedil;&atilde;o e subluxa&ccedil;&atilde;o lateral da patela &#91;tese
&#93;.    S&atilde;o Paulo: Faculdade de Ci&ecirc;ncias M&eacute;dicas da Santa 
Casa de    S&atilde;o Paulo; 1999.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#115#111#article#178#</font></p>     ^cY#08.h
tm##
00513000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704027500073002000700348#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#116#112#article#178#2#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">2. Mello WA, Penteado    PC
F, Brito WE, Stump X. Joelho do adulto. In: Hebert S. Xavier R. Ortopedia    e t
raumatologia: princ&iacute;pios e pr&aacute;tica. 4º ed. Porto Alegre: Artmed;  
  2009. p.505-39.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#117#113#article#178#</font></p>     ^cY#08.h
tm##
00426000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704018800073002000700261#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#118#114#article#178#3#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">3. Marczyk LRS,    Ellera G
omes JL. Instabilidade femoropatelar: conceitos atuais. Rev Bras Ortop.    2000;
35:275-81.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#119#115#article#178#</font></p>     ^cY#08.h
tm##
00479000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704024100073002000700314#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#120#116#article#178#4#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">4. Dejour H, Walch    G, No
ve-Josserand L, Guier C. Factors of patellar instability: an anatomic radiograph
ic    study. Knee Surg Sports Traumatol Arthrosc. 1994;2:19-28.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#121#117#article#178#</font></p>     ^cY#08.h
tm##
00439000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704020100073002000700274#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#122#118#article#178#5#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">5. Dejour H. Walch    G. La
 pathologie femoropatelaire. In: 6emes Journ&eacute;es Lyonnaises de Chirurgie  
  du Genou, Lyon; 1987.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#123#119#article#178#</font></p>     ^cY#08.h
tm##
00448000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704021000073002000700283#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#124#120#article#178#6#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">6. Dejour D, Reynaud    P, 
Lecoultre B. Douleurs et instabilit&eacute; rotulienne. Essai de classification.
    Med Hyg. 1998 ;56:1466-1471.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#125#121#article#178#</font></p>     ^cY#08.h
tm##
00421000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704018300073002000700256#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#126#122#article#178#7#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">7. Hernadez AJ,    Favaro E
, Laraya MH. Luxa&ccedil;&atilde;o aguda da patela. Rev Bras Ortop.    2004;39:6
5-74.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#127#123#article#178#</font></p>     ^cY#08.h
tm##
00480000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704024200073002000700315#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#128#124#article#178#8#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">8. Trillat A, Dejour    H, 
Couette A. &#91;Diagnosis and treatment of recurrent dislocations of the    pate
lla&#93;. Rev Chir Orthop Reparatrice Appar Mot. 1964;50:813-24.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#129#125#article#178#</font></p>     ^cY#08.h
tm##
00401000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704016300073002000700236#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#130#126#article#178#9#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">9. Smilie IS. Injuries    o
f the knee joint. 2th ed. Baltimore: Williams &amp;Wilkins; 1951.    ^cY#08.htm#
#
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#131#127#article#178#</font></p>     ^cY#08.h
tm##
00427000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704018800074002000700262#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#132#128#article#178#10#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Albee FH. The    bone 
graft wedge in the treatment of habitual dislocation of patella. Med Rec.    191
5;88:257-9.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#133#129#article#178#</font></p>     ^cY#08.h
tm##
00458000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704021900074002000700293#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#134#130#article#178#11#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Brattstrom    H. Shape
 of the intercondylar grove normally and in the recurrent dislocation    of the 
patella. Acta Scand. 1964;68(Suppl):1-148.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#135#131#article#178#</font></p>     ^cY#08.h
tm##
00536000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029700074002000700371#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#136#132#article#178#12#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Maldague B,    Malghem
 J. Apport du clich&eacute; de profil du genou dans le depistage les    instabil
itt&eacute;es rotuliennes. Rapport pr&eacute;liminaire. Rev Chir Orthop    Repar
atrice Appar Mot. 1985;71(Suppl 2):5-13.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#137#133#article#178#</font></p>     ^cY#08.h
tm##
00426000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704018700074002000700261#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#138#134#article#178#13#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Dejour D, Le    Coultr
e B. Osteotomies in patello-femoral instabillities. Sports Med Arthrosc.    2007
;15:39-46.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#139#135#article#178#</font></p>     ^cY#08.h
tm##
00419000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704018000074002000700254#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#140#136#article#178#14#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Hougstom JC,    Walsh 
Wm, Puddu G. Patellar subluxation and dislocation. Philadelphia: Saunders;    19
84.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#141#137#article#178#</font></p>     ^cY#08.h
tm##
00467000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022800074002000700302#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#142#138#article#178#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Insall J, Bullough    
PG, Burnstein AH. Proximal "tube"realignment of the patella for chondromalacia  
  patellae. Clin Orthop Relat Res. 1979;(144):63-9.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#143#139#article#178#</font></p>     ^cY#08.h
tm##
00454000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704021500074002000700289#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#144#140#article#178#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Aglietti P,    Insall 
JN, Walker PS, Trent P. A new patella prosthesis. Design and application.    Cli
n Orthop Relat Res. 1975;(107):175-87.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#145#141#article#178#</font></p>     ^cY#08.h
tm##
00497000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704025800074002000700332#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#146#142#article#178#17#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Gali JC, Caetano    EB
, Moreira BL, Galv&atilde;o MRR, Oliveira VM. A altura patelar na subluxa&ccedil
;&atilde;o    femoropatelar em extens&atilde;o. Rev Bras Ortop. 1998;33(4):301-6
.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#147#143#article#178#</font></p>     ^cY#08.h
tm##
00431000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704019200074002000700266#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#148#144#article#178#18#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Insall J, Salvatti    
E. Recurrent dislocation and the high-riding patella. Clin Orthop Relat Res.    
1972;(88):67-9.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#149#145#article#178#</font></p>     ^cY#08.h
tm##
00423000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704018400074002000700258#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#150#146#article#178#19#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Blackburne    JS, Peel
 TE. A new method of measuring patellar height. J Bone Joint Surg Br.    1977;59
:241-2.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#151#147#article#178#</font></p>     ^cY#08.h
tm##
00506000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026700074002000700341#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#152#148#article#178#20#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Pozzi JF, Konkewicz   
 ER. Joelho do adulto. In: Hebert S, Xavier R. Ortopedia e traumatologia: princ&
iacute;pios    e atualiza&ccedil;&otilde;es. 3º ed., Porto Alegre: Artmed; 2003.
 p.444-72.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#153#149#article#178#</font></p>     ^cY#08.h
tm##
00443000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704020400074002000700278#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#154#150#article#178#21#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Pozzi JFA,    Konkewic
z ER, Nora B. Tratamento cir&uacute;rgico das instabilidades rotulianas.    Rev 
Bras Ortop. 1993;28:277-83.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#155#151#article#178#</font></p>     ^cY#08.h
tm##
00496000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704025700074002000700331#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#156#152#article#178#22#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Masse Y. &#91;Trochleo
plasty.    Restoration of the intercondylar groove in subluxations and dislocati
ons of    the patella&#93;. Rev Chir Orthop Reparatrice Appar Mot. 1978;64:3-17.
    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#157#153#article#178#</font></p>     ^cY#08.h
tm##
00460000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022100074002000700295#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#158#154#article#178#23#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Dejour H, Walch    G, 
Neyret Ph, Adeleine P. La dysplasia de la trochl&eacute;e femorale. Rev Chir    
Orthop Reparatrice Appar Mot. 1990;76:45-54.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#159#155#article#178#</font></p>     ^cY#08.h
tm##
00395000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704015600074002000700230#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#160#156#article#178#24#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Hughston J.    Subluxa
tion of the patella. J Bone Joint Surg Am. 1968;50:1003-26.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#161#157#article#178#</font></p>     ^cY#08.h
tm##
00545000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030600074002000700380#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#162#158#article#178#25#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Nove-Josserand    l. L
es facteurs de l'instabilit&eacute; rotulienne objective. Etude d&ecirc;s    sca
nners pr&eacute; et post-operatoire. A prop&ocirc;s de 143 cas &#91;th&eacute;se
&#93;.    Universidade de Medicina de Lyon; 1991.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#163#159#article#178#</font></p>     ^cY#08.h
tm##
00447000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704020800074002000700282#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#164#160#article#178#26#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Dejour H. Walch    G. 
Les facteurs d'instabilit&eacute; rotulliene. Rev Chir Orthop Reparatrice    App
ar Mot. 1989;75(Suppl 1):141-2.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#165#161#article#178#</font></p>     ^cY#08.h
tm##
00409000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704017000074002000700244#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#166#162#article#178#27#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Insall J, Salvatti    
E. Patella junction in the normal knee joint. Radiology. 1971; 101:101-4.    ^cY
#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#167#163#article#178#</font></p>     ^cY#08.h
tm##
00397000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704015800074002000700232#v19
n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#p#168#164#article#178#28#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Colvin AC,    West RV.
 Patellar instability. J Bone Joint Surg Am. 2008;90:2751-62.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#169#165#article#178#</font></p>     ^cY#08.h
tm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#170#166#article#178#<p>&nbsp;</p>     ^cY#08
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#171#167#article#178#<p>&nbsp;</p>     ^cY#08
.htm##
00430000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704020600071002000700277#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#172#168#article#178#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top"><img sr
c="/img/revistas/aob/v19n1/seta.jpg" border="0"></a>    <b>Endereço para Corresp
ondência:</b>     ^cY#08.htm##
00281000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005700071002000700128#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#173#169#article#178#<br>   Rua: Doutor Tim&o
acute;teo, 616, apto. 203    ^cY#08.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003100071002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#174#170#article#178#<br>   Bairro: Floresta 
   ^cY#08.htm##
00263000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003900071002000700110#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#175#171#article#178#<br>   Porto Alegre, RS.
 Brazil    ^cY#08.htm##
00252000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002800071002000700099#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#176#172#article#178#<br>   Cep: 90570040    
^cY#08.htm##
00325000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704010100071002000700172#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#177#173#article#178#<br>   E-mail: <a href="
mailto:vburmann@yahoo.com.br">vburmann@yahoo.com.br</a></font>  </p>     ^cY#08.
htm##
00360000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013600071002000700207#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#178#174#article#178#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Artigo recebido    em 25/10/09, aprovado 
em 07/05/10.</font></p>     ^cY#08.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#179#175#article#178#<p>&nbsp;</p>     ^cY#08
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#180#176#article#178#<p>&nbsp;</p>     ^cY#08
.htm##
00418000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704019400071002000700265#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#181#177#article#178#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Trabalho realizado    no Hospital Indepen
d&ecirc;ncia da Ulbra e Hospital Benefic&ecirc;ncia Portuguesa    de Porto Alegr
e.    ^cY#08.htm##
00361000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013700071002000700208#v19n1#V:\SciELO
\serial\aob\v19n1\markup\08.htm#S#p#182#178#article#178#<br>   Todos os autores 
declaram n&atilde;o haver nenhum potencial conflito de interesses    referente a
 este artigo.</font></p>     ^cY#08.htm##
00489000000000241000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680160018000700180057000880510
00500145046001000150050005700160045000900217044000500226865000900231002000700240
#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#c#183#1#article#28#1#^rND^sMai
nine^nS.#Tratamento da luxação e subluxação lateral da patela^lpt#tese#São Paulo
#Faculdade de Ciências Médicas da Santa Casa de São Paulo#19990000#1999#20110000
#08.htm##
00628000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100020000860100
01600106010001500122012002100137016001600158016001600174018005200190063000300242
06600130024506200070025806500090026506400050027401400070027986500090028600200070
0295#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#c#184#2#article#28#2#^rND^
sMello^nWA#^rND^sPenteado^nPCF#^rND^sBrito^nWE#^rND^sStump^nX#Joelho do adulto^l
pt#^rND^sHebert^nS#^rND^sXavier^nR#Ortopedia e traumatologia: princípios e práti
ca^lpt#4º#Porto Alegre#Artmed#20090000#2009#505-39#20110000#08.htm##
00520000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700100023000890120
05000112030001500162065000900177064000500186031000300191014000700194865000900201
002000700210035001000217801001500227#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.
htm#S#c#185#3#article#28#3#^rND^sMarczyk^nLRS#^rND^sEllera Gomes^nJL#Instabilida
de femoropatelar: conceitos atuais^lpt#Rev Bras Ortop#20000000#2000#35#275-81#20
110000#08.htm#0486-6401#Rev Bras Ortop##
00630000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100015000860100
02400101010001500125012006800140030003600208065000900244064000500253031000200258
014000600260865000900266002000700275035001000282801003600292#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\08.htm#S#c#186#4#article#28#4#^rND^sDejour^nH#^rND^sWalch^n
G#^rND^sNove-Josserand^nL#^rND^sGuier^nC#Factors of patellar instability: an ana
tomic radiographic study^len#Knee Surg Sports Traumatol Arthrosc#19940000#1994#2
#19-28#20110000#08.htm#0942-2056#Knee Surg Sports Traumatol Arthrosc##
00464000000000241000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100015000860120
03400101018005200135066000500187065000900192064000500201865000900206002000700215
#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#c#187#5#article#28#5#^rND^sDej
our^nH#^rND^sWalch^nG#La pathologie femoropatelaire^lfr#6emes Journées Lyonnaise
s de Chirurgie du Genou^lfr#Lyon#19870000#1987#20110000#08.htm##
00528000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100017000860100
01900103012003900122030002400161710000200185062000800187065000900195064000500204
031000300209014001000212865000900222002000700231#v19n1#V:\SciELO\serial\aob\v19n
1\markup\08.htm#S#c#188#6#article#28#6#^rND^sDejour^nD#^rND^sReynaud^nP#^rND^sLe
coultre^nB#Douleurs et instabilité rotulienne^lfr#Essai de classification#2#Med 
Hyg#19980000#1998#56#1466-1471#20110000#08.htm##
00519000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700100016000890100
01700105012002800122030001500150065000900165064000500174031000300179014000600182
865000900188002000700197035001000204801001500214#v19n1#V:\SciELO\serial\aob\v19n
1\markup\08.htm#S#c#189#7#article#28#7#^rND^sHernadez^nAJ#^rND^sFavaro^nE#^rND^s
Laraya^nMH#Luxação aguda da patela^lpt#Rev Bras Ortop#20040000#2004#39#65-74#201
10000#08.htm#0486-6401#Rev Bras Ortop##
00605000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100016000870100
01700103012006900120030003800189065000900227064000500236031000300241014000700244
865000900251002000700260035001000267801003800277#v19n1#V:\SciELO\serial\aob\v19n
1\markup\08.htm#S#c#190#8#article#28#8#^rND^sTrillat^nA#^rND^sDejour^nH#^rND^sCo
uette^nA#Diagnosis and treatment of recurrent dislocations of the patella^len#Re
v Chir Orthop Reparatrice Appar Mot#19640000#1964#50#813-24#20110000#08.htm#0035
-1040#Rev Chir Orthop Reparatrice Appar Mot##
00422000000000241000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680160017000700180031000870630
00400118066001000122062001800132065000900150064000500159865000900164002000700173
#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#c#191#9#article#28#9#^rND^sSmi
lie^nIS#Injuries of the knee joint^len#2th#Baltimore#Williams &Wilkins#19510000#
1951#20110000#08.htm##
00468000000000253000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720120077000880300
00800165710000200173065000900175064000500184031000300189014000600192865000900198
002000700207#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#c#192#10#article#2
8#10#^rND^sAlbee^nFH#The bone graft wedge in the treatment of habitual dislocati
on of patella^len#Med Rec#2#19150000#1915#88#257-9#20110000#08.htm##
00512000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720120094000920300
01100186710000200197065000900199064000500208031000300213032000800216014000600224
865000900230002000700239#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#c#193#
11#article#28#11#^rND^sBrattstrom^nH#Shape of the intercondylar grove normally a
nd in the recurrent dislocation of the patella^len#Acta Scand#2#19640000#1964#68
#^sSuppl#1-148#20110000#08.htm##
00636000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100017000900120
11100107030003800218065000900256064000500265031000300270032000400273014000500277
865000900282002000700291035001000298801003800308#v19n1#V:\SciELO\serial\aob\v19n
1\markup\08.htm#S#c#194#12#article#28#12#^rND^sMaldague^nB#^rND^sMalghem^nJ#Appo
rt du cliché de profil du genou dans le depistage les instabilittées rotuliennes
: Rapport préliminaire^lfr#Rev Chir Orthop Reparatrice Appar Mot#19850000#1985#7
1#^s2#5-13#20110000#08.htm#0035-1040#Rev Chir Orthop Reparatrice Appar Mot##
00485000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100020000880120
05000108030002000158710000200178065000900180064000500189031000300194014000600197
865000900203002000700212#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#c#195#
13#article#28#13#^rND^sDejour^nD#^rND^sLe Coultre^nB#Osteotomies in patello-femo
ral instabillities^len#Sports Med Arthrosc#2#20070000#2007#15#39-46#20110000#08.
htm##
00469000000000253000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160019000720160016000910160
01500107018004100122066001300163062000900176065000900185064000500194865000900199
002000700208#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#c#196#14#article#2
8#14#^rND^sHougstom^nJC#^rND^sWalsh^nWm#^rND^sPuddu^nG#Patellar subluxation and 
dislocation^len#Philadelphia#Saunders#19840000#1984#20110000#08.htm##
00542000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100019000880100
02000107012007400127030002200201710000200223065000900225064000500234031000400239
014000500243865000900248002000700257#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.
htm#S#c#197#15#article#28#15#^rND^sInsall^nJ#^rND^sBullough^nPG#^rND^sBurnstein^
nAH#Proximal "tube"realignment of the patella for chondromalacia patellae^len#Cl
in Orthop Relat Res#2#19790000#1979#144#63-9#20110000#08.htm##
00547000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100017000900100
01700107010001500124012005300139030002200192710000200214065000900216064000500225
031000400230014000700234865000900241002000700250#v19n1#V:\SciELO\serial\aob\v19n
1\markup\08.htm#S#c#198#16#article#28#16#^rND^sAglietti^nP#^rND^sInsall^nJN#^rND
^sWalker^nPS#^rND^sTrent^nP#A new patella prosthesis: Design and application^len
#Clin Orthop Relat Res#2#19750000#1975#107#175-87#20110000#08.htm##
00628000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100018000870100
01800105010001800123010001900141012006100160030001500221065000900236064000500245
03100030025003200020025301400060025586500090026100200070027003500100027780100150
0287#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#c#199#17#article#28#17#^rN
D^sGali^nJC#^rND^sCaetano^nEB#^rND^sMoreira^nBL#^rND^sGalvão^nMRR#^rND^sOliveira
^nVM#A altura patelar na subluxação femoropatelar em extensão^lpt#Rev Bras Ortop
#19980000#1998#33#4#301-6#20110000#08.htm#0486-6401#Rev Bras Ortop##
00488000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100018000880120
05400106030002200160710000200182065000900184064000500193031000300198014000500201
865000900206002000700215#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#c#200#
18#article#28#18#^rND^sInsall^nJ#^rND^sSalvatti^nE#Recurrent dislocation and the
 high-riding patella^len#Clin Orthop Relat Res#2#19720000#1972#88#67-9#20110000#
08.htm##
00523000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100015000930120
04600108030002100154065000900175064000500184031000300189014000600192865000900198
002000700207035001000214801002100224#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.
htm#S#c#201#19#article#28#19#^rND^sBlackburne^nJS#^rND^sPeel^nTE#A new method of
 measuring patellar height^len#J Bone Joint Surg Br#19770000#1977#59#241-2#20110
000#08.htm#0301-620X#J Bone Joint Surg Br##
00580000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100020000880120
02100108016001600129016001600145018005700161063000300218066001300221062000700234
065000900241064000500250014000700255865000900262002000700271#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\08.htm#S#c#202#20#article#28#20#^rND^sPozzi^nJF#^rND^sKonke
wicz^nER#Joelho do adulto^lpt#^rND^sHebert^nS#^rND^sXavier^nR#Ortopedia e trauma
tologia: princípios e atualizações^lpt#3º#Porto Alegre#Artmed#20030000#2003#444-
72#20110000#08.htm##
00548000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100020000890100
01400109012005500123030001500178065000900193064000500202031000300207014000700210
865000900217002000700226035001000233801001500243#v19n1#V:\SciELO\serial\aob\v19n
1\markup\08.htm#S#c#203#21#article#28#21#^rND^sPozzi^nJFA#^rND^sKonkewicz^nER#^r
ND^sNora^nB#Tratamento cirúrgico das instabilidades rotulianas^lpt#Rev Bras Orto
p#19930000#1993#28#277-83#20110000#08.htm#0486-6401#Rev Bras Ortop##
00585000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720120108000870300
03800195065000900233064000500242031000300247014000500250865000900255002000700264
035001000271801003800281#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#c#204#
22#article#28#22#^rND^sMasse^nY#Trochleoplasty: Restoration of the intercondylar
 groove in subluxations and dislocations of the patella^len#Rev Chir Orthop Repa
ratrice Appar Mot#19780000#1978#64#3-17#20110000#08.htm#0035-1040#Rev Chir Ortho
p Reparatrice Appar Mot##
00606000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100015000880100
01700103010001800120012004100138030003800179065000900217064000500226031000300231
014000600234865000900240002000700249035001000256801003800266#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\08.htm#S#c#205#23#article#28#23#^rND^sDejour^nH#^rND^sWalch
^nG#^rND^sNeyret^nPh#^rND^sAdeleine^nP#La dysplasia de la trochlée femorale^les#
Rev Chir Orthop Reparatrice Appar Mot#19900000#1990#76#45-54#20110000#08.htm#003
5-1040#Rev Chir Orthop Reparatrice Appar Mot##
00480000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720120031000900300
02100121065000900142064000500151031000300156014000800159865000900167002000700176
035001000183801002100193#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.htm#S#c#206#
24#article#28#24#^rND^sHughston^nJ#Subluxation of the patella^len#J Bone Joint S
urg Am#19680000#1968#50#1003-26#20110000#08.htm#0021-9355#J Bone Joint Surg Am##
00514000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160024000720180119000960510
00600215050003300221045000900254044000500263865000900268002000700277#v19n1#V:\Sc
iELO\serial\aob\v19n1\markup\08.htm#S#c#207#25#article#28#25#^rND^sNove-Josseran
d^nl#Les facteurs de l'instabilité rotulienne objective: Etude dês scanners pré 
et post-operatoire. A propôs de 143 cas^lfr#thése#Universidade de Medicina de Ly
on#19910000#1991#20110000#08.htm##
00564000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100015000880120
04200103030003800145065000900183064000500192031000300197032000400200014000600204
865000900210002000700219035001000226801003800236#v19n1#V:\SciELO\serial\aob\v19n
1\markup\08.htm#S#c#208#26#article#28#26#^rND^sDejour^nH#^rND^sWalch^nG#Les fact
eurs d'instabilité rotulliene^lfr#Rev Chir Orthop Reparatrice Appar Mot#19890000
#1989#75#^s1#141-2#20110000#08.htm#0035-1040#Rev Chir Orthop Reparatrice Appar M
ot##
00500000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100018000880120
04600106030001000152065000900162064000500171031000400176014000600180865000900186
002000700195035001000202801001000212#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.
htm#S#c#209#27#article#28#27#^rND^sInsall^nJ#^rND^sSalvatti^nE#Patella junction 
in the normal knee joint^len#Radiology#19710000#1971#101#101-4#20110000#08.htm#0
033-8419#Radiology##
00500000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100015000890120
02500104030002100129065000900150064000500159031000300164014000800167865000900175
002000700184035001000191801002100201#v19n1#V:\SciELO\serial\aob\v19n1\markup\08.
htm#S#c#210#28#article#28#28#^rND^sColvin^nAC#^rND^sWest^nRV#Patellar instabilit
y^len#J Bone Joint Surg Am#20080000#2008#90#2751-62#20110000#08.htm#0021-9355#J 
Bone Joint Surg Am##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v19n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#o#1#1#article#1#201104
11#111907#09.htm#167##
04343000000000649000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083121000300087049000700090158000300097030001800100
03100030011803200020012106500090012301400090013203500100014101200980015101200750
02490100040003240100034003640100040003980100028004380100037004660100035005030100
03700538070012200575083133800697085000802035085002402043085003602067085001802103
08500360212108313670215708500080352408500240353208500300355608500210358608500340
36071170006036410720003036471120009036501110009036591140009036681130009036770020
00703686#v19n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#h#2#1#article#1#oa#pt#
br1.1#1#4.0#TAB#09#AOB140#nd#Acta ortop. bras.#19#1#20110000#^f41^l44#1413-7852#
Tratamento artroscópico da instabilidade anterior do ombro: estudo retrospectivo
 de 159 casos^lpt#Anterior instability of the shoulder: retrospective study on 1
59 cases^len#^rND^1A01^nArnaldo Amado^sFerreira Neto#^rND^1A01^nGilberto Luis^sC
amanho#^rND^1A01^nAlessandro Monterroso^sFelix#^rND^1A01^nEduardo^sBenegas#^rND^
1A01^nAlexandre Carneiro^sBitar#^rND^1A01^nLucas Busnardo^sRamadan#^rND^1A01^nEd
uardo Angeli^sMalavolta#FMUSP^iA01^1Department of Orthopedics and Traumatology^2
Laboratory of Medical Investigation of the Musculoskeletal System#^lpt^aOBJETIVO
: Análise dos resultados de 159 pacientes com instabilidade anterior do ombro su
bmetidos ao tratamento artroscópico de janeiro de 2001 a dezembro de 2005. MÉTOD
OS: Estudo retrospectivo de prontuários com dados completos. RESULTADOS: Em 108 
pacientes notou-se a lesão de Bankart e em 62 pacientes a lesão do tipo SLAP est
ava presente. Utilizou-se em média 2,7 âncoras. Apresentaram complicações 42 cas
os; 14 tinham dor aos esforços, 12 tinham algum grau de diminuição da rotação ex
terna, 16 apresentaram recidiva. Os pacientes que evoluíram com complicações uti
lizaram em média 2,5 âncoras, enquanto naqueles sem complicações a média foi de 
2,8 (p<0,05). De 35 pacientes com lesão óssea da borda anterior da glenóide 8 ti
veram recidiva e de 124 casos sem fratura 8 recidivaram (p<0,05). De 113 pacient
es com primo-luxação traumática 12 evoluíram com limitação da rotação externa en
quanto em 46 casos atraumáticos nenhum apresentou limitação (p<0,05). Dos casos 
que apresentavam lesão SLAP 11 evoluíram com dor, enquanto que nos casos sem est
a lesão três apresentaram dor (p<0,05). CONCLUSÃO: Houve maior índice de recidiv
a na presença da lesão óssea da borda anterior da glenóide. Dor pós-operatória f
oi mais frequente quando presente a lesão SLAP. Limitação da rotação externa est
á relacionada com instabilidade traumática.#^dnd^i1#^tm^lpt^kArtroscopia^i1#^tm^
lpt^kInstabilidade articular^i1#^tm^lpt^kOmbro^i1#^tm^lpt^kEstudos retroscpectiv
os^i1#^len^aOBJECTIVE: To analyze the results of 159 patients with anterior inst
ability of the shoulder submitted to arthroscopic treatment from January 2001 to
 December 2005. METHODS: Retrospective study of complete patient records. RESULT
S: In 108 patients the Bankart lesion was found, while in 62 patients, SLAP type
 lesions were found. An average of 2.7 anchors was used. 42 cases presented comp
lications; 14 had pain on effort, 12 had some degree of reduction of external ro
tation, and 16 had recorrence. The patients who developed complications used an 
average of 2.5 anchors, while those without complications used an average of 2.8
 anchors (p<0.05). Of the 35 patients with anterior glenoid bone lesion, 8 had r
ecorrence, while of the 124 patients without fractures, 8 had recorrence (p<0.05
). Of the 113 patients with first-time traumatic dislocations, 12 developed limi
tation of external rotation, while in 46 atraumatic cases none developed limitat
ion (p<0.05). Of the patients with SLAP lesion, 11 developed pain, while in the 
cases without this lesion, only 3 presented pain (p<0.05). CONCLUSION: There wer
e more recurrences (deveria ser plural e recurrences, nao recurrence) in cases o
f anterior glenoid bone lesion. Post-operative pain was more frequent when the l
esion type was SLAP. Limitation of external rotation is associated to traumatic 
instability.#^dnd^i2#^tm^len^kArthroscopy^i2#^tm^len^kJoint instability^i2#^tm^l
en^kShoulder^i2#^tm^len^kRetrospective studies^i2#other#26#20080807#07/08/08#200
80922#22/09/08#09.htm##
04451000000000649000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083121000300087049000700090158000300097030001800100
03100030011803200020012106500090012301400090013203500100014101201120015101200890
02630100040003520100034003920100040004260100028004660100037004940100035005310100
03700566070012200603083137800725085000802103085002402111085003602135085001802171
08500360218908314070222508500080363208500240364008500300366408500210369408500340
37151170006037490720003037551120009037581110009037671140009037761130009037850020
00703794#v19n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#f#3#1#article#1#oa#pt#
br1.1#1#4.0#TAB#09#AOB140#nd#Acta ortop. bras.#19#1#20110000#^f41^l44#1413-7852#
<b>Tratamento artroscópico da instabilidade anterior do ombro</b>: <b>estudo ret
rospectivo de 159 casos</b>^lpt#<b>Anterior instability of the shoulder</b>: <b>
retrospective study on 159 cases</b>^len#^rND^1A01^nArnaldo Amado^sFerreira Neto
#^rND^1A01^nGilberto Luis^sCamanho#^rND^1A01^nAlessandro Monterroso^sFelix#^rND^
1A01^nEduardo^sBenegas#^rND^1A01^nAlexandre Carneiro^sBitar#^rND^1A01^nLucas Bus
nardo^sRamadan#^rND^1A01^nEduardo Angeli^sMalavolta#FMUSP^iA01^1Department of Or
thopedics and Traumatology^2Laboratory of Medical Investigation of the Musculosk
eletal System#^lpt^a<b>OBJETIVO:</b> Análise dos resultados de 159 pacientes com
 instabilidade anterior do ombro submetidos ao tratamento artroscópico de janeir
o de 2001 a dezembro de 2005. <b>MÉTODOS:</b> Estudo retrospectivo de prontuário
s com dados completos. <b>RESULTADOS:</b> Em 108 pacientes notou-se a lesão de B
ankart e em 62 pacientes a lesão do tipo SLAP estava presente. Utilizou-se em mé
dia 2,7 âncoras. Apresentaram complicações 42 casos; 14 tinham dor aos esforços,
 12 tinham algum grau de diminuição da rotação externa, 16 apresentaram recidiva
. Os pacientes que evoluíram com complicações utilizaram em média 2,5 âncoras, e
nquanto naqueles sem complicações a média foi de 2,8 (p&lt;0,05). De 35 paciente
s com lesão óssea da borda anterior da glenóide 8 tiveram recidiva e de 124 caso
s sem fratura 8 recidivaram (p&lt;0,05). De 113 pacientes com primo-luxação trau
mática 12 evoluíram com limitação da rotação externa enquanto em 46 casos atraum
áticos nenhum apresentou limitação (p&lt;0,05). Dos casos que apresentavam lesão
 SLAP 11 evoluíram com dor, enquanto que nos casos sem esta lesão três apresenta
ram dor (p&lt;0,05). <b>CONCLUSÃO:</b> Houve maior índice de recidiva na presenç
a da lesão óssea da borda anterior da glenóide. Dor pós-operatória foi mais freq
uente quando presente a lesão SLAP. Limitação da rotação externa está relacionad
a com instabilidade traumática.#^dnd^i1#^tm^lpt^kArtroscopia^i1#^tm^lpt^kInstabi
lidade articular^i1#^tm^lpt^kOmbro^i1#^tm^lpt^kEstudos retroscpectivos^i1#^len^a
<b>OBJECTIVE:</b> To analyze the results of 159 patients with anterior instabili
ty of the shoulder submitted to arthroscopic treatment from January 2001 to Dece
mber 2005. <b>METHODS:</b> Retrospective study of complete patient records. <b>R
ESULTS:</b> In 108 patients the Bankart lesion was found, while in 62 patients, 
SLAP type lesions were found. An average of 2.7 anchors was used. 42 cases prese
nted complications; 14 had pain on effort, 12 had some degree of reduction of ex
ternal rotation, and 16 had recorrence. The patients who developed complications
 used an average of 2.5 anchors, while those without complications used an avera
ge of 2.8 anchors (p&lt;0.05). Of the 35 patients with anterior glenoid bone les
ion, 8 had recorrence, while of the 124 patients without fractures, 8 had recorr
ence (p&lt;0.05). Of the 113 patients with first-time traumatic dislocations, 12
 developed limitation of external rotation, while in 46 atraumatic cases none de
veloped limitation (p&lt;0.05). Of the patients with SLAP lesion, 11 developed p
ain, while in the cases without this lesion, only 3 presented pain (p&lt;0.05). 
<b>CONCLUSION:</b> There were more recurrences (deveria ser plural e recurrences
, nao recurrence) in cases of anterior glenoid bone lesion. Post-operative pain 
was more frequent when the lesion type was SLAP. Limitation of external rotation
 is associated to traumatic instability.#^dnd^i2#^tm^len^kArthroscopy^i2#^tm^len
^kJoint instability^i2#^tm^len^kShoulder^i2#^tm^len^kRetrospective studies^i2#ot
her#26#20080807#07/08/08#20080922#22/09/08#09.htm##
04464000000000673000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000400090121000300094049000700097158000300104
03000170010703100030012403200020012706500090012901400090013803500100014701200980
01570120075002550100040003300100034003700100040004040100028004440100037004720100
03500509010003700544070012400581083133800705085000802043085002402051085003602075
08500180211108500360212908313670216508500080353208500240354008500300356408500210
35940850034036151170006036490720003036551120009036581110009036671140009036761130
00903685002000703694008008903701#v19n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#
S#l#4#1#article#1#^a2011#oa#pt#br1.1#1#4.0#tab#09#AOB140#nd#Acta ortop. bras#19#
1#20110000#^f41^l44#1413-7852#Tratamento artroscópico da instabilidade anterior 
do ombro: estudo retrospectivo de 159 casos^lpt#Anterior instability of the shou
lder: retrospective study on 159 cases^len#^rND^1A01^nArnaldo Amado^sFerreira Ne
to#^rND^1A01^nGilberto Luis^sCamanho#^rND^1A01^nAlessandro Monterroso^sFelix#^rN
D^1A01^nEduardo^sBenegas#^rND^1A01^nAlexandre Carneiro^sBitar#^rND^1A01^nLucas B
usnardo^sRamadan#^rND^1A01^nEduardo Angeli^sMalavolta#^iA01^1FMUSP^2Department o
f Orthopedics and Traumatology^3Laboratory of Medical Investigation of the Muscu
loskeletal System#^lpt^aOBJETIVO: Análise dos resultados de 159 pacientes com in
stabilidade anterior do ombro submetidos ao tratamento artroscópico de janeiro d
e 2001 a dezembro de 2005. MÉTODOS: Estudo retrospectivo de prontuários com dado
s completos. RESULTADOS: Em 108 pacientes notou-se a lesão de Bankart e em 62 pa
cientes a lesão do tipo SLAP estava presente. Utilizou-se em média 2,7 âncoras. 
Apresentaram complicações 42 casos; 14 tinham dor aos esforços, 12 tinham algum 
grau de diminuição da rotação externa, 16 apresentaram recidiva. Os pacientes qu
e evoluíram com complicações utilizaram em média 2,5 âncoras, enquanto naqueles 
sem complicações a média foi de 2,8 (p<0,05). De 35 pacientes com lesão óssea da
 borda anterior da glenóide 8 tiveram recidiva e de 124 casos sem fratura 8 reci
divaram (p<0,05). De 113 pacientes com primo-luxação traumática 12 evoluíram com
 limitação da rotação externa enquanto em 46 casos atraumáticos nenhum apresento
u limitação (p<0,05). Dos casos que apresentavam lesão SLAP 11 evoluíram com dor
, enquanto que nos casos sem esta lesão três apresentaram dor (p<0,05). CONCLUSÃ
O: Houve maior índice de recidiva na presença da lesão óssea da borda anterior d
a glenóide. Dor pós-operatória foi mais frequente quando presente a lesão SLAP. 
Limitação da rotação externa está relacionada com instabilidade traumática.#^dnd
^i1#^tm^lpt^kArtroscopia^i1#^tm^lpt^kInstabilidade articular^i1#^tm^lpt^kOmbro^i
1#^tm^lpt^kEstudos retroscpectivos^i1#^len^aOBJECTIVE: To analyze the results of
 159 patients with anterior instability of the shoulder submitted to arthroscopi
c treatment from January 2001 to December 2005. METHODS: Retrospective study of 
complete patient records. RESULTS: In 108 patients the Bankart lesion was found,
 while in 62 patients, SLAP type lesions were found. An average of 2.7 anchors w
as used. 42 cases presented complications; 14 had pain on effort, 12 had some de
gree of reduction of external rotation, and 16 had recorrence. The patients who 
developed complications used an average of 2.5 anchors, while those without comp
lications used an average of 2.8 anchors (p<0.05). Of the 35 patients with anter
ior glenoid bone lesion, 8 had recorrence, while of the 124 patients without fra
ctures, 8 had recorrence (p<0.05). Of the 113 patients with first-time traumatic
 dislocations, 12 developed limitation of external rotation, while in 46 atrauma
tic cases none developed limitation (p<0.05). Of the patients with SLAP lesion, 
11 developed pain, while in the cases without this lesion, only 3 presented pain
 (p<0.05). CONCLUSION: There were more recurrences (deveria ser plural e recurre
nces, nao recurrence) in cases of anterior glenoid bone lesion. Post-operative p
ain was more frequent when the lesion type was SLAP. Limitation of external rota
tion is associated to traumatic instability.#^dnd^i2#^tm^len^kArthroscopy^i2#^tm
^len^kJoint instability^i2#^tm^len^kShoulder^i2#^tm^len^kRetrospective studies^i
2#other#26#20080807#07/08/08#20080922#22/09/08#09.htm#Internet^ihttp://www.sciel
o.br/scielo.php?script=sci_arttext&pid=S1413-78522011000100009##
00343000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704012300067002000700190#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#5#1#article#137#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTIGO    ORIGINAL</b> </fon
t></p>     ^cY#09.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#6#2#article#137#<p>&nbsp;</p>     ^cY#09.htm
##
00434000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704021400067002000700281#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#7#3#article#137#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Tratamento    artrosc&oa
cute;pico da instabilidade anterior do ombro. estudo retrospectivo    de 159 cas
os</b></font></p>     ^cY#09.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#8#4#article#137#<p>&nbsp;</p>     ^cY#09.htm
##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#9#5#article#137#<p>&nbsp;</p>     ^cY#09.htm
##
00489000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704026800068002000700336#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#10#6#article#137#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Arnaldo Amado    Ferreira Neto; Gilberto 
Luis Camanho; Alessandro Monterroso Felix; Eduardo Benegas;    Alexandre Carneir
o Bitar; Lucas Busnardo Ramadan; Eduardo Angeli Malavolta</b></font></p>     ^cY
#09.htm##
00442000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704022100068002000700289#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#11#7#article#137#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2">Laboratory of Medical    Investigation of th
e Musculoskeletal System - LIM41 of the Department of Orthopedics    and Traumat
ology of FMUSP</font></p>     ^cY#09.htm##
00369000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704014800068002000700216#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#12#8#article#137#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><a href="#back">Endere&ccedil;o    para Corr
espond&ecirc;ncia</a></font></p>     ^cY#09.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#13#9#article#137#<p>&nbsp;</p>     ^cY#09.ht
m##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#14#10#article#137#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#09.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#15#11#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#09.htm##
00485000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704026300069002000700332#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#16#12#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    An&aacute;lise dos resu
ltados de 159 pacientes com instabilidade anterior do    ombro submetidos ao tra
tamento artrosc&oacute;pico de janeiro de 2001 a dezembro    de 2005.    ^cY#09.
htm##
00326000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010400069002000700173#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#17#13#article#137#<br>   <b>M&Eacute;TODOS:<
/b> Estudo retrospectivo de prontu&aacute;rios com dados    completos.    ^cY#09
.htm##
01409000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704118700069002000701256#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#18#14#article#137#<br>   <b>RESULTADOS:</b> 
Em 108 pacientes notou-se a les&atilde;o de Bankart e em    62 pacientes a les&a
tilde;o do tipo SLAP estava presente. Utilizou-se em m&eacute;dia    2,7 &acirc;
ncoras. Apresentaram complica&ccedil;&otilde;es 42 casos; 14 tinham    dor aos e
sfor&ccedil;os, 12 tinham algum grau de diminui&ccedil;&atilde;o da    rota&cced
il;&atilde;o externa, 16 apresentaram recidiva. Os pacientes que evolu&iacute;ra
m    com complica&ccedil;&otilde;es utilizaram em m&eacute;dia 2,5 &acirc;ncoras
,    enquanto naqueles sem complica&ccedil;&otilde;es a m&eacute;dia foi de 2,8 
(p&lt;0,05).    De 35 pacientes com les&atilde;o &oacute;ssea da borda anterior 
da glen&oacute;ide    8 tiveram recidiva e de 124 casos sem fratura 8 recidivara
m (p&lt;0,05). De    113 pacientes com primo-luxa&ccedil;&atilde;o traum&aacute;
tica 12 evolu&iacute;ram    com limita&ccedil;&atilde;o da rota&ccedil;&atilde;o
 externa enquanto em 46    casos atraum&aacute;ticos nenhum apresentou limita&cc
edil;&atilde;o (p&lt;0,05).    Dos casos que apresentavam les&atilde;o SLAP 11 e
volu&iacute;ram com dor, enquanto    que nos casos sem esta les&atilde;o tr&ecir
c;s apresentaram dor (p&lt;0,05).    ^cY#09.htm##
00613000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704039100069002000700460#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#19#15#article#137#<br>   <b>CONCLUS&Atilde;O
:</b> Houve maior &iacute;ndice de recidiva na presen&ccedil;a    da les&atilde;
o &oacute;ssea da borda anterior da glen&oacute;ide. Dor p&oacute;s-operat&oacut
e;ria    foi mais frequente quando presente a les&atilde;o SLAP. Limita&ccedil;&
atilde;o    da rota&ccedil;&atilde;o externa est&aacute; relacionada com instabi
lidade traum&aacute;tica.</font></p>     ^cY#09.htm##
00419000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704019700069002000700266#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#20#16#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Descritores:</b>    Artroscopia. Instabi
lidade articular. Ombro. Estudos retroscpectivos.</font></p> <hr size="1" noshad
e>     ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#21#17#article#137#<p>&nbsp;</p>     ^cY#09.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#22#18#article#137#<p>&nbsp;</p>     ^cY#09.h
tm##
00336000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011400069002000700183#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#23#19#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b></font></p> 
    ^cY#09.htm##
01521000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704129900069002000701368#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#24#20#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A instabilidade    glenoumeral anterior &ea
cute; a mais comum das instabilidades da articula&ccedil;&atilde;o    glenoumera
l. Diversos estudos mostram a import&acirc;ncia das estruturas c&aacute;psulo-li
gamentares    &acirc;ntero-inferiores na manuten&ccedil;&atilde;o da estabilidad
e articular<sup>1-4</sup>.    O l&aacute;bio glenoidal &eacute; importante estru
tura estabilizadora aumentando    a congru&ecirc;ncia da cavidade glen&oacute;id
e em rela&ccedil;&atilde;o &agrave;    cabe&ccedil;a do &uacute;mero e, na sua p
or&ccedil;&atilde;o &acirc;ntero-inferior,    serve como ponto de ancoragem para
 o ligamento glenoumeral inferior, que &eacute;    o &uacute;ltimo elemento esta
bilizador do ombro na posi&ccedil;&atilde;o de    abdu&ccedil;&atilde;o e rota&c
cedil;&atilde;o externa. Perthes<sup>5</sup> foi    um dos primeiros a descrever
 a avuls&atilde;o dessas estruturas da borda anterior    da glen&oacute;ide como
 sendo causa de luxa&ccedil;&otilde;es recidivantes.    Posteriormente Bankart<s
up>6</sup> descreve as mesmas les&otilde;es e o princ&iacute;pio    do tratament
o da instabilidade do ombro que consiste no reparo destas les&otilde;es    resta
urando a anatomia do complexo capsulolabioligamentar.</font></p>     ^cY#09.htm#
#
01382000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704116000069002000701229#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#25#21#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Estudos biomec&acirc;nicos    e achados int
ra-operat&oacute;rios mostraram que, na instabilidade do ombro,    a les&atilde;
o de Bankart est&aacute; presente em aproximadamente 80% dos casos.<sup>7,8</sup
>    O tratamento preconizado para os casos de luxa&ccedil;&otilde;es recidivant
es    e, segundo alguns autores, ap&oacute;s a primoluxa&ccedil;&atilde;o traum&
aacute;tica    no jovem (quando os &iacute;ndices de recidiva chegam a 80%)<sup>
7</sup> &eacute;    o cir&uacute;rgico. Esta interven&ccedil;&atilde;o tradicion
almente era feita    por via aberta, com bons resultados e baixo &iacute;ndice d
e recidiva.<sup>9,10</sup>    As desvantagens desta t&eacute;cnica em rela&ccedi
l;&atilde;o &agrave; artrosc&oacute;pica    s&atilde;o: maior agress&atilde;o ci
r&uacute;rgica levando a maior ader&ecirc;ncia    e consequente diminui&ccedil;&
atilde;o da rota&ccedil;&atilde;o externa; fraqueza    do tend&atilde;o subescap
ular, devido &agrave; necessidade de sua abordagem;    maior possibilidade de le
s&atilde;o do nervo axilar e risco de infec&ccedil;&atilde;o.<sup>11</sup></font
></p>     ^cY#09.htm##
01036000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704081400069002000700883#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#26#22#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A artroscopia pela    menor agress&atilde;o
 cir&uacute;rgica e baixa morbidade passou a ser mais indicada    como procedime
nto no tratamento da instabilidade do ombro. Inicialmente, as    formas de fixa&
ccedil;&atilde;o das estruturas capsulolabioligamentares eram    inadequadas, le
vando a altos &iacute;ndices de recorr&ecirc;ncia. Com o desenvolvimento    tecn
ol&oacute;gico de novos materiais cir&uacute;rgicos (&acirc;ncoras de fixa&ccedi
l;&atilde;o    e passadores de sutura) e com o pr&oacute;prio avan&ccedil;o das 
t&eacute;cnicas    cir&uacute;rgicas artrosc&oacute;picas consegue-se hoje repro
duzir a repara&ccedil;&atilde;o    das les&otilde;es de maneira muito semelhante
 a que era feita por via aberta.<sup>12-15</sup></font></p>     ^cY#09.htm##
00666000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704044400069002000700513#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#27#23#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Atualmente, o uso    do atualmente o uso da
 artroscopia &eacute; preferida para o tratamento da instabilidade    anterior d
o ombro, na maioria dos casos, sendo contra-indicado na presen&ccedil;a    de le
s&otilde;es &oacute;sseas significativas (glen&oacute;ide em forma de p&ecirc;ra
    invertida e a les&atilde;o de Hill-Sachs do tipo "engaging").<sup>16</sup></
font></p>     ^cY#09.htm##
00530000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704030800069002000700377#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#28#24#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O objetivo do presente    estudo foi avalia
r o resultado das cirurgias realizadas por via artrosc&oacute;pica    no nosso s
ervi&ccedil;o, em pacientes com instabilidade anterior sem les&atilde;o    &oacu
te;ssea significativa.</font></p>     ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#29#25#article#137#<p>&nbsp;</p>     ^cY#09.h
tm##
00341000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011900069002000700188#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#30#26#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>MATERIAIS E    M&Eacute;TODOS</b></font>
</p>     ^cY#09.htm##
00742000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704052000069002000700589#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#31#27#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Foram avaliados    190 pacientes, de maneir
a retrospectiva, atrav&eacute;s de revis&atilde;o de    prontu&aacute;rios. Todo
s apresentavam instabilidade anterior do ombro, tendo    sido submetidos ao trat
amento cir&uacute;rgico por via artrosc&oacute;pica,    como primeira op&ccedil;
&atilde;o, no per&iacute;odo de janeiro de 2001 a dezembro    de 2005. Os dados 
foram coletados no per&iacute;odo de outubro de 2006 a janeiro    de 2007.</font
></p>     ^cY#09.htm##
01320000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704109800069002000701167#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#32#28#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Todos os prontu&aacute;rios    inclu&iacute
;dos no protocolo apresentaram as seguintes informa&ccedil;&otilde;es:    data d
e nascimento do paciente, data do procedimento cir&uacute;rgico, anamnese    com
 relato bem caracterizado do quadro de instabilidade traum&aacute;tica ou    atr
aum&aacute;tica, queixa &aacute;lgica e limita&ccedil;&atilde;o funcional;    ex
ame f&iacute;sico pr&eacute;-operat&oacute;rio com busca ativa por sinais    de 
instabilidade, resultado dos exames de imagem pr&eacute;-operat&oacute;rios,    
descri&ccedil;&atilde;o cir&uacute;rgica com inspe&ccedil;&atilde;o articular   
 e busca por les&otilde;es &oacute;sseas, capsulares, de manguito rotador e SLAP
    e n&uacute;mero de &acirc;ncoras utilizadas, avalia&ccedil;&atilde;o avalia&
ccedil;&atilde;o    p&oacute;s-operat&oacute;ria com pelo menos 12 meses de segu
imento buscando    queixas, sinais cl&iacute;nicos e de exame f&iacute;sico de l
imita&ccedil;&atilde;o    funcional e de rota&ccedil;&atilde;o externa, instabil
idade e dor.</font></p>     ^cY#09.htm##
00567000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704034500069002000700414#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#33#29#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Todos os pacientes    foram submetidos a ra
diografias. Exames complementares tamb&eacute;m foram realizados    de rotina, v
ariando entre a Resson&acirc;ncia Magn&eacute;tica (a maioria),    Artro-Resson&
acirc;ncia e Artro-Tomografia. (<a href="#an1">Anexo 1</a>)</font></p>     ^cY#0
9.htm##
00256000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003400069002000700103#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#34#30#article#137#<p><a name="an1"></a></p> 
    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#35#31#article#137#<p>&nbsp;</p>     ^cY#09.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#36#32#article#137#<p align="center"><img src
="/img/revistas/aob/v19n1/09an1.jpg"></p>     ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#37#33#article#137#<p>&nbsp;</p>     ^cY#09.h
tm##
00833000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704061100069002000700680#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#38#34#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Adotamos os seguintes    crit&eacute;rios p
ara contra-indicar o reparo artrosc&oacute;pico da instabilidade    glenoumeral 
anterior: perda &oacute;ssea maior que 25% da glen&oacute;ide, les&atilde;o    d
a superf&iacute;cie articular da cabe&ccedil;a umeral (avaliada por tomografia) 
   que fizesse contato com a borda anterior da glen&oacute;ide podendo reproduzi
r    a posi&ccedil;&atilde;o de luxa&ccedil;&atilde;o e les&atilde;o por avuls&a
tilde;o    do ligamento glenoumeral inferior do colo anat&ocirc;mico do &uacute;
mero.</font></p>     ^cY#09.htm##
01299000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704107700069002000701146#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#39#35#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Todos os pacientes    foram operados em pos
i&ccedil;&atilde;o de cadeira de praia. Os portais artrosc&oacute;picos    utili
zados foram os convencionais (posterior, anterior e antero-lateral), com    flux
o de irriga&ccedil;&atilde;o mantido. Inicialmente todas as estruturas eram    s
istematicamente inventariadas. Realizava-se a libera&ccedil;&atilde;o capsulolab
ial    do colo da glen&oacute;ide e a seguir o debridamento da borda labial. A p
r&oacute;xima    etapa era a cruenta&ccedil;&atilde;o suave da borda e do colo d
a glen&oacute;ide,    seguida da coloca&ccedil;&atilde;o de duas a quatro &acirc
;ncoras (na grande    maioria met&aacute;lica), dependendo do tamanho da les&ati
lde;o, com fio multifilamentar    inabsorv&iacute;vel, junto ao limite da superf
&iacute;cie articular da glen&oacute;ide,    realizando-se a sutura com o tecido
 capsulolabial. A capsuloplastia era realizada    quando havia frouxid&atilde;o 
capsular, eliminando a redund&acirc;ncia da c&aacute;psula    inferior.</font></
p>     ^cY#09.htm##
00532000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704031000069002000700379#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#40#36#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Quando presente    a les&atilde;o SLAP inst
&aacute;vel era abordada inicialmente com o seu desbridamento    junto a cabe&cc
edil;a longa do b&iacute;ceps, e fixada com uma ou duas &acirc;ncoras    posicio
nadas entre 11 e 1 hora.</font></p>     ^cY#09.htm##
01008000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704078600069002000700855#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#41#37#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Todos os pacientes    tiveram o mesmo proto
colo de reabilita&ccedil;&atilde;o. Durante as primeiras    tr&ecirc;s semanas, 
mantinha-se a imobiliza&ccedil;&atilde;o do ombro com a    tip&oacute;ia do tipo
 Velpeau, e trabalhava-se movimenta&ccedil;&atilde;o do    punho e cotovelo; som
ente eram permitidos movimentos pendulares do ombro. Ap&oacute;s    esse per&iac
ute;odo, eram iniciados movimentos passivos, sendo liberada a rota&ccedil;&atild
e;o    externa al&eacute;m de 20° apenas ap&oacute;s a sexta semana. Exerc&iacut
e;cios    de fortalecimento eram iniciados quando o arco de movimento se aproxim
ava do    normal, ao redor de 3 meses, e o retorno para atividades ocorria ao re
dor de    5-6 meses.</font></p>     ^cY#09.htm##
01082000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704086000069002000700929#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#42#38#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Para a coleta dos    dados, foi elaborado u
m protocolo que deveria ser preenchido &agrave; an&aacute;lise    de cada prontu
&aacute;rio contendo informa&ccedil;&otilde;es pr&eacute;-determinadas.    Na an
&aacute;lise dos resultados foram exclu&iacute;dos 21 pacientes por apresentarem
    dados incompletos no prontu&aacute;rio, restando 159 casos. Cento e quarenta
    e sete pacientes (92,5%) eram homens e 12 (7,5%) mulheres; 113 (71%) tiveram
    o primeiro epis&oacute;dio traum&aacute;tico e 46 (29%) atraum&aacute;tico; 
   19 pacientes foram operados ap&oacute;s o primeiro epis&oacute;dio de luxa&cc
edil;&atilde;o.    A idade variou de 16 a 71 anos (m&eacute;dia 29); o tempo de 
seguimento p&oacute;s-operat&oacute;rio    variou de 12 a 72 meses (m&eacute;dia
 de 37 meses).</font></p>     ^cY#09.htm##
01047000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704082500069002000700894#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#43#39#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Durante a avalia&ccedil;&atilde;o    dos da
dos p&oacute;s-operat&oacute;rios considerou-se os relatos subjetivos    dos pac
ientes que se queixaram de dor, limita&ccedil;&atilde;o na atividade    cotidian
a, sensa&ccedil;&atilde;o de inseguran&ccedil;a e novos epis&oacute;dios    de l
uxa&ccedil;&atilde;o e subluxa&ccedil;&atilde;o al&eacute;m de dados objetivos  
  de exame f&iacute;sico com testes espec&iacute;ficos para avaliar instabilidad
e    e amplitude de movimento. N&atilde;o houve re-convoca&ccedil;&atilde;o dos 
pacientes,    mas s&oacute; foram inclu&iacute;dos no protocolo aqueles que apre
sentavam estas    informa&ccedil;&otilde;es bem descritas em retorno ambulatoria
l com pelo menos    um ano de p&oacute;s-operat&oacute;rio.</font></p>     ^cY#0
9.htm##
00644000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704042200069002000700491#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#44#40#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Os dados obtidos    foram sistematicamente 
cruzados buscando rela&ccedil;&atilde;o de causalidade    e a valida&ccedil;&ati
lde;o estat&iacute;stica foi pelo teste de chi quadrado    e pelo teste de Fishe
r no caso das vari&aacute;veis qualitativas e as quantitativas    pelo teste-t c
om duas amostras presumindo vari&acirc;ncias diferentes.</font></p>     ^cY#09.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#45#41#article#137#<p>&nbsp;</p>     ^cY#09.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#46#42#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>     ^cY#09.htm
##
02649000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704242700069002000702496#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#47#43#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Em 108 (69%) pacientes    estava presente a
 les&atilde;o de Bankart e em 62 (39%) havia associa&ccedil;&atilde;o    com a l
es&atilde;o do tipo SLAP. Foram utilizadas em m&eacute;dia 2,7 &acirc;ncoras    
por paciente, sendo a maioria met&aacute;lica. Quarenta e dois pacientes (26,5%)
    apresentaram as seguintes complica&ccedil;&otilde;es: 14 (8,8%) tinham dor a
os    esfor&ccedil;os; 12 (7,5%) evolu&iacute;ram com algum grau de diminui&cced
il;&atilde;o    da rota&ccedil;&atilde;o externa; 16 (10%) apresentaram recidiva
 (10 - 6,2%    - com sinal da apreens&atilde;o sem luxa&ccedil;&atilde;o e 6 - 3
,8% - com luxa&ccedil;&atilde;o).    Os casos que evolu&iacute;ram com recidiva 
utilizaram em m&eacute;dia 2,5 &acirc;ncoras,    enquanto naqueles em que n&atil
de;o houve recidiva a m&eacute;dia foi de 2,8    &acirc;ncoras. Nos pacientes em
 que o primeiro epis&oacute;dio foi traum&aacute;tico    12 (10,6%) tiveram reci
diva, e quando atraum&aacute;tico quatro recidivaram    (8,6%). Entre os operado
s ap&oacute;s o primeiro epis&oacute;dio de luxa&ccedil;&atilde;o    apenas um (
5,2%) apresentou recidiva. Naqueles submetidos &agrave; artroscopia,    que tive
ram v&aacute;rios epis&oacute;dios de luxa&ccedil;&atilde;o, 15 (10,7%)    apres
entaram recidivas. Nos pacientes que tinham les&atilde;o de Bankart 14    (13%) 
apresentaram recidivas ou sinais de instabilidade. Naqueles sem esta les&atilde;
o    somente dois (3,9%) se queixaram de recidivas. Nos pacientes com les&atilde
;o    &oacute;ssea da borda anterior da glen&oacute;ide (35) oito (22,8%) recidi
varam    e sem esta les&atilde;o oito (6,4%) de 124 pacientes tiveram recidivas 
(p&lt;0,05).    (<a href="#t1">Tabela 1</a>) Naqueles com primo-luxa&ccedil;&ati
lde;o traum&aacute;tica    (113) 12 (11,9%) evolu&iacute;ram com algum tipo de l
imita&ccedil;&atilde;o    da rota&ccedil;&atilde;o externa, enquanto naqueles co
m primo-luxa&ccedil;&atilde;o    atraum&aacute;tica (46) n&atilde;o tiveram este
 tipo de limita&ccedil;&atilde;o    (p&lt;0,05). (<a href="#t2">Tabela 2</a>) No
s pacientes com les&atilde;o SLAP    associada (62) submetidos ao tratamento art
rosc&oacute;pico desta les&atilde;o    11 (17,7%) apresentaram dor no p&oacute;s
-operat&oacute;rio. No grupo sem esta    les&atilde;o (97) somente tr&ecirc;s (3
,1%) tiveram dor (p&lt;0,05). (<a href="#t3">Tabela    3</a>)</font></p>     ^cY
#09.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#48#44#article#137#<p><a name="t1"></a></p>  
   ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#49#45#article#137#<p>&nbsp;</p>     ^cY#09.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#50#46#article#137#<p align="center"><img src
="/img/revistas/aob/v19n1/09t01.jpg"></p>     ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#51#47#article#137#<p>&nbsp;</p>     ^cY#09.h
tm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#52#48#article#137#<p><a name="t2"></a></p>  
   ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#53#49#article#137#<p>&nbsp;</p>     ^cY#09.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#54#50#article#137#<p align="center"><img src
="/img/revistas/aob/v19n1/09t02.jpg"></p>     ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#55#51#article#137#<p>&nbsp;</p>     ^cY#09.h
tm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#56#52#article#137#<p><a name="t3"></a></p>  
   ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#57#53#article#137#<p>&nbsp;</p>     ^cY#09.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#58#54#article#137#<p align="center"><img src
="/img/revistas/aob/v19n1/09t03.jpg"></p>     ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#59#55#article#137#<p>&nbsp;</p>     ^cY#09.h
tm##
00328000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010600069002000700175#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#60#56#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font></p>     ^cY#
09.htm##
00718000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704049600069002000700565#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#61#57#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Neste estudo os    pacientes n&atilde;o for
am pr&eacute;-selecionados com base em sua atividade    f&iacute;sica, grau de i
nstabilidade, tempo de doen&ccedil;a ou achados patol&oacute;gicos    associados
, assim apresentamos um grupo heterog&ecirc;neo de forma a podermos    estratifi
car os resultados de acordo com as m&uacute;ltiplas vari&aacute;veis    e identi
ficarmos fatores relacionados aos maus resultados.</font></p>     ^cY#09.htm##
00436000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704021400069002000700283#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#62#58#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Observamos 10%    de recidiva, o que confer
e com a m&eacute;dia encontrada na literatura que varia    de oito a 18,5%.<sup>
17</sup></font></p>     ^cY#09.htm##
00755000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704053300069002000700602#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#63#59#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Conforme descrito    em estudos pr&eacute;v
ios, les&atilde;o &oacute;ssea (tanto na borda anterior    da glen&oacute;ide co
mo na cabe&ccedil;a umeral) aumentam de maneira significativa    os &iacute;ndic
es de recidiva.<sup>16,18,19</sup> Pacientes que apresentavam    les&atilde;o &o
acute;ssea da borda anterior da glen&oacute;ide apresentaram    um n&uacute;mero
 significativamente maior de recidivas - 22,8%(8/35) contra    6,4%(8/124) (p&lt
;0,05).</font></p>     ^cY#09.htm##
00796000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704057400069002000700643#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#64#60#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Ainda que n&atilde;o    tenha sido poss&iac
ute;vel demonstrar de forma estat&iacute;stica a rela&ccedil;&atilde;o    entre 
o numero de &acirc;ncoras e recidiva p&oacute;s cir&uacute;rgica, pacientes    q
ue recidivaram utilizaram em m&eacute;dia 2,5 &acirc;ncoras e aqueles sem recidi
va    utilizaram em m&eacute;dia 2,8 &acirc;ncoras, concordando com outros estud
os    que descrevem a import&acirc;ncia de um n&uacute;mero maior de &acirc;ncor
as    para o sucesso do tratamento.<sup>17</sup></font></p>     ^cY#09.htm##
00805000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704058300069002000700652#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#65#61#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">N&atilde;o houve    diferen&ccedil;a signif
icativa entre os tipos traum&aacute;tico e atraum&aacute;tico    no que diz resp
eito &agrave; recorr&ecirc;ncia (10,6 contra 8,6%), e tal fato    possivelmente 
se deve aos crit&eacute;rios de sele&ccedil;&atilde;o para o tratamento    artro
sc&oacute;pico, que exclu&iacute;am os pacientes com les&otilde;es &oacute;sseas
    importantes, mais prevalentes nos indiv&iacute;duos com epis&oacute;dios tra
um&aacute;ticos    de luxa&ccedil;&atilde;o.<sup>18</sup></font></p>     ^cY#09.
htm##
01748000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704152600069002000701595#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#66#62#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Encontramos maior    limita&ccedil;&atilde;
o da rota&ccedil;&atilde;o externa, no p&oacute;s-operat&oacute;rio,    nos caso
s de instabilidade traum&aacute;tica (p&lt;0,05). Atribu&iacute;mos    este fato
 a uma condi&ccedil;&atilde;o intr&iacute;nseca do tecido c&aacute;psulo-ligamen
tar    que &eacute; caracter&iacute;stica nos pacientes com instabilidade atraum
&aacute;tica.<sup>16,    20</sup> Embora fossem submetidos ao um re-tensionament
o c&aacute;psulo-ligamentar    eles podem apresentam uma maior acomoda&ccedil;&a
tilde;o tecidual durante o    per&iacute;odo de reabilita&ccedil;&atilde;o quand
o comparados com aqueles que    tem instabilidade traum&aacute;tica.<sup>19</sup
> Embora n&atilde;o seja necess&aacute;rio    o re-tensionamento c&aacute;psulo-
ligamentar nas instabilidade traum&aacute;tica,    alguns autores indicam este p
rocedimento devido a deformidade pl&aacute;stica    nesta estrutura ligamentar.<
sup>18,21,22</sup> Entretanto durante a repara&ccedil;&atilde;o    da les&atilde
;o de Bankart o complexo c&aacute;psulo-ligamentar &eacute; automaticamente    t
ensionado. Cabe ao cirurgi&atilde;o, durante o ato operat&oacute;rio, julgar    
a necessidade de associar um maior tensionamento para uma corre&ccedil;&atilde;o
    maior da frouxid&atilde;o. O correto tensionamento, muitas vezes dif&iacute;
cil    de se quantificar, &eacute; a chave para se evitar a limita&ccedil;&atild
e;o    da rota&ccedil;&atilde;o externa.</font></p>     ^cY#09.htm##
01283000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704106100069002000701130#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#67#63#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Pacientes com dor    no p&oacute;s-operat&o
acute;rio pode estar relacionada com a repara&ccedil;&atilde;o    da les&atilde;
o SLAP associada a repara&ccedil;&atilde;o de les&atilde;o de    Bankart. Encont
ramos este tipo de queixa em 17,7% dos pacientes submetidos a    repara&ccedil;&
atilde;o da les&atilde;o SLAP (p&lt;0,05). Embora alguns trabalhos    mostrem qu
e a dor no p&oacute;s-operat&oacute;rio pode ser queixa nos pacientes    submeti
dos repara&ccedil;&atilde;o isolada da les&atilde;o SLAP<sup>23</sup>,    n&atil
de;o encontramos na literatura este tipo de achado quando o reparo da    les&ati
lde;o SLAP estava associada ao reparo da les&atilde;o de Bankart. Autores    atr
ibuem tamb&eacute;m que a dor pode estar relacionada a outras les&otilde;es    n
&atilde;o diagnosticadas como roturas parciais do manguito rotador e altera&cced
il;&otilde;es    degenerativas articulares.<sup>24,25,26</sup> Entretanto n&atil
de;o encontramos    essas les&otilde;es em nossos casos</font></p>     ^cY#09.ht
m##
00963000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704074100069002000700810#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#68#64#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Assim o tratamento    da instabilidade glen
oumeral deve priorizar a estabiliza&ccedil;&atilde;o da    les&atilde;o de Banka
rt e a corre&ccedil;&atilde;o da frouxid&atilde;o capsular    sendo o uso de &ac
irc;ncoras indispens&aacute;vel para o bom resultado do procedimento.    A sele&
ccedil;&atilde;o dos casos, a correta identifica&ccedil;&atilde;o das    les&oti
lde;es associadas e a qualidade do tecido capsular s&atilde;o a chave    para o 
sucesso do tratamento artrosc&oacute;pico, sendo fundamental o reparo    de toda
s as les&otilde;es de partes moles para preservar a congru&ecirc;ncia    e a cor
reta fun&ccedil;&atilde;o da articula&ccedil;&atilde;o.</font></p>     ^cY#09.ht
m##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#69#65#article#137#<p>&nbsp;</p>     ^cY#09.h
tm##
00328000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010600069002000700175#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#70#66#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>CONCLUS&Atilde;O</b></font></p>     ^cY#
09.htm##
00399000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704017700069002000700246#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#71#67#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Conclu&iacute;mos    que no tratamento artr
osc&oacute;pico da instabilidade anterior do ombro:</font></p>     ^cY#09.htm##
00414000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704019200069002000700261#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#72#68#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Existe maior &iacute;ndice    de recidiva n
a presen&ccedil;a da fratura da borda anterior da glen&oacute;ide.</font></p>   
  ^cY#09.htm##
00418000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704019600069002000700265#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#73#69#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A dor no p&oacute;s-operat&oacute;rio    es
t&aacute; relacionada com a presen&ccedil;a da les&atilde;o tipo SLAP.</font></p
>     ^cY#09.htm##
00474000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704025200069002000700321#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#74#70#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A limita&ccedil;&atilde;o    da rota&ccedil
;&atilde;o externa no p&oacute;s-operat&oacute;rio est&aacute;    relacionada co
m o tipo de instabilidade (traum&aacute;tica).</font></p>     ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#75#71#article#137#<p>&nbsp;</p>     ^cY#09.h
tm##
00329000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010700069002000700176#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#76#72#article#137#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font></p>     ^cY
#09.htm##
00450000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704021400071002000700285#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#77#73#article#137#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1. Baker CL, Uribe    JN, Whi
tman C. Arthroscopic evaluation of acute initial anterior shoulder dislocations.
    Am J Sports Med. 1990;18:25-8.    ^cY#09.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#78#74#article#137#</font></p>     ^cY#09.htm
##
00576000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704034000071002000700411#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#79#75#article#137#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2. Moseley HF,    Overgaard B
. The anterior capsular mechanism in recurrent anterior dislocation    of the sh
oulder: morphological and clinical studies with special reference to    the glen
oid labrum and the glenohumeral ligaments. J Bone Joint Surg Br. 1964;44:913-27.
    ^cY#09.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#80#76#article#137#</font></p>     ^cY#09.htm
##
00518000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704028200071002000700353#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#81#77#article#137#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">3. O'Brien SJ,    Neves MC, A
rnoczky SP, Rozbruck SR, Dicarlo EF, Warren RF, et al. The anatomy    and histol
ogy of the inferior glenohumeral ligament complex of the shoulder.    Am J Sport
s Med. 1990;18:449-56.    ^cY#09.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#82#78#article#137#</font></p>     ^cY#09.htm
##
00491000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704025500071002000700326#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#83#79#article#137#4#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">4. Torchia ME,    Caspari RB,
 Asselmeier MA, Beach WR, Gayari M. Arthroscopic transglenoid multiple    suture
 repair: 2 to 8 year results in 150 shoulders. Arthroscopy. 1997;13:609-19.    ^
cY#09.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#84#80#article#137#</font></p>     ^cY#09.htm
##
00414000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704017800071002000700249#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#85#81#article#137#5#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">5. Perthes G. Uber    operati
onen der habituelien schulterluxation. Dtsch Zeitschrift Chir. 1906;56:149-51.  
  ^cY#09.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#86#82#article#137#</font></p>     ^cY#09.htm
##
00396000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704016000071002000700231#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#87#83#article#137#6#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">6. Bankart ASB.    Recurrent 
or habitual dislocation of the shoulder. BMJ. 1923;1:1132-3.    ^cY#09.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#88#84#article#137#</font></p>     ^cY#09.htm
##
00450000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704021400071002000700285#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#89#85#article#137#7#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">7. Baker CL, Uribe    JN, Whi
tman C. Arthroscopic evaluation of acute initial anterior shoulder dislocations.
    Am J Sports Med. 1990;18:25-8.    ^cY#09.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#90#86#article#137#</font></p>     ^cY#09.htm
##
00502000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704026600071002000700337#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#91#87#article#137#8#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">8. Mohammed KD,    Sonnabend 
DH, Goldberg JA, Hutabarat S, Walker P, Walsh WR. Biomechanical performance    o
f Bankart repairs in a human cadaveric shoulder model. Am J Sports Med. 1998;26:
831-5.    ^cY#09.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#92#88#article#137#</font></p>     ^cY#09.htm
##
00436000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704020000071002000700271#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#93#89#article#137#9#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">9. Rowe CR, Patel    D, South
mayd WW. The bankart procedure. A long-term end-result study. J Bone    Joint Su
rg Am. 1978;60:1-16.    ^cY#09.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#94#90#article#137#</font></p>     ^cY#09.htm
##
00504000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704026700072002000700339#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#95#91#article#137#10#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">10. Bigliani LU,    Kurzweil
 PR, Schwartzbach CC, Wolfe IN, Flatow EL. Inferior capsular shift procedure    
for anterior-inferior shoulder instability in athletes. Am J Sports Med. 1994;22
:578-84.    ^cY#09.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#96#92#article#137#</font></p>     ^cY#09.htm
##
00492000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704025500072002000700327#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#97#93#article#137#11#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">11. Leedle BP,    Miller MD.
 Pullout strength of knotless suture anchors. Department of Orthopedics,    Wilf
ord Hall Medical Center, San Antonio, Texas, USA. Arthroscopy. 2005;21:81-5.    
^cY#09.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#98#94#article#137#</font></p>     ^cY#09.htm
##
00446000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704020900072002000700281#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#99#95#article#137#12#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">12. Bacilla P,    Field LD, 
Savoie FH 3rd. Arthroscopic Bankart repair in a high demand patient    populatio
n. Arthroscopy. 1997;13:51-60.    ^cY#09.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#100#96#article#137#</font></p>     ^cY#09.ht
m##
00480000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000300070704024200073002000700315#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#101#97#article#137#13#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">13. Wang C, Ghalambor    N,
 Zarins B, Warner JJ. Arthroscopic versus open Bankart repair: Analysis of    pa
tient subjective outcome and cost. Arthroscopy. 2005;21:1219-22.    ^cY#09.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#102#98#article#137#</font></p>     ^cY#09.ht
m##
00493000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000300070704025500073002000700328#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#103#99#article#137#14#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">14. Ide J, Maeda    S, Taka
gi K. Arthroscopic Bankart repair using suture anchors in athletes. Patient    s
election and postoperative sports activity. Am J Sports Med. 2004;32:899-905.   
 ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#104#100#article#137#</font></p>     ^cY#09.h
tm##
00476000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704023700074002000700311#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#105#101#article#137#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Cho NS, Lubis    AM, H
a JH, Rhee YG. Clinical Results of Arthroscopic Bankart Repair With Knot-Tying  
  and Knotless Suture Anchors. Arthroscopy. 2006;22:1276-82.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#106#102#article#137#</font></p>     ^cY#09.h
tm##
00565000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032600074002000700400#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#107#103#article#137#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Burkhart SS,    De Bee
r JF. Traumatic glenohumeral bone defects and their relationship to failure    o
f arthroscopic Bankart repairs: significance of the inverted-pear glenoid and   
 the humeral engaging Hill-Sachs lesion. Arthroscopy. 2000;16:677-94.    ^cY#09.
htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#108#104#article#137#</font></p>     ^cY#09.h
tm##
00515000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027600074002000700350#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#109#105#article#137#17#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Boileau P,    Villalba
 M, H&eacute;ry JY, Balg F, Ahrens P, Neyton L. Risk factors for recurrence    o
f shoulder instability after arthroscopic bankart repair. J Bone Joint Surg    A
m. 2003;88:1755-63.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#110#106#article#137#</font></p>     ^cY#09.h
tm##
00475000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704023600074002000700310#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#111#107#article#137#18#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Kim SH, Ha    KI, Cho 
YB, Ryu BD, Oh I. Arthroscopic anterior stabilization of the shoulder    - two t
o six-year follow-up. J Bone Joint Surg Am. 2003;85:1511-8.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#112#108#article#137#</font></p>     ^cY#09.h
tm##
00530000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029100074002000700365#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#113#109#article#137#19#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Taylor DC,    Arciero 
RA. Pathologic changes associated with shoulder dislocations: arthroscopic    an
d physical examination Findings in first time, traumatic anterior dislocations. 
   Am J Spots Med. 1997;25:306-11.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#114#110#article#137#</font></p>     ^cY#09.h
tm##
00458000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704021900074002000700293#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#115#111#article#137#20#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Zabinski SJ,    Callaw
ay GH, Cohen S, Warren RF. Revision shoulder stabilization: 2- to 10-    year re
sult. J Shoulder Elbow Surg. 1999;8:58-65.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#116#112#article#137#</font></p>     ^cY#09.h
tm##
00520000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028100074002000700355#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#117#113#article#137#21#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Hayashida K,    Yoneda
 M, Nakagawa S, Okamura K, Fukushima S. Arthroscopic Bankart suture repair    fo
r traumatic anterior instability: analyses of the causes of recurrence. Arthrosc
opy.    1998;14:295-301.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#118#114#article#137#</font></p>     ^cY#09.h
tm##
00595000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704035600074002000700430#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#119#115#article#137#22#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Larrain MV,    Montene
gro HJ, Mauas DM, Collazo CC, Pav&oacute;n F. Arthroscopic management    of ante
rior shoulder instability in collision athletes: analysis of 204 cases    with a
 4 - 9 year Follow-up and results with the suture anchor technique. Arthroscopy.
    2006;22:1283-9.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#120#116#article#137#</font></p>     ^cY#09.h
tm##
00518000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027900074002000700353#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#121#117#article#137#23#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Paxinos A,    Walton J
, R&uuml;tten S, M&uuml;ller M, Murrell GA. Arthroscopic stabilization    of sup
erior labral tears (SLAP) with biodegradable take: outcome to 2 years.    Arthro
scopy. 2006;22:627-34.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#122#118#article#137#</font></p>     ^cY#09.h
tm##
00444000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704020500074002000700279#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#123#119#article#137#24#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Enad JG, Gaines    RJ,
 White SM, Kurtz CA. Arthroscopic SLAP repair in military patients. J Shoulder  
  Elbow Surg. 2007;16:300-5.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#124#120#article#137#</font></p>     ^cY#09.h
tm##
00506000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026700074002000700341#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#125#121#article#137#25#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Buscayret F,    Edward
s TB, Szabo I, Adeleine P, Coudane H, Walch G. Glenohumeral arthrosis    in ante
rior instability before and after surgical treatment. Am J Sports Med.    2004;3
2:1165-72.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#126#122#article#137#</font></p>     ^cY#09.h
tm##
00605000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704036600074002000700440#v19
n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#p#127#123#article#137#26#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Jaeger A, Braune    C,
 Welsch F, Sarikaya Y, Graichen H. Postoperative functional outcome and stabilit
y    in recurrent traumatic anteroinferior glenohumeral instability: comparison 
of    two different surgical capsular reconstruction techniques. Arch Orthop Tra
uma    Surg. 2004;124:226-31.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#128#124#article#137#</font></p>     ^cY#09.h
tm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#129#125#article#137#<p>&nbsp;</p>     ^cY#09
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#130#126#article#137#<p>&nbsp;</p>     ^cY#09
.htm##
00430000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704020600071002000700277#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#131#127#article#137#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top"><img sr
c="/img/revistas/aob/v19n1/seta.jpg" border="0"></a>    <b>Endereço para Corresp
ondência:</b>     ^cY#09.htm##
00266000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004200071002000700113#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#132#128#article#137#<br>   Alessandro Monter
roso Felix    ^cY#09.htm##
00270000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004600071002000700117#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#133#129#article#137#<br>   Rua: Frei Caneca 
1140 apto. 703    ^cY#09.htm##
00267000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004300071002000700114#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#134#130#article#137#<br>   S&atilde;o Paulo,
 SP, Brasil    ^cY#09.htm##
00253000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002900071002000700100#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#135#131#article#137#<br>   CEP: 01307-002   
 ^cY#09.htm##
00339000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704011500071002000700186#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#136#132#article#137#<br>   E-mail: <a href="
mailto:alessandromfelix@hotmail.com">alessandromfelix@hotmail.com</a></font>  </
p>     ^cY#09.htm##
00362000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013800071002000700209#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#137#133#article#137#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Trabalho recebido    em 07/08/08, aprovad
o em 22/09/08.</font></p>     ^cY#09.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#138#134#article#137#<p>&nbsp;</p>     ^cY#09
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#139#135#article#137#<p>&nbsp;</p>     ^cY#09
.htm##
00371000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704014700071002000700218#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#140#136#article#137#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Trabalho realizado    no Instituto de Ort
opedia e Traumatologia do HC-FMUSP.    ^cY#09.htm##
00361000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013700071002000700208#v19n1#V:\SciELO
\serial\aob\v19n1\markup\09.htm#S#p#141#137#article#137#<br>   Todos os autores 
declaram n&atilde;o haver nenhum potencial conflito de interesses    referente a
 este artigo.</font></p>     ^cY#09.htm##
00531000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100016000860100
01800102012007600120030001700196710000200213065000900215064000500224031000300229
014000500232865000900237002000700246#v19n1#V:\SciELO\serial\aob\v19n1\markup\09.
htm#S#c#142#1#article#26#1#^rND^sBaker^nCL#^rND^sUribe^nJN#^rND^sWhitman^nC.#Art
hroscopic evaluation of acute initial anterior shoulder dislocations^len#Am J Sp
orts Med.#2#19900000#1990#18#25-8#20110000#09.htm##
00636000000000265000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100020000880120
19800108030002200306710000200328065000900330064000500339031000300344014000700347
865000900354002000700363#v19n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#c#143#
2#article#26#2#^rND^sMoseley^nHF#^rND^sOvergaard^nB.#The anterior capsular mecha
nism in recurrent anterior dislocation of the shoulder: morphological and clinic
al studies with special reference to the glenoid labrum and the glenohumeral lig
aments^len#J Bone Joint Surg Br.#2#19640000#1964#44#913-27#20110000#09.htm##
00661000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100016000880100
01900104010001900123010001800142010001700160810000700177012009200184030001700276
71000020029306500090029506400050030403100030030901400070031286500090031900200070
0328#v19n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#c#144#3#article#26#3#^rND^
sO'Brien^nSJ#^rND^sNeves^nMC#^rND^sArnoczky^nSP#^rND^sRozbruck^nSR#^rND^sDicarlo
^nEF#^rND^sWarren^nRF#et al.#The anatomy and histology of the inferior glenohume
ral ligament complex of the shoulder^len#Am J Sports Med.#2#19900000#1990#18#449
-56#20110000#09.htm##
00638000000000313000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100018000880100
02100106010001600127010001600143012009100159030001200250065000900262064000500271
031000300276014000700279865000900286002000700295035001000302801001200312#v19n1#V
:\SciELO\serial\aob\v19n1\markup\09.htm#S#c#145#4#article#26#4#^rND^sTorchia^nME
#^rND^sCaspari^nRB#^rND^sAsselmeier^nMA#^rND^sBeach^nWR#^rND^sGayari^nM#Arthrosc
opic transglenoid multiple suture repair: 2 to 8 year results in 150 shoulders^l
en#Arthroscopy#19970000#1997#13#609-19#20110000#09.htm#0749-8063#Arthroscopy##
00462000000000253000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700120054000880300
02400142710000200166065000900168064000500177031000300182014000700185865000900192
002000700201#v19n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#c#146#5#article#26
#5#^rND^sPerthes^nG.#Uber operationen der habituelien schulterluxation^lde#Dtsch
 Zeitschrift Chir.#2#19060000#1906#56#149-51#20110000#09.htm##
00444000000000253000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100020000700120054000900300
00500144710000200149065000900151064000500160031000200165014000700167865000900174
002000700183#v19n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#c#147#6#article#26
#6#^rND^sBankart^nASB.#Recurrent or habitual dislocation of the shoulder^len#BMJ
.#2#19230000#1923#1#1132-3#20110000#09.htm##
00531000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100016000860100
01800102012007600120030001700196710000200213065000900215064000500224031000300229
014000500232865000900237002000700246#v19n1#V:\SciELO\serial\aob\v19n1\markup\09.
htm#S#c#148#7#article#26#7#^rND^sBaker^nCL#^rND^sUribe^nJN#^rND^sWhitman^nC.#Art
hroscopic evaluation of acute initial anterior shoulder dislocations^len#Am J Sp
orts Med.#2#19900000#1990#18#25-8#20110000#09.htm##
00637000000000313000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700100020000890100
01900109010001900128010001600147010001700163012008500180030001700265710000200282
065000900284064000500293031000300298014000600301865000900307002000700316#v19n1#V
:\SciELO\serial\aob\v19n1\markup\09.htm#S#c#149#8#article#26#8#^rND^sMohammed^nK
D#^rND^sSonnabend^nDH#^rND^sGoldberg^nJA#^rND^sHutabarat^nS#^rND^sWalker^nP#^rND
^sWalsh^nWR.#Biomechanical performance of Bankart repairs in a human cadaveric s
houlder model^len#Am J Sports Med.#2#19980000#1998#26#831-5#20110000#09.htm##
00517000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100015000700100015000850100
02100100012005600121030002200177710000200199065000900201064000500210031000300215
014000500218865000900223002000700232#v19n1#V:\SciELO\serial\aob\v19n1\markup\09.
htm#S#c#150#9#article#26#9#^rND^sRowe^nCR#^rND^sPatel^nD#^rND^sSouthmayd^nWW.#Th
e bankart procedure: A long-term end-result study^len#J Bone Joint Surg Am.#2#19
780000#1978#60#1-16#20110000#09.htm##
00621000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100019000910100
02300110010001600133010001800149012009300167030001700260710000200277065000900279
064000500288031000300293014000700296865000900303002000700312#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\09.htm#S#c#151#10#article#26#10#^rND^sBigliani^nLU#^rND^sKu
rzweil^nPR#^rND^sSchwartzbach^nCC#^rND^sWolfe^nIN#^rND^sFlatow^nEL.#Inferior cap
sular shift procedure for anterior-inferior shoulder instability in athletes^len
#Am J Sports Med.#2#19940000#1994#22#578-84#20110000#09.htm##
00585000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100017000890120
12900106030001200235065000900247064000500256031000300261014000500264865000900269
002000700278035001000285801001200295#v19n1#V:\SciELO\serial\aob\v19n1\markup\09.
htm#S#c#152#11#article#26#11#^rND^sLeedle^nBP#^rND^sMiller^nMD#Pullout strength 
of knotless suture anchors. Department of Orthopedics, Wilford Hall Medical Cent
er, San Antonio, Texas, USA^len#Arthroscopy#20050000#2005#21#81-5#20110000#09.ht
m#0749-8063#Arthroscopy##
00557000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100016000890100
02100105012006800126030001200194065000900206064000500215031000300220014000600223
865000900229002000700238035001000245801001200255#v19n1#V:\SciELO\serial\aob\v19n
1\markup\09.htm#S#c#153#12#article#26#12#^rND^sBacilla^nP#^rND^sField^nLD#^rND^s
Savoie^nFH 3rd#Arthroscopic Bankart repair in a high demand patient population^l
en#Arthroscopy#19970000#1997#13#51-60#20110000#09.htm#0749-8063#Arthroscopy##
00609000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100014000720100019000860100
01600105010001800121012009300139030001200232065000900244064000500253031000300258
014000800261865000900269002000700278035001000285801001200295#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\09.htm#S#c#154#13#article#26#13#^rND^sWang^nC#^rND^sGhalamb
or^nN#^rND^sZarins^nB#^rND^sWarner^nJJ.#Arthroscopic versus open Bankart repair:
 Analysis of patient subjective outcome and cost^len#Arthroscopy#20050000#2005#2
1#1219-22#20110000#09.htm#0749-8063#Arthroscopy##
00572000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100013000720100015000850100
01600100012011800116030001700234710000200251065000900253064000500262031000300267
014000800270865000900278002000700287#v19n1#V:\SciELO\serial\aob\v19n1\markup\09.
htm#S#c#155#14#article#26#14#^rND^sIde^nJ#^rND^sMaeda^nS#^rND^sTakagi^nK#Arthros
copic Bankart repair using suture anchors in athletes: Patient selection and pos
toperative sports activity^len#Am J Sports Med.#2#20040000#2004#32#899-905#20110
000#09.htm##
00604000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100014000720100016000860100
01300102010001600115012009600131030001200227065000900239064000500248031000300253
014000800256865000900264002000700273035001000280801001200290#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\09.htm#S#c#156#15#article#26#15#^rND^sCho^nNS#^rND^sLubis^n
AM#^rND^sHa^nJH#^rND^sRhee^nYG.#Clinical Results of Arthroscopic Bankart Repair 
With Knot-Tying and Knotless Suture Anchors^len#Arthroscopy#20060000#2006#22#127
6-82#20110000#09.htm#0749-8063#Arthroscopy##
00653000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100018000910120
19200109030001200301065000900313064000500322031000300327014000700330865000900337
002000700346035001000353801001200363#v19n1#V:\SciELO\serial\aob\v19n1\markup\09.
htm#S#c#157#16#article#26#16#^rND^sBurkhart^nSS#^rND^sDe Beer^nJF#Traumatic glen
ohumeral bone defects and their relationship to failure of arthroscopic Bankart 
repairs: significance of the inverted-pear glenoid and the humeral engaging Hill
-Sachs lesion^len#Arthroscopy#20000000#2000#16#677-94#20110000#09.htm#0749-8063#
Arthroscopy##
00637000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100018000890100
01500107010001400122010001600136010001600152012009000168030002200258710000200280
065000900282064000500291031000300296014000800299865000900307002000700316#v19n1#V
:\SciELO\serial\aob\v19n1\markup\09.htm#S#c#158#17#article#26#17#^rND^sBoileau^n
P#^rND^sVillalba^nM#^rND^sHéry^nJY#^rND^sBalg^nF#^rND^sAhrens^nP#^rND^sNeyton^nL
#Risk factors for recurrence of shoulder instability after arthroscopic bankart 
repair^len#J Bone Joint Surg Am.#2#20030000#2003#88#1755-63#20110000#09.htm##
00590000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100014000720100013000860100
01400099010001400113010001300127012008400140030002200224710000200246065000900248
064000500257031000300262014000700265865000900272002000700281#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\09.htm#S#c#159#18#article#26#18#^rND^sKim^nSH#^rND^sHa^nKI#
^rND^sCho^nYB#^rND^sRyu^nBD#^rND^sOh^nI.#Arthroscopic anterior stabilization of 
the shoulder - two to six-year follow-up^len#J Bone Joint Surg Am.#2#20030000#20
03#85#1511-8#20110000#09.htm##
00587000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100018000890120
15600107030001600263710000200279065000900281064000500290031000300295014000700298
865000900305002000700314#v19n1#V:\SciELO\serial\aob\v19n1\markup\09.htm#S#c#160#
19#article#26#19#^rND^sTaylor^nDC#^rND^sArciero^nRA#Pathologic changes associate
d with shoulder dislocations: arthroscopic and physical examination Findings in 
first time, traumatic anterior dislocations^len#Am J Spots Med.#2#19970000#1997#
25#306-11#20110000#09.htm##
00555000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100019000910100
01500110010001800125012005900143030002300202710000200225065000900227064000500236
031000200241014000600243865000900249002000700258#v19n1#V:\SciELO\serial\aob\v19n
1\markup\09.htm#S#c#161#20#article#26#20#^rND^sZabinski^nSJ#^rND^sCallaway^nGH#^
rND^sCohen^nS#^rND^sWarren^nRF.#Revision shoulder stabilization: 2- to 10- year 
result^len#J Shoulder Elbow Surg.#2#19990000#1999#8#58-65#20110000#09.htm##
00663000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100016000910100
01800107010001700125010002000142012011200162030001200274065000900286064000500295
031000300300014000800303865000900311002000700320035001000327801001200337#v19n1#V
:\SciELO\serial\aob\v19n1\markup\09.htm#S#c#162#21#article#26#21#^rND^sHayashida
^nK#^rND^sYoneda^nM#^rND^sNakagawa^nS#^rND^sOkamura^nK#^rND^sFukushima^nS.#Arthr
oscopic Bankart suture repair for traumatic anterior instability: analyses of th
e causes of recurrence^len#Arthroscopy#19980000#1998#14#295-301#20110000#09.htm#
0749-8063#Arthroscopy##
00727000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100021000900100
01600111010001800127010001500145012017900160030001200339065000900351064000500360
031000300365014000700368865000900375002000700384035001000391801001200401#v19n1#V
:\SciELO\serial\aob\v19n1\markup\09.htm#S#c#163#22#article#26#22#^rND^sLarrain^n
MV#^rND^sMontenegro^nHJ#^rND^sMauas^nDM#^rND^sCollazo^nCC#^rND^sPavón^nF#Arthros
copic management of anterior shoulder instability in collision athletes: analysi
s of 204 cases with a 4 - 9 year Follow-up and results with the suture anchor te
chnique^len#Arthroscopy#20060000#2006#22#1283-9#20110000#09.htm#0749-8063#Arthro
scopy##
00650000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100016000890100
01600105010001600121010001800137012010700155030001200262065000900274064000500283
031000300288014000700291865000900298002000700307035001000314801001200324#v19n1#V
:\SciELO\serial\aob\v19n1\markup\09.htm#S#c#164#23#article#26#23#^rND^sPaxinos^n
A#^rND^sWalton^nJ#^rND^sRütten^nS#^rND^sMüller^nM#^rND^sMurrell^nGA#Arthroscopic
 stabilization of superior labral tears (SLAP) with biodegradable take: outcome 
to 2 years^len#Arthroscopy#20060000#2006#22#627-34#20110000#09.htm#0749-8063#Art
hroscopy##
00541000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100017000870100
01600104010001700120012005000137030002300187710000200210065000900212064000500221
031000300226014000600229865000900235002000700244#v19n1#V:\SciELO\serial\aob\v19n
1\markup\09.htm#S#c#165#24#article#26#24#^rND^sEnad^nJG#^rND^sGaines^nRJ#^rND^sW
hite^nSM#^rND^sKurtz^nCA.#Arthroscopic SLAP repair in military patients^len#J Sh
oulder Elbow Surg.#2#20070000#2007#16#300-5#20110000#09.htm##
00636000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100018000910100
01500109010001800124010001700142010001600159012008700175030001700262710000200279
065000900281064000500290031000300295014000800298865000900306002000700315#v19n1#V
:\SciELO\serial\aob\v19n1\markup\09.htm#S#c#166#25#article#26#25#^rND^sBuscayret
^nF#^rND^sEdwards^nTB#^rND^sSzabo^nI#^rND^sAdeleine^nP#^rND^sCoudane^nH#^rND^sWa
lch^nG.#Glenohumeral arthrosis in anterior instability before and after surgical
 treatment^len#Am J Sports Med.#2#20040000#2004#32#1165-72#20110000#09.htm##
00714000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100016000880100
01600104010001800120010001900138012018700157030002500344710000200369065000900371
064000500380031000400385014000700389865000900396002000700405#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\09.htm#S#c#167#26#article#26#26#^rND^sJaeger^nA#^rND^sBraun
e^nC#^rND^sWelsch^nF#^rND^sSarikaya^nY#^rND^sGraichen^nH.#Postoperative function
al outcome and stability in recurrent traumatic anteroinferior glenohumeral inst
ability: comparison of two different surgical capsular reconstruction techniques
^len#Arch Orthop Trauma Surg.#2#20040000#2004#124#226-31#20110000#09.htm##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v19n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#o#1#1#article#1#201104
11#111912#10.htm#131##
04431000000000697000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000500083038000400088121000300092049000700095158000300102
03000180010503100030012303200020012606500090012801400090013703500100014601200710
01560120067002270100041002940100033003350100027003680100044003950100035004390100
04100474070006000515083139000575085000801965085002701973085003902000085003302039
08500240207208500240209608500250212008313500214508500080349508500250350308500470
35280850031035750850025036060850024036310850026036551170006036810720003036871120
00903690111000903699114000903708113000903717002000703726#v19n1#V:\SciELO\serial\
aob\v19n1\markup\10.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#10#AOB140#n
d#Acta ortop. bras.#19#1#20110000#^f45^l48#1413-7852#Fraturas transtrocanteriana
s: uso de alendronato no pós-operatório^lpt#Transtrochanterian fractures: postop
erative use of alendronate^len#^rND^1A01^nFrancisco José Nunes^sCardoso#^rND^1A0
1^nAugusto Sadao^sNakano#^rND^1A01^nMarcel^sFrisene#^rND^1A01^nManoel Emilio de 
Freitas^sHereda#^rND^1A01^nBruno de Faria^sBatista#^rND^1A01^nPaulo Rogério Card
ozo^sKanaji#Hospital Beneficência Portuguesa de Ribeirão Preto^iA01^sSP#^lpt^aOB
JETIVO: Avaliar resultados do uso de alendronato de sódio em pós operatório de f
ratura transtrocanteriana. MÉTODO: Durante seis meses, 75 pacientes foram atendi
dos no Serviço de Ortopedia devido à fratura transtrocanteriana de fêmur, sendo 
submetidos a tratamento cirúrgico com fixação através de placa DHS 135°. Foram s
elecionados 19 pacientes, hígidos, cooperativos, previamente deambuladores, clas
sificados segundo Tronzo em tipo III e cujos quadris contra laterais não haviam 
sido submetidos a nenhuma cirurgia prévia, permitindo a realização de Densitomet
ria Óssea Mineral no pós-operatório imediato e após seis meses. Os pacientes for
am divididos em grupos I e II, com e sem uso de alendronato de sódio, a partir d
o pós-operatório imediato, respectivamente. O seguimento mínimo foi de seis mese
s. Após quatro semanas, os pacientes foram avaliados de acordo com a Escala Visu
al Analógica de Dor (EVA), para observação do índice de reabsorção óssea, a mass
a óssea e a consolidação radiológica da fratura. RESULTADOS: Houve uma tendência
 estatística de consolidação radiológica mais precoce com menor reabsorção óssea
 nos pacientes com uso de alendronato de sódio na pós-fratura com osteoporose es
tabelecida. CONCLUSÃO: Concluímos que, radiologicamente, os pacientes que utiliz
aram alendronato de sódio tiveram uma consolidação óssea mais rápida, com menor 
índice de reabsorção.#^dnd^i1#^tm^lpt^kPós-operatório^i1#^tm^lpt^kFratura transt
rocanteriana^i1#^tm^lpt^kAlendronato de sódio^i1#^tm^lpt^kOsteoporose^i1#^tm^lpt
^kRadiografia^i1#^tm^lpt^kConsolidação^i1#^len^aOBJECTIVE: To evaluate the resul
ts of the use of alendronate sodium in postoperative transtrochanteric femoral f
ractures. METHOD: Over a six-month period, 75 patients were treated at the Ortho
pedic Service for transtrochanteric femoral fractures, undergoing surgery with 1
35 degree DHS plate fixation. We selected 19 patients who were healthy, cooperat
ive, previously unable to walk, classified as type III according to Tronzo, whos
e contralateral hips had not undergone any previous surgery, enabling the evalua
tion of bone mineral density (BMD) in the immediate postoperative period and aft
er six months. The patients were divided into groups I and II, with and without 
the use of alendronate sodium in the immediate postoperative period, respectivel
y. The minimum follow-up was six months. After four weeks, the patients were eva
luated according to the Visual Analogue Scale for Pain (VAS) in order to verify 
the rate of bone resorption, bone mass and radiological consolidation of the fra
cture. RESULTS: There was a statistical trend of earlier radiological consolidat
ion and lower bone resorption in patients with the use of alendronate sodium in 
post-fracture with established osteoporosis. CONCLUSION: We concluded that radio
logically, patients using alendronate sodium showed faster bone consolidation, w
ith a lower rate of resorption.#^dnd^i2#^tm^len^kPost-surgery^i2#^tm^len^kTranst
rochanteric femoral fracture^i2#^tm^len^kAlendronate sodium^i2#^tm^len^kOsteopor
osis^i2#^tm^len^kRadiography^i2#^tm^len^kConsolidation^i2#other#18#20080912#12/0
9/08#20090612#12/06/09#10.htm##
04515000000000697000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000500083038000400088121000300092049000700095158000300102
03000180010503100030012303200020012606500090012801400090013703500100014601200850
01560120081002410100041003220100033003630100027003960100044004230100035004670100
04100502070006000543083141800603085000802021085002702029085003902056085003302095
08500240212808500240215208500250217608313780220108500080357908500250358708500470
36120850031036590850025036900850024037150850026037391170006037650720003037711120
00903774111000903783114000903792113000903801002000703810#v19n1#V:\SciELO\serial\
aob\v19n1\markup\10.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#10#AOB140#n
d#Acta ortop. bras.#19#1#20110000#^f45^l48#1413-7852#<b>Fraturas transtrocanteri
anas</b>: <b>uso de alendronato no pós-operatório</b>^lpt#<b>Transtrochanterian 
fractures</b>: <b>postoperative use of alendronate</b>^len#^rND^1A01^nFrancisco 
José Nunes^sCardoso#^rND^1A01^nAugusto Sadao^sNakano#^rND^1A01^nMarcel^sFrisene#
^rND^1A01^nManoel Emilio de Freitas^sHereda#^rND^1A01^nBruno de Faria^sBatista#^
rND^1A01^nPaulo Rogério Cardozo^sKanaji#Hospital Beneficência Portuguesa de Ribe
irão Preto^iA01^sSP#^lpt^a<b>OBJETIVO:</b> Avaliar resultados do uso de alendron
ato de sódio em pós operatório de fratura transtrocanteriana. <b>MÉTODO:</b> Dur
ante seis meses, 75 pacientes foram atendidos no Serviço de Ortopedia devido à f
ratura transtrocanteriana de fêmur, sendo submetidos a tratamento cirúrgico com 
fixação através de placa DHS 135°. Foram selecionados 19 pacientes, hígidos, coo
perativos, previamente deambuladores, classificados segundo Tronzo em tipo III e
 cujos quadris contra laterais não haviam sido submetidos a nenhuma cirurgia pré
via, permitindo a realização de Densitometria Óssea Mineral no pós-operatório im
ediato e após seis meses. Os pacientes foram divididos em grupos I e II, com e s
em uso de alendronato de sódio, a partir do pós-operatório imediato, respectivam
ente. O seguimento mínimo foi de seis meses. Após quatro semanas, os pacientes f
oram avaliados de acordo com a Escala Visual Analógica de Dor (EVA), para observ
ação do índice de reabsorção óssea, a massa óssea e a consolidação radiológica d
a fratura. <b>RESULTADOS:</b> Houve uma tendência estatística de consolidação ra
diológica mais precoce com menor reabsorção óssea nos pacientes com uso de alend
ronato de sódio na pós-fratura com osteoporose estabelecida. <b>CONCLUSÃO:</b> C
oncluímos que, radiologicamente, os pacientes que utilizaram alendronato de sódi
o tiveram uma consolidação óssea mais rápida, com menor índice de reabsorção.#^d
nd^i1#^tm^lpt^kPós-operatório^i1#^tm^lpt^kFratura transtrocanteriana^i1#^tm^lpt^
kAlendronato de sódio^i1#^tm^lpt^kOsteoporose^i1#^tm^lpt^kRadiografia^i1#^tm^lpt
^kConsolidação^i1#^len^a<b>OBJECTIVE:</b> To evaluate the results of the use of 
alendronate sodium in postoperative transtrochanteric femoral fractures. <b>METH
OD:</b> Over a six-month period, 75 patients were treated at the Orthopedic Serv
ice for transtrochanteric femoral fractures, undergoing surgery with 135 degree 
DHS plate fixation. We selected 19 patients who were healthy, cooperative, previ
ously unable to walk, classified as type III according to Tronzo, whose contrala
teral hips had not undergone any previous surgery, enabling the evaluation of bo
ne mineral density (BMD) in the immediate postoperative period and after six mon
ths. The patients were divided into groups I and II, with and without the use of
 alendronate sodium in the immediate postoperative period, respectively. The min
imum follow-up was six months. After four weeks, the patients were evaluated acc
ording to the Visual Analogue Scale for Pain (VAS) in order to verify the rate o
f bone resorption, bone mass and radiological consolidation of the fracture. <b>
RESULTS:</b> There was a statistical trend of earlier radiological consolidation
 and lower bone resorption in patients with the use of alendronate sodium in pos
t-fracture with established osteoporosis. <b>CONCLUSION:</b> We concluded that r
adiologically, patients using alendronate sodium showed faster bone consolidatio
n, with a lower rate of resorption.#^dnd^i2#^tm^len^kPost-surgery^i2#^tm^len^kTr
anstrochanteric femoral fracture^i2#^tm^len^kAlendronate sodium^i2#^tm^len^kOste
oporosis^i2#^tm^len^kRadiography^i2#^tm^len^kConsolidation^i2#other#18#20080912#
12/09/08#20090612#12/06/09#10.htm##
04552000000000721000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000500090038000400095121000300099049000700102
15800030010903000170011203100030012903200020013206500090013401400090014303500100
01520120071001620120067002330100041003000100033003410100027003740100044004010100
03500445010004100480070006200521083139000583085000801973085002701981085003902008
08500330204708500240208008500240210408500250212808313500215308500080350308500250
35110850047035360850031035830850025036140850024036390850026036631170006036890720
00303695112000903698111000903707114000903716113000903725002000703734008008903741
#v19n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#l#4#1#article#1#^a2011#oa#pt#b
r1.1#1#4.0#ilus#tab#10#AOB140#nd#Acta ortop. bras#19#1#20110000#^f45^l48#1413-78
52#Fraturas transtrocanterianas: uso de alendronato no pós-operatório^lpt#Transt
rochanterian fractures: postoperative use of alendronate^len#^rND^1A01^nFrancisc
o José Nunes^sCardoso#^rND^1A01^nAugusto Sadao^sNakano#^rND^1A01^nMarcel^sFrisen
e#^rND^1A01^nManoel Emilio de Freitas^sHereda#^rND^1A01^nBruno de Faria^sBatista
#^rND^1A01^nPaulo Rogério Cardozo^sKanaji#^iA01^1Hospital Beneficência Portugues
a de Ribeirão Preto^sSP#^lpt^aOBJETIVO: Avaliar resultados do uso de alendronato
 de sódio em pós operatório de fratura transtrocanteriana. MÉTODO: Durante seis 
meses, 75 pacientes foram atendidos no Serviço de Ortopedia devido à fratura tra
nstrocanteriana de fêmur, sendo submetidos a tratamento cirúrgico com fixação at
ravés de placa DHS 135°. Foram selecionados 19 pacientes, hígidos, cooperativos,
 previamente deambuladores, classificados segundo Tronzo em tipo III e cujos qua
dris contra laterais não haviam sido submetidos a nenhuma cirurgia prévia, permi
tindo a realização de Densitometria Óssea Mineral no pós-operatório imediato e a
pós seis meses. Os pacientes foram divididos em grupos I e II, com e sem uso de 
alendronato de sódio, a partir do pós-operatório imediato, respectivamente. O se
guimento mínimo foi de seis meses. Após quatro semanas, os pacientes foram avali
ados de acordo com a Escala Visual Analógica de Dor (EVA), para observação do ín
dice de reabsorção óssea, a massa óssea e a consolidação radiológica da fratura.
 RESULTADOS: Houve uma tendência estatística de consolidação radiológica mais pr
ecoce com menor reabsorção óssea nos pacientes com uso de alendronato de sódio n
a pós-fratura com osteoporose estabelecida. CONCLUSÃO: Concluímos que, radiologi
camente, os pacientes que utilizaram alendronato de sódio tiveram uma consolidaç
ão óssea mais rápida, com menor índice de reabsorção.#^dnd^i1#^tm^lpt^kPós-opera
tório^i1#^tm^lpt^kFratura transtrocanteriana^i1#^tm^lpt^kAlendronato de sódio^i1
#^tm^lpt^kOsteoporose^i1#^tm^lpt^kRadiografia^i1#^tm^lpt^kConsolidação^i1#^len^a
OBJECTIVE: To evaluate the results of the use of alendronate sodium in postopera
tive transtrochanteric femoral fractures. METHOD: Over a six-month period, 75 pa
tients were treated at the Orthopedic Service for transtrochanteric femoral frac
tures, undergoing surgery with 135 degree DHS plate fixation. We selected 19 pat
ients who were healthy, cooperative, previously unable to walk, classified as ty
pe III according to Tronzo, whose contralateral hips had not undergone any previ
ous surgery, enabling the evaluation of bone mineral density (BMD) in the immedi
ate postoperative period and after six months. The patients were divided into gr
oups I and II, with and without the use of alendronate sodium in the immediate p
ostoperative period, respectively. The minimum follow-up was six months. After f
our weeks, the patients were evaluated according to the Visual Analogue Scale fo
r Pain (VAS) in order to verify the rate of bone resorption, bone mass and radio
logical consolidation of the fracture. RESULTS: There was a statistical trend of
 earlier radiological consolidation and lower bone resorption in patients with t
he use of alendronate sodium in post-fracture with established osteoporosis. CON
CLUSION: We concluded that radiologically, patients using alendronate sodium sho
wed faster bone consolidation, with a lower rate of resorption.#^dnd^i2#^tm^len^
kPost-surgery^i2#^tm^len^kTranstrochanteric femoral fracture^i2#^tm^len^kAlendro
nate sodium^i2#^tm^len^kOsteoporosis^i2#^tm^len^kRadiography^i2#^tm^len^kConsoli
dation^i2#other#18#20080912#12/09/08#20090612#12/06/09#10.htm#Internet^ihttp://w
ww.scielo.br/scielo.php?script=sci_arttext&pid=S1413-78522011000100010##
00343000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704012300067002000700190#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#5#1#article#109#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTIGO    ORIGINAL</b> </fon
t></p>     ^cY#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#6#2#article#109#<p>&nbsp;</p>     ^cY#10.htm
##
00411000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704019100067002000700258#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#7#3#article#109#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Fraturas    transtrocant
erianas: uso de alendronato no p&oacute;s-operat&oacute;rio</b></font></p>     ^
cY#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#8#4#article#109#<p>&nbsp;</p>     ^cY#10.htm
##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#9#5#article#109#<p>&nbsp;</p>     ^cY#10.htm
##
00484000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704026300068002000700331#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#10#6#article#109#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Francisco Jos&eacute;    Nunes Cardoso; A
ugusto Sadao Nakano; Marcel Frisene; Manoel Emilio de Freitas    Hereda; Bruno d
e Faria Batista; Paulo Rog&eacute;rio Cardozo Kanaji</b></font></p>     ^cY#10.h
tm##
00375000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704015400068002000700222#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#11#7#article#109#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2">Hospital Benefic&ecirc;ncia    Portuguesa de
 Ribeir&atilde;o Preto - SP</font></p>     ^cY#10.htm##
00369000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704014800068002000700216#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#12#8#article#109#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><a href="#back">Endere&ccedil;o    para Corr
espond&ecirc;ncia</a></font></p>     ^cY#10.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#13#9#article#109#<p>&nbsp;</p>     ^cY#10.ht
m##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#14#10#article#109#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#10.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#15#11#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#10.htm##
00435000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704021300069002000700282#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#16#12#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Avaliar resultados do u
so de alendronato de s&oacute;dio em p&oacute;s operat&oacute;rio    de fratura 
transtrocanteriana.    ^cY#10.htm##
01417000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704119500069002000701264#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#17#13#article#109#<br>   <b>M&Eacute;TODO:</
b> Durante seis meses, 75 pacientes foram atendidos no Servi&ccedil;o    de Orto
pedia devido &agrave; fratura transtrocanteriana de f&ecirc;mur, sendo    submet
idos a tratamento cir&uacute;rgico com fixa&ccedil;&atilde;o atrav&eacute;s    d
e placa DHS 135°. Foram selecionados 19 pacientes, h&iacute;gidos, cooperativos,
    previamente deambuladores, classificados segundo Tronzo em tipo III e cujos 
   quadris contra laterais n&atilde;o haviam sido submetidos a nenhuma cirurgia 
   pr&eacute;via, permitindo a realiza&ccedil;&atilde;o de Densitometria &Oacute
;ssea    Mineral no p&oacute;s-operat&oacute;rio imediato e ap&oacute;s seis mes
es. Os    pacientes foram divididos em grupos I e II, com e sem uso de alendrona
to de    s&oacute;dio, a partir do p&oacute;s-operat&oacute;rio imediato, respec
tivamente.    O seguimento m&iacute;nimo foi de seis meses. Ap&oacute;s quatro s
emanas, os    pacientes foram avaliados de acordo com a Escala Visual Anal&oacut
e;gica de    Dor (EVA), para observa&ccedil;&atilde;o do &iacute;ndice de reabso
r&ccedil;&atilde;o    &oacute;ssea, a massa &oacute;ssea e a consolida&ccedil;&a
tilde;o radiol&oacute;gica    da fratura.    ^cY#10.htm##
00524000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704030200069002000700371#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#18#14#article#109#<br>   <b>RESULTADOS:</b> 
Houve uma tend&ecirc;ncia estat&iacute;stica de consolida&ccedil;&atilde;o    ra
diol&oacute;gica mais precoce com menor reabsor&ccedil;&atilde;o &oacute;ssea   
 nos pacientes com uso de alendronato de s&oacute;dio na p&oacute;s-fratura com 
   osteoporose estabelecida.    ^cY#10.htm##
00501000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704027900069002000700348#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#19#15#article#109#<br>   <b>CONCLUS&Atilde;O
:</b> Conclu&iacute;mos que, radiologicamente, os pacientes    que utilizaram al
endronato de s&oacute;dio tiveram uma consolida&ccedil;&atilde;o    &oacute;ssea
 mais r&aacute;pida, com menor &iacute;ndice de reabsor&ccedil;&atilde;o.</font>
</p>     ^cY#10.htm##
00493000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704027100069002000700340#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#20#16#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Descritores:</b>    P&oacute;s-operat&oa
cute;rio, Fratura transtrocanteriana, Alendronato de s&oacute;dio,    Osteoporos
e; Radiografia. Consolida&ccedil;&atilde;o.</font></p> <hr size="1" noshade>    
 ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#21#17#article#109#<p>&nbsp;</p>     ^cY#10.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#22#18#article#109#<p>&nbsp;</p>     ^cY#10.h
tm##
00336000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011400069002000700183#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#23#19#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b></font></p> 
    ^cY#10.htm##
00815000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704059300069002000700662#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#24#20#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A fratura transtrocanteriana    ocorre em u
ma &aacute;rea entre o trocanter maior e o trocanter menor e &eacute;    extraca
psular. Em levantamentos de 1941 a 1971 citados por DeLee,<sup>1</sup>    a idad
e m&eacute;dia variou entre 66 e 76 anos. H&aacute; um predom&iacute;nio    do s
exo feminino na raz&atilde;o de 3,3:1,<sup>2</sup> com um aumento na frequ&ecirc
;ncia    quanto maior for a idade. O &iacute;ndice de mortalidade ap&oacute;s 12
 meses    da fratura &eacute; de aproximadamente 11,7%.<sup>3</sup></font></p>  
   ^cY#10.htm##
01359000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704113700069002000701206#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#25#21#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Este tipo de fratura    permanece um grande
 desafio aos ortopedistas nos dias atuais, n&atilde;o s&oacute;    pela grande m
orbimortalidade, mas tamb&eacute;m pelas dificuldades t&eacute;cnicas    de esta
biliza&ccedil;&atilde;o. Com o aumento da expectativa de vida da popula&ccedil;&
atilde;o,    o n&uacute;mero de casos de fraturas em idosos com osteoporose aume
ntou consideravelmente,    gerando gastos m&eacute;dico-hospitalares excessivos 
e problemas s&oacute;cio-familiares.    A combina&ccedil;&atilde;o da resist&eci
rc;ncia diminu&iacute;da do esqueleto    com o impacto do trauma &eacute; a caus
a desse tipo de fraturas na popula&ccedil;&atilde;o    senil, juntamente com a p
r&eacute;-disposi&ccedil;&atilde;o a quedas.<sup>4</sup>    A resist&ecirc;ncia 
de um osso est&aacute; diretamente relacionada &agrave;    sua densidade mineral
 &oacute;ssea, variando com a diminui&ccedil;&atilde;o    da atividade di&aacute
;ria, a remodela&ccedil;&atilde;o &oacute;ssea e a forma&ccedil;&atilde;o    de 
calo &oacute;sseo ap&oacute;s fraturas.<sup>5</sup></font></p>     ^cY#10.htm##
01029000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704080700069002000700876#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#26#22#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Em 1974, Tronzo<sup>6</sup>    subdividiu a
s fraturas transtrocanterianas em cinco tipos, sendo que no tipo    III (inst&aa
cute;vel) a di&aacute;fise est&aacute; medializada e o espor&atilde;o    proxima
l encaixado na mesma; havendo tamb&eacute;m fratura do grande trocanter,    &eac
ute; classificada como variante do tipo III. Para fixa&ccedil;&atilde;o    deste
 tipo de fratura, um dos implantes usados &eacute; o DHS, com &acirc;ngulo    de
 135°, pois seu ponto de entrada &eacute; mais cranial e o risco de enfraquecer 
   a cortical lateral do f&ecirc;mur pelo orif&iacute;cio de entrada do pino &ea
cute;    menor do que com o pino de 150°, apesar deste &uacute;ltimo ter maior f
acilidade    de telescopagem.<sup>7</sup></font></p>     ^cY#10.htm##
01334000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704111200069002000701181#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#27#23#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Atualmente, definimos    osteoporose como u
m dist&uacute;rbio metab&oacute;lico caracterizado pela diminui&ccedil;&atilde;o
    da densidade mineral &oacute;ssea, com deterioriza&ccedil;&atilde;o da micro
arquitetura    &oacute;ssea, levando a um aumento da fragilidade esquel&eacute;t
ica e do risco    de fraturas.<sup>8-11</sup> Acredita-se que 75% das fraturas q
ue ocorrem em    homens e mulheres acima de 45 anos estejam relacionadas &agrave
; osteoporose.<sup>4</sup>    A osteoporose prim&aacute;ria &eacute; subdividida
 em tipo I (p&oacute;s-menopausa)    e tipo II (senil). Riggs e Melton<sup>12</s
up> relacionaram a osteoporose tipo    II com a ocorr&ecirc;ncia de fraturas do 
quadril. A Densitometria Mineral &Oacute;ssea    (DMO) realizada por t&eacute;cn
ica de DEXA (absorciometria por raios-X com dupla    energia) &eacute; hoje o ex
ame de refer&ecirc;ncia para o diagn&oacute;stico    da osteoporose e fornece va
lores reprodut&iacute;veis em s&iacute;tios de fraturas    associadas &agrave; o
steoporose.<sup>9-13</sup></font></p>     ^cY#10.htm##
01419000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704119700069002000701266#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#28#24#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Para o tratamento    farmacol&oacute;gico d
a osteoporose, consideram-se como eficazes os f&aacute;rmacos    que primariamen
te reduzem o risco de fraturas, e s&atilde;o classificados em    dois grupos: es
timulantes da forma&ccedil;&atilde;o &oacute;ssea (PTH) e os    agentes anti-rea
bsortivos do tecido &oacute;sseo, que s&atilde;o drogas que    inibem a atividad
e osteocl&aacute;stica, como os Bisfosfonatos. Apesar disso,    at&eacute; 20% d
os pacientes ainda podem perder densidade mineral &oacute;ssea    no primeiro an
o ap&oacute;s o in&iacute;cio do tratamento com agentes anti-reabsortivos.<sup>9
</sup>    Estudos randomizados e placebo controlado com etidronato c&iacute;clic
o, alendronato    e risedronato revelaram um aumento na massa &oacute;ssea na co
luna e f&ecirc;mur    e redu&ccedil;&atilde;o no risco de fraturas vertebrais de
 30% a 50%.<sup>9</sup>    A dose recomendada de alendronato de s&oacute;dio pel
a FDA (Federal Drug Administration)    &eacute; 10 mg/dia ou 70 mg/semana por vi
a oral, n&atilde;o havendo ainda um    consenso sobre quanto tempo o medicamento
 deve ser usado.<sup>8-14</sup></font></p>     ^cY#10.htm##
00621000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704039900069002000700468#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#29#25#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O objetivo deste    trabalho foi avaliar o 
tempo de consolida&ccedil;&atilde;o &oacute;ssea cl&iacute;nica    e radiol&oacu
te;gica, a perda de massa &oacute;ssea e o grau de reabsor&ccedil;&atilde;o    n
o foco da fratura em pacientes com e sem o uso de alendronato de s&oacute;dio   
 no p&oacute;s-operat&oacute;rio.</font></p>     ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#30#26#article#109#<p>&nbsp;</p>     ^cY#10.h
tm##
00341000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011900069002000700188#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#31#27#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>MATERIAIS E    M&Eacute;TODOS</b></font>
</p>     ^cY#10.htm##
00685000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704046300069002000700532#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#32#28#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Entre maio e setembro    de 2005, setenta e
 cinco pacientes com fratura transtrocanteriana de f&ecirc;mur    foram internad
os e tratados cirurgicamente no Servi&ccedil;o de Ortopedia. O    servi&ccedil;o
 faz parte da DIR dezoito, recebendo pacientes regulados pela    Central de Regu
la&ccedil;&atilde;o M&eacute;dica, de acordo com as vagas dispon&iacute;veis    
em cada hospital.</font></p>     ^cY#10.htm##
00470000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704024800069002000700317#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#33#29#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Os procedimentos    seguiram as normas do C
omite &Eacute;tico sobre Experi&ecirc;ncias Humanas do    Hospital Benefic&ecirc
;ncia Portuguesa de Ribeir&atilde;o Preto.</font></p>     ^cY#10.htm##
01057000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704083500069002000700904#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#34#30#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Desses setenta    e cinco pacientes atendid
os no servi&ccedil;o, dezenove pacientes (25,3%) foram    consultados e selecion
ados para a realiza&ccedil;&atilde;o do estudo, considerando    aqueles h&iacute
;gidos, cooperativos, previamente deambuladores, classificados    segundo Tronzo
 em tipo III, e cujos quadris contra laterais n&atilde;o haviam    sido submetid
os a nenhuma cirurgia pr&eacute;via, permitindo a realiza&ccedil;&atilde;o    de
 Densitometria &Oacute;ssea Mineral, segundo protocolo empregado. No atendimento
    inicial, foi realizado estudo radiol&oacute;gico em antero-posterior de baci
a    e perfil de quadril acometido e avalia&ccedil;&atilde;o pela Classifica&cce
dil;&atilde;o    de Singh para osteoporose em quadril contra lateral.</font></p>
     ^cY#10.htm##
00582000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704036000069002000700429#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#35#31#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A mediana da idade    dos pacientes selecio
nados foi de 73 anos (variando de 53 a 93 anos); sendo    cinco do sexo masculin
o (26,32%) e quatorze do sexo feminino (73,68%). O lado    direito foi acometido
 em onze pacientes (57,9%) e o lado esquerdo em oito pacientes    (42,1%).</font
></p>     ^cY#10.htm##
01350000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704112800069002000701197#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#36#32#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Os pacientes foram    submetidos &agrave; r
edu&ccedil;&atilde;o cir&uacute;rgica em mesa ortop&eacute;dica    com auxilio d
e radioscopia, atrav&eacute;s de tra&ccedil;&atilde;o longitudinal    e rota&cce
dil;&atilde;o interna do membro acometido, sendo a cirurgia realizada    pela me
sma equipe, procurando fazer a redu&ccedil;&atilde;o mais anat&ocirc;mica    pos
s&iacute;vel, seguindo os m&eacute;todos da AO de coloca&ccedil;&atilde;o    da 
placa DHS, com angula&ccedil;&atilde;o de 135º, sem o uso do pino anti-rotat&oac
ute;rio.    A cirurgia demorou em m&eacute;dia uma hora e trinta minutos. Os pac
ientes receberam    alta hospitalar no segundo dia de p&oacute;s-operat&oacute;r
io, ap&oacute;s    realiza&ccedil;&atilde;o de Densitometria &Oacute;ssea Minera
l no quadril contra    lateral. Foram orientados quanto ao uso de antiinflamat&o
acute;rio por cinco    dias, antibi&oacute;tico por sete dias, profilaxia medica
mentosa para trombose    venosa profunda e movimenta&ccedil;&atilde;o ativa e pa
ssiva dos membros inferiores    sem carga.</font></p>     ^cY#10.htm##
00738000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704051600069002000700585#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#37#33#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Para a realiza&ccedil;&atilde;o    do estud
o, foram divididos aleatoriamente dois grupos: grupo I, no qual os pacientes    
fizeram uso de alendronato de s&oacute;dio na dose de 70 mg/semana por via oral 
   a partir do p&oacute;s-operat&oacute;rio imediato, e grupo II (controle), no 
   qual os pacientes n&atilde;o fizeram uso do medicamento. O medicamento foi fo
rnecido    aos pacientes sem &ocirc;nus durante o tratamento completo.</font></p
>     ^cY#10.htm##
01133000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704091100069002000700980#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#38#34#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Todos os pacientes    foram seguidos por pe
r&iacute;odo m&iacute;nimo de seis meses, com controle    radiol&oacute;gico per
i&oacute;dico na segunda, quarta, sexta, oitava, d&eacute;cima-segunda,    d&eac
ute;cima-sexta, vig&eacute;sima e vig&eacute;sima-quarta semanas. O exame    rad
iol&oacute;gico foi feito com o paciente em dec&uacute;bito dorsal, com a    amp
ola centrada na pelve a uma de dist&acirc;ncia de um metro da mesma. Todos    fo
ram submetidos &agrave; outra Densitometria &Oacute;ssea Mineral na vig&eacute;s
ima-quarta    semana de p&oacute;s-operat&oacute;rio. Foi permitida carga parcia
l com andador    na quarta semana, junto com o m&eacute;dico respons&aacute;vel,
 sendo os pacientes    avaliados quanto &agrave; Escala Visual Anal&oacute;gica 
de Dor (EVA) no momento    da carga. (<a href="#f1">Figura 1</a>)</font></p>    
 ^cY#10.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#39#35#article#109#<p><a name="f1"></a></p>  
   ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#40#36#article#109#<p>&nbsp;</p>     ^cY#10.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#41#37#article#109#<p align="center"><img src
="/img/revistas/aob/v19n1/10f01.jpg"></p>     ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#42#38#article#109#<p>&nbsp;</p>     ^cY#10.h
tm##
00616000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704039400069002000700463#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#43#39#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Nas radiografias    com evid&ecirc;ncia de 
consolida&ccedil;&atilde;o &oacute;ssea, foi feita a    an&aacute;lise do desliz
amento do parafuso no canh&atilde;o da placa (extrus&atilde;o),    medindo a dis
t&acirc;ncia da borda da placa do DHS &agrave; cabe&ccedil;a do    contra pino. 
(<a href="#f2">Figura 2</a>)</font></p>     ^cY#10.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#44#40#article#109#<p><a name="f2"></a></p>  
   ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#45#41#article#109#<p>&nbsp;</p>     ^cY#10.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#46#42#article#109#<p align="center"><img src
="/img/revistas/aob/v19n1/10f02.jpg"></p>     ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#47#43#article#109#<p>&nbsp;</p>     ^cY#10.h
tm##
00436000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704021400069002000700283#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#48#44#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Todos os par&acirc;metros    e dados encont
rados foram avaliados estatisticamente pelo m&eacute;todo <i>t</i>    de <i>Stud
ent.</i></font></p>     ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#49#45#article#109#<p>&nbsp;</p>     ^cY#10.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#50#46#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>     ^cY#10.htm
##
01458000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704123600069002000701305#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#51#47#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Foram estudados    dezenove pacientes separ
ados em dois grupos: no grupo I foram selecionados nove    pacientes que receber
am alendronato de s&oacute;dio no p&oacute;s-operat&oacute;rio    com dose de 70
mg por via oral, uma vez por semana. A idade m&eacute;dia foi    de 76,6 anos, s
endo 20,2% do sexo masculino e 79,8% do sexo feminino, com diagn&oacute;stico   
 de osteoporose em 100% dos pacientes. O tratamento cir&uacute;rgico foi realiza
do    de acordo com o protocolo estabelecido por esse estudo. Neste grupo, um pa
ciente    perdeu continuidade ao tratamento, outro foi a &oacute;bito devido a c
omplica&ccedil;&otilde;es    cardiopulmonares e um terceiro sofreu uma nova qued
a, evoluindo com uma re-fratura.    O tempo m&eacute;dio de consolida&ccedil;&at
ilde;o radiol&oacute;gica foi de    7,6 semanas, com a m&eacute;dia da escala vi
sual anal&oacute;gica para dor (EVA)    de 1,57 pontos, uma varia&ccedil;&atilde
;o de massa &oacute;ssea densitom&eacute;trica    com diminui&ccedil;&atilde;o d
e 1,04%, tendo uma m&eacute;dia de reabsor&ccedil;&atilde;o    do foco de fratur
a de 2,3mm. (<a href="/img/revistas/aob/v19n1/10t01.jpg">Tabela 1</a>)</font></p
>     ^cY#10.htm##
01263000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704104100069002000701110#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#52#48#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">No grupo II foram    selecionados dez pacie
ntes que n&atilde;o fizeram uso de alendronato de s&oacute;dio    no p&oacute;s-
operat&oacute;rio, sendo 30% do sexo masculino e 70% do sexo feminino,    com id
ade m&eacute;dia de 75,6 anos. O diagn&oacute;stico de osteoporose foi    estabe
lecido em 70% dos pacientes e o tratamento cir&uacute;rgico foi realizado    de 
acordo com o protocolo estabelecido por esse estudo. Neste grupo, tr&ecirc;s    
pacientes foram a &oacute;bito no per&iacute;odo p&oacute;s-operat&oacute;rio.  
  O tempo m&eacute;dio de consolida&ccedil;&atilde;o radiol&oacute;gica foi de  
  11 semanas, com a m&eacute;dia da escala visual anal&oacute;gica para dor (EVA
)    de 1,57 pontos, uma varia&ccedil;&atilde;o de massa &oacute;ssea densitom&e
acute;trica    com diminui&ccedil;&atilde;o de 1,6%, tendo uma m&eacute;dia de r
eabsor&ccedil;&atilde;o    do foco de fratura de 2,57mm. (<a href="/img/revistas
/aob/v19n1/10t02.jpg">Tabela 2</a>)</font></p>     ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#53#49#article#109#<p>&nbsp;</p>     ^cY#10.h
tm##
00328000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010600069002000700175#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#54#50#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font></p>     ^cY#
10.htm##
00529000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704030700069002000700376#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#55#51#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A fratura transtrocanteriana    &eacute; ca
usa importante de morbidade e mortalidade em idosos, responsabilizando-se    por
 grande parte das cirurgias e ocupa&ccedil;&atilde;o de leitos em enfermidades  
  ortop&eacute;dicas.</font></p>     ^cY#10.htm##
00811000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704058900069002000700658#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#56#52#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O &iacute;ndice    de mortalidade dos pacie
ntes em estudo, ap&oacute;s 12 meses de seguimento,    foi de 20%, sendo 11,1% n
o grupo I, e 30 % no grupo II. Esta taxa de mortalidade    &eacute; semelhante &
agrave;s encontradas na literatura, que relata varia&ccedil;&atilde;o    de 12 a
 24% no primeiro ano.<sup>15</sup> A dem&ecirc;ncia, o <i>delirium</i>    e a de
press&atilde;o aumentam o risco de mortalidade nos dois anos p&oacute;s-fratura 
   de f&ecirc;mur, chegando a 30 % em 24 meses.<sup>16,17</sup></font></p>     ^
cY#10.htm##
01724000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704150200069002000701571#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#57#53#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Os valores absolutos    de massa &oacute;ss
ea, obtidos com a realiza&ccedil;&atilde;o de dois exames    de DMO com a t&eacu
te;cnica de DEXA, s&atilde;o utilizados comparativamente    para monitorar mudan
&ccedil;as da densidade mineral &oacute;ssea ao longo do    tempo, avaliando a e
volu&ccedil;&atilde;o da doen&ccedil;a e a efic&aacute;cia    terap&ecirc;utica.
 Os pacientes do grupo I, os quais fizeram uso de alendronato    de s&oacute;dio
 a partir do p&oacute;s-operat&oacute;rio imediato tiveram uma    perda de massa
 &oacute;ssea m&eacute;dia de 1,04% comparada com 1,60% do grupo    II, que n&at
ilde;o fez uso. Estes valores n&atilde;o foram estatisticamente    significativo
s (p&gt;0,05), apesar dos pacientes do grupo I terem perdido uma    quantidade m
enor de massa &oacute;ssea. As altera&ccedil;&otilde;es de massa    &oacute;ssea
 resultantes de interven&ccedil;&otilde;es terap&ecirc;uticas s&atilde;o    cons
ideradas modestas na literatura, uma vez que a resposta &agrave; terap&ecirc;uti
ca    n&atilde;o &eacute; uniforme em todos os indiv&iacute;duos. Os estudos mos
tram    que at&eacute; 20% dos pacientes podem apresentar redu&ccedil;&atilde;o 
de massa    &oacute;ssea no primeiro ano ap&oacute;s inicio do tratamento; consi
derando    como efic&aacute;cia terap&ecirc;utica uma redu&ccedil;&atilde;o na v
elocidade    de reabsor&ccedil;&atilde;o, que &eacute; em m&eacute;dia de 4% ao 
ano.<sup>9</sup></font></p>     ^cY#10.htm##
01210000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704098800069002000701057#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#58#54#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A partir dos exames    radiol&oacute;gicos,
 foi avaliado o &iacute;ndice de reabsor&ccedil;&atilde;o    &oacute;ssea segund
o o protocolo estabelecido e o grupo I obteve um &iacute;ndice    de reabsor&cce
dil;&atilde;o menor (2,33mm) se comparado com os 2,57mm do grupo    II, contudo 
estes dados n&atilde;o foram estatisticamente significativos (p&gt;0,05).    &Ea
cute; v&aacute;lido ressaltar que houve uma intercorr&ecirc;ncia com um paciente
    do grupo I, que sofreu uma nova queda, sendo submetido a uma segunda interve
n&ccedil;&atilde;o    cir&uacute;rgica, n&atilde;o sendo inclu&iacute;da a medid
a da extrus&atilde;o    do contra pino neste estudo comparativo. Com base no tra
balho de Canto <i>et    al.</i><sup>16</sup>, que quantificaram o deslizamento d
o parafuso no canh&atilde;o    da placa, obtivemos 100% de telescopagem entre ze
ro e cinco mil&iacute;metros    no grupo I, e 75% no grupo II.</font></p>     ^c
Y#10.htm##
00734000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704051200069002000700581#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#59#55#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Os pacientes foram    submetidos a controle
 radiol&oacute;gico peri&oacute;dico, de acordo com a metodologia,    para avali
a&ccedil;&atilde;o da consolida&ccedil;&atilde;o. A m&eacute;dia de    consolida
&ccedil;&atilde;o radiol&oacute;gica do grupo I foi de 7,6 semanas    se compara
do ao grupo II, cuja m&eacute;dia foi de 11 semanas. Estes dados parecem    ser 
estatisticamente significativos (p=0,086), considerando p&gt;0,05.</font></p>   
  ^cY#10.htm##
01077000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704085500069002000700924#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#60#56#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A Escala Visual    Anal&oacute;gica da Dor 
(EVA),<sup>18</sup> feita com express&otilde;es faciais    correlacionadas com u
ma escala num&eacute;rica de zero a dez, foi utilizada    para quantifica&ccedil
;&atilde;o da dor. &Eacute; importante salientar que a    dor &eacute; um sintom
a, sendo este subjetivo, e que n&atilde;o foi discriminado    pelo sexo devido &
agrave; baixa amostragem do sexo masculino. O par&acirc;metro    foi utilizado p
ara correlacionar uma consolida&ccedil;&atilde;o radiol&oacute;gica    mais prec
oce com menor intensidade de dor no in&iacute;cio da marcha (quatro    semanas),
 n&atilde;o havendo nenhuma altera&ccedil;&atilde;o significativa nos    grupos 
I e II, sem dados na literatura para an&aacute;lise comparativa deste    par&aci
rc;metro.</font></p>     ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#61#57#article#109#<p>&nbsp;</p>     ^cY#10.h
tm##
00328000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010600069002000700175#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#62#58#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>CONCLUS&Atilde;O</b></font></p>     ^cY#
10.htm##
00527000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704030500069002000700374#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#63#59#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Conclu&iacute;mos    que radiologicamente o
s pacientes em uso de alendronato de s&oacute;dio tiveram    uma consolida&ccedi
l;&atilde;o &oacute;ssea mais r&aacute;pida com menor &iacute;ndice    de reabso
r&ccedil;&atilde;o.</font></p>     ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#64#60#article#109#<p>&nbsp;</p>     ^cY#10.h
tm##
00329000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010700069002000700176#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#65#61#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font></p>     ^cY
#10.htm##
00476000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704024000071002000700311#v19
n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#p#66#62#article#109#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1. DeLee JC. Fractures    and
 dislocations of the hip in fractures in adults. In: Rockwood CA Jr, Green    DP
, editors. Philadelphia: J.B. Lippincott; 1984. p. 1211-356.    ^cY#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#67#63#article#109#</font></p>     ^cY#10.htm
##
00561000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704032500071002000700396#v19
n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#p#68#64#article#109#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2. Ramalho AC,    Lazaretti-C
astro M, Hauache O, Vieira JG, Takata E, Cafalli F et al. Osteoporotic    fractu
res of proximal femur: clinical and epidemiological features in a population    
of the city of S&atilde;o Paulo. Sao Paulo Med J. 2001;119:48-53.    ^cY#10.htm#
#
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#69#65#article#109#</font></p>     ^cY#10.htm
##
00494000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704025800071002000700329#v19
n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#p#70#66#article#109#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">3. R&ouml;der F,    Schwab M,
 Aleker T, M&ouml;rike K, Thon KP, Klotz U. Proximal femur fracture    in older 
patients - rehabilitation and clinical outcome. Age Ageing. 2003;32:74-    89.  
  ^cY#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#71#67#article#109#</font></p>     ^cY#10.htm
##
00457000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704022100071002000700292#v19
n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#p#72#68#article#109#4#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">4. Stolnicki B,    Aronson D.
 Avalia&ccedil;&atilde;o densitometria em portadores de fraturas osteopor&oacute
;ticas.    Rev Bras Ortop. 1993;28:304-8.    ^cY#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#73#69#article#109#</font></p>     ^cY#10.htm
##
00468000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704023200071002000700303#v19
n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#p#74#70#article#109#5#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">5. Iida Y, Kuroda    T, Kitan
o T, Mizuno K. Dexa-measured bone density changes over time after intertrochante
ric    hip fractures. Kobe J Med Sci. 2000;46: 1-12.    ^cY#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#75#71#article#109#</font></p>     ^cY#10.htm
##
00400000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704016400071002000700235#v19
n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#p#76#72#article#109#6#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">6. Tronzo RG. Special    cons
iderations in management. Orthop Clin North Am 5: 571-583, 1974.    ^cY#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#77#73#article#109#</font></p>     ^cY#10.htm
##
00384000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704014800071002000700219#v19
n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#p#78#74#article#109#7#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">7. Koberle G. Fraturas    tra
nstrocanterianas. Rev Bras Ortop. 2001;36:325-9.    ^cY#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#79#75#article#109#</font></p>     ^cY#10.htm
##
00489000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704025300071002000700324#v19
n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#p#80#76#article#109#8#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">8. Guarnieiro R,    Oliveira 
LG. Osteoporose: atualiza&ccedil;&atilde;o no diagn&oacute;stico e    princ&iacu
te;pios b&aacute;sicos para o tratamento. Rev Bras Ortop. 2004;39:477-85.    ^cY
#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#81#77#article#109#</font></p>     ^cY#10.htm
##
00467000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704023100071002000700302#v19
n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#p#82#78#article#109#9#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">9. Pinto Neto AM,    Soares A
, Urbanetz AA, Souza AC, Ferrari AE, Amaral B et al. Consenso Brasileiro    de O
steoporose 2002. Rev Bras Reumatol. 2002;42:343-54.    ^cY#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#83#79#article#109#</font></p>     ^cY#10.htm
##
00633000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704039600072002000700468#v19
n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#p#84#80#article#109#10#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">10. Harris ST,    Watts NB, 
Genant HK, McKeever CD, Hangartner T, Keller M et al. Effects of risedronate    
treatment on vertebral and nonvertebral fractures in women with postmenopausal  
  osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedrona
te    Therapy (VERT) Study Group. JAMA. 1999;282:1344-52.    ^cY#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#85#81#article#109#</font></p>     ^cY#10.htm
##
00604000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704036700072002000700439#v19
n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#p#86#82#article#109#11#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">11. Reginster J,    Minne HW
, Sorensen OH, Hooper M, Roux C, Brandi ML et al. Randomized trial of    the eff
ects of risedronate on fractures in women with established postmenopausal    ost
eoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.    Os
teoporos Int. 2000;11:83-91.    ^cY#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#87#83#article#109#</font></p>     ^cY#10.htm
##
00454000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704021700072002000700289#v19
n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#p#88#84#article#109#12#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">12. Riggis BL,    Melton LJ 
3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology.  
  Bone. 1995 Nov;17(5 Suppl):505S-11S.    ^cY#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#89#85#article#109#</font></p>     ^cY#10.htm
##
00480000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704024300072002000700315#v19
n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#p#90#86#article#109#13#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">13. Lu Y, Genant    HK, Shep
herd J, Zhao S, Mathur A, Fuerst TP et al. Classification of osteoporosis    bas
ed on bone mineral densities. J Bone Miner Res. 2001;16: 901-10.    ^cY#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#91#87#article#109#</font></p>     ^cY#10.htm
##
00570000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704033300072002000700405#v19
n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#p#92#88#article#109#14#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">14. Black DM, Cummings    SR
, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al. Randomized trial of effect 
   of alendronate on risk of fracture in women with existing vertebral fractures
.    Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-41.    ^c
Y#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#93#89#article#109#</font></p>     ^cY#10.htm
##
00429000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704019200072002000700264#v19
n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#p#94#90#article#109#15#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">15. Huddleston    JM, Whitfo
rd KJ. Medical care of elderly patients with hip fractures. Mayo Clin    Proc. 2
001;76:295-8.    ^cY#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#95#91#article#109#</font></p>     ^cY#10.htm
##
00469000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704023200072002000700304#v19
n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#p#96#92#article#109#16#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">16. Canto RST,    Luciano RC
, Souza MR, Ilton J, Martins AP. Uso do DHS no tratamento das fraturas    intert
rocant&eacute;ricas. Rev Bras Ortop. 1996;31:1007-12.    ^cY#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#97#93#article#109#</font></p>     ^cY#10.htm
##
00479000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704024200072002000700314#v19
n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#p#98#94#article#109#17#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">17. Cunha U, Veado    MA. Fr
atura da extremidade proximal do f&ecirc;mur em idoso: independ&ecirc;ncia    fu
ncional e mortalidade em um ano. Rev Bras Ortop. 2006;41:195-9.    ^cY#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#99#95#article#109#</font></p>     ^cY#10.htm
##
00534000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000300070704029600073002000700369#v19
n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#p#100#96#article#109#18#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">18. Polesello GC,    Honda 
EK, Ono NK, Guimar&atilde;es RP, Oliveira LA, Boulos- Dumans M et al.    Artrosc
opia do quadril: experi&ecirc;ncia ap&oacute;s seguimento m&eacute;dio    de 33 
meses. Rev Bras Ortop. 2006;41:145-50.    ^cY#10.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#101#97#article#109#</font></p>     ^cY#10.ht
m##
00245000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002200070002000700092#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#102#98#article#109#<p>&nbsp;</p>     ^cY#10.
htm##
00245000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002200070002000700092#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#103#99#article#109#<p>&nbsp;</p>     ^cY#10.
htm##
00430000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704020600071002000700277#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#104#100#article#109#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top"><img sr
c="/img/revistas/aob/v19n1/seta.jpg" border="0"></a>    <b>Endereço para Corresp
ondência:</b>     ^cY#10.htm##
00262000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003800071002000700109#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#105#101#article#109#<br>   Rua Rui Barbosa, 
nº 330    ^cY#10.htm##
00281000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005700071002000700128#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#106#102#article#109#<br>   Centro. Ribeir&at
ilde;o Preto -SP - Brasil    ^cY#10.htm##
00253000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002900071002000700100#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#107#103#article#109#<br>   CEP: 14091-220   
 ^cY#10.htm##
00470000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704024600071002000700317#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#108#104#article#109#<br>   E-mail: <a href="
mailto:nakanomed@yahoo.com.br">nakanomed@yahoo.com.br</a>,    <a href="mailto:di
rceu.lima@gmail.com">dirceu.lima@gmail.com</a>, <a href="mailto:marcelfrisene@ho
tmail.com">marcelfrisene@hotmail.com</a></font>  </p>     ^cY#10.htm##
00357000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013300071002000700204#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#109#105#article#109#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Artigo recebido    em 12/09/08, aprovado 
12/06/09.</font></p>     ^cY#10.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#110#106#article#109#<p>&nbsp;</p>     ^cY#10
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#111#107#article#109#<p>&nbsp;</p>     ^cY#10
.htm##
00439000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704021500071002000700286#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#112#108#article#109#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Trabalho realizado    no Servi&ccedil;o d
e Ortopedia e Traumatologia do Hospital Benefic&ecirc;ncia    Portuguesa de Ribe
ir&atilde;o Preto - SP.    ^cY#10.htm##
00361000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013700071002000700208#v19n1#V:\SciELO
\serial\aob\v19n1\markup\10.htm#S#p#113#109#article#109#<br>   Todos os autores 
declaram n&atilde;o haver nenhum potencial conflito de interesses    referente a
 este artigo.</font></p>     ^cY#10.htm##
00523000000000265000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700120065000860160
02200151016001600173066001300189062001600202065000900218064000500227014000900232
865000900241002000700250#v19n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#c#114#
1#article#18#1#^rND^sDeLee^nJC#Fractures and dislocations of the hip in fracture
s in adults^len#^rED^sRockwood^nCA Jr#^rED^sGreen^nDP#Philadelphia#J.B. Lippinco
tt#19840000#1984#1211-356#20110000#10.htm##
00696000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100026000880100
01700114010001700131010001600148010001700164810000600181012012500187030001600312
71000020032806500090033006400050033903100040034401400060034886500090035400200070
0363#v19n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#c#115#2#article#18#2#^rND^
sRamalho^nAC#^rND^sLazaretti-Castro^nM#^rND^sHauache^nO#^rND^sVieira^nJG#^rND^sT
akata^nE#^rND^sCafalli^nF#et al#Osteoporotic fractures of proximal femur: clinic
al and epidemiological features in a population of the city of São Paulo^len#Sao
 Paulo Med J#2#20010000#2001#119#48-53#20110000#10.htm##
00644000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100015000700100016000850100
01600101010001600117010001500133010001500148012008300163030001100246065000900257
06400050026603100030027101400070027486500090028100200070029003500100029780100110
0307#v19n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#c#116#3#article#18#3#^rND^
sRöder^nF#^rND^sSchwab^nM#^rND^sAleker^nT#^rND^sMörike^nK#^rND^sThon^nKP#^rND^sK
lotz^nU#Proximal femur fracture in older patients: rehabilitation and clinical o
utcome^len#Age Ageing#20030000#2003#32#74- 89#20110000#10.htm#0002-0729#Age agei
ng##
00532000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700100017000890120
06900106030001500175065000900190064000500199031000300204014000600207865000900213
002000700222035001000229801001500239#v19n1#V:\SciELO\serial\aob\v19n1\markup\10.
htm#S#c#117#4#article#18#4#^rND^sStolnicki^nB#^rND^sAronson^nD#Avaliação densito
metria em portadores de fraturas osteoporóticas^lpt#Rev Bras Ortop#19930000#1993
#28#304-8#20110000#10.htm#0486-6401#Rev Bras Ortop##
00599000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100014000700100016000840100
01600100010001600116012008700132030001500219065000900234064000500243031000300248
014000500251865000900256002000700265035001000272801001500282#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\10.htm#S#c#118#5#article#18#5#^rND^sIida^nY#^rND^sKuroda^nT
#^rND^sKitano^nT#^rND^sMizuno^nK#Dexa-measured bone density changes over time af
ter intertrochanteric hip fractures^len#Kobe J Med Sci#20000000#2000#46#1-12#201
10000#10.htm#0023-2513#Kobe J Med Sci##
00486000000000265000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700120041000870300
02100128031000200149014000800151065000900159064000500168865000900173002000700182
035001000189801002100199#v19n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#c#119#
6#article#18#6#^rND^sTronzo^nRG#Special considerations in management^len#Orthop 
Clin North Am#5#571-583#19740000#1974#20110000#10.htm#0030-5898#Orthop Clin Nort
h Am##
00465000000000265000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700120033000870300
01500120065000900135064000500144031000300149014000600152865000900158002000700167
035001000174801001500184#v19n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#c#120#
7#article#18#7#^rND^sKoberle^nG#Fraturas transtrocanterianas^lpt#Rev Bras Ortop#
20010000#2001#36#325-9#20110000#10.htm#0486-6401#Rev Bras Ortop##
00550000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100020000700100019000900120
08300109030001500192065000900207064000500216031000300221014000700224865000900231
002000700240035001000247801001500257#v19n1#V:\SciELO\serial\aob\v19n1\markup\10.
htm#S#c#121#8#article#18#8#^rND^sGuarnieiro^nR#^rND^sOliveira^nLG#Osteoporose: a
tualização no diagnóstico e princípios básicos para o tratamento^lpt#Rev Bras Or
top#20040000#2004#39#477-85#20110000#10.htm#0486-6401#Rev Bras Ortop##
00612000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100021000700100016000910100
01900107010001600126010001800142010001600160810000600176012004400182030001800226
71000020024406500090024606400050025503100030026001400070026386500090027000200070
0279#v19n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#c#122#9#article#18#9#^rND^
sPinto Neto^nAM#^rND^sSoares^nA#^rND^sUrbanetz^nAA#^rND^sSouza^nAC#^rND^sFerrari
^nAE#^rND^sAmaral^nB#et al#Consenso Brasileiro de Osteoporose 2002^lpt#Rev Bras 
Reumatol#2#20020000#2002#42#343-54#20110000#10.htm##
00797000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100016000890100
01700105010001900122010002000141010001600161810000600177012021400183030000500397
06500090040206400050041103100040041601400080042086500090042800200070043703500100
0444801000500454#v19n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#c#123#10#artic
le#18#10#^rND^sHarris^nST#^rND^sWatts^nNB#^rND^sGenant^nHK#^rND^sMcKeever^nCD#^r
ND^sHangartner^nT#^rND^sKeller^nM#et al#Effects of risedronate treatment on vert
ebral and nonvertebral fractures in women with postmenopausal osteoporosis: a ra
ndomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) St
udy Group^len#JAMA#19990000#1999#282#1344-52#20110000#10.htm#0098-7484#JAMA##
00778000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100016000910100
01900107010001600126010001400142010001700156810000600173012018200179030001500361
06500090037606400050038503100030039001400060039386500090039900200070040803500100
0415801001500425#v19n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#c#124#11#artic
le#18#11#^rND^sReginster^nJ#^rND^sMinne^nHW#^rND^sSorensen^nOH#^rND^sHooper^nM#^
rND^sRoux^nC#^rND^sBrandi^nML#et al#Randomized trial of the effects of risedrona
te on fractures in women with established postmenopausal osteoporosis: Vertebral
 Efficacy with Risedronate Therapy (VERT) Study Group^len#Osteoporos Int#2000000
0#2000#11#83-91#20110000#10.htm#0937-941X#Osteoporos Int##
00552000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100021000890120
07700110030000500187065000900192064000900201031000300210032000900213014000900222
865000900231002000700240035001000247801000500257#v19n1#V:\SciELO\serial\aob\v19n
1\markup\10.htm#S#c#125#12#article#18#12#^rND^sRiggis^nBL#^rND^sMelton^nLJ 3rd#T
he worldwide problem of osteoporosis: insights afforded by epidemiology^len#Bone
#19951100#1995 Nov#17#5^sSuppl#505S-11S#20110000#10.htm#8756-3282#Bone##
00661000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100012000720100017000840100
01800101010001400119010001600133010001700149810000600166012006700172030001700239
06500090025606400050026503100030027001400070027386500090028000200070028903500100
0296801001700306#v19n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#c#126#13#artic
le#18#13#^rND^sLu^nY#^rND^sGenant^nHK#^rND^sShepherd^nJ#^rND^sZhao^nS#^rND^sMath
ur^nA#^rND^sFuerst^nTP#et al#Classification of osteoporosis based on bone minera
l densities^len#J Bone Miner Res#20010000#2001#16#901-10#20110000#10.htm#0884-04
31#J Bone Miner Res##
00739000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100019000880100
01600107010001700123010001900140010001700159810000600176012015300182030000700335
06500090034206400050035103100040035601400080036086500090036800200070037703500100
0384801000700394#v19n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#c#127#14#artic
le#18#14#^rND^sBlack^nDM#^rND^sCummings^nSR#^rND^sKarpf^nDB#^rND^sCauley^nJA#^rN
D^sThompson^nDE#^rND^sNevitt^nMC#et al#Randomized trial of effect of alendronate
 on risk of fracture in women with existing vertebral fractures: Fracture Interv
ention Trial Research Group^len#Lancet#19960000#1996#348#1535-41#20110000#10.htm
#0099-5355#Lancet##
00525000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100019000930120
05600112030001500168065000900183064000500192031000300197014000600200865000900206
002000700215035001000222801001500232#v19n1#V:\SciELO\serial\aob\v19n1\markup\10.
htm#S#c#128#15#article#18#15#^rND^sHuddleston^nJM#^rND^sWhitford^nKJ#Medical car
e of elderly patients with hip fractures^len#Mayo Clin Proc#20010000#2001#76#295
-8#20110000#10.htm#0025-6196#Mayo Clin Proc##
00612000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100018000890100
01600107010001500123010001800138012006100156030001500217065000900232064000500241
031000300246014000800249865000900257002000700266035001000273801001500283#v19n1#V
:\SciELO\serial\aob\v19n1\markup\10.htm#S#c#129#16#article#18#16#^rND^sCanto^nRS
T#^rND^sLuciano^nRC#^rND^sSouza^nMR#^rND^sIlton^nJ#^rND^sMartins^nAP#Uso do DHS 
no tratamento das fraturas intertrocantéricas^lpt#Rev Bras Ortop#19960000#1996#3
1#1007-12#20110000#10.htm#0486-6401#Rev Bras Ortop##
00563000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100016000870120
10300103030001500206065000900221064000500230031000300235014000600238865000900244
002000700253035001000260801001500270#v19n1#V:\SciELO\serial\aob\v19n1\markup\10.
htm#S#c#130#17#article#18#17#^rND^sCunha^nU#^rND^sVeado^nMA#Fratura da extremida
de proximal do fêmur em idoso: independência funcional e mortalidade em um ano^l
pt#Rev Bras Ortop#20060000#2006#41#195-9#20110000#10.htm#0486-6401#Rev Bras Orto
p##
00683000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100016000920100
01400108010002000122010001900142010002400161810000600185012007400191030001500265
06500090028006400050028903100030029401400070029786500090030400200070031303500100
0320801001500330#v19n1#V:\SciELO\serial\aob\v19n1\markup\10.htm#S#c#131#18#artic
le#18#18#^rND^sPolesello^nGC#^rND^sHonda^nEK#^rND^sOno^nNK#^rND^sGuimarães^nRP#^
rND^sOliveira^nLA#^rND^sBoulos- Dumans^nM#et al#Artroscopia do quadril: experiên
cia após seguimento médio de 33 meses^lpt#Rev Bras Ortop#20060000#2006#41#145-50
#20110000#10.htm#0486-6401#Rev Bras Ortop##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v19n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#o#1#1#article#1#201104
11#111916#11.htm#144##
03988000000000637000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083121000300087049000700090158000300097030001800100
03100030011803200020012106500090012301400090013203500100014101200760015101200820
02270100036003090100042003450100034003870100041004210100033004620100040004950700
03900535083123700574085000801811085003001819085001901849085003501868085002501903
08312490192808500080317708500270318508500170321208500440322908500250327311700060
3298072000303304112000903307111000903316114000903325113000903334002000703343#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#
TAB#11#AOB160#nd#Acta ortop. bras.#19#1#20110000#^f49^l51#1413-7852#Complicações
 das endopróteses em pacientes com tumores ósseos do joelho^lpt#Endoprostheses-r
elated complications in patients with bone tumors of the knee^len#^rND^1A01^nVin
icius Ynoe de^sMoraes#^rND^1A01^nGuilherme Conforto^sGracitelli#^rND^1A01^nFerna
ndo Cury^sRezende#^rND^1A01^nMaria Stella Peccin da^sSilva#^rND^1A01^nDan Caraí 
Maia^sViola#^rND^1A01^nReynaldo Jesus^sGarcia Filho#Universidade Federal de São 
Paulo^iA01#^lpt^aAs endopróteses não convencionais (ENC) são frequentemente util
izadas na ortopedia oncológica. As complicações do procedimento é motivo de pesq
uisa, pois há a instituição deste em população jovem e com grande potencial de s
obrevida. Nós conduzimos uma revisão da literatura com o objetivo de buscar a me
lhor evidência científica relativa ao tema. A pesquisa englobou as bases: MEDLIN
E, EMBASE, CINAHL e o Registro Central Cochrane de ensaios clínicos randomizados
 (ECR), objetivando identificar estudos reportando complicações, e a substituiçã
o ou não da superfície articular da patela. Os estudos foram selecionados de aco
rdo com a melhor qualidade metodológica existente para o assunto. Cento e quaren
ta e seis (146) estudos foram avaliados. Nenhum ERC foi encontrado. Realizamos u
ma avaliação qualitativa e quantitativa dos trabalhos encontrados (níveis de evi
dência IV e V). Utilizou-se o teste de U de Mann-Whitney para a análise estatíst
ica. Os resultados apontam para a necessidade de produção de novos estudos, para
 que se possa chegar a uma conclusão mais sólida. Pode-se considerar altas as ta
xas de complicações pós ENC, a despeito da baixa qualidade dos estudos, conforme
 demonstra os estudos existentes na literatura.#^dnd^i1#^tm^lpt^kNeoplasias ósse
as^i1#^tm^lpt^kJoelho^i1#^tm^lpt^kArtroplastia do joelho^i1#^tm^lpt^kOsteosarcom
a^i1#^len^aNon-conventional endoprostheses (NCE) are frequently used in orthoped
ic oncology. The complications associated with this procedure have prompted rese
arch, due to the fact that it is commonly performed on young patients, with a hi
gher survival rate. We conducted a systematic review of the literature, searchin
g for the best scientific evidence on the subject. The research was carried out 
in the following databases: MEDLINE, EMBASE, CINAHL and the Cochrane Central Reg
ister of randomized controlled trials (CCTR), seeking to identify studies that r
eport complications, and compare patellar resurfacing versus retention. The stud
ies were selected according to the best methodological quality that exists for t
he subject. One hundred and forty six (146) studies were evaluated. No randomize
d clinical trial was found. We conducted a qualitative and quantitative evaluati
on of the work found (evidence levels IV and V). We used the Mann-Whitney U test
 for the statistical analysis. The results indicate a need for further studies t
hat will enable us to reach a more solid conclusion. The rate of complications a
fter NCE can be considered high, despite the low quality of the studies, as demo
nstrated by the studies that exist in the literature.#^dnd^i2#^tm^len^kBone neop
lasms^i2#^tm^len^kKnee^i2#^tm^len^kArthroplasty, Replacement, Knee^i2#^tm^len^kO
steosarcoma^i2#other#25#20090905#05/09/09#20100527#27/05/10#11.htm##
04009000000000637000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083121000300087049000700090158000300097030001800100
03100030011803200020012106500090012301400090013203500100014101200830015101200890
02340100036003230100042003590100034004010100041004350100033004760100040005090700
03900549083124400588085000801832085003001840085001901870085003501889085002501924
08312490194908500080319808500270320608500170323308500440325008500250329411700060
3319072000303325112000903328111000903337114000903346113000903355002000703364#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#
TAB#11#AOB160#nd#Acta ortop. bras.#19#1#20110000#^f49^l51#1413-7852#<b>Complicaç
ões das endopróteses em pacientes com tumores ósseos do joelho</b>^lpt#<b>Endopr
ostheses-related complications in patients with bone tumors of the knee</b>^len#
^rND^1A01^nVinicius Ynoe de^sMoraes#^rND^1A01^nGuilherme Conforto^sGracitelli#^r
ND^1A01^nFernando Cury^sRezende#^rND^1A01^nMaria Stella Peccin da^sSilva#^rND^1A
01^nDan Caraí Maia^sViola#^rND^1A01^nReynaldo Jesus^sGarcia Filho#Universidade F
ederal de São Paulo^iA01#^lpt^aAs endopróteses não convencionais (ENC) são frequ
entemente utilizadas na ortopedia oncológica. As complicações do procedimento é 
motivo de pesquisa, pois há a instituição deste em população jovem e com grande 
potencial de sobrevida. Nós conduzimos uma revisão da literatura com o objetivo 
de buscar a melhor evidência científica relativa ao tema. A pesquisa englobou as
 bases: <i>MEDLINE, EMBASE, CINAHL</i> e o Registro Central Cochrane de ensaios 
clínicos randomizados (ECR), objetivando identificar estudos reportando complica
ções, e a substituição ou não da superfície articular da patela. Os estudos fora
m selecionados de acordo com a melhor qualidade metodológica existente para o as
sunto. Cento e quarenta e seis (146) estudos foram avaliados. Nenhum ERC foi enc
ontrado. Realizamos uma avaliação qualitativa e quantitativa dos trabalhos encon
trados (níveis de evidência IV e V). Utilizou-se o teste de U de Mann-Whitney pa
ra a análise estatística. Os resultados apontam para a necessidade de produção d
e novos estudos, para que se possa chegar a uma conclusão mais sólida. Pode-se c
onsiderar altas as taxas de complicações pós ENC, a despeito da baixa qualidade 
dos estudos, conforme demonstra os estudos existentes na literatura.#^dnd^i1#^tm
^lpt^kNeoplasias ósseas^i1#^tm^lpt^kJoelho^i1#^tm^lpt^kArtroplastia do joelho^i1
#^tm^lpt^kOsteosarcoma^i1#^len^aNon-conventional endoprostheses (NCE) are freque
ntly used in orthopedic oncology. The complications associated with this procedu
re have prompted research, due to the fact that it is commonly performed on youn
g patients, with a higher survival rate. We conducted a systematic review of the
 literature, searching for the best scientific evidence on the subject. The rese
arch was carried out in the following databases: MEDLINE, EMBASE, CINAHL and the
 Cochrane Central Register of randomized controlled trials (CCTR), seeking to id
entify studies that report complications, and compare patellar resurfacing versu
s retention. The studies were selected according to the best methodological qual
ity that exists for the subject. One hundred and forty six (146) studies were ev
aluated. No randomized clinical trial was found. We conducted a qualitative and 
quantitative evaluation of the work found (evidence levels IV and V). We used th
e Mann-Whitney U test for the statistical analysis. The results indicate a need 
for further studies that will enable us to reach a more solid conclusion. The ra
te of complications after NCE can be considered high, despite the low quality of
 the studies, as demonstrated by the studies that exist in the literature.#^dnd^
i2#^tm^len^kBone neoplasms^i2#^tm^len^kKnee^i2#^tm^len^kArthroplasty, Replacemen
t, Knee^i2#^tm^len^kOsteosarcoma^i2#other#25#20090905#05/09/09#20100527#27/05/10
#11.htm##
04109000000000661000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000400090121000300094049000700097158000300104
03000170010703100030012403200020012706500090012901400090013803500100014701200760
01570120082002330100036003150100042003510100034003930100041004270100033004680100
04000501070004100541083123700582085000801819085003001827085001901857085003501876
08500250191108312490193608500080318508500270319308500170322008500440323708500250
32811170006033060720003033121120009033151110009033241140009033331130009033420020
00703351008008903358#v19n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#l#4#1#arti
cle#1#^a2011#oa#pt#br1.1#1#4.0#tab#11#AOB160#nd#Acta ortop. bras#19#1#20110000#^
f49^l51#1413-7852#Complicações das endopróteses em pacientes com tumores ósseos 
do joelho^lpt#Endoprostheses-related complications in patients with bone tumors 
of the knee^len#^rND^1A01^nVinicius Ynoe de^sMoraes#^rND^1A01^nGuilherme Confort
o^sGracitelli#^rND^1A01^nFernando Cury^sRezende#^rND^1A01^nMaria Stella Peccin d
a^sSilva#^rND^1A01^nDan Caraí Maia^sViola#^rND^1A01^nReynaldo Jesus^sGarcia Filh
o#^iA01^1Universidade Federal de São Paulo#^lpt^aAs endopróteses não convenciona
is (ENC) são frequentemente utilizadas na ortopedia oncológica. As complicações 
do procedimento é motivo de pesquisa, pois há a instituição deste em população j
ovem e com grande potencial de sobrevida. Nós conduzimos uma revisão da literatu
ra com o objetivo de buscar a melhor evidência científica relativa ao tema. A pe
squisa englobou as bases: MEDLINE, EMBASE, CINAHL e o Registro Central Cochrane 
de ensaios clínicos randomizados (ECR), objetivando identificar estudos reportan
do complicações, e a substituição ou não da superfície articular da patela. Os e
studos foram selecionados de acordo com a melhor qualidade metodológica existent
e para o assunto. Cento e quarenta e seis (146) estudos foram avaliados. Nenhum 
ERC foi encontrado. Realizamos uma avaliação qualitativa e quantitativa dos trab
alhos encontrados (níveis de evidência IV e V). Utilizou-se o teste de U de Mann
-Whitney para a análise estatística. Os resultados apontam para a necessidade de
 produção de novos estudos, para que se possa chegar a uma conclusão mais sólida
. Pode-se considerar altas as taxas de complicações pós ENC, a despeito da baixa
 qualidade dos estudos, conforme demonstra os estudos existentes na literatura.#
^dnd^i1#^tm^lpt^kNeoplasias ósseas^i1#^tm^lpt^kJoelho^i1#^tm^lpt^kArtroplastia d
o joelho^i1#^tm^lpt^kOsteosarcoma^i1#^len^aNon-conventional endoprostheses (NCE)
 are frequently used in orthopedic oncology. The complications associated with t
his procedure have prompted research, due to the fact that it is commonly perfor
med on young patients, with a higher survival rate. We conducted a systematic re
view of the literature, searching for the best scientific evidence on the subjec
t. The research was carried out in the following databases: MEDLINE, EMBASE, CIN
AHL and the Cochrane Central Register of randomized controlled trials (CCTR), se
eking to identify studies that report complications, and compare patellar resurf
acing versus retention. The studies were selected according to the best methodol
ogical quality that exists for the subject. One hundred and forty six (146) stud
ies were evaluated. No randomized clinical trial was found. We conducted a quali
tative and quantitative evaluation of the work found (evidence levels IV and V).
 We used the Mann-Whitney U test for the statistical analysis. The results indic
ate a need for further studies that will enable us to reach a more solid conclus
ion. The rate of complications after NCE can be considered high, despite the low
 quality of the studies, as demonstrated by the studies that exist in the litera
ture.#^dnd^i2#^tm^len^kBone neoplasms^i2#^tm^len^kKnee^i2#^tm^len^kArthroplasty,
 Replacement, Knee^i2#^tm^len^kOsteosarcoma^i2#other#25#20090905#05/09/09#201005
27#27/05/10#11.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&
pid=S1413-78522011000100011##
00352000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704013200067002000700199#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#5#1#article#115#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTIGO    DE REVIS&Atilde;O<
/b> </font></p>     ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#6#2#article#115#<p>&nbsp;</p>     ^cY#11.htm
##
00430000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704021000067002000700277#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#7#3#article#115#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Complica&ccedil;&otilde;
es    das endopr&oacute;teses em pacientes com tumores &oacute;sseos do joelho</
b></font></p>     ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#8#4#article#115#<p>&nbsp;</p>     ^cY#11.htm
##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#9#5#article#115#<p>&nbsp;</p>     ^cY#11.htm
##
00482000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704026100068002000700329#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#10#6#article#115#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Vinicius Ynoe    de Moraes; Guilherme Con
forto Gracitelli; Fernando Cury Rezende; Maria Stella    Peccin da Silva; Dan Ca
ra&iacute; Maia Viola; Reynaldo Jesus Garcia Filho</b></font></p>     ^cY#11.htm
##
00357000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704013600068002000700204#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#11#7#article#115#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2">Universidade Federal    de S&atilde;o Paulo 
- UNIFESP</font></p>     ^cY#11.htm##
00369000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704014800068002000700216#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#12#8#article#115#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><a href="#back">Endere&ccedil;o    para Corr
espond&ecirc;ncia</a></font></p>     ^cY#11.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#13#9#article#115#<p>&nbsp;</p>     ^cY#11.ht
m##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#14#10#article#115#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#11.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#15#11#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#11.htm##
01853000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704163100069002000701700#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#16#12#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As endopr&oacute;teses    n&atilde;o conven
cionais (ENC) s&atilde;o frequentemente utilizadas na ortopedia    oncol&oacute;
gica. As complica&ccedil;&otilde;es do procedimento &eacute; motivo    de pesqui
sa, pois h&aacute; a institui&ccedil;&atilde;o deste em popula&ccedil;&atilde;o 
   jovem e com grande potencial de sobrevida. N&oacute;s conduzimos uma revis&at
ilde;o    da literatura com o objetivo de buscar a melhor evid&ecirc;ncia cient&
iacute;fica    relativa ao tema. A pesquisa englobou as bases: <i>MEDLINE, EMBAS
E, CINAHL</i>    e o Registro Central Cochrane de ensaios cl&iacute;nicos random
izados (ECR),    objetivando identificar estudos reportando complica&ccedil;&oti
lde;es, e a substitui&ccedil;&atilde;o    ou n&atilde;o da superf&iacute;cie art
icular da patela. Os estudos foram selecionados    de acordo com a melhor qualid
ade metodol&oacute;gica existente para o assunto.    Cento e quarenta e seis (14
6) estudos foram avaliados. Nenhum ERC foi encontrado.    Realizamos uma avalia&
ccedil;&atilde;o qualitativa e quantitativa dos trabalhos    encontrados (n&iacu
te;veis de evid&ecirc;ncia IV e V). Utilizou-se o teste de    U de Mann-Whitney 
para a an&aacute;lise estat&iacute;stica. Os resultados apontam    para a necess
idade de produ&ccedil;&atilde;o de novos estudos, para que se possa    chegar a 
uma conclus&atilde;o mais s&oacute;lida. Pode-se considerar altas as    taxas de
 complica&ccedil;&otilde;es p&oacute;s ENC, a despeito da baixa qualidade    dos
 estudos, conforme demonstra os estudos existentes na literatura.</font></p>    
 ^cY#11.htm##
00421000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704019900069002000700268#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#17#13#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Descritores:</b>    Neoplasias &oacute;s
seas. Joelho. Artroplastia do joelho. Osteosarcoma.</font></p> <hr size="1" nosh
ade>     ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#18#14#article#115#<p>&nbsp;</p>     ^cY#11.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#19#15#article#115#<p>&nbsp;</p>     ^cY#11.h
tm##
00336000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011400069002000700183#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#20#16#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b></font></p> 
    ^cY#11.htm##
00780000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704055800069002000700627#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#21#17#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O uso de endopr&oacute;teses    n&atilde;o 
convencionais (ENC) para o tratamento de tumores &oacute;sseos ao    n&iacute;ve
l do joelho &eacute; uma realidade da ortopedia oncol&oacute;gica.    O fato des
sas les&otilde;es serem frequentes em pacientes jovens e com potencial    de sob
revida acima de 10 anos nos leva &agrave; preocupa&ccedil;&atilde;o de    determ
inar o melhor m&eacute;todo de tratamento, em especial para a reconstru&ccedil;&
atilde;o    articular do joelho.</font></p>     ^cY#11.htm##
00899000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704067700069002000700746#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#22#18#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A endopr&oacute;tese    n&atilde;o convenci
onal <i>(ENC)</i> apresenta vantagens em rela&ccedil;&atilde;o    aos outros m&e
acute;todos, uma vez que possibilita a preserva&ccedil;&atilde;o    do membro e 
suas de fun&ccedil;&otilde;es articulares.<sup>1-3</sup> &Eacute;    tamb&eacute
;m fato que a preserva&ccedil;&atilde;o do membro n&atilde;o est&aacute;    asso
ciada com diminui&ccedil;&atilde;o da sobrevida do paciente oncol&oacute;gico.<s
up>1,2</sup>    Isso torna poss&iacute;vel a indica&ccedil;&atilde;o de endopr&o
acute;teses    n&atilde;o-convencionais em 85% dos casos.<sup>3-5</sup></font></
p>     ^cY#11.htm##
00851000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704062900069002000700698#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#23#19#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Neste escopo surge    o questionamento da t
axa de complica&ccedil;&otilde;es inerentes ao procedimento,    dentre estes - e
 em especial - aos relacionados a fun&ccedil;&atilde;o do mecanismo    extensor.
 Este encontra-se melhor resolvido em popula&ccedil;&atilde;o n&atilde;o-oncol&o
acute;gica.<sup>6,7</sup>    A literatura mundial descreve diversas complica&cce
dil;&otilde;es relativas    &agrave; substitui&ccedil;&atilde;o da patela, como 
a soltura do componente    patelar, fratura patelar e ruptura do tend&atilde;o p
atelar.<sup>6,8,9</sup></font></p>     ^cY#11.htm##
00784000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704056200069002000700631#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#24#20#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Na realidade da    ortopedia oncol&oacute;g
ica, h&aacute; dificuldade na abordagem do tema j&aacute;    que as pesquisas s&
atilde;o focadas em sobrevida, tamanho da ressec&ccedil;&atilde;o    e escores f
uncionais do membro afetado, o que transforma o tema num campo de    pesquisa e 
explora&ccedil;&atilde;o.<sup>1,2,5,10-12</sup> Entretanto, parece-nos    dif&ia
cute;cil a realiza&ccedil;&atilde;o de estudos cl&iacute;nicos sem colabora&cced
il;&atilde;o    multic&ecirc;ntrica.</font></p>     ^cY#11.htm##
00883000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704066100069002000700730#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#25#21#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As revis&otilde;es    sistem&aacute;ticas s
&atilde;o uma s&iacute;ntese da literatura que aborda os    dados dispon&iacute;
veis e promove a aquisi&ccedil;&atilde;o de informa&ccedil;&otilde;es    raciona
is para decis&otilde;es cl&iacute;nicas.<sup>13-15</sup> O objetivo desta    pes
quisa &eacute; promover uma revis&atilde;o sistem&aacute;tica para responder    
as seguintes perguntas cl&iacute;nicas: 1) Qual a taxa de complica&ccedil;&otild
e;es    p&oacute;s ENC? 2) Qual a contribui&ccedil;&atilde;o das complica&ccedil
;&otilde;es    patelares nesta popula&ccedil;&atilde;o?</font></p>     ^cY#11.ht
m##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#26#22#article#115#<p>&nbsp;</p>     ^cY#11.h
tm##
00341000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011900069002000700188#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#27#23#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>MATERIAIS E    M&Eacute;TODOS</b></font>
</p>     ^cY#11.htm##
00786000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704056400069002000700633#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#28#24#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Foram pesquisadas    as seguintes bases na 
l&iacute;ngua inglesa, espanhola e portuguesa, at&eacute;    junho de 2009: <i>M
EDLINE; EMBASE; CINAHL</i>; LILACS; <i>Cochrane Database    of Systematic Review
s</i>. Os crit&eacute;rios de inclus&atilde;o est&atilde;o    expostos no <a hre
f="#q1">Quadro 1</a>. Foi utilizada a estrat&eacute;gia de    pesquisa para ensa
ios cl&iacute;nicos randomizados de acordo com a metodologia    da colabora&cced
il;&atilde;o Cochrane.<sup>14,16</sup></font></p>     ^cY#11.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#29#25#article#115#<p><a name="q1"></a></p>  
   ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#30#26#article#115#<p>&nbsp;</p>     ^cY#11.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#31#27#article#115#<p align="center"><img src
="/img/revistas/aob/v19n1/11q01.jpg"></p>     ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#32#28#article#115#<p>&nbsp;</p>     ^cY#11.h
tm##
01103000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704088100069002000700950#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#33#29#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Usou-se estrat&eacute;gia    para procura d
e publica&ccedil;&otilde;es n&atilde;o-ECR com o uso de termos    MeSH/DeCS (qua
ndo dispon&iacute;veis) e n&atilde;o MeSH/DeCS. Os termos utilizados    est&atil
de;o descritos no <a href="#q2">Quadro 2</a>. Quando na impossibilidade    da ut
iliza&ccedil;&atilde;o de termo MeSH/DeCS, procedeu-se a utiliza&ccedil;&atilde;
o    de termos n&atilde;o-MESH. Ap&oacute;s a localiza&ccedil;&atilde;o de traba
lhos    congruentes aos par&acirc;metros a serem analisados, deu-se, em seguida,
 a avalia&ccedil;&atilde;o    metodol&oacute;gica de cada trabalho eleg&iacute;v
el por dois pesquisadores    (V.Y.M. e D.C.V) com a inclus&atilde;o e exclus&ati
lde;o baseada em crit&eacute;rios    metodol&oacute;gicos estabelecido por instr
umentos conhecidos.<sup>17,18</sup></font></p>     ^cY#11.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#34#30#article#115#<p><a name="q2"></a></p>  
   ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#35#31#article#115#<p>&nbsp;</p>     ^cY#11.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#36#32#article#115#<p align="center"><img src
="/img/revistas/aob/v19n1/11q02.jpg"></p>     ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#37#33#article#115#<p>&nbsp;</p>     ^cY#11.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#38#34#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>     ^cY#11.htm
##
01221000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704099900069002000701068#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#39#35#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Cento e quarenta    e seis (146) artigos fo
ram analisados. Ensaios Cl&iacute;nicos randomizados    n&atilde;o foram encontr
ados. N&atilde;o se encontrou aloca&ccedil;&atilde;o    em grupos distintos para
 o desfecho proposto por esta publica&ccedil;&atilde;o,    tanto como desfecho p
rim&aacute;rio ou secund&aacute;rio. Quatro estudos foram    inclu&iacute;dos na
 an&aacute;lise, pois representavam as melhores evid&ecirc;ncias    sobre o tema
 previsto. Encontrou-se um trabalho que trata do assunto de interesse    desta p
ublica&ccedil;&atilde;o, tratado como desfecho secund&aacute;rio e com    amostr
a identificada pelos autores como insuficiente.<sup>8</sup> As caracter&iacute;s
ticas    metodol&oacute;gicas, assim como a an&aacute;lise descritiva e inferenc
ial destes    estudos est&atilde;o resumidos nas <a href="/img/revistas/aob/v19n
1/11t01.jpg">Tabelas 1</a>,    <a href="#t2">2</a> e <a href="#t3">3</a>.</font>
</p>     ^cY#11.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#40#36#article#115#<p><a name="t2"></a></p>  
   ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#41#37#article#115#<p>&nbsp;</p>     ^cY#11.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#42#38#article#115#<p align="center"><img src
="/img/revistas/aob/v19n1/11t02.jpg"></p>     ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#43#39#article#115#<p>&nbsp;</p>     ^cY#11.h
tm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#44#40#article#115#<p><a name="t3"></a></p>  
   ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#45#41#article#115#<p>&nbsp;</p>     ^cY#11.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#46#42#article#115#<p align="center"><img src
="/img/revistas/aob/v19n1/11t03.jpg"></p>     ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#47#43#article#115#<p>&nbsp;</p>     ^cY#11.h
tm##
00328000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010600069002000700175#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#48#44#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font></p>     ^cY#
11.htm##
01024000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704080200069002000700871#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#49#45#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Os ensaios cl&iacute;nicos    randomizados,
 alvos preferidos das revis&otilde;es sistem&aacute;ticas sobre    terap&ecirc;u
tica, n&atilde;o foram encontrados at&eacute; o momento para o    tema em quest&
atilde;o. No &acirc;mbito da ortopedia, muito se tem discutido    sobre a valida
de e a necessidade de que se conduzam ERCs e h&aacute; um esfor&ccedil;o    mund
ial para tal, principalmente quando relacionados a doen&ccedil;as de alta    com
plexidade e de baixa preval&ecirc;ncia, como &eacute; o caso dos tumores    &oac
ute;sseos malignos. Nesta contexto, o desenho de estudo ideal seria o de    ensa
io cl&iacute;nico (multic&ecirc;ntrico), e que previsse como desfecho as    comp
lica&ccedil;&otilde;es.<sup>19</sup></font></p>     ^cY#11.htm##
00771000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704054900069002000700618#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#50#46#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Neste panorama,    o uso da literatura disp
on&iacute;vel nos parece ser evid&ecirc;ncia que deve    ser valorizada, em espe
cial em situa&ccedil;&otilde;es cl&iacute;nicas, como    as que envolvem popula&
ccedil;&otilde;es oncol&oacute;gicas. Destarte, os resultados    desta pesquisa 
devem servir de par&acirc;metro e como poss&iacute;vel ferramenta    para nortea
r a validade externa de prov&aacute;veis trabalhos sobre o assunto    gerados po
r outros pesquisadores.</font></p>     ^cY#11.htm##
00877000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704065500069002000700724#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#51#47#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Quanto aos m&eacute;todos    de pesquisa qu
e utilizados para o projeto, devemos atentar para alguns vieses    de sele&ccedi
l;&atilde;o. S&atilde;o vieses importantes: a restri&ccedil;&atilde;o    da ling
uagem, a aus&ecirc;ncia da procura de pesquisas n&atilde;o publicadas    e/ou n&
atilde;o indexadas (exemplo: anais de congresso). Houve tamb&eacute;m    dificul
dade, em algumas ocasi&otilde;es, de definir e caracterizar desfechos,    por ve
zes pouco precisos e espec&iacute;ficos, e em geral, tratando as complica&ccedil
;&otilde;es    como desfechos secund&aacute;rios.</font></p>     ^cY#11.htm##
00793000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704057100069002000700640#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#52#48#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A falta de estudos    de melhor qualidade m
etodol&oacute;gica foi uma barreira ao nosso estudo. No    entanto, causaram-nos
 grande surpresa os achados que a literatura nos fornece    sobre o assunto. Enc
ontramos diversos trabalhos com baixo n&iacute;vel de evid&ecirc;ncia    (n&iacu
te;vel de evid&ecirc;ncia III ou IV).<sup>1-5,8,10,11,20,21,22-25</sup>    Isso 
&eacute; reflexo do desafio e da dificuldade em que se insere a pesquisa    cl&i
acute;nica sobre oncologia ortop&eacute;dica.</font></p>     ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#53#49#article#115#<p>&nbsp;</p>     ^cY#11.h
tm##
00328000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010600069002000700175#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#54#50#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>CONCLUS&Atilde;O</b></font></p>     ^cY#
11.htm##
00936000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704071400069002000700783#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#55#51#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Existe a necessidade    de que haja a produ
&ccedil;&atilde;o de trabalhos com o enfoque no tema proposto,    em especial os
 ensaios cl&iacute;nicos randomizados, para que se possa chegar    a uma conclus
&atilde;o mais s&oacute;lida, no que diz respeito &agrave; substitui&ccedil;&ati
lde;o    da patela em pacientes portadores de tumores &oacute;sseos no joelho. N
ovas    pesquisas s&atilde;o necess&aacute;rias para se chegar a conclus&otilde;
es sobre    o tema proposto. A despeito da baixa qualidade metodol&oacute;gica, 
podem-se    considerar altas a taxas de complica&ccedil;&otilde;es p&oacute;s EN
C, na literatura    mundial.</font></p>     ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#56#52#article#115#<p>&nbsp;</p>     ^cY#11.h
tm##
00329000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010700069002000700176#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#57#53#article#115#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font></p>     ^cY
#11.htm##
00566000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704033000071002000700401#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#58#54#article#115#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1. Rougraff BT,    Simon MA, 
Kneisl JS, Greenberg DB, Mankin HJ. Limb salvage compared with amputation    for
 osteosarcoma of the distal end of the femur. A long-term oncological, functiona
l,    and quality-of-life study. J Bone Joint Surg Am. 1994;76:649-56.    ^cY#11
.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#59#55#article#115#</font></p>     ^cY#11.htm
##
00488000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704025200071002000700323#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#60#56#article#115#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2. Simon MA, Aschliman    MA,
 Thomas N, Mankin HJ. Limb-salvage treatment versus amputation for osteosarcoma 
   of the distal end of the femur. J Bone Joint Surg Am. 1986;68:1331-7.    ^cY#
11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#61#57#article#115#</font></p>     ^cY#11.htm
##
00499000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704026300071002000700334#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#62#58#article#115#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">3. Frink SJ, Rutledge    J, L
ewis VO, Lin PP, Yasko AW. Favorable long-term results of prosthetic arthroplast
y    of the knee for distal femur neoplasms. Clin Orthop Relat Res. 2005;438:65-
70.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#63#59#article#115#</font></p>     ^cY#11.htm
##
00429000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704019300071002000700264#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#64#60#article#115#4#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">4. Lewis MM, Chekofsky    KM.
 Proximal femur replacement for neoplastic disease. Clin Orthop Relat Res.    19
82(171):72-9.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#65#61#article#115#</font></p>     ^cY#11.htm
##
00483000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704024700071002000700318#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#66#62#article#115#5#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">5. Zehr RJ, Enneking    WF, S
carborough MT. Allograft-prosthesis composite versus megaprosthesis in    proxim
al femoral reconstruction. Clin Orthop Relat Res. 1996;(322):207-3.    ^cY#11.ht
m##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#67#63#article#115#</font></p>     ^cY#11.htm
##
00494000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704025800071002000700329#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#68#64#article#115#6#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">6. Nizard RS, Biau    D, Porc
her R, Ravaud P, Bizot P, Hannouche D, et al. A meta-analysis of patellar    rep
lacement in total knee arthroplasty. Clin Orthop Relat Res. 2005(432):196-203.  
  ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#69#65#article#115#</font></p>     ^cY#11.htm
##
00456000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704022000071002000700291#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#70#66#article#115#7#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">7. Pakos EE, Ntzani    EE, Tr
ikalinos TA. Patellar resurfacing in total knee arthroplasty. A meta-analysis.  
  J Bone Joint Surg Am. 2005;87:1438-45.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#71#67#article#115#</font></p>     ^cY#11.htm
##
00498000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704026200071002000700333#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#72#68#article#115#8#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">8. Schwab JH, Agarwal    P, B
oland PJ, Kennedy JG, Healey JH. Patellar complications following distal    femo
ral replacement after bone tumor resection. J Bone Joint Surg Am. 2006;88:2225-3
0.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#73#69#article#115#</font></p>     ^cY#11.htm
##
00650000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704041400071002000700485#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#74#70#article#115#9#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">9. Mendon&ccedil;a    SM, Cas
sone AE, Brandalise SR. Avalia&ccedil;&atilde;o funcional dos pacientes    porta
dores de sarcomas &oacute;sseos submetidos &agrave; tratamento cir&uacute;rgico 
   utilizando a endopr&oacute;tese total ou parcial, na substitui&ccedil;&atilde
;o    da extremidade distal do f&ecirc;mur. Acta Ortop Bras. 2008;16:13-8.    ^c
Y#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#75#71#article#115#</font></p>     ^cY#11.htm
##
00599000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704036200072002000700434#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#76#72#article#115#10#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">10. Kawai A, Backus    SI, O
tis JC, Healey JH. Interrelationships of clinical outcome, length of resection, 
   and energy cost of walking after prosthetic knee replacement following resect
ion    of a malignant tumor of the distal aspect of the femur. J Bone Joint Surg
 Am.    1998;80:822-31.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#77#73#article#115#</font></p>     ^cY#11.htm
##
00552000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704031500072002000700387#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#78#74#article#115#11#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">11. Kawai A, Lin    PP, Bola
nd PJ, Athanasian EA, Healey JH. Relationship between magnitude of resection,   
 complication, and prosthetic survival after prosthetic knee reconstructions    
for distal femoral tumors. J Surg Oncol. 1999;70:109-15.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#79#75#article#115#</font></p>     ^cY#11.htm
##
00469000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704023200072002000700304#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#80#76#article#115#12#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">12. Shin DS, Weber    KL, Ch
ao EY, An KN, Sim FH. Reoperation for failed prosthetic replacement used    for 
limb salvage. Clin Orthop Relat Res. 1999(358):53-63.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#81#77#article#115#</font></p>     ^cY#11.htm
##
00456000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704021900072002000700291#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#82#78#article#115#13#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">13. Atallah AN.    The Cochr
ane Collaboration: shared evidence for improving decision-making in    human hea
lth. Sao Paulo Med J. 1999;117(5):183-4.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#83#79#article#115#</font></p>     ^cY#11.htm
##
00512000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704027500072002000700347#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#84#80#article#115#14#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">14. Castro AA,    Clark OA, 
Atallah AN. Optimal search strategy for clinical trials in the Latin    American
 and Caribbean Health Science Literature Database (LILACS). Sao Paulo    Med J. 
1997;115:1423-6.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#85#81#article#115#</font></p>     ^cY#11.htm
##
00452000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704021500072002000700287#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#86#82#article#115#15#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">15. Cook DJ, Mulrow    CD, H
aynes RB. Systematic reviews: synthesis of best evidence for clinical decisions.
    Ann Intern Med. 1997;126:376-80.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#87#83#article#115#</font></p>     ^cY#11.htm
##
00522000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704028500072002000700357#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#88#84#article#115#16#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">16. Cochrane Handbook    for
 Systematic Reviews of Interventions 4.2.4 &#91;updated March 2005&#93;.    In: 
Higgins JPT, Green S, editors. The Cochrane Library. Chichester, UK: John    Wil
ey &amp; Sons, Ltd.; 2005.    ^cY#11.htm##
00248000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002600069002000700095#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#89#85#article#115#&nbsp;</font></p>     ^cY#
11.htm##
00518000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704028100072002000700353#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#90#86#article#115#17#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">17. Jadad AR, Moore    RA, C
arroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al. Assessing the quality    
of reports of randomized clinical trials: is blinding necessary? Control Clin   
 Trials. 1996;17:1-12.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#91#87#article#115#</font></p>     ^cY#11.htm
##
00521000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704028400072002000700356#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#92#88#article#115#18#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">18. Schulz KF,    Chalmers I
, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological 
   quality associated with estimates of treatment effects in controlled trials. 
   Jama. 1995;273:408-12.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#93#89#article#115#</font></p>     ^cY#11.htm
##
00484000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704024700072002000700319#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#94#90#article#115#19#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">19. Wright JG,    Gebhardt M
C. Multicenter clinical trials in orthopaedics: time for musculoskeletal    spec
ialty societies to take action. J Bone Joint Surg Am. 2005;87:214-7.    ^cY#11.h
tm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#95#91#article#115#</font></p>     ^cY#11.htm
##
00529000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704029200072002000700364#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#96#92#article#115#20#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">20. Bickels J,    Wittig JC,
 Kollender Y, Henshaw RM, Kellar-Graney KL, Meller I et al. Distal    femur rese
ction with endoprosthetic reconstruction: a long-term followup study.    Clin Or
thop Relat Res. 2002(400):225-35.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#97#93#article#115#</font></p>     ^cY#11.htm
##
00536000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704029900072002000700371#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#98#94#article#115#21#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">21. Kawai A, Muschler    GF,
 Lane JM, Otis JC, Healey JH. Prosthetic knee replacement after resection    of 
a malignant tumor of the distal part of the femur. Medium to long-term results. 
   J Bone Joint Surg Am. 1998;80:636-47.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#99#95#article#115#</font></p>     ^cY#11.htm
##
00484000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000300070704024600073002000700319#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#100#96#article#115#22#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">22. Kabukcuoglu    Y, Grime
r RJ, Tillman RM, Carter SR. Endoprosthetic replacement for primary    malignant
 tumors of the proximal femur Clin Orthop Relat Res. 1999(358):8-14.    ^cY#11.h
tm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#101#97#article#115#</font></p>     ^cY#11.ht
m##
00484000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000300070704024600073002000700319#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#102#98#article#115#23#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">23. Shih LY, Sim    FH, Pri
tchard DJ, Rock MG, Chao EY. Segmental total knee arthroplasty after    distal f
emoral resection for tumor. Clin Orthop Relat Res. 1993(292):269-81.    ^cY#11.h
tm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#103#99#article#115#</font></p>     ^cY#11.ht
m##
00508000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026900074002000700343#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#104#100#article#115#24#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Zeegen EN,    Aponte-T
inao LA, Hornicek FJ, Gebhardt MC, Mankin HJ. Survivorship analysis    of 141 mo
dular metallic endoprostheses at early followup. Clin Orthop Relat    Res. 2004(
420):239-50.    ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#105#101#article#115#</font></p>     ^cY#11.h
tm##
00566000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032700074002000700401#v19
n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#p#106#102#article#115#25#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Viola DCM,    Cardozo 
Filho NS, Nunes RT, Godoy FAC, Petrilli MdT, Korukian M et al. O uso    de espa&
ccedil;adores com antibi&oacute;tico no tratamento das infec&ccedil;&otilde;es  
  em endopr&oacute;teses de joelho. Acta Ortop Bras. 2009;17(3):144-8.    ^cY#11
.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#107#103#article#115#</font></p>     ^cY#11.h
tm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#108#104#article#115#<p>&nbsp;</p>     ^cY#11
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#109#105#article#115#<p>&nbsp;</p>     ^cY#11
.htm##
00430000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704020600071002000700277#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#110#106#article#115#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top"><img sr
c="/img/revistas/aob/v19n1/seta.jpg" border="0"></a>    <b>Endereço para Corresp
ondência:</b>     ^cY#11.htm##
00270000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004600071002000700117#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#111#107#article#115#<br>   Av. Onze de Junho
, 685, Apto 66    ^cY#11.htm##
00284000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704006000071002000700131#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#112#108#article#115#<br>   Vila Clementino, 
S&atilde;o Paulo, SP, Brazil    ^cY#11.htm##
00253000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002900071002000700100#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#113#109#article#115#<br>   CEP: 04041-052   
 ^cY#11.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009400071002000700165#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#114#110#article#115#<br>   E-mail: <a href="
mailto:vym70@yahoo.com.br">vym70@yahoo.com.br</a></font> </p>     ^cY#11.htm##
00360000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013600071002000700207#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#115#111#article#115#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Artigo recebido    em 05/09/09, aprovado 
em 27/05/10.</font></p>     ^cY#11.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#116#112#article#115#<p>&nbsp;</p>     ^cY#11
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#117#113#article#115#<p>&nbsp;</p>     ^cY#11
.htm##
00441000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704021700071002000700288#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#118#114#article#115#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Trabalho realizado    no Departamento de 
Ortopedia e Traumatologia da Escola Paulista de Medicina    - UNIFESP/EPM - S&at
ilde;o Paulo, SP, Brasil.    ^cY#11.htm##
00361000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013700071002000700208#v19n1#V:\SciELO
\serial\aob\v19n1\markup\11.htm#S#p#119#115#article#115#<br>   Todos os autores 
declaram n&atilde;o haver nenhum potencial conflito de interesses    referente a
 este artigo.</font></p>     ^cY#11.htm##
00680000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700100016000890100
01700105010002000122010001800142012015400160030002200314710000200336065000900338
064000500347031000300352014000700355865000900362002000700371#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\11.htm#S#c#120#1#article#25#1#^rND^sRougraff^nBT#^rND^sSimo
n^nMA#^rND^sKneisl^nJS#^rND^sGreenberg^nDB#^rND^sMankin^nHJ.#Limb salvage compar
ed with amputation for osteosarcoma of the distal end of the femur: A long-term 
oncological, functional, and quality-of-life study^len#J Bone Joint Surg Am.#2#1
9940000#1994#76#649-56#20110000#11.htm##
00586000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100020000860100
01600106010001700122012009300139030002200232710000200254065000900256064000500265
031000300270014000700273865000900280002000700289#v19n1#V:\SciELO\serial\aob\v19n
1\markup\11.htm#S#c#121#2#article#25#2#^rND^sSimon^nMA#^rND^sAschliman^nMA#^rND^
sThomas^nN#^rND^sMankin^nHJ#Limb-salvage treatment versus amputation for osteosa
rcoma of the distal end of the femur^len#J Bone Joint Surg Am.#2#19860000#1986#6
8#1331-7#20110000#11.htm##
00615000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100018000860100
01600104010001400120010001600134012009800150030002300248710000200271065000900273
064000500282031000400287014000600291865000900297002000700306#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\11.htm#S#c#122#3#article#25#3#^rND^sFrink^nSJ#^rND^sRutledg
e^nJ#^rND^sLewis^nVO#^rND^sLin^nPP#^rND^sYasko^nAW#Favorable long-term results o
f prosthetic arthroplasty of the knee for distal femur neoplasms^len#Clin Orthop
 Relat Res.#2#20050000#2005#438#65-70#20110000#11.htm##
00493000000000265000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100020000860100
05700106030002300163710000200186065000900188064000500197032000400202014000500206
865000900211002000700220#v19n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#c#123#
4#article#25#4#^rND^sLewis^nMM#^rND^sChekofsky^nKM#^rND^sProximal femur replacem
ent for neoplastic^ndisease#Clin Orthop Relat Res.#2#19820000#1982#171#72-9#2011
0000#11.htm##
00561000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100015000700100019000850100
02200104012009200126030002300218710000200241065000900243064000500252032000400257
014000600261865000900267002000700276#v19n1#V:\SciELO\serial\aob\v19n1\markup\11.
htm#S#c#124#5#article#25#5#^rND^sZehr^nRJ#^rND^sEnneking^nWF#^rND^sScarborough^n
MT#Allograft-prosthesis composite versus megaprosthesis in proximal femoral reco
nstruction^len#Clin Orthop Relat Res.#2#19960000#1996#322#207-3#20110000#11.htm#
#
00639000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100014000870100
01700101010001600118010001500134010001900149810000700168012007100175030002300246
71000020026906500090027106400050028003200040028501400080028986500090029700200070
0306#v19n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#c#125#6#article#25#6#^rND^
sNizard^nRS#^rND^sBiau^nD#^rND^sPorcher^nR#^rND^sRavaud^nP#^rND^sBizot^nP#^rND^s
Hannouche^nD#et al.#A meta-analysis of patellar replacement in total knee arthro
plasty^len#Clin Orthop Relat Res.#2#20050000#2005#432#196-203#20110000#11.htm##
00536000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100017000860100
02100103012006900124030002200193710000200215065000900217064000500226031000300231
014000800234865000900242002000700251#v19n1#V:\SciELO\serial\aob\v19n1\markup\11.
htm#S#c#126#7#article#25#7#^rND^sPakos^nEE#^rND^sNtzani^nEE#^rND^sTrikalinos^nTA
#Patellar resurfacing in total knee arthroplasty: A meta-analysis^len#J Bone Joi
nt Surg Am.#2#20050000#2005#87#1438-45#20110000#11.htm##
00615000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100017000870100
01700104010001800121010001800139012009100157030002200248710000200270065000900272
064000500281031000300286014000800289865000900297002000700306#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\11.htm#S#c#127#8#article#25#8#^rND^sSchwab^nJH#^rND^sAgarwa
l^nP#^rND^sBoland^nPJ#^rND^sKennedy^nJG#^rND^sHealey^nJH.#Patellar complications
 following distal femoral replacement after bone tumor resection^len#J Bone Join
t Surg Am.#2#20060000#2006#88#2225-30#20110000#11.htm##
00655000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700100018000890100
02100107012019200128030001700320710000200337065000900339064000500348031000300353
014000500356865000900361002000700370#v19n1#V:\SciELO\serial\aob\v19n1\markup\11.
htm#S#c#128#9#article#25#9#^rND^sMendonça^nSM#^rND^sCassone^nAE#^rND^sBrandalise
^nSR#Avaliação funcional dos pacientes portadores de sarcomas ósseos submetidos 
à tratamento cirúrgico utilizando a endoprótese total ou parcial, na substituiçã
o da extremidade distal do fêmur^lpt#Acta Ortop Bras.#2#20080000#2008#16#13-8#20
110000#11.htm##
00691000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100017000870100
01500104010001700119012020100136030002200337710000200359065000900361064000500370
031000300375014000700378865000900385002000700394#v19n1#V:\SciELO\serial\aob\v19n
1\markup\11.htm#S#c#129#10#article#25#10#^rND^sKawai^nA#^rND^sBackus^nSI#^rND^sO
tis^nJC#^rND^sHealey^nJH#Interrelationships of clinical outcome, length of resec
tion, and energy cost of walking after prosthetic knee replacement following res
ection of a malignant tumor of the distal aspect of the femur^len#J Bone Joint S
urg Am.#2#19980000#1998#80#822-31#20110000#11.htm##
00665000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100014000870100
01700101010002100118010001700139012015100156030001400307710000200321065000900323
064000500332031000300337014000700340865000900347002000700356#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\11.htm#S#c#130#11#article#25#11#^rND^sKawai^nA#^rND^sLin^nP
P#^rND^sBoland^nPJ#^rND^sAthanasian^nEA#^rND^sHealey^nJH#Relationship between ma
gnitude of resection, complication, and prosthetic survival after prosthetic kne
e reconstructions for distal femoral tumors^len#J Surg Oncol.#2#19990000#1999#70
#109-15#20110000#11.htm##
00584000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100016000870100
01500103010001300118010001400131012007200145030002300217710000200240065000900242
064000500251032000400256014000600260865000900266002000700275#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\11.htm#S#c#131#12#article#25#12#^rND^sShin^nDS#^rND^sWeber^
nKL#^rND^sChao^nEY#^rND^sAn^nKN#^rND^sSim^nFH#Reoperation for failed prosthetic 
replacement used for limb salvage^len#Clin Orthop Relat Res.#2#19990000#1999#358
#53-63#20110000#11.htm##
00512000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720120094000910300
01700185710000200202065000900204064000500213031000400218032000200222014000600224
865000900230002000700239#v19n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#c#132#
13#article#25#13#^rND^sAtallah^nAN.#The Cochrane Collaboration: shared evidence 
for improving decision-making in human health^len#Sao Paulo Med J.#2#19990000#19
99#117#5#183-4#20110000#11.htm##
00589000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100016000890100
01800105012012800123030001700251710000200268065000900270064000500279031000400284
014000700288865000900295002000700304#v19n1#V:\SciELO\serial\aob\v19n1\markup\11.
htm#S#c#133#14#article#25#14#^rND^sCastro^nAA#^rND^sClark^nOA#^rND^sAtallah^nAN#
Optimal search strategy for clinical trials in the Latin American and Caribbean 
Health Science Literature Database (LILACS)^len#Sao Paulo Med J.#2#19970000#1997
#115#1423-6#20110000#11.htm##
00532000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100017000870100
01700104012007400121030001600195710000200211065000900213064000500222032000400227
014000700231865000900238002000700247#v19n1#V:\SciELO\serial\aob\v19n1\markup\11.
htm#S#c#134#15#article#25#15#^rND^sCook^nDJ#^rND^sMulrow^nCD#^rND^sHaynes^nRB#Sy
stematic reviews: synthesis of best evidence for clinical decisions^len#Ann Inte
rn Med.#2#19970000#1997#126#376-80#20110000#11.htm##
00529000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690110064000720160019001360160
01500155018002500170066001100195067000300206062002400209065000900233064000500242
865000900247002000700256#v19n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#c#135#
16#article#25#16#Cochrane Handbook for Systematic Reviews of Interventions 4.2.4
#^rED^sHiggins^nJPT#^rED^sGreen^nS#The Cochrane Library^len#Chichester#UK#John W
iley & Sons, Ltd.#20050000#2005#20110000#11.htm##
00663000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100016000880100
01700104010001900121010001900140010001900159810000700178012009100185030002100276
71000020029706500090029906400050030803100030031301400050031686500090032100200070
0330#v19n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#c#136#17#article#25#17#^rN
D^sJadad^nAR#^rND^sMoore^nRA#^rND^sCarroll^nD#^rND^sJenkinson^nC#^rND^sReynolds^
nDJ#^rND^sGavaghan^nDJ#et al.#Assessing the quality of reports of randomized cli
nical trials: is blinding necessary?^len#Control Clin Trials.#2#19960000#1996#17
#1-12#20110000#11.htm##
00641000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100018000890100
01600107010001800123012013700141030000500278065000900283064000500292031000400297
014000700301865000900308002000700317035001000324801000500334#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\11.htm#S#c#137#18#article#25#18#^rND^sSchulz^nKF#^rND^sChal
mers^nI#^rND^sHayes^nRJ#^rND^sAltman^nDG.#Empirical evidence of bias: Dimensions
 of methodological quality associated with estimates of treatment effects in con
trolled trials^len#Jama#19950000#1995#273#408-12#20110000#11.htm#0098-7484#JAMA#
#
00546000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100019000890120
10900108030002200217710000200239065000900241064000500250031000300255014000600258
865000900264002000700273#v19n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#c#138#
19#article#25#19#^rND^sWright^nJG#^rND^sGebhardt^nMC#Multicenter clinical trials
 in orthopaedics: time for musculoskeletal specialty societies to take action^le
n#J Bone Joint Surg Am.#2#20050000#2005#87#214-7#20110000#11.htm##
00672000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100017000890100
01900106010001800125010002400143010001600167810000700183012009000190030002300280
71000020030306500090030506400050031403200040031901400070032386500090033000200070
0339#v19n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#c#139#20#article#25#20#^rN
D^sBickels^nJ#^rND^sWittig^nJC#^rND^sKollender^nY#^rND^sHenshaw^nRM#^rND^sKellar
-Graney^nKL#^rND^sMeller^nI#et al.#Distal femur resection with endoprosthetic re
construction: a long-term followup study^len#Clin Orthop Relat Res.#2#20020000#2
002#400#225-35#20110000#11.htm##
00650000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100019000870100
01500106010001500121010001800136012013000154030002200284710000200306065000900308
064000500317031000300322014000700325865000900332002000700341#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\11.htm#S#c#140#21#article#25#21#^rND^sKawai^nA#^rND^sMuschl
er^nGF#^rND^sLane^nJM#^rND^sOtis^nJC#^rND^sHealey^nJH.#Prosthetic knee replaceme
nt after resection of a malignant tumor of the distal part of the femur: Medium 
to long-term results^len#J Bone Joint Surg Am.#2#19980000#1998#80#636-47#2011000
0#11.htm##
00582000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100017000930100
01800110010001800128012008200146030002300228710000200251065000900253064000500262
032000400267014000500271865000900276002000700285#v19n1#V:\SciELO\serial\aob\v19n
1\markup\11.htm#S#c#141#22#article#25#22#^rND^sKabukcuoglu^nY#^rND^sGrimer^nRJ#^
rND^sTillman^nRM#^rND^sCarter^nSR.#Endoprosthetic replacement for primary malign
ant tumors of the proximal femur^len#Clin Orthop Relat Res.#2#19990000#1999#358#
8-14#20110000#11.htm##
00599000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100014000870100
02000101010001500121010001600136012007900152030002300231710000200254065000900256
064000500265032000400270014000700274865000900281002000700290#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\11.htm#S#c#142#23#article#25#23#^rND^sShih^nLY#^rND^sSim^nF
H#^rND^sPritchard^nDJ#^rND^sRock^nMG#^rND^sChao^nEY.#Segmental total knee arthro
plasty after distal femoral resection for tumor^len#Clin Orthop Relat Res.#2#199
30000#1993#292#269-81#20110000#11.htm##
00619000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100023000890100
01900112010001900131010001800150012008300168030002300251710000200274065000900276
064000500285032000400290014000700294865000900301002000700310#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\11.htm#S#c#143#24#article#25#24#^rND^sZeegen^nEN#^rND^sApon
te-Tinao^nLA#^rND^sHornicek^nFJ#^rND^sGebhardt^nMC#^rND^sMankin^nHJ.#Survivorshi
p analysis of 141 modular metallic endoprostheses at early followup^len#Clin Ort
hop Relat Res.#2#20040000#2004#420#239-50#20110000#11.htm##
00684000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100024000890100
01600113010001700129010002000146010001800166810000700184012009500191030001700286
71000020030306500090030506400050031403100030031903200020032201400060032486500090
0330002000700339#v19n1#V:\SciELO\serial\aob\v19n1\markup\11.htm#S#c#144#25#artic
le#25#25#^rND^sViola^nDCM#^rND^sCardozo Filho^nNS#^rND^sNunes^nRT#^rND^sGodoy^nF
AC#^rND^sPetrilli^nMdT#^rND^sKorukian^nM#et al.#O uso de espaçadores com antibió
tico no tratamento das infecções em endopróteses de joelho^lpt#Acta Ortop Bras.#
2#20090000#2009#17#3#144-8#20110000#11.htm##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#o#1#1#article#1#201104
11#111922#12.htm#188##
03570000000000625000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000500083038000400088121000300092049000700095158000300102
03000180010503100030012303200020012606500090012801400090013703500100014601200660
01560120034002220100036002560100025002920100038003170100036003550700039003910831
12900430085000801559085002401567085002901591085002201620085003001642083110501672
08500080277708500250278508500250281008500250283508500280286011700060288807200030
2894112000902897111001102906114000902917113001102926002000702937#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#12#
AOB160#nd#Acta ortop. bras.#19#1#20110000#^f52^l57#1413-7852#Terapia gênica para
 osteoporose gene therapy for osteoporosis^lpt#Gene therapy for osteoporosis^len
#^rND^1A01^nRafael Pacheco da^sCosta#^rND^1A01^nSang Won^sHan#^rND^1A01^nAlberto
 de Castro^sPochini#^rND^1A01^nRejane Daniele^sReginato#Universidade Federal de 
São Paulo^iA01#^lpt^aA osteoporose é considerada um dos problemas de saúde mais 
comuns e sérios da população idosa mundial. É uma doença crônica e progressiva, 
caracterizada pela diminuição da massa óssea e deterioração da microarquitetura 
do tecido ósseo. A terapia gênica representa uma nova abordagem para o tratament
o da osteoporose e tem como princípio devolver a função comprometida pelo metabo
lismo. Esta revisão visa focar os trabalhos relevantes desenvolvidos nos últimos
 anos, disponibilizados nas bases de dados médicas, e que utilizaram a terapia g
ênica para o tratamento da osteoporose em modelos animais, bem como, as perspect
ivas futuras desta terapia. A maioria dos estudos utiliza os genes BMPs, PTH e O
PG na tentativa de restabelecer a massa óssea. Apesar da carência de novas moléc
ulas, todos os genes empregados nos estudos se mostraram eficientes no tratament
o da doença. Os benefícios que a terapia gênica proporcionará aos pacientes no f
uturo devem contribuir substancialmente para o aumento na qualidade de vida dos 
idosos. Em breve, protocolos clínicos envolvendo humanos irão beneficiar os indi
víduos com osteoporose.#^dnd^i1#^tm^lpt^kOsteoporose^i1#^tm^lpt^kTerapia de gene
s^i1#^tm^lpt^kOrtopedia^i1#^tm^lpt^kVetores genéticos^i1#^len^aOsteoporosis is c
onsidered one of the most common and serious problems affecting the elderly popu
lation worldwide. It is a chronic and progressive disease, characterized by decr
eased bone mass and degeneration of the microarchitecture of the bone tissue. Ge
ne therapy represents a new approach in osteoporosis treatment, and its main fun
ction is to restore the compromised function in the metabolism. This review aims
 to elucidate the main studies on gene therapy in recent years, in the medical d
atabases, that use gene therapy for the treatment of osteoporosis in animal mode
ls, as well as the future prospects of this therapy. The majority of the studies
 use the BMP, PTH and OPG genes, in an attempt to reestablish bone mass. Despite
 the lack of new molecules, all genes employed in these studies have proven to b
e efficient in the treatment of the disease. The benefits that gene therapy will
 provide for patients in the future should contribute substantially to increasin
g the quality of life for the elderly. Soon, clinical trials involving humans wi
ll benefit individuals with osteoporosis.#^dnd^i2#^tm^len^kOsteoporosis^i2#^tm^l
en^kGene therapy^i2#^tm^len^kOrthopaedics^i2#^tm^len^kGenetic vectors^i2#other#3
3#20081008#08/10/2008#20090426#26/04/2009#12.htm##
03584000000000625000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000500083038000400088121000300092049000700095158000300102
03000180010503100030012303200020012606500090012801400090013703500100014601200730
01560120041002290100036002700100025003060100038003310100036003690700039004050831
12900444085000801573085002401581085002901605085002201634085003001656083110501686
08500080279108500250279908500250282408500250284908500280287411700060290207200030
2908112000902911111001102920114000902931113001102940002000702951#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#12#
AOB160#nd#Acta ortop. bras.#19#1#20110000#^f52^l57#1413-7852#<b>Terapia gênica p
ara osteoporose gene therapy for osteoporosis</b>^lpt#<b>Gene therapy for osteop
orosis</b>^len#^rND^1A01^nRafael Pacheco da^sCosta#^rND^1A01^nSang Won^sHan#^rND
^1A01^nAlberto de Castro^sPochini#^rND^1A01^nRejane Daniele^sReginato#Universida
de Federal de São Paulo^iA01#^lpt^aA osteoporose é considerada um dos problemas 
de saúde mais comuns e sérios da população idosa mundial. É uma doença crônica e
 progressiva, caracterizada pela diminuição da massa óssea e deterioração da mic
roarquitetura do tecido ósseo. A terapia gênica representa uma nova abordagem pa
ra o tratamento da osteoporose e tem como princípio devolver a função comprometi
da pelo metabolismo. Esta revisão visa focar os trabalhos relevantes desenvolvid
os nos últimos anos, disponibilizados nas bases de dados médicas, e que utilizar
am a terapia gênica para o tratamento da osteoporose em modelos animais, bem com
o, as perspectivas futuras desta terapia. A maioria dos estudos utiliza os genes
 BMPs, PTH e OPG na tentativa de restabelecer a massa óssea. Apesar da carência 
de novas moléculas, todos os genes empregados nos estudos se mostraram eficiente
s no tratamento da doença. Os benefícios que a terapia gênica proporcionará aos 
pacientes no futuro devem contribuir substancialmente para o aumento na qualidad
e de vida dos idosos. Em breve, protocolos clínicos envolvendo humanos irão bene
ficiar os indivíduos com osteoporose.#^dnd^i1#^tm^lpt^kOsteoporose^i1#^tm^lpt^kT
erapia de genes^i1#^tm^lpt^kOrtopedia^i1#^tm^lpt^kVetores genéticos^i1#^len^aOst
eoporosis is considered one of the most common and serious problems affecting th
e elderly population worldwide. It is a chronic and progressive disease, charact
erized by decreased bone mass and degeneration of the microarchitecture of the b
one tissue. Gene therapy represents a new approach in osteoporosis treatment, an
d its main function is to restore the compromised function in the metabolism. Th
is review aims to elucidate the main studies on gene therapy in recent years, in
 the medical databases, that use gene therapy for the treatment of osteoporosis 
in animal models, as well as the future prospects of this therapy. The majority 
of the studies use the BMP, PTH and OPG genes, in an attempt to reestablish bone
 mass. Despite the lack of new molecules, all genes employed in these studies ha
ve proven to be efficient in the treatment of the disease. The benefits that gen
e therapy will provide for patients in the future should contribute substantiall
y to increasing the quality of life for the elderly. Soon, clinical trials invol
ving humans will benefit individuals with osteoporosis.#^dnd^i2#^tm^len^kOsteopo
rosis^i2#^tm^len^kGene therapy^i2#^tm^len^kOrthopaedics^i2#^tm^len^kGenetic vect
ors^i2#other#33#20081008#08/10/2008#20090426#26/04/2009#12.htm##
03691000000000649000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000500090038000400095121000300099049000700102
15800030010903000170011203100030012903200020013206500090013401400090014303500100
01520120066001620120034002280100036002620100025002980100038003230100036003610700
04100397083112900438085000801567085002401575085002901599085002201628085003001650
08311050168008500080278508500250279308500250281808500250284308500280286811700060
28960720003029021120009029051110011029141140009029251130011029340020007029450080
08902952#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#l#4#1#article#1#^a2011
#oa#pt#br1.1#1#4.0#ilus#tab#12#AOB160#nd#Acta ortop. bras#19#1#20110000#^f52^l57
#1413-7852#Terapia gênica para osteoporose gene therapy for osteoporosis^lpt#Gen
e therapy for osteoporosis^len#^rND^1A01^nRafael Pacheco da^sCosta#^rND^1A01^nSa
ng Won^sHan#^rND^1A01^nAlberto de Castro^sPochini#^rND^1A01^nRejane Daniele^sReg
inato#^iA01^1Universidade Federal de São Paulo#^lpt^aA osteoporose é considerada
 um dos problemas de saúde mais comuns e sérios da população idosa mundial. É um
a doença crônica e progressiva, caracterizada pela diminuição da massa óssea e d
eterioração da microarquitetura do tecido ósseo. A terapia gênica representa uma
 nova abordagem para o tratamento da osteoporose e tem como princípio devolver a
 função comprometida pelo metabolismo. Esta revisão visa focar os trabalhos rele
vantes desenvolvidos nos últimos anos, disponibilizados nas bases de dados médic
as, e que utilizaram a terapia gênica para o tratamento da osteoporose em modelo
s animais, bem como, as perspectivas futuras desta terapia. A maioria dos estudo
s utiliza os genes BMPs, PTH e OPG na tentativa de restabelecer a massa óssea. A
pesar da carência de novas moléculas, todos os genes empregados nos estudos se m
ostraram eficientes no tratamento da doença. Os benefícios que a terapia gênica 
proporcionará aos pacientes no futuro devem contribuir substancialmente para o a
umento na qualidade de vida dos idosos. Em breve, protocolos clínicos envolvendo
 humanos irão beneficiar os indivíduos com osteoporose.#^dnd^i1#^tm^lpt^kOsteopo
rose^i1#^tm^lpt^kTerapia de genes^i1#^tm^lpt^kOrtopedia^i1#^tm^lpt^kVetores gené
ticos^i1#^len^aOsteoporosis is considered one of the most common and serious pro
blems affecting the elderly population worldwide. It is a chronic and progressiv
e disease, characterized by decreased bone mass and degeneration of the microarc
hitecture of the bone tissue. Gene therapy represents a new approach in osteopor
osis treatment, and its main function is to restore the compromised function in 
the metabolism. This review aims to elucidate the main studies on gene therapy i
n recent years, in the medical databases, that use gene therapy for the treatmen
t of osteoporosis in animal models, as well as the future prospects of this ther
apy. The majority of the studies use the BMP, PTH and OPG genes, in an attempt t
o reestablish bone mass. Despite the lack of new molecules, all genes employed i
n these studies have proven to be efficient in the treatment of the disease. The
 benefits that gene therapy will provide for patients in the future should contr
ibute substantially to increasing the quality of life for the elderly. Soon, cli
nical trials involving humans will benefit individuals with osteoporosis.#^dnd^i
2#^tm^len^kOsteoporosis^i2#^tm^len^kGene therapy^i2#^tm^len^kOrthopaedics^i2#^tm
^len^kGenetic vectors^i2#other#33#20081008#08/10/2008#20090426#26/04/2009#12.htm
#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-78522011
000100012##
00351000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704013100067002000700198#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#5#1#article#151#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTIGO    DE REVIS&Atilde;O<
/b></font></p>     ^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#6#2#article#151#<p>&nbsp;</p>     ^cY#12.htm
##
00399000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704017900067002000700246#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#7#3#article#151#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Terapia    g&ecirc;nica 
para osteoporose gene therapy for osteoporosis</b> </font></p>     ^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#8#4#article#151#<p>&nbsp;</p>     ^cY#12.htm
##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#9#5#article#151#<p>&nbsp;</p>     ^cY#12.htm
##
00403000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704018200068002000700250#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#10#6#article#151#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Rafael Pacheco    da Costa; Sang Won Han;
 Alberto de Castro Pochini; Rejane Daniele Reginato</b></font></p>     ^cY#12.ht
m##
00357000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704013600068002000700204#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#11#7#article#151#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2">Universidade Federal    de S&atilde;o Paulo 
- UNIFESP</font></p>     ^cY#12.htm##
00369000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704014800068002000700216#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#12#8#article#151#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><a href="#back">Endere&ccedil;o    para Corr
espond&ecirc;ncia</a></font></p>     ^cY#12.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#13#9#article#151#<p>&nbsp;</p>     ^cY#12.ht
m##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#14#10#article#151#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#12.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#15#11#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#12.htm##
01697000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704147500069002000701544#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#16#12#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A osteoporose &eacute;    considerada um do
s problemas de sa&uacute;de mais comuns e s&eacute;rios da    popula&ccedil;&ati
lde;o idosa mundial. &Eacute; uma doen&ccedil;a cr&ocirc;nica    e progressiva, 
caracterizada pela diminui&ccedil;&atilde;o da massa &oacute;ssea    e deteriora
&ccedil;&atilde;o da microarquitetura do tecido &oacute;sseo. A terapia    g&eci
rc;nica representa uma nova abordagem para o tratamento da osteoporose    e tem 
como princ&iacute;pio devolver a fun&ccedil;&atilde;o comprometida pelo    metab
olismo. Esta revis&atilde;o visa focar os trabalhos relevantes desenvolvidos    
nos &uacute;ltimos anos, disponibilizados nas bases de dados m&eacute;dicas,    
e que utilizaram a terapia g&ecirc;nica para o tratamento da osteoporose em    m
odelos animais, bem como, as perspectivas futuras desta terapia. A maioria    do
s estudos utiliza os genes BMPs, PTH e OPG na tentativa de restabelecer a    mas
sa &oacute;ssea. Apesar da car&ecirc;ncia de novas mol&eacute;culas, todos    os
 genes empregados nos estudos se mostraram eficientes no tratamento da doen&cced
il;a.    Os benef&iacute;cios que a terapia g&ecirc;nica proporcionar&aacute; ao
s pacientes    no futuro devem contribuir substancialmente para o aumento na qua
lidade de vida    dos idosos. Em breve, protocolos cl&iacute;nicos envolvendo hu
manos ir&atilde;o    beneficiar os indiv&iacute;duos com osteoporose.</font></p>
     ^cY#12.htm##
00417000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704019500069002000700264#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#17#13#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Descritores:</b>    Osteoporose. Terapia
 de genes. Ortopedia. Vetores gen&eacute;ticos.</font></p> <hr size="1" noshade>
     ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#18#14#article#151#<p>&nbsp;</p>     ^cY#12.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#19#15#article#151#<p>&nbsp;</p>     ^cY#12.h
tm##
00336000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011400069002000700183#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#20#16#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b></font></p> 
    ^cY#12.htm##
00680000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704045800069002000700527#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#21#17#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A osteoporose &eacute;    considerada uma d
oen&ccedil;a cr&ocirc;nica e progressiva, caracterizada pela    diminui&ccedil;&
atilde;o da massa &oacute;ssea e deteriora&ccedil;&atilde;o    da microarquitetu
ra do tecido &oacute;sseo. Essas altera&ccedil;&otilde;es levam    ao aumento da
 fragilidade &oacute;ssea e consequentemente, a um maior risco    para fraturas.
<sup>1</sup></font></p>     ^cY#12.htm##
01176000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704095400069002000701023#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#22#18#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Fraturas osteopor&oacute;ticas    s&atilde;
o causas significativas de perda funcional e diminui&ccedil;&atilde;o    na qual
idade de vida do indiv&iacute;duo afetado. A perda mais acentuada de    massa &o
acute;ssea ocorre nas mulheres a partir da menopausa, e est&aacute;    associada
 &agrave; insufici&ecirc;ncia de estrog&ecirc;nio.<sup>2</sup> Dentre    as frat
uras decorrentes da osteoporose na p&oacute;s-menopausa, a mais grave    &eacute
; a fratura de f&ecirc;mur. Em um estudo desenvolvido por Jiang <i>et    al</i>.
<sup>3</sup> no Canad&aacute;, o &iacute;ndice de mortalidade alcan&ccedil;ou   
 6,3% no primeiro ano e 30,8% no segundo ano ap&oacute;s a fratura. Esta taxa   
 de mortalidade est&aacute; de acordo com o resto do mundo, que varia de 1,02   
 a 10% durante a estadia no hospital e 23 a 30% durante o primeiro ano ap&oacute
;s    a fratura.<sup>4</sup></font></p>     ^cY#12.htm##
00914000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704069200069002000700761#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#23#19#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">No Brasil, os n&uacute;meros    do censo al
ertam para o grande n&uacute;mero de idosos (14 milh&otilde;es),    popula&ccedi
l;&atilde;o de maior risco para desenvolver a osteoporose. Durante    o per&iacu
te;odo de um ano foram diagnosticados 129.611 casos de osteoporose    no sistema
 privado de sa&uacute;de, sendo a incid&ecirc;ncia de 4,99% em fraturas    de f&
ecirc;mur na popula&ccedil;&atilde;o feminina. O tempo m&eacute;dio de    perman
&ecirc;ncia hospitalar foi superior a nove dias e o custo direto por paciente   
 ap&oacute;s a hospitaliza&ccedil;&atilde;o foi calculado em R$ 24.000,00.<sup>5
</sup></font></p>     ^cY#12.htm##
00545000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704032300069002000700392#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#24#20#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Na cidade de S&atilde;o    Paulo, um estudo
 com indiv&iacute;duos acima de 65 anos, demonstrou que 92,8%    das mulheres ap
resentavam osteopenia e ou osteoporose em pelo menos um local    do sistema esqu
el&eacute;tico analisado.<sup>6</sup></font></p>     ^cY#12.htm##
00478000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704025600069002000700325#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#25#21#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Calcula-se que    em 2050 haver&aacute; apr
oximadamente 6,3 milh&otilde;es de fraturas por ano,    a maioria ocorrendo na &
Aacute;sia e na Am&eacute;rica Latina.<sup>7</sup></font></p>     ^cY#12.htm##
00622000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704040000069002000700469#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#26#22#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A maioria das drogas    atualmente utilizad
as para o tratamento da osteoporose tem a&ccedil;&atilde;o    anti-reabsortiva (
estr&oacute;genos, raloxifeno, c&aacute;lcio e vitamina D,    alendronato, etidr
onato, residronato e calcitonina) e / ou anab&oacute;lica    (PTH 1-34 e ranelat
o de estr&ocirc;ncio).<sup>8</sup></font></p>     ^cY#12.htm##
00669000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704044700069002000700516#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#27#23#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A terapia g&ecirc;nica    vem sendo apontad
a como um m&eacute;todo promissor para o tratamento de doen&ccedil;as    osteome
tab&oacute;licas e representa uma nova abordagem no tratamento da osteoporose.  
  A terapia g&ecirc;nica insere o gene que codifica uma prote&iacute;na que, cas
o    fosse injetada de forma isolada, seria rapidamente degradada.<sup>9,10</sup
></font></p>     ^cY#12.htm##
00660000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704043800069002000700507#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#28#24#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O princ&iacute;pio    b&aacute;sico desta t
erapia &eacute; introduzir um material gen&eacute;tico    ex&oacute;geno para co
rrigir ou modificar a fun&ccedil;&atilde;o celular. O    material gen&eacute;tic
o, denominado de gene terap&ecirc;utico, pode ser introduzido    na c&eacute;lul
a-alvo por t&eacute;cnicas de engenharia gen&eacute;tica.<sup>9,11</sup></font><
/p>     ^cY#12.htm##
01026000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704080400069002000700873#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#29#25#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A terapia tem in&iacute;cio    com a modifi
ca&ccedil;&atilde;o de uma estrutura b&aacute;sica, denominada de    plasm&iacut
e;deo. O plasm&iacute;deo &eacute; um pequeno DNA circular encontrado    em bact
&eacute;rias. A modifica&ccedil;&atilde;o do plasm&iacute;deo consiste    basica
mente na altera&ccedil;&atilde;o do cassete de express&atilde;o (promotor,    DN
A complementar do gene terap&ecirc;utico e um sinal de poliadenila&ccedil;&atild
e;o),    que possui os sinais regulat&oacute;rios necess&aacute;rios para a expr
ess&atilde;o    do gene de interesse. A escolha equivocada de qualquer elemento 
pode resultar    no insucesso da terapia ou at&eacute; mesmo ser prejudicial &ag
rave; c&eacute;lula-alvo.<sup>11</sup></font></p>     ^cY#12.htm##
01781000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704155900069002000701628#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#30#26#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Ap&oacute;s a constru&ccedil;&atilde;o    d
o plasm&iacute;deo com as sequ&ecirc;ncias espec&iacute;ficas e necess&aacute;ri
as    para a sua manuten&ccedil;&atilde;o e express&atilde;o, este pode ser tran
sferido    para a c&eacute;lula-alvo com aux&iacute;lio de vetores virais (trans
du&ccedil;&atilde;o)    e n&atilde;o-virais (transfec&ccedil;&atilde;o).<sup>11,
12</sup> Sabe-se que    para a transdu&ccedil;&atilde;o de c&eacute;lulas hosped
eiras os v&iacute;rus    s&atilde;o efetivos em transmitir seu material gen&eacu
te;tico, por isso dentre    os vetores virais alguns grupos se destacam como os 
retrov&iacute;rus, adenov&iacute;rus,    adeno-associados e o herpes-v&iacute;ru
s simples. Na transfec&ccedil;&atilde;o,    o plasm&iacute;deo com o gene terap&
ecirc;utico pode ser incorporado &agrave;    c&eacute;lula-alvo por m&eacute;tod
os f&iacute;sicos (eletropora&ccedil;&atilde;o,    biobal&iacute;stica, sonopora
&ccedil;&atilde;o, hidrodin&acirc;mica e magnetofec&ccedil;&atilde;o),    qu&iac
ute;micos (lipoplexo, poliplexo), ou biol&oacute;gicos (infec&ccedil;&atilde;o  
  via bact&eacute;ria, virossomo, Ad-lipo). (<a href="#t1">Tabela 1</a>) A escol
ha    do vetor atual baseia-se no tipo doen&ccedil;a, no tamanho do gene terap&e
circ;utico,    na via da terapia e na dura&ccedil;&atilde;o da express&atilde;o 
g&ecirc;nica;    estas caracter&iacute;sticas s&atilde;o importantes para que a 
transfer&ecirc;ncia    g&ecirc;nica ocorra com sucesso.<sup>9,11,12</sup></font>
</p>     ^cY#12.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#31#27#article#151#<p><a name="t1"></a></p>  
   ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#32#28#article#151#<p>&nbsp;</p>     ^cY#12.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#33#29#article#151#<p align="center"><img src
="/img/revistas/aob/v19n1/12t01.jpg"></p>     ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#34#30#article#151#<p>&nbsp;</p>     ^cY#12.h
tm##
00926000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704070400069002000700773#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#35#31#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Al&eacute;m disso,    o gene terap&ecirc;ut
ico pode ser entregue ao local de interesse pela estrat&eacute;gia    <i>in vivo
</i>, da qual o gene &eacute; transferido diretamente ao local. Este    tipo de 
estrat&eacute;gia se mostrou ser simples, de baixo custo e minimamente    invasi
va. Em contrapartida, na estrat&eacute;gia <i>ex vivo</i> a transfer&ecirc;ncia 
   do gene de interesse &eacute; realizada nas c&eacute;lulas que foram coletada
s    do paciente, seguido da re(implanta&ccedil;&atilde;o) no tecido-alvo. (Figu
ra    1) Por essa raz&atilde;o, esse tipo de abordagem &eacute; mais minuciosa e
 cara.<sup>9</sup></font></p>     ^cY#12.htm##
00754000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704053200069002000700601#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#36#32#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Cada estrat&eacute;gia    apresenta vantage
ns e desvantagens, enquanto que na <i>in vivo</i> o material    parece ficar res
trito ao local injetado e apresentar uma baixa efici&ecirc;ncia    na transdu&cc
edil;&atilde;o, j&aacute; na <i>ex vivo</i> essa efici&ecirc;ncia    &eacute; ma
ior, com a possibilidade de controlar as part&iacute;culas virais    e os plasm&
iacute;deos, no entanto, o tempo deste processo &eacute; mais longo.<sup>9,11,12
</sup></font></p>     ^cY#12.htm##
00536000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704031400069002000700383#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#37#33#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Esta revis&atilde;o    visa focar os trabal
hos mais relevantes de terapia g&ecirc;nica para o tratamento    da osteoporose 
desenvolvidos nos &uacute;ltimos anos em modelos animais, bem    como as perspec
tivas futuras desta terapia.</font></p>     ^cY#12.htm##
01227000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704100500069002000701074#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#38#34#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A metodologia utilizada    foi a revis&atil
de;o da literatura realizada por busca eletr&ocirc;nica nas    bases de dados <i
>MEDLINE/PubMed</i>, LILACS, ISI -<i>Web of Science</i> e SciELO    com especial
 refer&ecirc;ncia aos artigos originais envolvendo as palavras-chave    <i>osteo
porosis, gene therapy, viral vector, non-viral vector, adenovirus, retrovirus,  
  adeno-associated virus, lentivirus, bone morphogenetic protein</i> e <i>osteop
rotegerin,</i>    usando como refer&ecirc;ncia o <i>MeSH</i> (<i>Medical Subject
 Headings)</i>    ou DeCS (Descritores em Ci&ecirc;ncias da Sa&uacute;de). O cri
t&eacute;rio de    inclus&atilde;o foram os estudos publicados nos idiomas ingl&
ecirc;s, portugu&ecirc;s    e espanhol realizados nos &uacute;ltimos anos. Os pr
incipais artigos experimentais    est&atilde;o expressos na <a href="/img/revist
as/aob/v19n1/12t02.jpg">Tabela 2</a> e alguns destes    foram citados no texto.<
/font></p>     ^cY#12.htm##
00344000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012200069002000700191#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#39#35#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Fisiopatologia    da osteoporose</b></fo
nt></p>     ^cY#12.htm##
01681000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704145900069002000701528#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#40#36#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O esqueleto humano    &eacute; constantemen
te renovado pela a&ccedil;&atilde;o conjunta e coordenada    dos osteoblastos e 
osteoclastos, tipos celulares especializados, respons&aacute;veis    pela remode
la&ccedil;&atilde;o &oacute;ssea. O desequil&iacute;brio entre a    atividade fo
rmadora dos osteoblastos e atividade reabsortiva dos osteoclastos    resultam em
 perda de massa &oacute;ssea e fragilidade esquel&eacute;tica, contribuindo    p
ara a fisiopatologia da osteoporose.<sup>2</sup> O paratorm&ocirc;nio (PTH)    e
 a calcitonina s&atilde;o os principais reguladores da homeostase do c&aacute;lc
io    e respondem &agrave;s altera&ccedil;&otilde;es da calcemia. A baixa da cal
cemia    induz ao aumento na produ&ccedil;&atilde;o do PTH, enquanto que, eleva&
ccedil;&otilde;es    diminuem sua produ&ccedil;&atilde;o. A presen&ccedil;a do r
eceptor de PTH do    tipo 1 (PTHR1) acoplado a prote&iacute;na G no osteoblasto 
possibilita o reconhecimento    da por&ccedil;&atilde;o amino-terminal do PTH, q
ue resulta na ativa&ccedil;&atilde;o    das vias da prote&iacute;na-quinase C (P
KC) e a via da prote&iacute;na-quinase    A (PKA). Apesar das duas vias serem at
ivadas pelo PTH, a PKA &eacute; a principal    via de ativa&ccedil;&atilde;o,<su
p>8</sup> conduzindo ao aumento no n&uacute;mero    de osteoclastos. O mecanismo
 simplificado est&aacute; demonstrado na Figura    2.</font></p>     ^cY#12.htm#
#
00472000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704025000069002000700319#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#41#37#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Ao contr&aacute;rio    do PTH, a calcitonin
a age diminuindo o n&iacute;vel do c&aacute;lcio s&eacute;rio    por estimular a
 atividade osteobl&aacute;stica.<sup>2</sup></font></p>     ^cY#12.htm##
00688000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704046600069002000700535#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#42#38#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Causas multifatoriais    podem ser atribu&i
acute;das para o desencadeamento da osteoporose como a diminui&ccedil;&atilde;o 
   na ingest&atilde;o ou da absor&ccedil;&atilde;o intestinal do c&aacute;lcio  
  e da vitamina D, dura&ccedil;&atilde;o do ciclo reprodutivo, fatores gen&eacut
e;ticos,    h&aacute;bitos como o &aacute;lcool e fumo, exerc&iacute;cios entre 
outros.<sup>13</sup></font></p>     ^cY#12.htm##
00438000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704021600069002000700285#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#43#39#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Apesar dos esfor&ccedil;os,    os mecanismo
s fisiopatol&oacute;gicos envolvidos no processo da osteoporose    permanecem in
completos.</font></p>     ^cY#12.htm##
00371000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704014900069002000700218#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#44#40#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Terapia g&ecirc;nica:    estudos pr&eacu
te;-cl&iacute;nicos</b></font></p>     ^cY#12.htm##
01708000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704148600069002000701555#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#45#41#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Um dos primeiros    trabalhos a avaliar a p
ossibilidade de utilizar um modelo murino para terapia    g&ecirc;nica para o tr
atamento da osteoporose foi desenvolvido por Baltzer <i>et    al</i>.<sup>14</su
p> Neste estudo os autores utilizaram um modelo de camundongos    f&ecirc;meas o
oforectomizados e o vetor adenoviral do sorotipo cinco para efetuar    a entrega
 do gene IL-1Ra humano na cavidade medular do osso f&ecirc;mur. O gene    IL-1Ra
 &eacute; respons&aacute;vel por codificar a prote&iacute;na "receptor    antago
nista da interleucina do tipo 1". A fun&ccedil;&atilde;o biol&oacute;gica    des
ta prote&iacute;na &eacute; inversa a uma das atividades da citocina inflamat&oa
cute;ria    IL-1 (Interleucina-1), que &eacute; indutora da reabsor&ccedil;&atil
de;o &oacute;ssea    e est&aacute; aumentada em mulheres na p&oacute;s-menopausa
. Desta maneira,    uma prote&iacute;na que inibe a atividade da IL-1, parece se
r uma importante    ferramenta na tentativa de diminuir a perda &oacute;ssea. Os
 resultados mostraram    que todos os ossos foram protegidos contra a perda da m
assa &oacute;ssea, e    n&atilde;o apenas o f&ecirc;mur que recebeu a inje&ccedi
l;&atilde;o com o vetor.    Os autores refor&ccedil;am a ideia proposta por Oyam
a <i>et al</i>.<sup>15</sup>    de que as c&eacute;lulas transduzidas tem a capa
cidade de trafegar atrav&eacute;s    da medula &oacute;ssea de diferentes ossos.
</font></p>     ^cY#12.htm##
01755000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704153300069002000701602#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#46#42#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Chen <i>et al</i>.<sup>16</sup>    tamb&eac
ute;m utilizaram o modelo de animal ooforectomizado para induzir a perda    &oac
ute;ssea, no entanto, usaram ratas com 56 semanas de idade. Ap&oacute;s    o pro
cedimento cir&uacute;rgico o m&uacute;sculo quadr&iacute;ceps de ambas    as pat
as foi transfectado com o plasm&iacute;deo nu contendo o gene do PTH ou    o gen
e codificador do pept&iacute;deo RGD. Ap&oacute;s tr&ecirc;s meses os animais   
 foram sacrificados e os resultados mostraram que houve o aumento na densidade  
  mineral &oacute;ssea em 10,1% no grupo que recebeu o gene do PTH e 8,9% no que
    recebeu o gene RGD. A perda &oacute;ssea foi evitada nos animais que receber
am    o gene RGD, pois este &eacute; antagonista de algumas integrinas respons&a
acute;veis    pela ades&atilde;o celular, como exemplo a integrina </font><font 
size="2">&#946;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2
">3    humana, desta maneira, os osteoclastos n&atilde;o conseguem se manter ade
ridos    &agrave; superf&iacute;cie celular, e a taxa de reabsor&ccedil;&atilde;
o diminui,    al&eacute;m disso, esta mol&eacute;cula tamb&eacute;m induz a apop
tose dos osteoclastos.    J&aacute; nos animais que receberam o gene codificante
 do PTH, o aumento nos    par&acirc;metros avaliados pode ser explicado pelo fat
o do PTH exercer a&ccedil;&atilde;o    anab&oacute;lica quando administrado de m
odo intermitente e em baixas doses.<sup>8</sup></font></p>     ^cY#12.htm##
01070000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704084800069002000700917#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#47#43#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Em um estudo anterior    conduzido por Liu 
<i>et al</i>.<sup>17</sup> os autores j&aacute; haviam realizado    com sucesso 
a transfec&ccedil;&atilde;o do m&uacute;sculo quadr&iacute;ceps    de camundongo
s f&ecirc;meas com gene codificador do PTH. Naquela ocasi&atilde;o    haviam obs
ervado que no final de oito semanas de tratamento a express&atilde;o    se mante
ve. A fim de aumentar a efici&ecirc;ncia da transfec&ccedil;&atilde;o    os auto
res usaram o m&eacute;todo conhecido como eletropora&ccedil;&atilde;o.    Neste 
m&eacute;todo uma descarga el&eacute;trica foi aplicada por meio de uma    pisto
la, provocando altera&ccedil;&atilde;o na permeabilidade da membrana plasm&aacut
e;tica,    o que facilitou a entrada do gene nas c&eacute;lulas-alvo.<sup>12</su
p></font></p>     ^cY#12.htm##
00557000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704033500069002000700404#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#48#44#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Muitos pesquisadores    utilizam as c&eacut
e;lulas-tronco mesenquimais (CTMs) como mediadoras para o    tratamento da osteo
porose, induzindo a sua diferencia&ccedil;&atilde;o em osteoblastos    e evitand
o a perda &oacute;ssea acentuada.<sup>18,19</sup></font></p>     ^cY#12.htm##
01168000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704094600069002000701015#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#49#45#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O primeiro trabalho    que mostrou a aplica
bilidade da transplanta&ccedil;&atilde;o sist&ecirc;mica    de CTMs manipuladas 
geneticamente e injetadas intravenosamente &eacute; recente.    Os autores ap&oa
cute;s induzirem a perda &oacute;ssea com glicocortic&oacute;ides,    transduzir
am CTMs com o adenov&iacute;rus portando o gene codificante da prote&iacute;na  
  CXCR4 ou CXCR4 com Cbfa-1 em camundongos f&ecirc;meas e notaram que a recupera
&ccedil;&atilde;o    total da massa &oacute;ssea ocorreu nos animais que express
avam a prote&iacute;na    CXCR4 enquanto a for&ccedil;a e dureza foi recuperada 
apenas no grupo que recebeu    os dois genes. A recupera&ccedil;&atilde;o da mas
sa &oacute;ssea ocorreu devido    ao fato das c&eacute;lulas transduzidas com CX
CR4 desempenharem um papel crucial    na diferencia&ccedil;&atilde;o osteog&ecir
c;nica.<sup>20</sup></font></p>     ^cY#12.htm##
00779000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704055700069002000700626#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#50#46#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Com o envelhecimento    do indiv&iacute;duo
, o n&uacute;mero de CTM diminui, mas a capacidade de diferencia&ccedil;&atilde;
o    n&atilde;o se altera, o que poderia representar um problema, pois os estudo
s    utilizam modelos de animais ooforectomizados relativamente jovens em compar
a&ccedil;&atilde;o    com o que ocorre na osteoporose prim&aacute;ria do tipo I<
sup>18</sup> (caracterizada    pela defici&ecirc;ncia do estr&oacute;geno em mul
heres na p&oacute;s-menopausa).</font></p>     ^cY#12.htm##
00564000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704034200069002000700411#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#51#47#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Diante do exposto,    &eacute; evidente a n
ecessidade de mais estudos que enfoquem a quantidade de    CTM e a capacidade de
 diferencia&ccedil;&atilde;o durante os diferentes est&aacute;gios    do desenvo
lvimento humano, principalmente ap&oacute;s a menopausa.</font></p>     ^cY#12.h
tm##
00854000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704063200069002000700701#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#52#48#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A maior parte dos    estudos em terapia g&e
circ;nica para osteoporose emprega os fatores de crescimento    conhecidos como 
BMPs (Prote&iacute;nas morfogen&eacute;ticas &oacute;sseas).    Estas prote&iacu
te;nas fazem parte da superfam&iacute;lia do TNF-&szlig; (Fator    de necrose tu
moral &szlig;) e agem atuando na diferencia&ccedil;&atilde;o, prolifera&ccedil;&
atilde;o    e quimiotaxia, estimulando a osteog&ecirc;nese em animais e humanos.
 As BMPs    mais estudadas e empregadas na terapia g&ecirc;nica incluem a BMP-2 
e a BMP-4.<sup>21-24</sup></font></p>     ^cY#12.htm##
01376000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704115400069002000701223#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#53#49#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Yue <i>et al</i>.<sup>22</sup>    mostraram
 que a quantidade de CTM diminui com o envelhecimento, no entanto,    a express&
atilde;o do gene BMP-2 pela CTM n&atilde;o se altera quando injetado    em anima
is de diferentes idades, estimulando inclusive a forma&ccedil;&atilde;o    &oacu
te;ssea em animais idosos. Para estudar reparo de fraturas, os mesmos autores   
 perfuraram o osso f&ecirc;mur e em seguida aplicaram sobre a perfura&ccedil;&at
ilde;o    um bloco poroso de fosfato de c&aacute;lcio. Este bloco antes de ser a
plicado    sobre o local foi cultivado por sete dias com CTMs transduzidas com o
 vetor    adenoviral (Ad5) contendo o gene BMP-2. Ap&oacute;s 6 semanas as CTM e
xpressaram    o BMP-2. Os dados mostraram que o gene BMP-2 devolveu o potencial 
osteog&ecirc;nico    &agrave;s CTMs. Os autores refor&ccedil;am a ideia de que a
 incorpora&ccedil;&atilde;o    do material gen&eacute;tico <i>ex</i> ou <i>in vi
vo</i> por meio das CTMs &eacute;    uma abordagem &uacute;til para o a preven&c
cedil;&atilde;o ou tratamento das    fraturas osteopor&oacute;ticas.</font></p> 
    ^cY#12.htm##
00659000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704043700069002000700506#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#54#50#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Kawai <i>et al</i>.<sup>23</sup>    demonst
raram que o plasm&iacute;deo transportando o gene BMP-2, al&eacute;m    de induz
ir a ossifica&ccedil;&atilde;o endocondral, foi capaz de induzir a ossifica&cced
il;&atilde;o    intramembranosa no m&uacute;sculo gastrocn&ecirc;mico de ratos c
om aux&iacute;lio    da eletropora&ccedil;&atilde;o transcut&acirc;nea.</font></
p>     ^cY#12.htm##
00717000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704049500069002000700564#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#55#51#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Os vetores adeno-associados,<sup>21</sup>  
  adenov&iacute;rus,<sup>22,24</sup> retrov&iacute;rus<sup>25</sup> e o plasm&ia
cute;deo    nu<sup>23</sup> j&aacute; foram utilizados para a transfer&ecirc;nci
a dos genes    BMP com sucesso. Em todos os vetores citados acima, houve respost
a positiva    no tecido &oacute;sseo, mas a escolha do melhor vetor para o trata
mento da osteoporose    ainda &eacute; discutida.</font></p>     ^cY#12.htm##
01772000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704155000069002000701619#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#56#52#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Al&eacute;m da    possibilidade de tratar a
 osteoporose por estimular a forma&ccedil;&atilde;o    &oacute;ssea, a terapia g
&ecirc;nica tamb&eacute;m pode atuar nos mecanismos    de reabsor&ccedil;&atilde
;o.<sup>26-28</sup> A osteoprotegerina (OPG) &eacute;    uma prote&iacute;na end
&oacute;gena sintetizada pelos osteoblastos, e &eacute;    respons&aacute;vel pe
la inibi&ccedil;&atilde;o da osteoclastog&ecirc;nese e    da atividade dos osteo
clastos. A OPG atua como um atrativo para o RANKL (Receptor    ativador do fator
 nuclear </font><font size="2">&#954;</font><font face="Verdana, Arial, Helvetic
a, sans-serif" size="2">B    ligante), prejudicando sua liga&ccedil;&atilde;o co
m o RANK (Receptor ativador    do fator nuclear </font><font size="2">&#954;</fo
nt><font face="Verdana, Arial, Helvetica, sans-serif" size="2">B),    como resul
tado n&atilde;o h&aacute; indu&ccedil;&atilde;o dos sinais intracelulares    res
pons&aacute;veis pela diferencia&ccedil;&atilde;o, fun&ccedil;&atilde;o e    sob
reviv&ecirc;ncia dos osteoclastos. A produ&ccedil;&atilde;o da OPG &eacute;    r
egulada por mol&eacute;culas que aumentam sua s&iacute;ntese (IL-1a, IL-6,    IL
-11, IL-17, IL-18, TNF-</font><font size="2">&#945;</font><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">,    TNF-&szlig;, BMP-2, estrog&ecirc;nio,
 c&aacute;lcio e vitamina D3) e outras    que a diminuem (paratorm&ocirc;nio, os
 glicocortic&oacute;ides e a prostaglandina    E2).<sup>29</sup></font></p>     
^cY#12.htm##
01135000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704091300069002000700982#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#57#53#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Kostenuik <i>et    al</i>.<sup>27</sup> con
seguiram estabilizar a perda &oacute;ssea no processo    inicial de osteopenia, 
no modelo de camundongos f&ecirc;meas ooforectomizados.    Os autores utilizaram
 o vetor adeno-associado como transportador do gene OPG    humano. A densidade m
ineral &oacute;ssea da t&iacute;bia aumentou significantemente    nos animais qu
e receberam o gene OPG, havendo tamb&eacute;m uma redu&ccedil;&atilde;o    na qu
antidade dos osteoclastos na superf&iacute;cie da met&aacute;fise proximal    da
 t&iacute;bia. Os camundongos sham-operados (exposi&ccedil;&atilde;o dos ov&aacu
te;rios,    mas sem a remo&ccedil;&atilde;o), tamb&eacute;m apresentaram aumento
 da densidade    mineral &oacute;ssea quando comparados com os outros animais qu
e receberam um    gene sem efeito sobre o metabolismo &oacute;sseo.</font></p>  
   ^cY#12.htm##
00936000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704071400069002000700783#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#58#54#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O adenov&iacute;rus    conduzindo o gene OP
G tamb&eacute;m foi estudado para o tratamento da osteoporose.    Este tipo de v
etor ao transduzir uma c&eacute;lula hospedeira mant&eacute;m    o genoma n&atil
de;o integrado ao cromossomo (forma epissomal), mas quando a    c&eacute;lula in
fectada se divide o epissomo pode se perder, podendo tamb&eacute;m    levar a um
a resposta imune, e consequentemente o efeito do gene terap&ecirc;utico    &eacu
te; perdido. Apesar disso, Bolon <i>et al</i>.<sup>28</sup> demonstraram    que 
a express&atilde;o pode ser mantida por pelo menos 18 meses e levar ao aumento  
  da densidade &oacute;ssea.</font></p>     ^cY#12.htm##
00742000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704052000069002000700589#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#59#55#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As interleucinas    representam um importan
te alvo para o tratamento e preven&ccedil;&atilde;o da    osteoporose. Foi demon
strada que a IL-11 &eacute; um importante fator estimulador    da osteoblastog&e
circ;nese e forma&ccedil;&atilde;o do osso, possivelmente por    aumentar a prod
u&ccedil;&atilde;o das BMPs. A IL-11 pode representar uma nova    estrat&eacute;
gia terap&ecirc;utica para o tratamento da osteoporose senil.<sup>29</sup></font
></p>     ^cY#12.htm##
00797000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704057500069002000700644#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#60#56#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Sabe-se que a defici&ecirc;ncia    do estro
g&ecirc;nio causa o aumento na produ&ccedil;&atilde;o da IL-7, refletindo    em 
uma maior quantidade de osteoclastos, dessa forma, a neutraliza&ccedil;&atilde;o
    da IL-7 repercute na diminui&ccedil;&atilde;o da reabsor&ccedil;&atilde;o &o
acute;ssea.    Cada vez mais o papel das interleucinas no metabolismo &oacute;ss
eo tem sido    investigado, e muito das descobertas podem ajudar a expor novos a
lvos para a    terapia g&ecirc;nica.<sup>30</sup></font></p>     ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#61#57#article#151#<p>&nbsp;</p>     ^cY#12.h
tm##
00328000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010600069002000700175#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#62#58#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>CONCLUS&Atilde;O</b></font></p>     ^cY#
12.htm##
00438000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704021600069002000700285#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#63#59#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Poucos relatos    na literatura cient&iacut
e;fica utilizaram a terapia g&ecirc;nica como um instrumento    para tratar a os
teoporose.</font></p>     ^cY#12.htm##
01228000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704100600069002000701075#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#64#60#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A matriz calcificada    do tecido &oacute;s
seo representa um obst&aacute;culo a mais no estudo da terapia    g&ecirc;nica p
ara as doen&ccedil;as osteometab&oacute;licas, pois a difus&atilde;o    do vetor
 atrav&eacute;s da matriz &eacute; praticamente imposs&iacute;vel, o    que torn
a esta terapia mais elaborada para osteoporose, afetando diretamente    no suces
so da transfec&ccedil;&atilde;o ou transdu&ccedil;&atilde;o das c&eacute;lulas  
  osteog&ecirc;nicas. Uma alternativa para contornar este obst&aacute;culo, diz 
   respeito &agrave; utiliza&ccedil;&atilde;o das c&eacute;lulas-tronco mesenqui
mais    portando o gene terap&ecirc;utico, pois s&atilde;o c&eacute;lulas precur
soras    dos osteoblastos e, refletem no aumento da massa &oacute;ssea por sinte
tizar    matriz.<sup>18,22</sup> Apesar disso, os trabalhos relatados restabelec
eram    a massa &oacute;ssea e com isso diminu&iacute;ram o risco para fraturas.
</font></p>     ^cY#12.htm##
00892000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704067000069002000700739#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#65#61#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A maioria dos trabalhos    relatou a utiliz
a&ccedil;&atilde;o de apenas um gene terap&ecirc;utico, teoricamente,    nada im
pede que o cassete de express&atilde;o do plasm&iacute;deo possua sequ&ecirc;nci
as    g&ecirc;nicas para atuar tanto nos osteoblastos, estimulando a forma&ccedi
l;&atilde;o    &oacute;ssea, quanto nos osteoclastos, diminuindo a taxa de reabs
or&ccedil;&atilde;o.    Desta maneira &eacute; poss&iacute;vel potencializar o t
ratamento para a osteoporose    e ter uma resposta positiva mais r&aacute;pida, 
principalmente para indiv&iacute;duos    com osteoporose severa.</font></p>     
^cY#12.htm##
00817000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704059500069002000700664#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#66#62#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Uma grande parte    dos estudos utiliza a O
PG, a BMP e o PTH como mol&eacute;culas promissoras para    o tratamento da oste
oporose, entretanto, h&aacute; uma car&ecirc;ncia de novas    mol&eacute;culas c
omo poss&iacute;veis alvos a serem estudados, limitando praticamente    os pesqu
isadores a utilizarem as mesmas mol&eacute;culas. Apesar de tudo, a    sequ&ecir
c;ncia RGD e o estudo com a integrina &szlig;3 humana se mostraram    alvos impo
rtantes para a terapia g&ecirc;nica anti-reabsortiva.<sup>16,31</sup></font></p>
     ^cY#12.htm##
00542000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704032000069002000700389#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#67#63#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Estudos futuros    devem ser realizados, fo
cando a utiliza&ccedil;&atilde;o de modelos animais    de grande porte, a utiliz
a&ccedil;&atilde;o de novos genes terap&ecirc;uticos    e do melhor vetor para a
 transfer&ecirc;ncia g&ecirc;nica.</font></p>     ^cY#12.htm##
00767000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704054500069002000700614#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#68#64#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O custo, a via    de administra&ccedil;&ati
lde;o e os efeitos colaterais s&atilde;o alguns dos    fatores indesej&aacute;ve
is que podem culminar no abandono ou interrup&ccedil;&atilde;o    no tratamento 
convencional, comprometendo a efic&aacute;cia do medicamento e    a sa&uacute;de
 do paciente.<sup>8</sup> Em pacientes tratados pela terapia g&ecirc;nica,    es
pera-se que, o abandono e ou a interrup&ccedil;&atilde;o no tratamento se    tor
ne menos frequente.</font></p>     ^cY#12.htm##
01045000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704082300069002000700892#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#69#65#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Na busca de diminuir    os aspectos negativ
os na terap&ecirc;utica atual para a osteoporose, a terapia    g&ecirc;nica se m
ostra uma ferramenta importante. Espera-se que no futuro, por    meio de uma ou 
poucas interven&ccedil;&otilde;es minimamente invasivas, o gene    terap&ecirc;u
tico possa restabelecer a fun&ccedil;&atilde;o do tecido &oacute;sseo    e causa
r pouco ou nenhum efeito colateral. Para isso, o controle do n&iacute;vel    da 
express&atilde;o &eacute; essencial, pois um baixo n&iacute;vel pode n&atilde;o 
   exercer os resultados terap&ecirc;uticos e o inverso pode ser prejudicial &ag
rave;    c&eacute;lula. Mecanismos de controle est&atilde;o sendo estudados para
 controlar    a express&atilde;o do gene.<sup>11,32</sup></font></p>     ^cY#12.
htm##
00719000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704049700069002000700566#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#70#66#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Com os avan&ccedil;os    das t&eacute;cnica
s de engenharia gen&eacute;tica, o custo desta terapia deve    cair consideravel
mente. Os benef&iacute;cios que esta ferramenta poder&aacute;    trazer no futur
o aos pacientes devem contribuir substancialmente para o aumento    na perspecti
va e na qualidade de vida dos idosos, principalmente da popula&ccedil;&atilde;o 
   feminina, que mais sofre com esta doen&ccedil;a.</font></p>     ^cY#12.htm##
00528000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704030600069002000700375#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#71#67#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A preven&ccedil;&atilde;o    ou o restabele
cimento mais r&aacute;pido de fraturas decorrentes da osteoporose    certamente 
acarretar&aacute; um menor impacto econ&ocirc;mico no or&ccedil;amento    govern
amental.<sup>5</sup></font></p>     ^cY#12.htm##
00469000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704024700069002000700316#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#72#68#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">No futuro pr&oacute;ximo,    protocolos cl&
iacute;nicos envolvendo humanos devem trazer esperan&ccedil;a    a milhares de p
essoas que sofrem com esta doen&ccedil;a.</font></p>     ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#73#69#article#151#<p>&nbsp;</p>     ^cY#12.h
tm##
00329000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010700069002000700176#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#74#70#article#151#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font></p>     ^cY
#12.htm##
00518000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704028200071002000700353#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#75#71#article#151#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1. WHO. World Health    Organ
ization. Assessment of fracture risk and its application to screening for    pos
tmenopausal osteoporosis: report of a WHO study group. WHO Technical Report    S
eries. 1994;843:1-129.    ^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#76#72#article#151#</font></p>     ^cY#12.htm
##
00377000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704014100071002000700212#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#77#73#article#151#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2. Compston JE.    Sex steroi
ds and bone. Physiol Rev. 2001;81:419-47.    ^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#78#74#article#151#</font></p>     ^cY#12.htm
##
00548000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704031200071002000700383#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#79#75#article#151#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">3. Jiang HX, Majumdar    SR, 
Dick DA, Moreau M, Raso J, Otto DD et al. Development and initial validation    
of a risk score for predicting in-hospital and 1-year mortality in patients    w
ith hip fracture. J Bone Miner Res. 2005;20:494-500.    ^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#80#76#article#151#</font></p>     ^cY#12.htm
##
00429000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704019300071002000700264#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#81#77#article#151#4#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">4. Riera-Espinoza    G. Epide
miology of osteoporosis in Latin America 2008. Salud Publica Mex. 2009;51(Suppl 
   1):52S-5S.    ^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#82#78#article#151#</font></p>     ^cY#12.htm
##
00509000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704027300071002000700344#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#83#79#article#151#5#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">5. Ara&uacute;jo    DV, Olive
ira JHA, Bracco OL. Custo da fratura osteopor&oacute;tica de f&ecirc;mur    no s
istema suplementar de sa&uacute;de brasileiro. Arq Bras Endocrinol Metab.    200
5;49:897-901.    ^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#84#80#article#151#</font></p>     ^cY#12.htm
##
00557000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704032100071002000700392#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#85#81#article#151#6#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">6. Camargo MB,    Cendoroglo 
MS, Ramos LR, Latorre MR, Saraiva GL, Lage A, et al. Bone mineral    density and
 osteoporosis among a predominantly caucasian elderly population    in the city 
of S&atilde;o Paulo, Brazil. Osteoporos Int. 2005;16:1451-60.    ^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#86#82#article#151#</font></p>     ^cY#12.htm
##
00397000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704016100071002000700232#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#87#83#article#151#7#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">7. Wark JD. Osteoporosis:    
a global perspective. Bull World Health Organ. 1999;77:424-6.    ^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#88#84#article#151#</font></p>     ^cY#12.htm
##
00524000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704028800071002000700359#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#89#85#article#151#8#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">8. Brixen KT, Christensen    
PM, Ejersted C, Langdahl L. Teriparatide (biosynthetic human parathyroid hormone
    1-34): a new paradigm in the treatment of osteoporosis. Basic Clin Pharmacol
    Toxicol. 2004;94:260-70.    ^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#90#86#article#151#</font></p>     ^cY#12.htm
##
00472000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704023600071002000700307#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#91#87#article#151#9#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">9. Fischer J, Kolk    A, Wolf
art S, Pautke C, Warnke PH, Plank X, et al. Future of local regeneration:    pro
tein versus gene therapy. J Craniomaxillofac Surg. 2010.    ^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#92#88#article#151#</font></p>     ^cY#12.htm
##
00501000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704026400072002000700336#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#93#89#article#151#10#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">10. Evans CH, Ghivizzani    
SC, Gouze E, Rediske JJ, Schwarz EM, Robbins PD. The 3rd International Meeting  
  on Gene Therapy in Rheumatology and Orthopaedics. Arthritis Res Ther. 2005;7:2
73-8.    ^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#94#90#article#151#</font></p>     ^cY#12.htm
##
00493000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704025600072002000700328#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#95#91#article#151#11#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">11. Morales MM,    organizad
or. Terapias avan&ccedil;adas: c&eacute;lulas-tronco, terapia g&ecirc;nica    e 
nanotecnologia aplicada &agrave; sa&uacute;de. Rio de Janeiro: Atheneu; 2007.   
 ^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#96#92#article#151#</font></p>     ^cY#12.htm
##
00441000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704020400072002000700276#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#97#93#article#151#12#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">12. Cohen M, Pochini    AC, 
Han S, Ingham SM, Ejnisman B, Abdalla RJ. Gene therapy in orthopedics. Rev    Br
as Ortop. 2006;41:233-40.    ^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#98#94#article#151#</font></p>     ^cY#12.htm
##
00485000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704024800072002000700320#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#99#95#article#151#13#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">13. Cohen AJ, Roe    FJ. Rev
iew of risk factors for osteoporosis with particular reference to a possible    
aetiological role of dietary salt. Food Chem Toxicol. 2000;38:237-53.    ^cY#12.
htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#100#96#article#151#</font></p>     ^cY#12.ht
m##
00488000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000300070704025000073002000700323#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#101#97#article#151#14#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">14. Baltzer AWA,    Whalen 
JD, Wooley P, Latterman C, Truchan LM, Robbins PD. Gene therapy for osteoporosis
:    evaluation in a murine ovariectomy model. Gene Ther. 2001;8:1770-6.    ^cY#
12.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#102#98#article#151#</font></p>     ^cY#12.ht
m##
00636000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000300070704039800073002000700471#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#103#99#article#151#15#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">15. Oyama M, Tatlock    A, 
Kavalkovich K, Nishimura K, Johstone B, Robbins PD, et al. Retrovirally transduc
ed    bone marrow stromal cells isolated from a mouse model of human osteogenesi
s    imperfecta (oim) persist in bone and retain the ability to form cartilage a
nd    bone after extended passaging. Gene Ther.1999;6:321-9.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#104#100#article#151#</font></p>     ^cY#12.h
tm##
00522000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028300074002000700357#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#105#101#article#151#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Chen W, Liu    J, Diao
 W, Tang J, Ji J. Bone loss induced by ovariectomy in rats is prevented    by ge
ne transfer of parathyroid hormone or an Arg-Gly-Asp-containing peptide.    Biot
echnol Lett. 2005;27:41-8.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#106#102#article#151#</font></p>     ^cY#12.h
tm##
00489000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704025000074002000700324#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#107#103#article#151#17#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Liu B, Tang    J, Ji J
, Gu J. Prevention of osteoporosis in ovariectomized mice by electroporational  
  gene transfer of parathyroid hormone. Biotechnol Lett. 2003;25:2117-22.    ^cY
#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#108#104#article#151#</font></p>     ^cY#12.h
tm##
00535000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029600074002000700370#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#109#105#article#151#18#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Kim D, Cho    SK, Her 
SJ, Yang JY, Kim SW, Kim SY et al. Retrovirus-mediated gene transfer    of recep
tor activator of nuclear factor-{kappa}B-Fc prevents bone loss in ovariectomized
    mice. Stem Cells. 2006;24:1798-805.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#110#106#article#151#</font></p>     ^cY#12.h
tm##
00444000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704020500074002000700279#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#111#107#article#151#19#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Bielby R, Jones    E, 
McGonagle D. The role of mesenchymal stem cells in maintenance and repair    of 
bone. Injury. 2007;38:26-32.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#112#108#article#151#</font></p>     ^cY#12.h
tm##
00552000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031300074002000700387#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#113#109#article#151#20#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Lien CY, Ho    KCY, Le
e OK, Blunn GW, Su Y. Restoration of bone mass and strength in glucocorticoid-tr
eated    mice by systemic transplantation of CXCR4 and Cbfa-1 co-expressing mese
nchymal    stem cells. J Bone Miner Res. 2009;24:837-48.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#114#110#article#151#</font></p>     ^cY#12.h
tm##
00525000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028600074002000700360#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#115#111#article#151#21#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Luk KDK, Chen    Y, Ch
eung KMC, Kung HF, Lu WW, Leong JCY. Adeno-associated virus-mediated bone    mor
phogenetic protein-4 gene therapy for in vivo bone formation. Biochem Biophys   
 Res Commun. 2003;308:636-45.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#116#112#article#151#</font></p>     ^cY#12.h
tm##
00469000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704023000074002000700304#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#117#113#article#151#22#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Yue B, Lu B,    Dai KR
, Zhang XL, Yu CF, Lou JR et al. BMP2 gene therapy on the repair of bone    defe
cts of aged rats. Calcif Tissue Int. 2005;77:395-403.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#118#114#article#151#</font></p>     ^cY#12.h
tm##
00565000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032600074002000700400#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#119#115#article#151#23#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Kawai M, Bessho    K, 
Maruyama H, Miyazaki JI, Yamamoto T. Human BMP-2 gene transfer using transcutane
ous    in vivo electroporation induced both intramembranous and endochondral oss
ification.    Anat Rec A Discov Mol Cell Evol Biol. 2005;287:1264-71.    ^cY#12.
htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#120#116#article#151#</font></p>     ^cY#12.h
tm##
00512000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027300074002000700347#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#121#117#article#151#24#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Gugala Z, Davis    AR,
 Fouletier-Dilling CM, Gannon FH, Lindsey RW, Olmsted-Davis EA. Adenovirus    BM
P2-induced osteogenesis in combination with collagen carriers. Biomaterials.    
2007;28:4469-79.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#122#118#article#151#</font></p>     ^cY#12.h
tm##
00533000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029400074002000700368#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#123#119#article#151#25#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Engstrand T,    Daluis
ki A, Bahamonde ME, Melhus H, Lyons KM. Transient production of bone morphogenet
ic    protein 2 by allogeneic transplanted transduced cells induces bone formati
on.    Hum Gene Ther. 2000;11:205-11.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#124#120#article#151#</font></p>     ^cY#12.h
tm##
00537000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029800074002000700372#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#125#121#article#151#26#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Ulrich-Vinther    M, S
chwarz EM, Pedersen FS, S&oslash;balle K, Andreassen TT. Gene therapy with    hu
man osteoprotegerin decreases callus remodeling with limited effects on biomecha
nical    properties. Bone. 2005;37:751-8.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#126#122#article#151#</font></p>     ^cY#12.h
tm##
00518000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027900074002000700353#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#127#123#article#151#27#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Kostenuik PJ,    Bolon
 B, Morony S, Daris M, Geng Z, Carter C et al. Gene therapy with human    recomb
inant osteoprotegerin reverses established osteopenia in ovariectomized    mice.
 Bone. 2004;34:656-64.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#128#124#article#151#</font></p>     ^cY#12.h
tm##
00528000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028900074002000700363#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#129#125#article#151#28#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Bolon B, Carter    C, 
Daris M, Morony S, Capparelli C, Hsieh A et al. Adenoviral delivery of osteoprot
egerin    ameliorates bone resorption in a mouse ovariectomy model of osteoporos
is. Mol    Ther. 2001;3:197-205.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#130#126#article#151#</font></p>     ^cY#12.h
tm##
00448000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704020900074002000700283#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#131#127#article#151#29#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Papadopouli    AE, Klo
naris CN, Theocharis SE. Role of OPG/RANKL/RANK axis on the vasculature.    Hist
ol Histopathol. 2008;23:497-506.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#132#128#article#151#</font></p>     ^cY#12.h
tm##
00518000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027900074002000700353#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#133#129#article#151#30#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Weitzmann MN,    Roggi
a C, Toraldo G, Weitzmann L, Pacifici R. Increased production of IL-7 uncouples 
   bone formation from bone resorption during estrogen deficiency. J Clin Invest
.    2002;110:1643-50.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#134#130#article#151#</font></p>     ^cY#12.h
tm##
00590000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704035100074002000700425#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#135#131#article#151#31#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Zhao H, Kitaura    H, 
Sands MS, Ross FP, Teitelbaum SL, Novack DV. Critical role of </font><font size=
"2">&#946;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3  
  integrin in experimental postmenopausal osteoporosis. J Bone Miner Res. 2005; 
   20:2116-23.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#136#132#article#151#</font></p>     ^cY#12.h
tm##
00602000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704036300074002000700437#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#137#133#article#151#32#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">32. W&uuml;bbenhortst    D
, Dumler K, Wagner B, Wexel G, Imhoff A, Gansbacher B, et al. Teracycline-regula
ted    bone morphogenetic protein 2 gene expression in lentivirally transduced p
rimary    rabbit chondrocytes for treatment of cartilage defects. Arthritis Rheu
m. 2010;    62(7):2037-46.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#138#134#article#151#</font></p>     ^cY#12.h
tm##
00477000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704023800074002000700312#v19
n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#p#139#135#article#151#33#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Liu B, Tang    J, Ji J
, Gu J. The expression of functional human parathyroid hormone in a gene    ther
apy model for osteoporosis. Cell Tissue Res. 2004; 317:57-63.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#140#136#article#151#</font></p>     ^cY#12.h
tm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#141#137#article#151#<p>&nbsp;</p>     ^cY#12
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#142#138#article#151#<p>&nbsp;</p>     ^cY#12
.htm##
00430000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704020600071002000700277#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#143#139#article#151#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top"><img sr
c="/img/revistas/aob/v19n1/seta.jpg" border="0"></a>    <b>Endereço para Corresp
ondência:</b>     ^cY#12.htm##
00283000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005900071002000700130#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#144#140#article#151#<br>   Departamento de M
orfologia e Gen&eacute;tica    ^cY#12.htm##
00294000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704007000071002000700141#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#145#141#article#151#<br>   Disciplina de His
tologia e Biologia Estrutural, UNIFESP    ^cY#12.htm##
00266000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004200071002000700113#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#146#142#article#151#<br>   Rua Botucatu, 740
, 2º andar    ^cY#12.htm##
00284000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704006000071002000700131#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#147#143#article#151#<br>   Edif&iacute;cio L
emos Torres, Vila Clementino    ^cY#12.htm##
00267000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004300071002000700114#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#148#144#article#151#<br>   S&atilde;o Paulo,
 SP, Brasil    ^cY#12.htm##
00253000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002900071002000700100#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#149#145#article#151#<br>   CEP: 04023-900   
 ^cY#12.htm##
00325000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704010100071002000700172#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#150#146#article#151#<br>   E-mail: <a href="
mailto:rafa.pacheco@ig.com.br">rafa.pacheco@ig.com.br</a></font></p>     ^cY#12.
htm##
00366000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704014200071002000700213#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#151#147#article#151#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Trabalho recebido    em 08/10/2008, aprov
ado em 26/04/2009.</font></p>     ^cY#12.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#152#148#article#151#<p>&nbsp;</p>     ^cY#12
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#153#149#article#151#<p>&nbsp;</p>     ^cY#12
.htm##
00389000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704016500071002000700236#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#154#150#article#151#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Trabalho realizado    no Centro Interdisc
iplinar de Terapia G&ecirc;nica da UNIFESP/CINTERGEN.    ^cY#12.htm##
00361000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013700071002000700208#v19n1#V:\SciELO
\serial\aob\v19n1\markup\12.htm#S#p#155#151#article#151#<br>   Todos os autores 
declaram n&atilde;o haver nenhum potencial conflito de interesses    referente a
 este artigo.</font></p>     ^cY#12.htm##
00546000000000253000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680110026000700120126000960300
02800222710000200250065000900252064000500261031000400266014000600270865000900276
002000700285#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#156#1#article#33
#1#World Health Organization#Assessment of fracture risk and its application to 
screening for postmenopausal osteoporosis: report of a WHO study group^len#WHO T
echnical Report Series#2#19940000#1994#843#1-129#20110000#12.htm##
00455000000000265000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700120026000890300
01200115065000900127064000500136031000300141014000700144865000900151002000700160
035001000167801001200177#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#157#
2#article#33#2#^rND^sCompston^nJE#Sex steroids and bone^len#Physiol Rev#20010000
#2001#81#419-47#20110000#12.htm#0031-9333#Physiol Rev##
00727000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100019000860100
01500105010001600120010001400136010001500150810000600165012013300171030001700304
06500090032106400050033003100030033501400080033886500090034600200070035503500100
0362801001700372#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#158#3#articl
e#33#3#^rND^sJiang^nHX#^rND^sMajumdar^nSR#^rND^sDick^nDA#^rND^sMoreau^nM#^rND^sR
aso^nJ#^rND^sOtto^nDD#et al#Development and initial validation of a risk score f
or predicting in-hospital and 1-year mortality in patients with hip fracture^len
#J Bone Miner Res#20050000#2005#20#494-500#20110000#12.htm#0884-0431#J Bone Mine
r Res##
00517000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100024000700120055000940300
01800149065000900167064000500176031000300181032000400184014000700188865000900195
002000700204035001000211801001800221#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.
htm#S#c#159#4#article#33#4#^rND^sRiera-Espinoza^nG#Epidemiology of osteoporosis 
in Latin America 2008^len#Salud Publica Mex#20090000#2009#51#^s1#52S-5S#20110000
#12.htm#0036-3634#Salud Publica Mex##
00631000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100020000870100
01700107012008700124030002600211065000900237064000500246031000300251014000800254
865000900262002000700271035001000278801005300288#v19n1#V:\SciELO\serial\aob\v19n
1\markup\12.htm#S#c#160#5#article#33#5#^rND^sAraújo^nDV#^rND^sOliveira^nJHA#^rND
^sBracco^nOL#Custo da fratura osteoporótica de fêmur no sistema suplementar de s
aúde brasileiro^lpt#Arq Bras Endocrinol Metab#20050000#2005#49#897-901#20110000#
12.htm#0004-2730#Arquivos Brasileiros de Endocrinologia & Metabologia##
00726000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100021000880100
01600109010001800125010001800143010001400161810000600175012012600181030001500307
06500090032206400050033103100030033601400080033986500090034700200070035603500100
0363801001500373#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#161#6#articl
e#33#6#^rND^sCamargo^nMB#^rND^sCendoroglo^nMS#^rND^sRamos^nLR#^rND^sLatorre^nMR#
^rND^sSaraiva^nGL#^rND^sLage^nA#et al#Bone mineral density and osteoporosis amon
g a predominantly caucasian elderly population in the city of São Paulo, Brazil^
len#Osteoporos Int#20050000#2005#16#1451-60#20110000#12.htm#0937-941X#Osteoporos
 Int##
00487000000000265000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100015000700120039000850300
02400124065000900148064000500157031000300162014000600165865000900171002000700180
035001000187801002400197#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#162#
7#article#33#7#^rND^sWark^nJD#Osteoporosis: a global perspective^len#Bull World 
Health Organ#19990000#1999#77#424-6#20110000#12.htm#0042-9686#Bull World Health 
Organ##
00618000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100022000870100
01800109010001800127012011200145030002900257710000200286065000900288064000500297
031000300302014000700305865000900312002000700321#v19n1#V:\SciELO\serial\aob\v19n
1\markup\12.htm#S#c#163#8#article#33#8#^rND^sBrixen^nKT#^rND^sChristensen^nPM#^r
ND^sEjersted^nC#^rND^sLangdahl^nL#Teriparatide (biosynthetic human parathyroid h
ormone 1-34): a new paradigm in the treatment of osteoporosis^len#Basic Clin Pha
rmacol Toxicol#2#20040000#2004#94#260-70#20110000#12.htm##
00636000000000313000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100014000870100
01700101010001600118010001700134010001500151810000600166012006200172030002400234
065000900258064000500267865000900272002000700281035001000288801002400298#v19n1#V
:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#164#9#article#33#9#^rND^sFischer^nJ#
^rND^sKolk^nA#^rND^sWolfart^nS#^rND^sPautke^nC#^rND^sWarnke^nPH#^rND^sPlank^nX#e
t al#Future of local regeneration: protein versus gene therapy^len#J Craniomaxil
lofac Surg#20100000#2010#20110000#12.htm#1010-5182#J Craniomaxillofac Surg##
00634000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100021000880100
01500109010001800124010001800142010001800160012008300178030001900261710000200280
065000900282064000500291031000200296014000600298865000900304002000700313#v19n1#V
:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#165#10#article#33#10#^rND^sEvans^nCH
#^rND^sGhivizzani^nSC#^rND^sGouze^nE#^rND^sRediske^nJJ#^rND^sSchwarz^nEM#^rND^sR
obbins^nPD#The 3rd International Meeting on Gene Therapy in Rheumatology and Ort
hopaedics^len#Arthritis Res Ther#2#20050000#2005#7#273-8#20110000#12.htm##
00463000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160019000720180089000910660
01500180062000800195065000900203064000500212865000900217002000700226#v19n1#V:\Sc
iELO\serial\aob\v19n1\markup\12.htm#S#c#166#11#article#33#11#^rORG^sMorales^nMM#
Terapias avançadas: células-tronco, terapia gênica e nanotecnologia aplicada à s
aúde^lpt#Rio de Janeiro#Atheneu#20070000#2007#20110000#12.htm##
00609000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100018000870100
01300105010001700118010001800135010001800153012003200171030001500203065000900218
06400050022703100030023201400070023586500090024200200070025103500100025880100150
0268#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#167#12#article#33#12#^rN
D^sCohen^nM#^rND^sPochini^nAC#^rND^sHan^nS#^rND^sIngham^nSM#^rND^sEjnisman^nB#^r
ND^sAbdalla^nRJ#Gene therapy in orthopedics^len#Rev Bras Ortop#20060000#2006#41#
233-40#20110000#12.htm#0486-6401#Rev Bras Ortop##
00584000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100014000880120
11800102030001800220065000900238064000500247031000300252014000700255865000900262
002000700271035001000278801001800288#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.
htm#S#c#168#13#article#33#13#^rND^sCohen^nAJ#^rND^sRoe^nFJ#Review of risk factor
s for osteoporosis with particular reference to a possible aetiological role of 
dietary salt^len#Food Chem Toxicol#20000000#2000#38#237-53#20110000#12.htm#0278-
6915#Food Chem Toxicol##
00650000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100017000910100
01600108010001900124010001800143010001800161012007600179030001000255065000900265
06400050027403100020027901400070028186500090028800200070029703500100030480100100
0314#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#169#14#article#33#14#^rN
D^sBaltzer^nAWA#^rND^sWhalen^nJD#^rND^sWooley^nP#^rND^sLatterman^nC#^rND^sTrucha
n^nLM#^rND^sRobbins^nPD#Gene therapy for osteoporosis: evaluation in a murine ov
ariectomy model^len#Gene Ther#20010000#2001#8#1770-6#20110000#12.htm#0969-7128#G
ene ther##
00804000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100017000870100
02100104010001900125010001800144010001800162810000600180012021200186030001000398
06500090040806400050041703100020042201400060042486500090043000200070043903500100
0446801001000456#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#170#15#artic
le#33#15#^rND^sOyama^nM#^rND^sTatlock^nA#^rND^sKavalkovich^nK#^rND^sNishimura^nK
#^rND^sJohstone^nB#^rND^sRobbins^nPD#et al#Retrovirally transduced bone marrow s
tromal cells isolated from a mouse model of human osteogenesis imperfecta (oim) 
persist in bone and retain the ability to form cartilage and bone after extended
 passaging^len#Gene Ther#19990000#1999#6#321-9#20110000#12.htm#0969-7128#Gene th
er##
00668000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100014000720100013000860100
01400099010001400113010001200127012013500139030001600274065000900290064000500299
031000300304014000500307865000900312002000700321035001000328801001600338#v19n1#V
:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#171#16#article#33#16#^rND^sChen^nW#^
rND^sLiu^nJ#^rND^sDiao^nW#^rND^sTang^nJ#^rND^sJi^nJ#Bone loss induced by ovariec
tomy in rats is prevented by gene transfer of parathyroid hormone or an Arg-Gly-
Asp-containing peptide^len#Biotechnol Lett#20050000#2005#27#41-8#20110000#12.htm
#0141-5492#Biotechnol Lett##
00620000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100013000720100014000850100
01200099010001200111012011200123030001600235065000900251064000500260031000300265
014000800268865000900276002000700285035001000292801001600302#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\12.htm#S#c#172#17#article#33#17#^rND^sLiu^nB#^rND^sTang^nJ#
^rND^sJi^nJ#^rND^sGu^nJ#Prevention of osteoporosis in ovariectomized mice by ele
ctroporational gene transfer of parathyroid hormone^len#Biotechnol Lett#20030000
#2003#25#2117-22#20110000#12.htm#0141-5492#Biotechnol Lett##
00706000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100013000720100014000850100
01400099010001500113010001400128010001400142810000600156012013200162030001100294
06500090030506400050031403100030031901400090032286500090033100200070034003500100
0347801001100357#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#173#18#artic
le#33#18#^rND^sKim^nD#^rND^sCho^nSK#^rND^sHer^nSJ#^rND^sYang^nJY#^rND^sKim^nSW#^
rND^sKim^nSY#et al#Retrovirus-mediated gene transfer of receptor activator of nu
clear factor-{kappa}B-Fc prevents bone loss in ovariectomized mice^len#Stem Cell
s#20060000#2006#24#1798-805#20110000#12.htm#0250-6793#STEM CELLS##
00548000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100015000880100
01900103012007300122030000700195065000900202064000500211031000300216014000600219
865000900225002000700234035001000241801000700251#v19n1#V:\SciELO\serial\aob\v19n
1\markup\12.htm#S#c#174#19#article#33#19#^rND^sBielby^nR#^rND^sJones^nE#^rND^sMc
Gonagle^nD#The role of mesenchymal stem cells in maintenance and repair of bone^
len#Injury#20070000#2007#38#26-32#20110000#12.htm#0020-1383#Injury##
00699000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100014000870100
01400101010001600115010001200131012015800143030001700301065000900318064000500327
031000300332014000700335865000900342002000700351035001000358801001700368#v19n1#V
:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#175#20#article#33#20#^rND^sLien^nCY#
^rND^sHo^nKCY#^rND^sLee^nOK#^rND^sBlunn^nGW#^rND^sSu^nY#Restoration of bone mass
 and strength in glucocorticoid-treated mice by systemic transplantation of CXCR
4 and Cbfa-1 co-expressing mesenchymal stem cells^len#J Bone Miner Res#20090000#
2009#24#837-48#20110000#12.htm#0884-0431#J Bone Miner Res##
00700000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100014000870100
01800101010001500119010001300134010001700147012010500164030002700269065000900296
06400050030503100040031001400070031486500090032100200070033003500100033780100270
0347#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#176#21#article#33#21#^rN
D^sLuk^nKDK#^rND^sChen^nY#^rND^sCheung^nKMC#^rND^sKung^nHF#^rND^sLu^nWW#^rND^sLe
ong^nJCY#Adeno-associated virus-mediated bone morphogenetic protein-4 gene thera
py for in vivo bone formation^len#Biochem Biophys Res Commun#20030000#2003#308#6
36-45#20110000#12.htm#0006-291X#Biochem Biophys Res Commun##
00650000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100013000720100012000850100
01400097010001600111010001300127010001400140810000600154012006500160030001800225
06500090024306400050025203100030025701400080026086500090026800200070027703500100
0284801001800294#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#177#22#artic
le#33#22#^rND^sYue^nB#^rND^sLu^nB#^rND^sDai^nKR#^rND^sZhang^nXL#^rND^sYu^nCF#^rN
D^sLou^nJR#et al#BMP2 gene therapy on the repair of bone defects of aged rats^le
n#Calcif Tissue Int#20050000#2005#77#395-403#20110000#12.htm#0171-967X#Calcif Ti
ssue Int##
00675000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100016000870100
01800103010001900121010001800140012013400158030003700292710000200329065000900331
064000500340031000400345014000800349865000900357002000700366#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\12.htm#S#c#178#23#article#33#23#^rND^sKawai^nM#^rND^sBessho
^nK#^rND^sMaruyama^nH#^rND^sMiyazaki^nJI#^rND^sYamamoto^nT#Human BMP-2 gene tran
sfer using transcutaneous in vivo electroporation induced both intramembranous a
nd endochondral ossification^len#Anat Rec A Discov Mol Cell Evol Biol#2#20050000
#2005#287#1264-71#20110000#12.htm##
00673000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100016000880100
02800104010001700132010001800149010002400167012007900191030001300270065000900283
06400050029203100030029701400080030086500090030800200070031703500100032480100130
0334#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#179#24#article#33#24#^rN
D^sGugala^nZ#^rND^sDavis^nAR#^rND^sFouletier-Dilling^nCM#^rND^sGannon^nFH#^rND^s
Lindsey^nRW#^rND^sOlmsted-Davis^nEA#Adenovirus BMP2-induced osteogenesis in comb
ination with collagen carriers^len#Biomaterials#20070000#2007#28#4469-79#2011000
0#12.htm#0142-9612#Biomaterials##
00677000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100018000910100
02000109010001600129010001600145012012400161030001400285065000900299064000500308
031000300313014000700316865000900323002000700332035001000339801001400349#v19n1#V
:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#180#25#article#33#25#^rND^sEngstrand
^nT#^rND^sDaluiski^nA#^rND^sBahamonde^nME#^rND^sMelhus^nH#^rND^sLyons^nKM#Transi
ent production of bone morphogenetic protein 2 by allogeneic transplanted transd
uced cells induces bone formation^len#Hum Gene Ther#20000000#2000#11#205-11#2011
0000#12.htm#1043-0342#Hum Gene Ther##
00665000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100024000720100018000960100
01900114010001700133010002100150012012100171030000500292065000900297064000500306
031000300311014000600314865000900320002000700329035001000336801000500346#v19n1#V
:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#181#26#article#33#26#^rND^sUlrich-Vi
nther^nM#^rND^sSchwarz^nEM#^rND^sPedersen^nFS#^rND^sSøballe^nK#^rND^sAndreassen^
nTT#Gene therapy with human osteoprotegerin decreases callus remodeling with lim
ited effects on biomechanical properties^len#Bone#20050000#2005#37#751-8#2011000
0#12.htm#8756-3282#Bone##
00683000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100015000920100
01600107010001500123010001400138010001600152810000600168012011100174030000500285
06500090029006400050029903100030030401400070030786500090031400200070032303500100
0330801000500340#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#182#27#artic
le#33#27#^rND^sKostenuik^nPJ#^rND^sBolon^nB#^rND^sMorony^nS#^rND^sDaris^nM#^rND^
sGeng^nZ#^rND^sCarter^nC#et al#Gene therapy with human recombinant osteoproteger
in reverses established osteopenia in ovariectomized mice^len#Bone#20040000#2004
#34#656-64#20110000#12.htm#8756-3282#Bone##
00668000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100016000870100
01500103010001600118010002000134010001500154810000600169012011600175030000900291
71000020030006500090030206400050031103100020031601400080031886500090032600200070
0335#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#183#28#article#33#28#^rN
D^sBolon^nB#^rND^sCarter^nC#^rND^sDaris^nM#^rND^sMorony^nS#^rND^sCapparelli^nC#^
rND^sHsieh^nA#et al#Adenoviral delivery of osteoprotegerin ameliorates bone reso
rption in a mouse ovariectomy model of osteoporosis^len#Mol Ther#2#20010000#2001
#3#197-205#20110000#12.htm##
00564000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100022000720100019000940100
02100113012005100134030001900185065000900204064000500213031000300218014000800221
865000900229002000700238035001000245801001900255#v19n1#V:\SciELO\serial\aob\v19n
1\markup\12.htm#S#c#184#29#article#33#29#^rND^sPapadopouli^nAE#^rND^sKlonaris^nC
N#^rND^sTheocharis^nSE#Role of OPG/RANKL/RANK axis on the vasculature^len#Histol
 Histopathol#20080000#2008#23#497-506#20110000#12.htm#0213-3911#Histol Histopath
ol##
00662000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100016000920100
01700108010001900125010001800144012010600162030001400268065000900282064000500291
031000400296014000800300865000900308002000700317035001000324801001400334#v19n1#V
:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#185#30#article#33#30#^rND^sWeitzmann
^nMN#^rND^sRoggia^nC#^rND^sToraldo^nG#^rND^sWeitzmann^nL#^rND^sPacifici^nR#Incre
ased production of IL-7 uncouples bone formation from bone resorption during est
rogen deficiency^len#J Clin Invest#20020000#2002#110#1643-50#20110000#12.htm#002
1-9738#J Clin Invest##
00665000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100014000720100017000860100
01600103010001500119010002100134010001700155012008200172030001700254065000900271
06400050028003100030028501400080028886500090029600200070030503500100031280100170
0322#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#186#31#article#33#31#^rN
D^sZhao^nH#^rND^sKitaura^nH#^rND^sSands^nMS#^rND^sRoss^nFP#^rND^sTeitelbaum^nSL#
^rND^sNovack^nDV#Critical role of &#946;3 integrin in experimental postmenopausa
l osteoporosis^len#J Bone Miner Res#20050000#2005#20#2116-23#20110000#12.htm#088
4-0431#J Bone Miner Res##
00779000000000349000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100022000720100016000940100
01600110010001500126010001600141010002000157810000600177012016100183030001600344
06500090036006400050036903100030037403200020037701400080037986500090038700200070
0396035001000403801001600413#v19n1#V:\SciELO\serial\aob\v19n1\markup\12.htm#S#c#
187#32#article#33#32#^rND^sWübbenhortst^nD#^rND^sDumler^nK#^rND^sWagner^nB#^rND^
sWexel^nG#^rND^sImhoff^nA#^rND^sGansbacher^nB#et al#Teracycline-regulated bone m
orphogenetic protein 2 gene expression in lentivirally transduced primary rabbit
 chondrocytes for treatment of cartilage defects^len#Arthritis Rheum#20100000#20
10#62#7#2037-46#20110000#12.htm#0004-3591#Arthritis rheum##
00607000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100013000720100014000850100
01200099010001200111012010000123030001600223065000900239064000500248031000400253
014000600257865000900263002000700272035001000279801001600289#v19n1#V:\SciELO\ser
ial\aob\v19n1\markup\12.htm#S#c#188#33#article#33#33#^rND^sLiu^nB#^rND^sTang^nJ#
^rND^sJi^nJ#^rND^sGu^nJ#The expression of functional human parathyroid hormone i
n a gene therapy model for osteoporosis^len#Cell Tissue Res#20040000#2004#317#57
-63#20110000#12.htm#0302-766X#Cell tissue res##
